
<html lang="en"     class="pb-page"  data-request-id="95e823a0-0bf4-46a5-b743-843f69dd246d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c01344;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer" /></meta><meta name="dc.Creator" content="M. Cynthia  Martin" /></meta><meta name="dc.Creator" content="Guihua  Zeng" /></meta><meta name="dc.Creator" content="Jindan  Yu" /></meta><meta name="dc.Creator" content="Gary E.  Schiltz" /></meta><meta name="dc.Description" content="The polycomb repressive complex 2 (PRC2) is composed of three core subunits, enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 (SUZ12), along with a numbe..." /></meta><meta name="Description" content="The polycomb repressive complex 2 (PRC2) is composed of three core subunits, enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 (SUZ12), along with a numbe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 7, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01344" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01344" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01344" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01344" /></link>
        
    
    

<title>Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01344" /></meta><meta property="og:title" content="Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0048.jpeg" /></meta><meta property="og:description" content="The polycomb repressive complex 2 (PRC2) is composed of three core subunits, enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 (SUZ12), along with a number of accessory proteins. It is the key enzymatic protein complex that catalyzes histone H3 lysine 27 (H3K27) methylation to mediate epigenetic silencing of target genes. PRC2 thus plays essential roles in maintaining embryonic stem cell identity and in controlling cellular differentiation. Studies in the past decade have reported frequent overexpression or mutation of PRC2 in various cancers including prostate cancer and lymphoma. Aberrant PRC2 function has been extensively studied and proven to contribute to a large number of abnormal cellular processes, including those that lead to uncontrolled proliferation and tumorigenesis. Significant efforts have recently been made to develop small molecules targeting PRC2 function for potential use as anticancer therapeutics. In this review, we describe recent approaches to identify and develop small molecules that target PRC2. These various strategies include the inhibition of the function of individual PRC2 core proteins, the disruption of PRC2 complex formation, and the degradation of its subunits." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01344"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01344">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01344&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01344&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01344&amp;href=/doi/10.1021/acs.jmedchem.0c01344" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15344-15370</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01340" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01348" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">M. Cynthia Martin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">M. Cynthia Martin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M.+Cynthia++Martin">M. Cynthia Martin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guihua Zeng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guihua Zeng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guihua++Zeng">Guihua Zeng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jindan Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jindan Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</div><div class="loa-info-affiliations-info">Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</div><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jindan++Yu">Jindan Yu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Gary E. Schiltz</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary E. Schiltz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, United States</div><div class="loa-info-affiliations-info">Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</div><div class="loa-info-affiliations-info">Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 847-467-2287. Email: <a href="/cdn-cgi/l/email-protection#82e5e3f0fbaff1e1eaebeef6f8c2ecedf0f6eaf5e7f1f6e7f0ecace7e6f7"><span class="__cf_email__" data-cfemail="2b4c4a59520658484342475f516b4544595f435c4e585f4e5945054e4f5e">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary+E.++Schiltz">Gary E. Schiltz</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4180-5051" title="Orcid link">http://orcid.org/0000-0003-4180-5051</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01344&amp;href=/doi/10.1021%2Facs.jmedchem.0c01344" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15344–15370</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 July 2020</li><li><span class="item_label"><b>Published</b> online</span>7 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01344" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01344</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15344%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DM.%2BCynthia%2BMartin%252C%2BGuihua%2BZeng%252C%2BJindan%2BYu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01344%26title%3DSmall%2BMolecule%2BApproaches%2Bfor%2BTargeting%2Bthe%2BPolycomb%2BRepressive%2BComplex%2B2%2B%2528PRC2%2529%2Bin%2BCancer%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15370%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01344"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1829</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01344" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Cynthia Martin&quot;},{&quot;first_name&quot;:&quot;Guihua&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Jindan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;E. Schiltz&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15344-15370&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01344&quot;},&quot;abstract&quot;:&quot;The polycomb repressive complex 2 (PRC2) is composed of three core subunits, enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 (SUZ12), along with a number of accessory proteins. It is the key enzymatic protein complex that catalyzes histone H3 lysine 27 (H3K27) methylation to mediate epigenetic silencing of target genes. PRC2 thus plays essential roles in maintaining embryonic stem cell identity and in controlling cellular differentiation. Studies in the past decade have reported frequent overexpression or mutation of PRC2 in various cancers including prostate cancer and lymphoma. Aberrant PRC2 function has been extensively studied and proven to contribute to a large number of abnormal cellular processes, including those that lead to uncontrolled proliferation and tumorigenesis. Significant efforts have recently been made to develop small molecules targeting PRC2 function for potential use as anticancer therapeutics. In this review, we describe recent approaches to &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01344&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01344" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01344&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01344" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01344&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01344" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01344&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01344&amp;href=/doi/10.1021/acs.jmedchem.0c01344" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01344" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01344" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01344%26sid%3Dliteratum%253Aachs%26pmid%3D33283516%26genre%3Darticle%26aulast%3DMartin%26date%3D2020%26atitle%3DSmall%2BMolecule%2BApproaches%2Bfor%2BTargeting%2Bthe%2BPolycomb%2BRepressive%2BComplex%2B2%2B%2528PRC2%2529%2Bin%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15344%26epage%3D15370%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0048.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The polycomb repressive complex 2 (PRC2) is composed of three core subunits, enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 (SUZ12), along with a number of accessory proteins. It is the key enzymatic protein complex that catalyzes histone H3 lysine 27 (H3K27) methylation to mediate epigenetic silencing of target genes. PRC2 thus plays essential roles in maintaining embryonic stem cell identity and in controlling cellular differentiation. Studies in the past decade have reported frequent overexpression or mutation of PRC2 in various cancers including prostate cancer and lymphoma. Aberrant PRC2 function has been extensively studied and proven to contribute to a large number of abnormal cellular processes, including those that lead to uncontrolled proliferation and tumorigenesis. Significant efforts have recently been made to develop small molecules targeting PRC2 function for potential use as anticancer therapeutics. In this review, we describe recent approaches to identify and develop small molecules that target PRC2. These various strategies include the inhibition of the function of individual PRC2 core proteins, the disruption of PRC2 complex formation, and the degradation of its subunits.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Polycomb repressive complex 2 (PRC2), well-known for its catalytic function specific on H3 lysine 27 (mono-, di-, or tri-) methylation and epigenetic silencing of target genes, is composed of three essential core subunits, enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 (SUZ12), and is essential for the maintenance of embryonic stem cell identify during development.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> These core subunit proteins are required for the maintenance of repression of homeotic genes during development. EZH2, the main enzymatic subunit of PRC2, has a SET domain that contains the active site for the catalysis of histone H3 lysine 27 methylation.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> EED is required to boost the catalytic activity of EZH2; it binds to H3K27me3 to stimulate the histone methyltransferase (HMTase) activity of the complex.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11">(7−11)</a> The interaction between EZH2 and EED is essential for PRC2 enzymatic activity.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> SUZ12 stabilizes EZH2 and is necessary for HMTase activity and the silencing function of the EED-EZH2 complex.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Loss of SUZ12 leads to the global loss of H3K27me3 and the destabilization of EZH2.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17−20)</a> Further, both EED and SUZ12 proteins are required for the stability of EZH2 on the chromatin and the subsequent H3K27 methylation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">PRC2 is the only known methyltransferase that specifically methylates H3K27 at different levels (mono-, di-, or tri-) through its HMTase activity, creating a binding site for the chromodomain-containing protein polycomb (Pc).<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> All three H3K27 methylation states have been correlated with transcriptional repression and heterochromatin formation,<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29">(25−29)</a> while only H3K27me3 is tightly linked to gene silencing at specific loci through chromatin compaction.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35">(30−35)</a> In addition, H3K27me3 is linked to the repair of DNA damage, particularly the repair of double-strand breaks by homologous recombination repair.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">PRC2 components have been reported to be overexpressed and highly disregulated in multiple types of cancers, including prostate, breast, lung, gastric bladder, pancreatic, and others, which have been thoroughly reviewed.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37−40)</a> Overexpression of EZH2 and gain-of-function somatic mutation of EZH2 (such as Y641) have been causatively associated with the development and progression of solid tumors and hematopoietic cancers, respectively, through mediating epigenetic silencing of target genes.<a onclick="showRef(event, 'ref41 ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44 ref45">(41−45)</a> Recently, more attention has been given to the noncanonical roles of PRC2 in various cancers. In addition to its methylation activity on H3K27, EZH2 and PRC2 have been reported to methylate a number of non-histone substrates to regulate their transcriptional activities or downstream signaling pathways.<a onclick="showRef(event, 'ref14 ref46 ref47 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref14 ref46 ref47 ref48 ref49 ref50">(14,46−50)</a> Furthermore, recent studies have reported methylation-independent functions of EZH2 in collaborating with non-PRC2 transcription factors to activate target genes or signaling pathways.<a onclick="showRef(event, 'ref20 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref20 ref51 ref52 ref53 ref54">(20,51−54)</a></div><div class="NLM_p">Due to the critical roles PRC2 plays in multiple types of cancer, there has been intense interest in the development of new small molecule drugs for its therapeutic targeting. These strategies, with an emphasis on new therapeutic modalities such as EED-targeting and protein degradation, will be reviewed here (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The first drug directly targeting PRC2, tazemetostat (EPZ-6438), trade name Tazverik, was approved in January, 2020, and is indicated for treating epithelioid sarcoma and follicular lymphoma. Epizyme is also developing tazemetostat in multiple clinical trials against other lymphomas and solid tumors. Besides tazemetostat, there are currently at least five additional distinct small molecule EZH2 inhibitors in clinical trials against various forms of cancer (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Constellation Pharmaceuticals is also testing multiple EZH2 inhibitors in clinical trials; CPI-1205 is their most advanced EZH2 inhibitor and is currently in phase 2 testing for metastatic castration-resistant prostate cancer (mCRPC). Besides investigating CPI-1205 in other tumor types as well, the Constellation group’s second-generation EZH2 inhibitor (CPI-0209) has also begun phase 1 testing for patients with solid tumors. The GlaxoSmithKline EZH2 inhibitor GSK2816126 was tested for pharmacokinetics (PK) in a phase 1 study (NCT02082977); however, further development was halted after PK data indicated that this compound was unlikely to provide any benefit. Besides EZH2 inhibitors, Novartis is currently studying the first EED inhibitor (MAK683, U.S. Patent 9,580,437) in a phase 1 trial (NCT02900651).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of various strategies to target PRC2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Clinical Development Status of Small Molecule Drugs Targeting PRC2 Complex Proteins</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">sponsor</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">indications</th><th class="colsep0 rowsep0" align="center">NCT ID</th><th class="colsep0 rowsep0" align="center">comments</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="13" align="left">Tazemetostat (EPZ-6438)</td><td class="colsep0 rowsep0" rowspan="10" align="left">Epizyme, Inc.</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">Epithelioid sarcoma</td><td class="colsep0 rowsep0" align="left">NCT04204941</td><td class="colsep0 rowsep0" align="left">Approved, January 2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">Synovial sarcoma</td><td class="colsep0 rowsep0" align="left">NCT02601950</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">Mesothelioma</td><td class="colsep0 rowsep0" align="left">NCT02860286</td><td class="colsep0 rowsep0" align="left">Completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">Solid tumors, lymphomas</td><td class="colsep0 rowsep0" align="left">NCT01897571</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Rhabdoid and other tumors</td><td class="colsep0 rowsep0" align="left">NCT02601937</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphomas, solid tumors</td><td class="colsep0 rowsep0" align="left">NCT03010982</td><td class="colsep0 rowsep0" align="left">Completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphomas, solid tumors</td><td class="colsep0 rowsep0" align="left">NCT02875548</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Metastatic prostate cancer</td><td class="colsep0 rowsep0" align="left">NCT04179864</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphomas, solid tumors</td><td class="colsep0 rowsep0" align="left">NCT03028103</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphomas, solid tumors</td><td class="colsep0 rowsep0" align="left">NCT03217253</td><td class="colsep0 rowsep0" align="left">Withdrawn</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCI</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Urothelial carcinoma</td><td class="colsep0 rowsep0" align="left">NCT03854474</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">Solid tumors, lymphomas</td><td class="colsep0 rowsep0" align="left">NCT03213665</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Eisai</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">NHL</td><td class="colsep0 rowsep0" align="left">NCT03456726</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">Valemetostat (DS-3201b)</td><td class="colsep0 rowsep0" rowspan="6" align="left">Daiichi Sankyo</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">T-cell leukemia/lymphoma</td><td class="colsep0 rowsep0" align="left">NCT04102150</td><td class="colsep0 rowsep0" align="left">Active.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">Small-cell lung cancer</td><td class="colsep0 rowsep0" align="left">NCT03879798</td><td class="colsep0 rowsep0" align="left">Active. Combination with irinotecan</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Acute leukemias</td><td class="colsep0 rowsep0" align="left">NCT03110354</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphoma</td><td class="colsep0 rowsep0" align="left">NCT02732275</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Metastatic urological cancers</td><td class="colsep0 rowsep0" align="left">NCT04388852</td><td class="colsep0 rowsep0" align="left">Active. Combination with ipilimumab</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">NCT04276662</td><td class="colsep0 rowsep0" align="left">Safety, tolerability, and PK study</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">CPI-1205</td><td class="colsep0 rowsep0" rowspan="4" align="left">Constellation Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">mCRPC</td><td class="colsep0 rowsep0" align="left">NCT03480646</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">B-Cell lymphoma</td><td class="colsep0 rowsep0" align="left">NCT02395601</td><td class="colsep0 rowsep0" align="left">Completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">NCT04104776</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">NCT03525795</td><td class="colsep0 rowsep0" align="left">Active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CPI-0209</td><td class="colsep0 rowsep0" align="left">Constellation Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">NCT04104776</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SHR2554</td><td class="colsep0 rowsep0" align="left">Jiangsu HengRui Medicine Co., Ltd.</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphomas</td><td class="colsep0 rowsep0" align="left">NCT03603951</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK2816126</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Lymphomas, solid tumors, multiple myeloma</td><td class="colsep0 rowsep0" align="left">NCT02082977</td><td class="colsep0 rowsep0" align="left">Terminated. This PK study showed insufficient data to proceed with further testing.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PF06821497</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">SCLC, CRPC, lymphoma</td><td class="colsep0 rowsep0" align="left">NCT03460977</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAK683<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">DLBCL</td><td class="colsep0 rowsep0" align="left">NCT02900651</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All compounds are EZH2 inhibitors unless otherwise noted.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Compound is an EED inhibitor. See the <a class="ref internalNav" href="#dl1" aria-label="Abbreviations Used">Abbreviations Used</a> section at the end for the definitions of these abbreviations.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Small Molecules That Inhibit PRC2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Small molecules targeting PRC2 can be broadly classified by the specific PRC2 core subunit they target. On the basis of this system, PRC2-targeting small molecules have been divided into three main categories for further discussion in this review. The largest class covers the small molecules that inhibit the enzymatic activity of EZH2. The second category reports compounds that bind to EED and inhibit its interaction with H3K27. The remaining group of PRC2-directed agents bind either to EZH2 or EED and induce the degradation of the target protein, by the use of hydrophobic tags or ligands that recruit an E3 ligase to induce proteasomal degradation.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  EZH2 Catalytic Inhibitors</h3><div class="NLM_p">Given the essential function EZH2 plays in H3K27 trimethylation and the role this histone mark has in cellular differentiation, proliferation, and tumorigenesis, a large number of enzymatic EZH2 inhibitors have been developed. Each of these molecules acts by inhibiting the enzymatic activity of the methyltransferase function of EZH2. Here we describe the most well-characterized and significant inhibitors reported to date. As they typically work by a similar mechanism of action, they have been differentiated here based on their structural features so that additional insights into structure–activity relationships (SAR) can be drawn.</div><div class="NLM_p">When considering the structures of the most significant EZH2 catalytic inhibitors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), it is noteworthy that they all contain the pyridone motif. The crystal structure of a representative inhibitor bound to EZH2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6">5LS6</a>) shows a clear hydrogen bond framework between the pyridone N–H and C═O groups to the backbone amide of EZH2 W624. This interaction appears to provide sufficient affinity to anchor the inhibitor in the active site. The crystal structure of the <i>S</i>-adenosyl methionine (SAM) methyltransferase product <i>S</i>-adenosyl homocysteine (SAH, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) bound to EZH2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HYN">5HYN</a>) shows that this same EZH2 W624 provides a critical hydrogen bond to the SAH terminal amino acid moiety. The competitive nature of pyridone-based inhibitors is evident by observing that the pyridone group occupies the same position as the SAH amino acid motif, thereby preventing simultaneous SAH/SAM binding. While it is understandable that inhibitors containing a pyridone group are able to bind to EZH2 through interaction with W624, it is nonetheless curious that there have been surprisingly few reports of EZH2 inhibitors that do not contain this group. It is possible that compound libraries enriched in pyridone-containing ligands have been used independently by different groups to identify hit starting points, although details of successes/failures in identifying non-pyridone-based inhibitors have not yet been reported.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (Top) Structures of significant EZH2 catalytic inhibitors. (Bottom) Crystal structure of inhibitor (<b>13</b>) bound to EZH2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6">5LS6</a>) (salmon) with key hydrogen bonds shown in red. Also shown is EZH2 ligand <i>S</i>-adenosyl-<span class="smallcaps smallerCapital">l</span>-homocysteine (SAH, <b>14</b>) (shown in gray) overlaid with the 5LS6 structure. Bound pose of SAH is taken from crystal structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HYN">5HYN</a>. Overlay shows the partial occupancy of the SAH site by pyridone-based EZH2 inhibitor <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">2.1.1.  Pyridone Indole</h4><div class="NLM_p">In an effort to develop EZH2 catalytic-site inhibitors, a group at Constellation Pharmaceuticals carried out a high throughput screening campaign to identify initial starting points.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Among the hits was CPI-905 (<b>15</b>), a pyridone-based inhibitor with weak activity (IC<sub>50</sub> = 39.6 μM) against EZH2 enzymatic activity. During medicinal chemistry optimization, this molecule was modified to generate a lead compound in which the original benzodiaxolane was replaced by an indole ring which had significantly improved properties (<b>16</b>, CPI-360, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Further characterization of this compound showed it possessed excellent inhibitory potency (IC<sub>50</sub> = 0.5 nM) of WT EZH2, was <i>S</i>-adenosyl-<span class="smallcaps smallerCapital">l</span>-methionine (SAM)-competitive, and showed attractive selectivity for EZH2 across a large panel of histone lysine and arginine and DNA methyltransferases.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of CPI-905 and CPI-360.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the potent characteristics of <b>16</b>, scientists at Constellation Pharmaceuticals combined structural features of <b>15</b> with the SAM-competitive PRC2 inhibitor compound <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The commonality of the benzoylamide motif between <b>17</b> and <b>15</b> led them to test the interchangeability of the tetramethylpiperidine with the dimethylpyridone as in compound <b>18</b>. While significant potency was lost relative to <b>17</b>, hybrid compound <b>18</b> showed improved potency relative to <b>15</b>. In addition, they found that removal of the chloro, cyano, and pyridazine substituents and replacement with a phenoxyphenyl group (<b>19</b>) provided better potency in the dimethylpyridone series.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Initial design strategy incorporating the structural combination of <b>17</b> and <b>15</b> (CPI-905) which led to the identification of potent EZH2 inhibitor <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial SAR based on compound <b>19</b> revealed that a methylene linker instead of the ether linker between the two phenyl rings led to a 3-fold improvement in potency (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). In an attempt to lower the log <i>P</i>, polarity was introduced onto the central ring by introducing a 3-indolyl group (compound <b>21</b>) which showed an 11-fold improvement in potency with sub-100 nM activity against both WT and mutant EZH2. Further modifications to the indole side chain showed preference for the <i>R</i>-enantiomer, providing submicromolar cell potency at inhibiting H3K27me3 in HeLa cells, leading to the new analog (<b>22</b>) with IC<sub>50</sub> = 1 nM against EZH2. Finally, replacement of one of the methyl groups on the pyridone ring of <b>22</b> with a methoxy group provided a significant improvement in microsomal stability with similar biochemical and cellular potency, resulting in <b>23</b> (CPI-169, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which was tested in a lymphoma xenograft model.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR-based elaboration of compound <b>20</b> leading to optimized EZH2 inhibitor <b>23</b> (CPI-169).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>in vivo</i> studies on <b>23</b> demonstrated good activity in a Karpas422 pharmacodynamic (PD) mouse model, with an approximately 84% reduction in tumor H3K27me3 after dosing at 200 mg/kg twice daily for 17 days. Compound <b>23</b> also produced strong antitumor efficacy (54%, 77%, and >100% tumor growth inhibition (TGI) at 50, 100, and 200 mg/kg, respectively) and little systemic toxicity (less than 10% body-weight loss). However, <b>23</b> had poor oral bioavailability in rats and dogs (0.09% <i>F</i> and 0.12% <i>F</i>, respectively), making its further development difficult. Therefore, additional medicinal chemistry optimization was carried out, focusing on different N-substituents on the piperidine ring.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The primary focus was on decreasing the piperidine’s basicity since perturbation of the piperidine p<i>K</i><sub>a</sub> had been shown to affect cellular potency, selectivity, toxicity, bioavailability, and other pharmacokinetic (PK) properties.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> A series of fluorinated analogs was synthesized, and it was found that the trifluoroethyl group on the piperidine ring showed comparable potency to <b>23</b> and good oral bioavailability. This led to a potent and selective inhibitor of EZH2 (<b>4</b>, CPI-1205, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) which is currently under evaluation in clinical trials for the treatment of B-cell lymphomas. At a single PO dose of 100 mg/kg, mouse pharmacokinetics studies showed compound <b>4</b> achieved an unbound <i>C</i><sub>max</sub> of 1.41 μM and an unbound exposure (area under the curve, AUC) of 1.87 μM·h while maintaining oral bioavailability of 100%.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Chemical structure of <b>4</b> (CPI-1205). (B) Chemical structure of derivative <b>13</b> in which the CF<sub>3</sub> group was modified to a CF<sub>2</sub>CH<sub>3</sub>. (C) Cocrystal structure of <b>13</b> bound to human PRC2 with key interactions between the pyridone and W624 backbone residues shown with yellow dotted lines (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6">5LS6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the Karpas422 mouse B-cell lymphoma xenograft model, <b>4</b> significantly reduced tumor growth (TGI) by 97% after 25 days’ treatment with twice-daily PO administration of 160 mg/kg. This also led to a substantial reduction of H3K27me3 (47%) without producing significant body weight loss. In addition, pharmacokinetic data showed that <b>4</b> possessed relatively high clearance and good oral bioavailability in both rats and dogs (44.6% and 46.2% <i>F</i>, respectively).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">During studies on the development of <b>4</b>, a cocrystal structure of a similar pyridone-containing inhibitor (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) bound to human PRC2 was obtained.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Electron density corresponding to compound <b>13</b> was identified in a pocket at the interface of the EZH2 SET domain, the SAL region of the EZH2 N-terminus, and EED. In addition, a partial overlap between the 2,2-difluoropropylpiperidine <b>13</b> and the SAH carboxylic acid was consistent with a SAM competitive mechanism of inhibition. Overall, the ligand adopted an interesting twisted conformation, likely due to a conformational preorganization induced by the chiral methyl group and the indoyl amide substituents that fit in the enzyme’s pocket. Additionally, the two potential hydrogen bond interactions between the pyridone motif and protein backbone Trp624 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) help explain its high affinity binding and the pyridone’s prevalence in a large number of EZH2 inhibitors.</div><div class="NLM_p">Even though <b>4</b> (CPI-1205) was found to be well-tolerated during phase 1 clinical trials,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> it required high doses of the drug (800 mg, three times per day). At the same time, extended dosing of some EZH2 inhibitors has resulted in decreased drug exposure due to induction of CYP3A4 leading to increased metabolism of the drug.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> This effect suggests the potential for drug–drug interactions when using such high doses of EZH2 inhibitors as part of combination therapies. To further improve the extent of EZH2 enzyme inhibition and consequently the <i>in vivo</i> properties of their EZH2 inhibitor series, further lead optimization of <b>4</b> was undertaken. Scientists at Constellation Pharmaceuticals investigated the electronic characteristics of the pyridone ring, which led to 4-thiomethylpyridone<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> as a key modification (<b>24</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), achieving a significant increase in potency (EZH2 IC<sub>50</sub> = 0.2 nM) and prolonged residence time (10-fold improvement over <b>4</b>). However, compound <b>24</b> showed a nearly 25-fold increase in CYP3A4 upregulation. Additional modifications around the piperidine side-chain and indole core were investigated, resulting in aza-indole <b>12</b> with improved potency (EZH2 IC<sub>50</sub> = 0.057 nM), negligible CYP3A4 upregulation, longer residence time (57 h), and modest (15% <i>F</i>) oral bioavailability. On the basis of these properties, compound <b>12</b> was tested in a mouse xenograft model.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Lead optimization of <b>4</b> (CPI-1205) to increase residence time which led to identification of EZH2 inhibitor <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Treatment of a Karpas422 lymphoma xenograft mouse model with aza-indole <b>12</b> displayed tumor regression at day 14 using a 25 mg/kg BID-PO dose. The study also showed a TGI of 75% at day 21, with no impact on mouse body weight. In addition, H3K27me3 was significantly decreased at day 14.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> PK/PD studies showed that the unbound plasma concentration of <b>12</b> was maintained above the EC<sub>50</sub> necessary to reduce H3K27me3 for 4 h.</div><div class="NLM_p">Scientists at Novartis carried out a high-throughput screen for new EZH2 inhibitors.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The resulting hit compound scaffold was used as a template for the design of compound <b>7</b> (El1, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Since mutations in the SET domain of EZH2 would contribute to maintaining high levels of H3K27me3 which promotes cell proliferation, the authors examined the ability of <b>7</b> to inhibit proliferation in cell lines carrying wild-type and Y641F mutant EZH2. Compound <b>7</b> showed potent inhibition of WT EZH2 (IC<sub>50</sub> = 15 nM) and Y641F mutant EZH2 (IC<sub>50</sub> = 13 nM). They also found that <b>7</b> produced genome-wide loss of H3K27 methylation and activation of PRC2 target genes. They showed that treatment of diffused large B-cell lymphoma cell lines with inhibitor <b>7</b> was able to potently block tumor proliferation in cells carrying both wild-type and Y641 mutant EZH2.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structure of Novartis EZH2 inhibitor <b>7</b> (El1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scientists at Integral Biosciences have developed a series of potent EZH2 inhibitors that contained an increased fraction of sp<sup>3</sup> carbons to increase the solubility of their inhibitors.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> While keeping the 4,6-dimethylpyridone methyl amide constant, they incorporated a bicyclic nonplanar indoline core in place of the indole and evaluated the effect of substitution at R<sup>1</sup> and R<sup>2</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The isopropyl substituted compound (<b>25</b>) was inactive, while the cyclopentyl substituted compound (<b>26</b>) showed a 47-fold improvement in potency. A tetrahydropyran substitution (<b>27</b>) at the 6-position led to a major loss in potency. However, when the substitution at the 6-position is replaced with a large morpholinobenzyl (compound <b>28</b>), potency was improved.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Initial SAR on the Indoline Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0036.gif" alt="" id="gr9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0037.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">EZH2 IC<sub>50</sub> of the active/inactive enantiomer.</p></div></div><div></div></div><div class="NLM_p last">The addition of a methyl group at the indoline 3-position resulted in enantiomeric pairs of compounds. After separation of the enantiomers, the active enantiomer of <b>29</b> possessed significantly improved potency (IC<sub>50</sub> = 0.029 μM) while the inactive one was dramatically less potent (6.98 μM). Lastly, additional modifications at the R<sup>2</sup> position, while keeping the tetrahydropyran (THP) group at the 1-position and a methyl group at 3-position, resulted in optimized compound <b>30</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) with improved potency (IC<sub>50</sub> = 0.011 μM), good kinetic solubility in PBS, and oxidative stability in human and mouse liver microsomes.</div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.1.2.  Pyridone Indazole</h4><div class="NLM_p">Scientists at Epizyme carried out a high-throughput screen of 175 000 compounds from their chemical library, which produced inhibitors of varying chemotypes with IC<sub>50</sub> values in the 3–30 μM range.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> They clustered the hits according to chemical structure similarity and screened additional analogs which led to compound <b>31</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) which possessed <i>K</i><sub>i</sub> = 310 nM against PRC2. However, <b>31</b> showed poor solubility in initial cellular assays. To overcome this, the structure of <b>31</b> was modified initially by incorporating a morpholine group at the 4-position of the phenyl ring (<b>32</b>), resulting in a major improvement in solubility with a slight increase in potency. Replacing the pyrazolopyridine core with indazole led to a 2-fold improvement in potency (<b>33</b>). Finally, increasing the size of the lipophilic group at the 1-position from an isopropyl to a cyclopentyl group produced a significant improvement in potency and led to compound <b>8</b> (EPZ-5687). This compound inhibited H3K27 methylation without a substantial decrease in any other histone methyl marks and notably does not disrupt the protein–protein interactions among the PRC2 subunits. Finally, <b>8</b> was shown to be an equally potent inhibitor of both wild-type and Tyr641 and Ala677 mutants of EZH2.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SAR leading to <b>8</b> (EPZ-5687).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scientists at the Dana-Farber Cancer Institute designed new EZH2 inhibitors based on previously reported EZH2 scaffolds and conducted SAR empirically from iterative analog synthesis and biochemical testing.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> This approach led to <b>9</b> (JQEZ5, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), featuring a pyrazolopyridine core with a 6-substituted solubilizing feature and a preserved pyridone moiety. This compound showed good enzymatic potency of EZH2 (IC<sub>50</sub> = 11 nM) and was used to target EZH2 in human lung cancer cell lines.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure of JQEZ5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Treatment of human oncogene WT NSCLC cell line H661 with <b>9</b> resulted in acutely reduced levels of H3K27me3 without affecting H3K27me2/me1, while there was no effect on H3K27me3 levels in the nonsensitive H292 human NSCLC cell line. The proliferation of EZH2-overexpressing H661 and H522 cell lines was suppressed by <b>9</b> after treatment for 7 days, while cell lines that were deemed insensitive to EZH2 knockdown were not affected.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">Scientists at the University of North Carolina at Chapel Hill docked <b>8</b> (EPZ-5687) into an EZH2 homology model, which indicated no interaction between the morpholinomethyl moiety and EZH2.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In addition, the central amide of <b>8</b> formed hydrogen bonds with Asn688 and the pyridone moiety made two hydrogen bonds with His689 in the EZH2 SAM binding site. These observations were used as a means to design a new series of compounds with improved physiochemical properties to enhance oral bioavailability. Among the inhibitors they designed and synthesized, <b>10</b> (UNC1999, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) was also docked into the same model which showed that the secondary amide and pyridone groups maintained the key hydrogen bonds found in other compounds from this chemotype. The indazole was buried in a hydrophobic pocket, and the <i>N</i>-isopropylpiperazine group was directed out toward the solvent. This molecule also showed a 27-fold improvement in potency compared to <b>8</b> (IC<sub>50</sub> = 54 nM), inhibiting EZH2 (IC<sub>50</sub> = 2 nM) and EZH1 (IC<sub>50</sub> = 45 nM). Furthermore, <b>10</b> had a higher calculated partition coefficient (clogP) value (3.1) than <b>8</b> (2.2) and <b>3</b> (2.6), which suggested that <b>10</b> may have superior oral bioavailability compared with these other two inhibitors. In pharmacokinetics (PK) studies of <b>10</b>, the drug was administered to mice at escalating doses by intraperitoneal (IP) and oral gavage (PO) routes.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> It was found that in contrast to <b>8</b> (EPZ-5687), which has poor <i>in vivo</i> PK,<a onclick="showRef(event, 'ref66 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref69">(66,69)</a><b>10</b> is able to achieve relatively high <i>C</i><sub>max</sub>, with plasma concentrations of nearly 12 μM at the highest tested dose of 150 mg/kg. After IP administration, drugs achieved plasma concentrations above the cellular IC<sub>50</sub> for 12–24 h, depending on the dose. Importantly, <b>10</b> was also shown to be orally bioavailable. Administration of 50 mg/kg of <b>10</b> PO resulted in plasma concentrations above the cellular IC<sub>50</sub> for 20 h.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Lead optimization development of <b>10</b> (UNC1999) based on potent EZH2 inhibitor <b>8</b> (EPZ-5687).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>10</b> potently inhibited H3K27me3 in MCF7 cells in a dose-dependent manner and showed low cell toxicity. It inhibited the proliferation of DB cells, which contain a Y641N EZH2 mutation, in a concentration-dependent manner, resulting in complete cell death at 5 μM after an 8-day treatment. Furthermore, after treatment with 3 μM <b>10</b> for 3 days, H3K27me3 was significantly reduced, while no significant change in EZH2 protein levels was detected.</div><div class="NLM_p">A high-throughput biochemical screen by a group at GlaxoSmithKline led to the identification of small-molecule EZH2 inhibitor <b>34</b> (GSK-A, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) with <i>K</i><sub>i</sub><sup>app</sup> = 700 nM.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Extensive medicinal chemistry optimization of this compound produced inhibitor <b>3</b> (GSK126, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> This compound potently inhibited both WT EZH2 and Y641 mutant EZH2 similarly, with <i>K</i><sub>i</sub><sup>app</sup> = 0.5–3 nM. Compound <b>3</b> showed greater than 1000-fold selectivity for EZH2 over 20 other human methyltransferases, including both SET-domain-containing and non-SET-domain-containing methyltransferases.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Moreover, <b>3</b> effectively inhibited the proliferation of EZH2 mutant DLBCL cell lines.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of initial GSK hit compound <b>34</b> (GSK-A) and optimized EZH2 inhibitor <b>3</b> (GSK126).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mouse pharmacokinetics studies of <b>3</b> after a 50 mg/kg intraperitoneal (IP) dose showed the compound achieved high exposure in the blood, with an area under the curve (AUC) of 101 μM·h and a <i>C</i><sub>max</sub> in blood of 72 μM.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> In Pfeiffer xenograft tumors, compound <b>3</b> attained an exposure of 37 μM·h and a <i>C</i><sub>max</sub> of 3 μM. While these values far exceeded the <i>in vitro</i> EC<sub>50</sub> for <b>3</b> in EZH2 inhibition or cell proliferation assays, unbound drug levels were not reported, making it difficult to fully evaluate. Upon treatment in the Karpas422 and Pfeiffer xenograft mouse models, inhibitor <b>3</b> induced global decrease in H3K27me3 and an increase in gene expression in a dose-dependent manner. Complete tumor growth inhibition was observed after dosing at 50 mg/kg daily in both models, which was correlated with a statistically significant survival benefit of mice bearing the more aggressive Karpas422 tumors. In addition, inhibitor <b>3</b> treatment on peripheral blood of immunocompetent mice revealed no significant changes in any blood cell types.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> However, one drawback to <b>3</b> was its lack of oral bioavailability, which necessitated intravenous (IV) administration in both mouse models and subsequent clinical trials.</div><div class="NLM_p">During their extensive SAR studies on <b>34</b>, the GSK group found that the aza-group at the 7-position of the azaindole core could be removed without losing EZH2 inhibitory activity. The studies also revealed that the cyclopropyl group at the 6-position could be replaced by an amine-containing group similar to <b>3</b>. Additional diversification of this amine-containing group led to a boost in potency, resulting in compounds <b>35</b> and <b>36</b> (GSK926 and GSK343, respectively, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Both <b>35</b> (EZH2 IC<sub>50</sub> = 0.02 μM) and <b>36</b> (EZH2 IC<sub>50</sub> = 0.004 μM) were highly selective EZH2 inhibitors, with decreased potency for EZH1 (2.5 μM and 0.24 μM, respectively). Further investigations of <b>36</b> revealed a SAM-competitive mechanism for this compound. An immunofluorescent cell imaging assay revealed that incubation of HCC1806 breast cancer cells with the <b>35</b> and <b>36</b> for 72 h led to dose-dependent reductions in nuclear H3K27me3. At higher doses (>1000 nM), <b>35</b> and <b>36</b> achieved greater than 90% inhibition of global H3K27me3 in HCC1806 breast cancer cells and inhibited cell proliferation in all tested prostate and breast cancer cell lines.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Unfortunately, compound <b>36</b> exhibited high clearance in rat PK studies and therefore was not suitable for additional <i>in vivo</i> studies.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0013.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of <b>35</b> (GSK926) and <b>36</b> (GSK343).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">2.1.3.  Pyridone Phenyl</h4><div class="NLM_p">Using a high-throughput screen of their library, scientists at Epizyme obtained a large number of hits, from which compound <b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), containing a 4,6-dimethylpyridone, was identified as an inhibitor of EZH2 (IC<sub>50</sub> = 3.4 μM).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Additional similar analogs of hit compound <b>37</b> were tested for activity against EZH2, leading to identification of compound <b>38</b> as a submicromolar inhibitor of EZH2 (IC<sub>50</sub> = 0.5 μM). However, this more-potent analog exhibited poor solubility (<10 μM at pH = 7) and poor oral bioavailability (0.5% <i>F</i>). They investigated the addition of polarity to the molecule, in particular by the introduction of amine groups at the 7-position, which improved solubility without substantial loss in potency (<b>39</b>). These studies led to the identification of lead compound <b>39</b> which exhibited significantly higher solubility, oral bioavailability (41% <i>F</i>), and moderate clearance.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0014.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Initial hit compound <b>37</b> and SAR leading to inhibitor <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional SAR was performed on the core of the molecule, and the indazole showed improvement in potency relative to the pyrazolopyridine core. They then decided to disconnect the five-membered ring of the 5,6-bicyclic ring to give substituted aniline (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), which can be functionalized further to improve activity. R<sup>1</sup> substitution was shown to be important to enhance activity in the biochemical assay (<b>40</b> vs <b>41</b>). Furthermore, disubstituted anilines showed strong improvements in potency (∼16-fold) compared to a monosubstituted aniline, leading to optimized ethyl and THP groups on the aniline (compound <b>44</b>, EZH2 IC<sub>50</sub> = 0.01 μM). The combination of the benzylmorpholine tail with the THP-decorated aniline resulted in the development of compound <b>1</b> (EPZ-6438, tazemetostat, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) which showed excellent potency, low clearance, and good bioavailability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimization of Substitution on the Benzene Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0038.gif" alt="" id="gr17" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0039.gif" alt="" id="gr18" /></img><div></div></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0015.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure of <b>1</b> (tazemetostat, EPZ-6438).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An <i>in vivo</i> study in mice bearing subcutaneous (SC) G401 xenografts showed that <b>1</b> (EPZ-6438) was well tolerated at all doses tested (oral dosing at 250–500 mg/kg twice daily) with minimal effect on body weight. In addition, tumor growth and H3K27me3 level were significantly inhibited for 21–28 days.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Pharmacokinetics studies showed that even at the lowest dose of 125 mg/kg BID, after 21 days the plasma concentration was approximately 8 μM 3 h after the last dose and there was a clear relationship between dose and plasma concentration. Later, the same group found that <b>1</b> inhibited intracellular H3K27me3 in a concentration- and time-dependent manner in lymphoma cells carrying wild-type and mutant EZH2, and this inhibition selectively killed cells bearing mutant EZH2. In addition, inhibitor <b>1</b> caused dose-dependent tumor growth inhibition in multiple EZH2 mutant lymphoma xenografts. Compound <b>1</b> (EPZ-6438) is currently under investigation in multiple clinical trials for the treatment of multiple solid tumors such as lymphoma or INI1-deficient tumors (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref73 ref75'); return false;" href="javascript:void(0);" class="ref ref73 ref75">(73,75)</a></div><div class="NLM_p">Further optimization of the THP-substituent of <b>1</b> and replacement of its second benzene ring with an acetylene linker led to the formation of <b>45</b> (EPZ011989, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> This compound showed equipotent inhibition of WT and mutant EZH2 with an inhibition constant (<i>K</i><sub>i</sub>) of <3 nM. It was also 15-fold selective for EZH2 over EZH1. Compound <b>45</b> exhibited good metabolic stability and oral exposure. In rat PK studies, a 300 mg/kg PO dose of <b>45</b> provided <i>C</i><sub>max</sub> = 2.9 μg/mL and AUC = 10 000 h·ng/mL, which was predicted to be above the lowest cytotoxic concentration (LCC) for 10 h. These data led to its testing in a xenograft model. Inhibitor <b>45</b> displayed significant tumor growth inhibition when examined in EZH2 mutant Karpas422 human DLBCL xenografts, dosing orally at 250 or 500 mg/kg for 21 days, with a minimal effect (5–10% reduction) on body weight. Robust H3K27me3 reduction was detected over the 12-h time course with 7-day treatment for both doses.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0016.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure of <b>45</b> (EPZ011989<b>)</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scientists at Shanghai Hengrui Pharmaceutical designed new EZH2 inhibitors with a strategy of decreasing the complexity and molecular weight of <b>1</b>.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> They envisioned that analogs bearing 6,5-fused heteroarenes (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) such as benzofuran (compound <b>46</b>) and benzothiophene (compound <b>47</b>) would maintain similar binding interactions to the protein in the orthosteric pocket. Both compounds showed comparable potency to <b>1</b> (EPZ-6438) in the EZH2 biochemical assay with IC<sub>50</sub> values in the single-digit nanomolar range. Benzofuran <b>46</b> displayed more potent activity (IC<sub>50</sub> = 240 nM) in inhibiting the growth of Pfeffier cells compared to benzothiophene <b>47</b> (IC<sub>50</sub> = 1830 nM). On the basis of these preliminary results, they focused their SAR efforts on the benzofuran series to improve potency and bioavailability of <b>46</b>.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0017.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Initial design for the benzofuran-derived EZH2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The SAR results (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) showed that switching R<sup>3</sup> from methyl (compound <b>46</b>) to methoxy (<b>48</b>) led to similar enzymatic activity but an 11-fold improvement (IC<sub>50</sub> = 20 nM) in an assay for Pfeiffer cell proliferation inhibition. In addition, the 2-methyl substitution at R<sup>1</sup> (<b>49</b>) was preferred over the 3-methyl substitution (<b>50</b>) since the latter exhibited weaker potency with an IC<sub>50</sub> of 1.3 μM. In an attempt to reduce metabolic issues, a drug-like fragment such as morpholinyl (compounds <b>51</b> and <b>52</b>) was introduced at R<sup>1</sup> while R<sup>2</sup> was substituted with an ethyl group. Changing the R<sup>3</sup> group to methyl led to similar Pfeiffer IC<sub>50</sub> values (14 nM). Lastly, additional substituents at R<sup>3</sup> were evaluated leading to the substituted piperidinyl compound (<b>11</b>), which showed improved potency and liver microsomal stability (>0.5 h). The inhibitor <b>11</b> (EBI-2511) significantly reduced the H3K27me3 level in a dose-dependent manner in both Pfeiffer and WSU-DLCL2 cells, although WSU-DLCL2 cells were more resistant (IC<sub>50</sub> = 55 nM versus 8 nM for Pfeiffer cells). On the basis of the superior potency against Pfeiffer cell proliferation, it was also tested by oral administration in a Pfeiffer xenograft mouse model. Compound <b>11</b> displayed a dose-dependent tumor growth inhibition, with 28% (10 mg/kg), 83% (30 mg/kg), and 97% (100 mg/kg) reduction in tumor size,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> suggesting potential utility as a treatment for non-Hodgkin’s lymphoma. Plasma concentrations of <b>11</b> at the 10 mg/kg PO dose showed it attained <i>C</i><sub>max</sub> = 0.4 μM and an exposure of 1.4 μM·h, which compared favorably to the observed 6 nM EC<sub>50</sub> in the <i>in vitro</i> cell viability experiments with Pfeiffer cells.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Results Leading to the Discovery of <b>11</b> (EBI-2511)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0040.gif" alt="" id="gr22" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0041.gif" alt="" id="gr23" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The R<sup>1</sup> group is attached to the benzofuran 2-position.</p></div></div><div></div></div></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.1.4.  Pyridone 3,4-Dihydroisoquinolin-1(2<i>H</i>)-one</h4><div class="NLM_p">Scientists at Pfizer synthesized a focused library of 180 compounds based on the dimethylpyridone motif common to many potent EZH2 inhibitors.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> This library incorporated a variety of substituted heteroaromatic/phenyl/heterocyclic carboxamides, out of which compound <b>53</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) exhibited modest potency (IC<sub>50</sub> = 7.2 μM) in inhibiting WT EZH2 in a biochemical assay. Their investigations into modifying the C1 substituents suggested that the torsional angle between the phenyl group and the amide carbonyl moiety played an important role in EZH2 inhibition potency. Their SAR (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) led to focusing optimization efforts on the six-membered lactam inhibitor series (<b>55</b>) due to its improved human liver microsome (HLM) stability compared to the seven-membered lactam inhibitor (<b>54</b>).</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0018.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Initial EZH2 SAR development by Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional SAR (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) showed that switching the R<sup>1</sup> substituent from methoxy (<b>55</b>) to isopropoxy moiety (<b>56</b>) resulted in 8-fold improvement in the biochemical assay. Compound <b>56</b> displayed reasonable biochemical potency against both WT and Y641N mutant EZH2, as well as moderate HLM clearance and permeability. However, compound <b>56</b> had significantly reduced cellular potency for H3K27me3 inhibition. It was found that by replacement of the isopropoxy moiety with a chiral tetrahydrofuran (THF) group (<b>57</b>), biochemical potency was maintained and lipophilic efficiency (LipE) was reduced by about 1.5 units. In addition, they found that by incorporating a small substituent such as Cl as the R<sup>2</sup> substituent (<b>58</b>), they gained a 3- to 5-fold improvement in cellular potency compared with <b>57</b>. Finally, replacing the chiral THF moiety with a 2,5-dimethylisoxazole and maintaining the Cl substituent as R<sup>2</sup> afforded a highly potent EZH2 inhibitor (<b>59</b>, PF06726304, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) that was a potent cellular inhibitor of H3K27me3 and had strong antiproliferative effects on Karpas422 cells.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Investigation of the R<sup>1</sup> and R<sup>2</sup> Substituents<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0042.gif" alt="" id="gr25" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0043.gif" alt="" id="gr26" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Asterisks (∗) indicate the <i>K</i><sub>i</sub> value. IC<sub>50</sub> values for <b>37</b> could not be accurately determined under assay conditions because of the high potency of the compound.</p></div></div><div></div></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0019.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of EZH2 inhibitors developed at Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It was found that treatment with <b>59</b> resulted in decreased H3K27me3 and upregulated EZH2 target genes (TNFRSF21 and PRDM1) in Karpas422 cells containing both wild-type and Y641N mutant EZH2 proteins. Pharmacokinetic studies of <b>59</b> showed that a dose of 300 mg/kg was required to achieve a plasma free drug concentration above the <i>in vitro</i> IC<sub>90</sub> for at least 6 h. At the 6 h time point, free drug of <b>59</b> in the plasma was approximately 1 μM. Compound <b>59</b> also displayed robust <i>in vivo</i> antitumor growth activity, with tumor stasis and regression after 20 days’ treatment at 200 and 300 mg/kg dose levels, respectively. In addition, approximately 55.5% and 66.4% reduction of the H3K27me3 was induced by compound <b>59</b> at the two testing dosages, respectively. Moreover, tumor growth inhibition was sustained for at least another 3 weeks after the last dose, suggesting its ability to mediate long-term epigenetic reprogramming in cells.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> It is worth noting that the doses used in the tumor study with <b>59</b> were significantly higher than those used with <b>1</b> (EPZ-6438<b>)</b> to achieve antitumor efficacy, indicating significant differences between the two drugs in terms of their PK/PD relationships.</div><div class="NLM_p">However, compound <b>59</b> also exhibited unfavorable metabolic stability in human liver microsome (HLM)/hepatocyte clearance assays and had poor thermodynamic solubility (2 μg/mL).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Pfizer carried out a more comprehensive SAR study around the R-substituent and found that introduction of the oxetane-methoxy group as a replacement for the dimethyl-substituted isoxazole group reduced lipophilicity, which resulted in improved <i>in vitro</i> HLM clearance. At the same time, this substitution increased the molecule’s sp<sup>3</sup> character, which gave better intrinsic solubility. The most potent enantiomer (<b>5</b>, PF068721497, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) exhibited superior biochemical and cell-based EZH2 inhibition activities compared to <b>59</b>. They were able to crystallize their lead compound (<b>5</b>) bound to EZH2 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). This confirmed that the 4-methoxypyridone substituent of <b>5</b> formed favorable hydrogen bond interactions with the backbone carbonyl and amide NH moieties of Trp624 in the EZH2 binding pocket relative to the corresponding 4-methylpyridone group of <b>59</b>, explaining the subtle potency improvements. To assess the pharmacokinetics of <b>5</b>, it was dosed at 300 mg/kg BID-PO, which showed a free drug concentration in the plasma that exceeded its <i>in vitro</i> cell viability IC<sub>90</sub> against Karpas422 cells for 24 h. Subcutaneous (SC) dosing of <b>5</b> resulted in significantly higher plasma free drug concentrations than PO dosing, along with concentrations greater than the Karpas422 IC<sub>90</sub> for longer than 24 h. Compound <b>5</b> was tested in a xenograft model where it exhibited robust tumor growth inhibition at 100 mg/kg or tumor regression at 300 mg/kg in mice bearing Karpas422 DLBCL tumor xenografts (Y641N EZH2 mutation) with twice-daily oral administration and no significant body weight loss. In addition, once-daily SC dosing of compound <b>5</b> at 100 mg/kg induced profound tumor regression, which was also sustained for another 40 days after the termination of 31 days of treatment.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The increased efficacy by SC dosing, as compared with PO administration, was likely due to the greater and more sustained plasma concentrations of the drug, which in turn were likely influenced by the decreased first-pass metabolism by SC administration.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0020.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Cocrystal structure of <b>5</b> (PF06821497) in complex with EZH2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R">4W2R</a>). Hydrogen bonds are shown in dotted yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">2.1.5.  Tetramethylpiperidinyl Benzamides</h4><div class="NLM_p">Scientists at Constellation Pharmaceuticals originally screened a total of 150 000 compounds from their unbiased compound collection, followed by a biochemical assay hit triage that led to the identification of 288 hits.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Those hits were further assessed using multiple criteria and subsequently screened in additional enzymatic assays, which allowed them to check for nonideal behavior and a preliminary classification of compounds based on potential mechanism of inhibition (MOI). This led to compound <b>60</b> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>), with modest potency of 51 μM against WT EZH2 and a LipE of 3.5. Compound <b>60</b> displayed good Hill coefficient (coefficients of 0.7–1.5 were considered) and shifted only with an increase in SAM, suggesting a SAM-competitive mechanism of inhibition. Their initial SAR involved replacement of the O-linker of the bis-phenylether with thio, ketone, sulfone, sulfoxide, and methylene linkages which mostly resulted in loss of EZH2 affinity. Keeping the diphenylether moiety, they evaluated the right-hand aryl ring and found that incorporation of a 2-cyano substituent (<b>61</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) led to a 15-fold increase in potency, suggesting the cyano nitrogen was making favorable interaction with the binding site in EZH2.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0021.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Initial SAR development of non-pyridone containing EZH2 inhibitor series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional SAR showed that monosubstitution adjacent to the ether linkage led to 3- to 6-fold improvement in potency over compound <b>61</b>, with Cl substitution (<b>62</b>) increasing potency 6-fold (0.45 μM) and efficiency (LipE = 5.1). Finally, in an attempt to further improve the biochemical potency of these tetramethylpiperidinyl-class inhibitors, they found that introduction of a six-membered heterocycle (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) enabled sub-100 nM potency against WT EZH2. Modifying the nitrogen aryl substitution from 4-pyridyl (<b>64</b>) to pyridazine (<b>65</b>) and then to pyrimidine (<b>17</b>) led to improvement in both affinity and lipophilic efficiency, resulting in compound <b>17</b> as a lead compound suitable for testing in a xenograft model.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Modifications of the Right-Hand Aryl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0044.gif" alt="" id="gr30" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0045.gif" alt="" id="gr31" /></img><div></div></div><div class="NLM_p last">Pyrimidine <b>17</b> decreased global H3K27me3 in Karpas422 lymphoma cells,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and bulk H3K27me3/me2 levels in a dose-dependent manner, without affecting the levels for H3K27me1 and other tested histone trimethylation markers. This compound decreased the viability of a mutant EZH2-containing GCB-DLBCL cell line. However, compound <b>17</b> did not inhibit cell viability of WT EZH2-containing OCI-LY19 GCB-DLBCL or PC3 prostate cancer cells in a dose- and time-dependent manner.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div></div><div id="sec2_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">2.1.6.  Miscellaneous Compounds</h4><div class="NLM_p">Scientists at Pfizer developed a biochemical assay to test isolated oligonucleosomes as substrates to inhibit EZH2-mediated methylation.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> They used a homology model containing cofactor product <i>S</i>-adenosyl homocysteine (SAH) to initiate SAR exploration. From the key interactions with the amino and carboxylic acid groups present in SAH observed, several amide-containing compounds were synthesized. These data revealed that secondary amides bridged by a methylene linker gained potency that was still far lower than SAH. They further explored SAR on compound <b>66</b> (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) based on space predicted to be available according to their modeling.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0022.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. SAR exploration of oligonucleosomes as EZH2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The investigation of N-substituted pyrazoles led to the 4-fluorophenyl moiety (<b>67</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) which showed a 30-fold improvement in potency (IC<sub>50</sub> = 1.4 μM) compared to <b>66</b> and about a 10-fold improvement compared with SAH. Replacing the 4-fluorophenyl group with a phenyl group (<b>68</b>) led to a further improvement in potency compared to both <b>67</b> and SAH. This potent SAH-derived inhibitor of the EZH2 PRC2 complex (compound <b>68</b>) displayed IC<sub>50</sub> values against WT PRC2 (0.27 μM) and Y641N mutant PRC2 (0.07 μM). The compound also had improved lipophilic efficiency and selectivity against other lysine methyltransferases compared to SAH.</div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.2.  EED Inhibitors: Chemical Approach and Biological Activity</h3><div class="NLM_p">The methyltransferase activity of PRC2 is due to the enzymatic function of the SET domain of EZH2. To promote the mono-, di-, and trimethylation of H3K27, existing H3K27 trimethyllysine residues interact with EED to stimulate EZH2 catalytic activity and thereby increase the H3K27me3 histone mark. Besides catalytic inhibitors of EZH2, another strategy that has been explored to inhibit PRC2 activity has been small molecule inhibitors of the EED-H3K27me3 interaction. Inhibiting this protein–protein interaction (PPI) would be expected to prevent activation of EZH2 activity by EED-H3K27me3 binding. A potential advantage of this approach is the possibility of increased selectivity in inhibiting EZH2 due to the specific nature of the EED-H3K27me3 interaction, whereas other SET-domain-containing enzymes may be targeted by nonselective enzymatic EZH2 inhibitors.</div><div class="NLM_p">Scientists at AbbVie recently described their success in identifying and optimizing a small molecule that inhibits the EED interaction with H3K27me3.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> By use of a thermal-shift-based HTS, moderately potent hit compound <b>69</b> was identified with <i>K</i><sub>i</sub> = 0.6 μM in a TR-FRET assay (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). Initial SAR focused on modifying the benzyl group attached to the pyrrolidine ring nitrogen. A variety of benzyl group substituents were tolerated, with the electron-withdrawing substituents providing enhanced binding (<b>70</b>, 330 nM). It was also found that alkyl groups ortho to the benzylamine further improved binding (<b>71</b>, 12 nM), with cyclization to give the indane affording highly potent EED ligands (<b>72</b>, 11 nM). After confirmation that the indane was the preferred N-substituent, optimization of the pyrrolidine 3-position was pursued. Here it was determined that extended bicyclic groups such as phenylpiperazine (<b>73</b>) gave the best results in the TR-FRET binding assay. Structure–activity data from further medicinal chemistry optimization also showed that significant modifications to either the pyrrolidine ring or dimethylamino group led to decreased potency which, coupled with structural biology work, suggested this portion of the molecule occupies the same position as the H3K27 lysine residue. Finally, extensive optimization of the piperazine ring was carried out in which a terminal sulfonamide (<b>74</b>, A-395) was found to afford the most potent EED inhibitor (0.31 nM). Notably, it was revealed that the indane amino 2-position epimerized to give a mixture of diastereomers that could not be readily separated and isolated. Therefore, this mixture was used in subsequent biological studies. The derivative of <b>74</b> in which the fluoroindane was replaced by a benzyl group (<b>75</b>, A-395N) was synthesized as a negative control compound.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0023.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. SAR optimization leading to A-395.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Extensive biophysical evaluation confirmed the characterization of <b>74</b> (A-395) as an EED-binding ligand that disrupts interaction with H3K27. Surface plasmon resonance (SPR) experiments gave <i>K</i><sub>D</sub> = 1.5 nM of <b>74</b> against EED, and fluorescence thermal shift showed a clear shift in EED melting temperature in the presence of <b>74</b>, in contrast to the negative control <b>75</b> which did not affect the EED melting temperature. X-ray crystallization of <b>74</b> bound to EED (ΔEED, residues 77–441) showed a number of notable features (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). Most interestingly, binding of <b>74</b> induced significant conformational changes of the H3K27me3-binding pocket of EED to accommodate ligand binding. The pocket formed by EED residues W364, Y365, and R367 which is normally occupied by the trimethylamine group of H3K27 is remodeled to form a new, larger hydrophobic pocket that accommodates the inhibitor. A new enclosure composed of several aromatic side chains forms a new binding pocket for the <b>74</b> central pyrrolidine core.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0024.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Cocrystal structure of <b>74</b> (A-395) in complex with EED (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JZG">3JZG</a>). Dashed yellow lines indicate hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>74</b> was shown to be highly selective for inhibition of H3K27me3 (and H3K27me2, albeit slightly less potently) over a panel of other histones, including several degrees of H3K4, H3K9, H3K36, and H4K20 methylation without affecting total PRC2 protein levels. Screening <b>74</b> for antiproliferative activity against a panel of cell lines showed potent ability to inhibit cell growth, with Pfeiffer cells being particularly sensitive (10-day IC<sub>50</sub> = 69 nM). Comparing the effects of EED inhibitor <b>74</b> to EZH2 catalytic inhibitors <b>3</b> (GSK126)<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and <b>1</b> (EPZ-6438)<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> allowed Abbvie scientists to conclude that EED inhibitor <b>74</b> (A-395) phenocopies the effects of catalytic EZH2 inhibitors.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">Pharmacokinetics studies of <b>74</b> (A-395) showed that subcutaneous (SC) dosing of a relatively high dose of the drug (300 mg/kg) was necessary to achieve suitable target inhibition for subsequent tumor studies. A dose of 300 mg/kg SC was able to achieve free drug concentrations in the plasma greater than the EC<sub>90</sub> for at least 48 h. On the basis of these data, dosing <b>74</b> twice per week SC at 300 mg/kg in a Pfeiffer xenograft model led to robust antitumor activity (84% TGI), which was stronger than dosing EZH2 catalytic inhibitor <b>3</b> (GSK126) at 50 mg/kg IP once-daily for 36 days, which showed a 62% TGI, or the negative control <b>75</b> (which showed no activity). Pharmacodynamics studies indicated H3K27me3 levels were also significantly reduced in Pfeiffer tumors after <b>74</b> treatment. Importantly, while EZH2 catalytic inhibitors such as <b>3</b> can become ineffective due to single point mutations,<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> treatment with <b>74</b> led to no similar resistance development, suggesting EED inhibitors such as <b>74</b> may provide a more durable response.</div><div class="NLM_p">Concurrent with the Abbvie publication of their discovery of <b>74</b> (A-395), a group at Novartis reported the identification and characterization of another EED inhibitor, <b>76</b> (EED226, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The Novartis approach carried out a high-throughput screen for compounds that inhibited the ability of PRC2 to methylate a H3K27me0 substrate. This functional HTS led to a number of hits with different mechanisms of action. When they looked at the compounds that inhibited enzymatic activity in a SAM noncompetitive manner, one was characterized as binding to EED in a way that prevented H3K27me3 interaction. It is interesting to note that the Abbvie approach<a onclick="showRef(event, 'ref83 ref88'); return false;" href="javascript:void(0);" class="ref ref83 ref88">(83,88)</a> and the present Novartis approach both ended up with molecules that inhibited EED-H3K27me3 binding but did so based on different HTS approaches. Specifically, the Abbvie group looked for direct binders of purified EED and followed up on those that inhibited H3K27me3 formation. Conversely, Novartis used the entire PRC2 complex and measured inhibition of H3K37 methylation as a readout, which was followed by detailed mechanism of action studies to identify compounds that acted by an EED-H3K27me3 PPI mechanism.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0025.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures of EED inhibitors EED226, BR-001, and MAK683.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent medicinal chemistry optimization of one of the Novartis SAM-noncompetitive hits led to the creation of potent EED inhibitor <b>76</b>,<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> which has IC<sub>50</sub> = 23.4 nM. It was found that <b>76</b> binds to the H3K27me3 binding pocket of EED (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>) and specifically inhibits H3K27 methylation in both WT EZH2 (G401) cells and mutant EZH2 (Karpas422) cells. Interestingly, synthesis of the biotinylated version of <b>76</b> allowed them to perform pull-down studies which showed that only PRC2 members EED, EZH2, SUZ12, and the PRC2-recruitng protein MTF2 were pulled down in Karpas422 lysate. Gene expression microarray and ChIP-PCR studies showed significant increase in PRC2-regulated gene expression upon treatment with <b>76</b>. Moreover, similar gene expression changes were seen when using either the EED inhibitor <b>76</b> or the EZH2 catalytic inhibitor <b>7</b> (EI1), a result that is consistent with the work by Abbvie with their EED inhibitor <b>74</b> (A-395).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0026.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (Left) X-ray crystal structure of <b>76</b> (EED226) bound to EED. Important ligand–protein and ligand–water interactions are shown with a yellow dotted line. (Right) Position of <b>76</b> binding to EED relative to the overall protein, indicating the location of the terminal sulfone group which points out toward solvent (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GSA">5GSA</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequently, <i>in vivo</i> studies showed that orally administered <b>76</b> induced a dose-dependent decrease in global H3K27me3 and proportionally upregulated PRC2 target genes in a Karpas422 mouse xenograft model with 21 days’ treatment. In addition, neither body-weight loss nor obvious adverse effects were observed. Moreover, complete tumor regression was induced at a dose of 40 mg/kg, and tumor growth was also inhibited and reached stasis with a 4 mg/kg dose for 32 days. Bioanalysis of plasma from the efficacy study showed <b>76</b> achieved a concentration of >30 μM after a single PO dose of 40 mg/kg. Interestingly, although <b>76</b> has not progressed into clinical trials, Novartis has developed another EED inhibitor based on this scaffold, <b>77</b> (MAK683, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>). While <b>77</b> has not been described in detail in the literature, it is currently being studied in clinical trials for treating lymphoma.</div><div class="NLM_p">Scientists at Shanghai Blueray Biopharma employed a different strategy in their development of an EED inhibitor.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Using the known EED inhibitor <b>76</b><a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> as a template, they carried out a scaffold-hopping approach to identify new core replacements. Subsequent lead optimization resulted in the identification of <b>78</b> as a novel and potent EED inhibitor (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> This compound was shown to bind to EED by fluorescence thermal shift and competitively displaced H3K27me3 from EED with a potency of 4.5 nM. The competitive displacement of H3K27me3, along with X-ray crystal structure data, confirmed that the molecule binds to EED in the H3K27me3-binding site.</div><div class="NLM_p">On the basis of a recent study showing a correlation between MLL and H3K27ac in EZH2 inhibitor resistance,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> the authors tested <b>78</b> against a panel of cell lines that contained varying levels of MLL expression. Differing levels of sensitivity to <b>78</b> were observed in the various cell lines. On the basis of measurements of both MLL and H3K27ac in these lines, the authors concluded that H3K27ac was primarily responsible for resistance (i.e., high levels of H3K27ac led to <b>78</b> resistance).</div><div class="NLM_p">In Karpas422 and Pfeiffer xenograft models, twice-daily oral dosing of <b>78</b> for 36 days at 40 or 100 mg/kg induced tumor inhibition with 85% and 96% TGI, respectively. Compound <b>78</b> treatment in these models caused substantial decrease of H3K27me3 in a dose-dependent manner and upregulated PRC2 target genes. Moreover, <b>78</b> was also efficacious in suppressing syngeneic CT26 colon tumor. Administration of <b>78</b> by oral dosing of 30 mg/kg resulted in 59% tumor growth suppression and increased frequency of effector CD8<sup>+</sup> T-cell infiltrates in tumors.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p">Scientists at the University of Michigan recently described a new series of EED inhibitors based on the cocrystal structure of <b>76</b> (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The key interactions between <b>76</b> and the EED protein (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) provided a foundation for structure-guided design and optimization of the new series starting with compound <b>79</b>.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The addition of an electron withdrawing group (ester group) on the imidazo[1,5-<i>c</i>]pyrimidine core of <b>79</b> led to a 2-fold improvement in the binding affinity of compound <b>80</b> to EED as well as inhibition of cell growth in Karpas422 cells, resulting in compound <b>80</b> as the lead compound for SAR optimization.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0027.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Initial structure-guided design from EED226 to inhibitor <b>80</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial work studied the replacement of the metabolically liable furan group with other aromatic rings (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Replacing the furan group with a phenyl group led to a major decrease in both the EED-H3K27me3 peptide competition binding assay and cell growth inhibition assay. However, addition of a fluorine group at C6 in the 2-methoxyphenyl ring (<b>81</b>) led to slight improvement in binding (IC<sub>50</sub> = 50 nM) and a 3-fold increase in cell growth inhibition potency in Karpas422 cells (IC<sub>50</sub> = 300 nM) compared to compound <b>80</b>. Further exploration of the deep binding pocket led to replacing the phenyl ring in compound <b>81</b> with a benzo[<i>d</i>][1,3]dioxole moiety (<b>82</b>), which resulted in an increase in binding to EED (IC<sub>50</sub> = 40 nM) and similar cell growth inhibitory activity. Compound <b>84</b> showed the preferred position of oxygen leading to a 7-fold increase in potency compared with <b>83</b> in binding to EED, and 30-fold greater potency than <b>83</b> in cell growth inhibition in Karpas422 cells. Finally, introduction of a 6-fluoro substituent on the phenyl ring (<b>85</b>) led to improvement in potency in both binding to EED and cell growth inhibition. A similar 5-fluoro-2,3-dihydroenzofuran moiety was also used by Novartis for their EED inhibitor <b>77</b> (MAK683) and turned out to be the best replacement for the metabolically labile furan ring in this study.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR to Replace the Metabolically Labile Furan Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0046.gif" alt="" id="gr38" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0047.gif" alt="" id="gr39" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Cell growth inhibition in Karpas422 cells.</p></div></div><div></div></div><div class="NLM_p">Compound <b>85</b> was further optimized by studying additional modifications of the ethyl ester electron withdrawing group leading to a methylsulfone moiety (<b>86</b>) with subnanomolar potency in binding to EED, IC<sub>50</sub> = 0.7 nM (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). Further modifications on the tail part of the inhibitors, involving replacing the phenyl ring with 3-pyridine, were carried out to improve their solubility. In addition, they investigated different substituents at the 4-position of 3-pyridine and also nonaromatic replacements of the phenyl ring, leading to the identification of the 4-cyclopropyl-3-pyridine moiety (<b>87</b>, EEDi-5285) as the optimal group resulting in 3- to 4-fold improvement in potency in both binding to EED and inhibition of Karpas422 cell growth.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0028.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. SAR modifications of the core and tail leading to <b>87</b> (EEDi-5285).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacokinetic studies revealed that <b>87</b> (EEDi-5285) has an excellent PK profile in mice, with <i>C</i><sub>max</sub> = 1.8 μM, AUC = 6.0 h·μg/mL after 10 mg/kg oral administration, and an oral bioavailability (<i>F</i>) of 75%. In Karpas422 xenograft models, daily treatment with PO administration of <b>87</b> at 50 and 100 mg/kg doses for 28 days resulted in complete tumor regression. No regrowth of the tumors was observed after treatment had been stopped for 72 h. Lastly, a single oral dose of 100 mg/kg of <b>87</b> effectively decreased the H3K27me3 level at 24 h.</div><div class="NLM_p">A group at Novartis recently published work on the identification and characterization of EED binders that inhibit interaction with H3K27me3.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> While one of these hit series led to the development of compound <b>76</b><a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> and related analogs, another hit was pursued that acted according to a different mechanism. After performing a screen for biochemical inhibitors of PRC2 activity, inhibitor <b>88</b> was interestingly found to be noncompetitive with SAM and H3K27me0 (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). On the basis of these data and X-ray structural analysis (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>), the inhibitor was found to bind in the H3K27me3-binding site on EED. The molecule was deconstructed because of its relatively inefficient inhibition (2.6 μM IC<sub>50</sub> with a molecular weight of 352) to define an active fragment that retained significant inhibition (<b>89</b>). Extensive medicinal chemistry optimization was undertaken to improve the inhibitor’s potency and physiochemical properties (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). Elaboration of the amine group into various arginine-like motifs found that the 2-aminoimidazole group provided improved potency compared to the secondary amine while also lowering the compounds’ p<i>K</i><sub>a</sub> and concurrently increasing its cell permeability (<b>90</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). Incorporation of the guanidine moiety as a 2-aminoimidazole fragment (<b>91</b>) further improved the inhibitor’s properties. Further optimization of this core structure found that the small alkyl isopropyl group (<b>92</b>) and the 2-fluoro-5-methoxybenzyl group afforded compound <b>93</b> which has an IC<sub>50</sub> of 0.43 μM in the biochemical assay and 2.9 μM in the cellular G-401 assay. Finally, evaluation of this compound for its effect on cell proliferation showed that it inhibited Pfeiffer cell proliferation with EC<sub>50</sub> = 4.4 μM after 6 days’ treatment.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0029.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Medicinal chemistry strategy for the development of the Novartis EED inhibitor <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0030.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. X-ray crystal structure of <b>93</b> bound to EED (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U5H">5U5H</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A group at the University of North Carolina at Chapel Hill has recently described an alternative approach for targeting EED.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> On the basis of the structure of the EED-binding peptide derived from trimethylated jumonji, AT-rich interactive domain 2 (Jarid2),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> a minimally effective 5-amino acid peptide (<b>94</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>), was identified that bound to the same region as H3K27me3 and inhibited PRC2 function. Combinatorial peptide library synthesis using the split-and-pool approach, followed by lead optimization, resulted in the identification of compounds <b>95</b> (UNC5114) and <b>96</b> (UNC5115). These two compounds displayed low single-digit micromolar potency in a fluorescence polarization (FP) ligand displacement assay and submicromolar binding affinity by ITC. These compounds were shown to inhibit PRC2 enzymatic methyltransferase activity with potency between 2 and 4 μM. On-target activity was further confirmed by synthesizing a biotinylated derivative of <b>95</b> and performing pull-down studies on PC3 cell lysate, which showed that the peptide inhibitor pulled down all three PRC2 components, EZH2, EED, and SUZ12.</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0031.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures of peptides derived from Jarid<sub>114–118</sub> that act as allosteric inhibitors or activators of PRC2 activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In follow-up work, the same group used these peptidic EED inhibitors as a basis upon which to create molecules that activate (instead of inhibit) PRC2.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Several EED mutations (including I363M) result in a loss of function for PRC2, which has been implicated in various types of hematological malignancies,<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> so activators of PRC2 may have therapeutic utility in these diseases. Molecular dynamics (MD) simulations were used to study the binding interactions between Jarid2 and PRC2 components, including both wild-type and I363M EED. On the basis of differences observed with I363M loss-of-function mutant EED, several new peptide analogs were designed. The group found that two of the compounds, <b>97</b> (UNC5635) and <b>98</b> (UNC5636), caused an increase in PRC2 activity selectively in the I363M EED complex. These data demonstrated the first compounds known to act as allosteric activators of PRC2.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.3.  EED–EZH2 Protein–Protein Inhibitors. Chemical Approaches and Biological Activity</h3><div class="NLM_p">Another strategy for inhibiting PRC2 activity has been the use of small molecules to block the EED–EZH2 interaction, thereby disrupting the PRC2 complex. A recent report demonstrated that the FDA-approved drug <b>99</b> (astemizole, <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>) could block the EED–EZH2 interaction and lead to PRC2 destabilization and subsequent degradation.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> By performing an <i>in silico</i> screen of FDA-approved drugs against a hot-spot on EED where it bound EZH2, <b>99</b> was identified as a potential hit and subsequently found to inhibit EED–EZH2 interaction by fluorescence polarization (FP) assay. Binding was also confirmed by fluorescence thermal shift as well as STD-NMR, in which increasing concentrations of EZH2 peptide were used to show that the molecule bound to EED in an EZH2-competitive manner. Interestingly, it was also found that as <b>99</b> disrupted the PRC2 complex, this led to the dose-dependent degradation of all PRC2 core components, EZH2, EED, and SUZ12 in both WT EZH2 (Toledo) and mutant EZH2 (DB) DLBCL cells. Inhibition of the EED–EZH2 interaction and PRC2 degradation led to a decrease in H3K27me3 which was found to be selective versus a panel of other histone positions. Compound <b>99</b> was found to inhibit cell viability of a panel of GCB-DLBCL cell lines with EC<sub>50</sub> values in the single-digit micromolar range. Finally, knockdown of EED or EZH2 using shRNA led to dramatically decreased sensitivity of cell viability to compound <b>99</b> treatment.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0032.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures of EZH2-EED inhibitor <b>99</b> (astemizole), EED inhibitor <b>100</b> (wedelolactone), and covalent PRC2 inhibitors <b>101</b> (gambogenic acid) and derivative <b>102</b> (GNA002).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The natural compound <b>100</b> (wedelolactone, <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>) binds to EED with moderate affinity (<i>K</i><sub>D</sub> = 2.8 μM) and disrupts the EZH2–EED interaction, promoting the degradation of PRC2 core components.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Also, <b>100</b> modulates PRC2 target genes and tumor-related genes expression in PRC2-dependent cancer cells, including human hepatocellular carcinoma cell lines HepG2, human monocytic leukemia cells THP1, and human myeloid leukemia cell lines K562. Moreover, <b>100</b> inhibited cell proliferation, induced apoptosis and cell cycle arrest, and suppressed cell migration in these cell lines at a relatively high concentration of 50 μM.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">2.4.  EZH2 Covalent Inhibitors</h3><div class="NLM_p last">Covalent inhibitors have continued to gain attention as a novel strategy for inhibiting target protein.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Wang et al. identified <b>101</b> (gambogenic acid) and a derivative (<b>102</b>, GNA002, <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>) as novel EZH2 inhibitors which specifically and covalently bound to Cys668 within the EZH2-SET domain, promoting its degradation through the COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a><b>102</b> significantly inhibited H3K27me3 and dissociated the functional PRC2 complex and upregulated PRC2-suppressed target genes. Anticancer growth effect of <b>102</b><i>in vivo</i> was examined by a Cal-27 xenograft mouse model. Treatment with <b>102</b> significantly decreased the size and weight of tumors following oral administration of 100 mg/kg without observed body weight loss. In addition, <b>102</b> efficiently decreased EZH2 protein levels in both WT EZH2 (Daudi) and mutant EZH2 (Pfeiffer) cell lines while not affecting EZH2 levels in mutant EZH2-C668S cells.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.5.  EZH2 Degraders: Chemical Approach and Biological Activity</h3><div class="NLM_p">Recently, a report by Jin and co-workers described the first targeted degraders of EZH2 (<b>103</b>, MS1943, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> It is interesting to note that based on their data, solely inhibiting EZH2 without decreasing protein level was insufficient at reducing breast cancer cell proliferation.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Therefore, they reasoned that degrading EZH2 would be a more effective approach. Molecular modeling of previously described potent and selective EZH2 inhibitor <b>105</b><a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> (C24, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>) indicated that the terminal piperazine ring was solvent-exposed and therefore presented an opportunity for attaching degron motifs. The group synthesized a series of molecules wherein the piperazine was attached through a linker to different hydrophobic tags. Although no SAR was shown, the group identified compound <b>103</b> (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>) as a promising EZH2 degrader that was further characterized.</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0033.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of EZH2 hydrophobic tag degrader <b>103</b> (MS1943), EZH2 catalytic inhibitor <b>105</b> (C24), and hydrophobic tag moiety <b>104</b> (AM41-44A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the important considerations in the decision to use <b>105</b> as the EZH2-binding ligand was its potency and selectivity for EZH2 inhibition. In an enzymatic assay of EZH2 catalytic activity, <b>103</b> retained potent inhibition of EZH2, with IC<sub>50</sub> = 120 nM, as compared to parent inhibitor <b>105</b>’s IC<sub>50</sub> = 12 nM.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The hydrophobic tag compound <b>103</b> retained good selectivity as it did not inhibit EZH1, a panel of 45 kinases, or a selection of 43 of 45 GPCR, ion channel, and transporter targets. By use of triple-negative breast cancer (TNBC) cell line MDA-MB-468 for screening, <b>103</b> was shown to decrease the amount of EZH2, while neither the parent catalytic inhibitor (<b>105</b>, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>) nor the adamantyl hydrophobic tag moiety alone (<b>104</b>, AM41-44A, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>) was able to reduce EZH2 protein levels. This effect was concentration- and time-dependent as significant degradation was only observed after 2 days of treatment and with single-digit micromolar concentrations. While <b>103</b> is less effective than <b>105</b> at suppressing the H3K27me3 mark, <b>103</b> was also able to induce degradation of PRC2 component, SUZ12. Interestingly, neither EZH2 catalytic inhibitor <b>105</b> nor hydrophobic tag-based degrader <b>103</b> caused the degradation of PRC2 component EED. In control experiments, the hydrophobic tag moiety <b>104</b> was unable to cause degradation of EZH2 or other PRC2 components by itself. By use of MDA-MB-468 cells treated with <b>103</b>, addition of the proteasome inhibitor MG132 was able to rescue EZH2 degradation, indicating a role for proteasomal degradation in the process.</div><div class="NLM_p last">These EZH2 degradation experiments were expanded to a variety of other cell lines which showed EZH2 degradation by <b>103</b> (but not by <b>105</b>) in breast cancer cell lines BT549, HCC70, MDA-MB-231, and MCF7, lymphoma cell lines Karpas422 and SUDHL8, and nonmalignant prostate cancer cell line PNT2. Interestingly, in at least one case (BT549 cells), SUZ12 was degraded in addition to EZH2, suggesting different PRC2 components have varying stability in different cell lines. Having established <b>103</b> as an EZH2 degrader, its effects at inhibiting cell proliferation were studied. When tested against a panel of breast cancer and other cell line types, <b>103</b> inhibited their proliferation with GI<sub>50</sub> values typically in the low single-digit micromolar range, whereas parent catalytic inhibitor <b>105</b> was far less potent in all cell lines except Karpas422, in which both compounds were equipotent. Some of the tested cell lines were resistant to the effects of both <b>103</b> and <b>105</b>. Pharmacokinetics studies of <b>103</b> showed that IP administration of 50 mg/kg provided a plasma concentration of >1 μM. Once-daily administration of <b>103</b> for 7 days also showed that drug levels in both plasma and MDA-MB-468 tumors were above the GI<sub>50</sub>. After confirmation that <b>103</b> was bioavailable using both IP and PO administration, the degrader was tested for antitumor efficacy in the MDA-MB-468 tumor model. With daily administration of 150 mg/kg of <b>103</b>, tumor growth was completely suppressed in this model. Pharmacodynamics studies confirmed on-target activity of <b>103</b>, with treated tumors showing decreased numbers of EZH2 and H3K27me3 positive cells and increased apoptosis as indicated by decreased Ki67 and increased cleaved caspase-3. Finally, to better understand the mechanism by which <b>103</b> induced apoptosis, <b>103</b>-sensitive MDA-MB-468 cells and <b>103</b>-insensitive MDA-MB-231 cells were treated with the compound and RNA-seq studies were performed. On the basis of the analysis of pathways differentially activated and ER stress-related gene transcripts in the two cell lines, it was found that <b>103</b> induced apoptosis, at least in part, by causing ER stress and aberrantly activating the unfolded protein response (UPR) pathway.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">2.6.  EED Degraders: Chemical Approach and Biological Activity</h3><div class="NLM_p">Recently, scientists at AstraZeneca described the first proteolysis targeting chimeras (PROTACs) that targeted EED for degradation.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Stability and methyltransferase activity of PRC2 require the binding of EED to EZH2 and SUZ12, and studies have shown that disruption of this complex leads to loss of competent PRC2 and its H3K27 methylation activity. With this in mind, design of PROTACs that target EED for degradation would be expected to lead to loss of PRC2 and its activity.</div><div class="NLM_p">Beginning with insights gained from the recent report of EED inhibitors (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>),<a onclick="showRef(event, 'ref87 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref89">(87,89)</a> the group identified a vector from which a solvent-exposed linker could be attached. PROTACs were made by incorporating a variety of linkers to a von Hippel–Lindau (VHL) ligand. No SAR was provided, but this work resulted in the synthesis of active degraders <b>106</b> (PROTAC 1) and <b>107</b> (PROTAC 2, <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>) that contained alkyl and phenyl ether linkers, respectively.</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0034.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Chemical structures of EED PROTACs based on EED inhibitor <b>76</b> (EED226).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds were thoroughly characterized in a series of experiments to confirm their binding to EED and proteasome-mediated degradation. Notably, incorporation of the PROTAC linker and E3 ligase-binding moiety had relatively little effect on the binding of the bifunctional molecule to EED and of its methyltransferase inhibitory activity. Binding of the PROTACs to EED, as measured by surface plasmon resonance (SPR), gave <i>K</i><sub>D</sub> < 1 nM and was within 10× of the parent EED inhibitor (<b>108</b>). By use of a TR-FRET assay to measure the formation of the EED-PROTAC-VHL ternary complex, maximum complex formation was observed at around 10 nM, with lower TR-FRET ratios above and below this concentration, suggestive of a commonly seen PROTAC Hook effect.</div><div class="NLM_p">Using Karpas422 cells, the PROTACs were shown to induce increasing EED degradation over time, with maximum degradation seen at 48 h. Importantly, in addition to degrading EED, the compounds were also found to cause degradation of EZH2 and SUZ12. On the basis of kinetics experiments, EED is degraded first, followed by EZH2 and then SUZ12. Degradation of these proteins led to loss in the H3K27 trimethylation mark. To confirm the mechanism of action for the EED degraders, Karpas422 cells were co-treated with PROTACs and either the proteasome inhibitor MG132 or the neddylation inhibitor MLN4924 (which inhibits E1 ubiquitin ligase activity). In each case, addition of the agent to suppress the ubiquitin proteasome system (UPS) blocked degradation by the PROTAC, indicating the compounds act by engaging the UPS for PRC2 protein degradation.</div><div class="NLM_p">The ability of PROTACs to selectively degrade their protein targets is a characteristic thought to derive from the spatial requirement for the E3 ligase, bifunctional molecule, and target protein to form a particular ternary complex structure that is necessary to induce the transfer of a ubiquitin molecule onto the target protein. While some bifunctional molecules may be able to potently bind the target protein and the E3 ligase, they are unable to promote ternary complex formation that allows ubiquitination to occur and will therefore not promote protein degradation. To assess the selectivity of <b>106</b> and <b>107</b> degradations of PRC2 proteins, unbiased global proteomics was performed on Karpas422 cells treated with <b>106</b>. It was found that the only proteins significantly degraded were PRC2 members EED, EZH2, and SUZ12. Finally, to determine the efficacy of the EED degraders at inhibiting cell proliferation, <b>106</b> and <b>107</b> were added to Karpas422 cells, which contain the gain of function Y641N EZH2 mutation. Cell proliferation was markedly reduced by both PROTACs, particularly at time points of 8, 12, and 14 days. Potency of cell proliferation inhibition was slightly reduced compared to that of parent EED inhibitor <b>108</b>. The GI<sub>50</sub> for <b>106</b> and <b>107</b> was 57 and 45 nM, respectively, versus GI<sub>50</sub> = 14 nM for the EED inhibitor after 14 days. Against a panel of 10 other cell lines, interestingly, <b>107</b> was ineffective at inhibiting cell proliferation of all except for the G401 kidney cancer cells. To help understand these results, <b>106</b> and <b>107</b>, along with the parental EED inhibitor, were added to G401 cells and subcellular concentrations measured (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Subcellular Localization of EED-Targeting PROTACs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">drug concentration (pmol/million cells)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>106</b></th><th class="colsep0 rowsep0" align="center"><b>107</b></th><th class="colsep0 rowsep0" align="center"><b>108</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">(PROTAC 1)</th><th class="colsep0 rowsep0" align="center">(PROTAC 2)</th><th class="colsep0 rowsep0" align="center">(capped EED inhibitor)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cytoplasm</td><td class="colsep0 rowsep0" align="left">0.03 ± 0.003</td><td class="colsep0 rowsep0" align="left">4.69 ± 0.47</td><td class="colsep0 rowsep0" align="left">0.34 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nucleus</td><td class="colsep0 rowsep0" align="left">0.79 ± 0.08</td><td class="colsep0 rowsep0" align="left">37.2 ± 3.72</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.02</td></tr></tbody></table></div></div><div class="NLM_p">Notably, <b>107</b> had significantly higher concentration in both the cytoplasm and nucleus than <b>106</b>, although in each case nuclear concentrations were far higher than the cytoplasm. The parental EED inhibitor had about 2× higher concentration in the cytoplasm than nucleus, and its abundance was similar to <b>106</b>. On the basis of the measured subcellular PROTAC concentrations and lack of efficacy against a panel of catalytically independent, EZH2-dependent, cell lines, the precise mechanism of EED degradation-dependent antiproliferative effects remains unclear.</div><div class="NLM_p">At the same time that scientists from AstraZeneca reported their EED PROTACs,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> a group from the University of North Carolina (UNC) Chapel Hill reported another set of EED-targeted PROTACs<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> based on the published EED inhibitor <b>76</b> (EED226).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Similar to the approach taken by AstraZeneca, the UNC group also started by analyzing the crystal structure of <b>76</b>-related compounds bound to EED (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). They noted that the existing sulfone group was directed toward the solvent, so their efforts focused on building their linkers off this position. In their report,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> only six potential PROTACs were described and contained different lengths of either alkyl or polethylene glycol (PEG) chain linkers. Similar to the AstraZeneca report, the UNC EED PROTAC that produced the greatest degradation contained a short (three-carbon) alkyl linker between the <b>76</b>-derived ligand and the VH032 VHL ligand. The most potent degrader (<b>109</b>, UNC6852) was approximately 5× less potent at binding EED than <b>76</b> (247 nM versus 45 nM) in a TR-FRET assay (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>). Degradation screening was performed in HeLa cells, and <b>109</b> degraded 80% of EED at a concentration of 5 μM.</div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0035.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structure of reported EED PROTAC degrader by UNC (<b>109</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">3.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The PRC2 is the only known protein complex that catalyzes H3K27 methylation which mediates epigenetic silencing. As such, it plays a critical role in the maintenance of embryonic stem cell pluripotency during development. Extensive work has shown that PRC2 and its three core subunits, EZH2, EED, and SUZ12, are reactivated, either through overexpression or gain-of-function mutations, in a wide variety of solid and hematological cancers. This reactivation of PRC2 induces cellular dedifferentiation and cancer cell stemness that are associated with aberrant cell proliferation and motility.<a onclick="showRef(event, 'ref44 ref108'); return false;" href="javascript:void(0);" class="ref ref44 ref108">(44,108)</a> For these reasons, substantial efforts have been undertaken to discover and develop small molecule drugs to therapeutically target PRC2 and its component proteins. The most prevalent approach has been the development of catalytic inhibitors of the EZH2 methyltransferase enzyme. These efforts have led to the first PRC2-directed drug to be FDA-approved, EPZ-6438 (tazemetostat, Tazverik), which is used to treat epithelioid sarcoma and follicular lymphoma, along with several other drugs in various stages of clinical and preclinical development (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). As additional noncatalytic functions of the PRC2 methyltransferase core subunit EZH2 continue to be discovered, new strategies to target PRC2 activity have been pursued as well. One such new approach that has been described is the discovery of small molecules that bind EED and inhibit its interaction with H3K27 (i.e., EED inhibitors). The reported EED inhibitors generally produce cellular effects similar to those seen with EZH2 catalytic inhibitors, and one of them (MAK683, which is based on the EED226 scaffold) is currently in clinical development.</div><div class="NLM_p">In addition to these two approaches, recent work has also explored the use of proximity-inducing agents that target respective PRC2 components for degradation. Several groups have published on the use of EED inhibitor ligands to develop targeted degraders (PROTACs) that induce degradation of EED protein. At the same time, another group has described their work in developing EZH2-targeting degraders that use hydrophobic tags to promote EZH2 degradation. In both of these cases (i.e., EED and EZH2 degradation), the effects may be more profound than reversible inhibitors as they would be expected to eliminate both enzymatic and nonenzymatic functions of PRC2, although the full consequences of PRC2 component degradation are yet to be elucidated.</div><div class="NLM_p">The complex nature of PRC2 offers a number of important biological and chemical challenges to the development of new cancer therapeutics. At the same time, it provides unique opportunities by which small molecules acting through new mechanisms can be developed to afford new cancer treatments. As noncanonical functions of PRC2<a onclick="showRef(event, 'ref20 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref20 ref51 ref52 ref53 ref54">(20,51−54)</a> become better characterized, there will be greater emphasis on inhibiting both catalytic and noncatalytic functions of PRC2 to fully suppress all of its oncogenic roles. Demonstration of the ability to target PRC2 components for degradation also opens up new avenues for therapeutics development against PRC2 with mutated component proteins. For instance, mutations in the catalytic pocket of EZH2 that desensitize the tumor to traditional EZH2 enzymatic inhibitors may still allow a targeted degrader to act by degradation of the protein if it retains sufficient EZH2 affinity. Furthermore, as PROTACs can work using targeting ligands that bind to more sites on a protein than a catalytic inhibitor, there are more options for the development of diverse chemotypes that can target the PRC2 using degrader approaches. Another direction in which PRC2 small molecule approaches may proceed is to increase the tissue specificity of PRC2-directed agents, particularly with targeted degraders. For example, a recent report raises the possibility of directing PROTACs to specific tissues by attaching them to antibodies directed against cancer targets.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Additionally, the current FDA-approved EZH2 inhibitor tazemetostat requires high doses for producing efficacy in tumor studies.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> However, as PROTACs degrade their target protein in a catalytic manner, they may require lower doses that could result in fewer off-target effects and a better safety profile. Finally, as additional PRC2-directed agents are developed, it would be interesting to see their effects when combined with one another. For instance, combining an EED inhibitor such as EED226 (which blocks interaction between EED and H3K27me3) and an EZH2 inhibitor may be significantly more effective at blocking PRC2 activity than either alone. Another intriguing possibility would be combining an agent that degrades a PRC2 component protein with an EZH2 catalytic inhibitor, which could theoretically more fully block all EZH2 function, particularly if the degrader was targeted at a noncatalytic site on the protein.</div><div class="NLM_p last">With the increased understanding of the role PRC2 plays in normal and pathophysiology a better roadmap has been developed for how to target this complex for treating disease. It is particularly exciting that this comes at the same time as new therapeutic modalities such as protein–protein inhibitors and proximity-induced molecules are becoming increasingly sophisticated. One would expect that that the application of new small molecule technologies toward PRC2 will continue to have an increasing impact on treating human disease.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01344" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary E. Schiltz</span> - <span class="hlFld-Affiliation affiliation">Center
for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Robert
H. Lurie Comprehensive Cancer Center, Northwestern
University Feinberg School of Medicine, Chicago, Illinois 60611, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Northwestern University
Feinberg School of Medicine, Chicago, Illinois 60611, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4180-5051" title="Orcid link">http://orcid.org/0000-0003-4180-5051</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4d2a2c3f34603e2e25242139370d23223f39253a283e39283f2363282938"><span class="__cf_email__" data-cfemail="0b6c6a79722678686362677f714b6564797f637c6e787f6e7965256e6f7e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Cynthia Martin</span> - <span class="hlFld-Affiliation affiliation">Center
for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guihua Zeng</span> - <span class="hlFld-Affiliation affiliation">Division
of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jindan Yu</span> - <span class="hlFld-Affiliation affiliation">Division
of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Robert
H. Lurie Comprehensive Cancer Center, Northwestern
University Feinberg School of Medicine, Chicago, Illinois 60611, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.C.M. and G.Z. are co-first-authors. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="36" class="article__inlineFigure"><h2 class="fig-label">M. Cynthia Martin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=BIO-d7e3433-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>M. Cynthia Martin</b> received her Ph.D. degree in Chemistry from Georgia Institute of Technology in 2017 under the supervision of Dr. Stefan France. Soon thereafter, she joined AbbVie as a postdoctoral fellow in their high throughput chemistry group studying automation and parallel medicinal chemistry. She is currently pursuing a second postdoctoral fellowship training in the Center for Molecular Innovation and Drug Discovery (CMIDD) at Northwestern University with research interests on the rational design and synthesis of small molecule inhibitors and degraders as novel pharmacological probes and therapeutics for cancer and other human diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Guihua Zeng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=BIO-d7e3438-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Guihua Zeng</b> received her Ph.D. in Chemistry from University of New Mexico in 2017 under the supervision of Prof. Fu-Sen Liang and then spent one year as a postdoc at the University of Florida (Dr. Lina Cui). She is currently a postdoctoral fellow in Dr. Jindan Yu’s group in the Feinberg School of Medicine at Northwestern University. Her research interests include developing chemical biology tools to control biological processes, combining chemical tools with CRISPR systems to regulate gene expression, drug screening to target proteins or control protein interactions, and functions of ILF3 in prostate cancers, especially its roles in histone acetylation.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Jindan Yu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=BIO-d7e3443-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jindan Yu</b> received her Ph.D. in Biomedical Engineering from University of Michigan—Ann Arbor. She started to work with EZH2 while completing her postdoctoral training with Dr. Arul M. Chinnaiyan, an HHMI investigator who made the initial discovery of EZH2 upregulation in cancer. In 2009, she joined the faculty of Northwestern University Feinberg School of Medicine, continuing the studies of EZH2 in prostate cancer. Her group reported a methylation-independent role of EZH2 in transcriptional activation of the androgen receptor (AR), driving prostate cancer progression that is insensitive to enzymatic inhibitors of EZH2. Additionally, she works with AR and its cofactors such as FOXA1 and HOXB13. She has published 67 peer-reviewed original research articles and 11 review articles, mostly on genomic and epigenomic regulations of prostate cancer.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Gary E. Schiltz</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=BIO-d7e3448-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gary E. Schiltz</b> received his Ph.D. in Chemistry in 2005 from the University of Illinois at Chicago under the guidance of Dr. Arun K. Ghosh. He went to the biopharmaceutical industry where he worked as a medicinal chemist at deCODE Genetics, helping to advance drug discovery programs for CNS, inflammation, cancer, and other disorders. He then moved to Northwestern University where he is currently a Research Professor and leads a chemistry group to help advance a variety of projects focused on the development of chemical probes and therapeutic agents. He has a particular interest and experience in developing new small molecule agents against undruggable targets and the development of new proximity-inducing small molecules.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Prostate Cancer Research Program under Awards W81XWH-17-1-0405 and W81XWH-17-1-0406. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BID-PO</td><td class="NLM_def"><p class="first last">two times a day by mouth</p></td></tr><tr><td class="NLM_term">CHIP</td><td class="NLM_def"><p class="first last">C-terminus of Hsc70-interacting protein</p></td></tr><tr><td class="NLM_term">CRPC</td><td class="NLM_def"><p class="first last">castration-resistant prostate cancer</p></td></tr><tr><td class="NLM_term">CYP3A4</td><td class="NLM_def"><p class="first last">cytochrome P450 3A4</p></td></tr><tr><td class="NLM_term">DIRAS3</td><td class="NLM_def"><p class="first last">GTP-binding Di-Ras3</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">EED</td><td class="NLM_def"><p class="first last">embryonic ectoderm development</p></td></tr><tr><td class="NLM_term">EZH2</td><td class="NLM_def"><p class="first last">enhancer of zeste homolog 2</p></td></tr><tr><td class="NLM_term">GCB-DLBCL</td><td class="NLM_def"><p class="first last">germinal center B-cell-like-diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">ITC</td><td class="NLM_def"><p class="first last">isothermal titration calorimetry</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">mCRPC</td><td class="NLM_def"><p class="first last">metastatic castration-resistant cancer</p></td></tr><tr><td class="NLM_term">MLL</td><td class="NLM_def"><p class="first last">mixed-lineage leukemia</p></td></tr><tr><td class="NLM_term">NCI</td><td class="NLM_def"><p class="first last">National Cancer Institute</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">Non-Hodgkins lymphoma</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PRC2</td><td class="NLM_def"><p class="first last">polycomb repressive complex 2</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimera</p></td></tr><tr><td class="NLM_term">SAL</td><td class="NLM_def"><p class="first last">SET active loop</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SCLC</td><td class="NLM_def"><p class="first last">small-cell lung cancer</p></td></tr><tr><td class="NLM_term">SET</td><td class="NLM_def"><p class="first last">Su(var)3-9, enhancer-of-zeste and trithorax</p></td></tr><tr><td class="NLM_term">sc</td><td class="NLM_def"><p class="first last">subcutaneous</p></td></tr><tr><td class="NLM_term">STD-NMR</td><td class="NLM_def"><p class="first last">saturated transfer difference nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence energy transfer</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 109 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitges, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusty, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraju, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiwazian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly-Hartig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoma, N. H.</span></span> <span> </span><span class="NLM_article-title">Histone methylation by PRC2 is inhibited by active chromatin marks</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2011.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2011.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=21549310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=330-341&issue=3&author=F.+W.+Schmitgesauthor=A.+B.+Prustyauthor=M.+Fatyauthor=A.+Stutzerauthor=G.+M.+Lingarajuauthor=J.+Aiwazianauthor=R.+Sackauthor=D.+Hessauthor=L.+Liauthor=S.+Zhouauthor=R.+D.+Bunkerauthor=U.+Wirthauthor=T.+Bouwmeesterauthor=A.+Bauerauthor=N.+Ly-Hartigauthor=K.+Zhaoauthor=H.+Chanauthor=J.+Guauthor=H.+Gutauthor=W.+Fischleauthor=J.+Mullerauthor=N.+H.+Thoma&title=Histone+methylation+by+PRC2+is+inhibited+by+active+chromatin+marks&doi=10.1016%2Fj.molcel.2011.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Methylation by PRC2 Is Inhibited by Active Chromatin Marks</span></div><div class="casAuthors">Schmitges, Frank W.; Prusty, Archana B.; Faty, Mahamadou; Stuetzer, Alexandra; Lingaraju, Gondichatnahalli M.; Aiwazian, Jonathan; Sack, Ragna; Hess, Daniel; Li, Ling; Zhou, Shaolian; Bunker, Richard D.; Wirth, Urs; Bouwmeester, Tewis; Bauer, Andreas; Ly-Hartig, Nga; Zhao, Kehao; Chan, Homan; Gu, Justin; Gut, Heinz; Fischle, Wolfgang; Mueller, Juerg; Thomae, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-341</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Polycomb repressive complex 2 (PRC2) confers transcriptional repression through histone H3 lysine 27 trimethylation (H3K27me3).  Here, we examd. how PRC2 is modulated by histone modifications assocd. with transcriptionally active chromatin.  We provide the mol. basis of histone H3 N terminus recognition by the PRC2 Nurf55-Su(z)12 submodule.  Binding of H3 is lost if lysine 4 in H3 is trimethylated.  We find that H3K4me3 inhibits PRC2 activity in an allosteric fashion assisted by the Su(z)12 C terminus.  In addn. to H3K4me3, PRC2 is inhibited by H3K36me2/3 (i.e., both H3K36me2 and H3K36me3).  Direct PRC2 inhibition by H3K4me3 and H3K36me2/3 active marks is conserved in humans, mouse, and fly, rendering transcriptionally active chromatin refractory to PRC2 H3K27 trimethylation.  While inhibition is present in plant PRC2, it can be modulated through exchange of the Su(z)12 subunit.  Inhibition by active chromatin marks, coupled to stimulation by transcriptionally repressive H3K27me3, enables PRC2 to autonomously template repressive H3K27me3 without overwriting active chromatin domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnXPqq7hTWOLVg90H21EOLACvtfcHk0lhFZujewhUIJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVyiurc%253D&md5=ac62c56650a4a4ede3c9c1491d3da6af</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitges%26aufirst%3DF.%2BW.%26aulast%3DPrusty%26aufirst%3DA.%2BB.%26aulast%3DFaty%26aufirst%3DM.%26aulast%3DStutzer%26aufirst%3DA.%26aulast%3DLingaraju%26aufirst%3DG.%2BM.%26aulast%3DAiwazian%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DBunker%26aufirst%3DR.%2BD.%26aulast%3DWirth%26aufirst%3DU.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DLy-Hartig%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DFischle%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DThoma%26aufirst%3DN.%2BH.%26atitle%3DHistone%2520methylation%2520by%2520PRC2%2520is%2520inhibited%2520by%2520active%2520chromatin%2520marks%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D42%26issue%3D3%26spage%3D330%26epage%3D341%26doi%3D10.1016%2Fj.molcel.2011.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuettengruber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chourrout, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vervoort, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, G.</span></span> <span> </span><span class="NLM_article-title">Genome regulation by Polycomb and trithorax proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2007.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17320510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12isr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=735-745&issue=4&author=B.+Schuettengruberauthor=D.+Chourroutauthor=M.+Vervoortauthor=B.+Leblancauthor=G.+Cavalli&title=Genome+regulation+by+Polycomb+and+trithorax+proteins&doi=10.1016%2Fj.cell.2007.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Genome regulation by polycomb and trithorax proteins</span></div><div class="casAuthors">Schuettengruber, Bernd; Chourrout, Daniel; Vervoort, Michel; Leblanc, Benjamin; Cavalli, Giacomo</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">735-745</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) and trithorax group (trxG) proteins are crit. regulators of numerous developmental genes.  To silence or activate gene expression, resp., PcG and trxG proteins bind to specific regions of DNA and direct the posttranslational modification of histones.  Recent work suggests that PcG proteins regulate the nuclear organization of their target genes and that PcG-mediated gene silencing involves noncoding RNAs and the RNAi machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAySqV0OrdULVg90H21EOLACvtfcHk0lhFZujewhUIJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12isr8%253D&md5=dc79b73ed4d2d5f1b11bb3e357997bff</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DSchuettengruber%26aufirst%3DB.%26aulast%3DChourrout%26aufirst%3DD.%26aulast%3DVervoort%26aufirst%3DM.%26aulast%3DLeblanc%26aufirst%3DB.%26aulast%3DCavalli%26aufirst%3DG.%26atitle%3DGenome%2520regulation%2520by%2520Polycomb%2520and%2520trithorax%2520proteins%26jtitle%3DCell%26date%3D2007%26volume%3D128%26issue%3D4%26spage%3D735%26epage%3D745%26doi%3D10.1016%2Fj.cell.2007.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span> <span> </span><span class="NLM_article-title">Understanding the words of chromatin regulation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2009.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=19167321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Kitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=200-206&issue=2&author=J.+I.+Wuauthor=J.+Lessardauthor=G.+R.+Crabtree&title=Understanding+the+words+of+chromatin+regulation&doi=10.1016%2Fj.cell.2009.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the words of chromatin regulation</span></div><div class="casAuthors">Wu, Jiang I.; Lessard, Julie; Crabtree, Gerald R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-206</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent studies indicate that chromatin regulatory complexes produce biol. specificity in the way that letters produce meanings by combinations into words.  A combinatorial assembly of chromatin regulatory complexes may be crit. for maximizing the information content provided by arrays of histone modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ4fG29930ubVg90H21EOLACvtfcHk0lhFZujewhUIJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Kitbc%253D&md5=6180d642563b24be264d1c2acfc9abb8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BI.%26aulast%3DLessard%26aufirst%3DJ.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26atitle%3DUnderstanding%2520the%2520words%2520of%2520chromatin%2520regulation%26jtitle%3DCell%26date%3D2009%26volume%3D136%26issue%3D2%26spage%3D200%26epage%3D206%26doi%3D10.1016%2Fj.cell.2009.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, V.</span></span> <span> </span><span class="NLM_article-title">Polycomb, epigenomes, and control of cell identity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(03)00157-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0092-8674%2803%2900157-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12628181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFykuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=599-606&issue=5&author=V.+Orlando&title=Polycomb%2C+epigenomes%2C+and+control+of+cell+identity&doi=10.1016%2FS0092-8674%2803%2900157-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb, epigenomes, and control of cell identity</span></div><div class="casAuthors">Orlando, Valerio</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">599-606</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  In development, cell identity is maintained by epigenetic functions that prevent changes in cell type-specific transcription programs.  Recent insights into gene silencing mechanisms by Polycomb group (PcG) and trithorax group (trxG) proteins reveal that the memory system involves a concerted process of chromatin modification, blocking of RNA polymerase II, and synthesis of noncoding RNA.  Remarkably, cell memory is regulated by a balance between repressors and activators that maintains both transcription status and at the same time the possibility of switching to a different state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh_WxAV7icnLVg90H21EOLACvtfcHk0ljr6aDcEtj8bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFykuro%253D&md5=1e6ea2b704929d93fb9e156ad243d6a3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900157-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900157-0%26sid%3Dliteratum%253Aachs%26aulast%3DOrlando%26aufirst%3DV.%26atitle%3DPolycomb%252C%2520epigenomes%252C%2520and%2520control%2520of%2520cell%2520identity%26jtitle%3DCell%26date%3D2003%26volume%3D112%26issue%3D5%26spage%3D599%26epage%3D606%26doi%3D10.1016%2FS0092-8674%2803%2900157-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmichev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span> <span> </span><span class="NLM_article-title">Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2893</span>– <span class="NLM_lpage">2905</span>, <span class="refDoi"> DOI: 10.1101/gad.1035902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fgad.1035902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12435631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVejsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=2893-2905&issue=22&author=A.+Kuzmichevauthor=K.+Nishiokaauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=D.+Reinberg&title=Histone+methyltransferase+activity+associated+with+a+human+multiprotein+complex+containing+the+Enhancer+of+Zeste+protein&doi=10.1101%2Fgad.1035902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein</span></div><div class="casAuthors">Kuzmichev, Andrei; Nishioka, Kenichi; Erdjument-Bromage, Hediye; Tempst, Paul; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2893-2905</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Enhancer of Zeste [E(z)] is a Polycomb-group transcriptional repressor and one of the founding members of the family of SET domain-contg. proteins.  Several SET-domain proteins possess intrinsic histone methyltransferase (HMT) activity.  However, recombinant E(z) protein was found to be inactive in a HMT assay.  Here we report the isolation of a multiprotein E(z) complex that contains extra sex combs, suppressor of zeste-12 [Su(z)12], and the histone binding proteins RbAp46/RbAp48.  This complex, which we termed Polycomb repressive complex (PRC) 2, possesses HMT activity with specificity for Lys 9 (K9) and Lys 27 (K27) of histone H3.  The HMT activity of PRC2 is dependent on an intact SET domain in the E(z) protein.  We hypothesize that transcriptional repression by the E(z) protein involves methylation-dependent recruitment of PRC1.  The presence of Su(z)12, a strong suppressor of position effect variegation, in PRC2 suggests that PRC2 may play a widespread role in heterochromatin-mediated silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxD09IiaeCvLVg90H21EOLACvtfcHk0ljr6aDcEtj8bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVejsLY%253D&md5=b61767bc9b30b403f5fc7bb202281da1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1101%2Fgad.1035902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1035902%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmichev%26aufirst%3DA.%26aulast%3DNishioka%26aufirst%3DK.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DHistone%2520methyltransferase%2520activity%2520associated%2520with%2520a%2520human%2520multiprotein%2520complex%2520containing%2520the%2520Enhancer%2520of%2520Zeste%2520protein%26jtitle%3DGenes%2520Dev.%26date%3D2002%26volume%3D16%26issue%3D22%26spage%3D2893%26epage%3D2905%26doi%3D10.1101%2Fgad.1035902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senisterra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span> <span> </span><span class="NLM_article-title">Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e83737</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0083737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1371%2Fjournal.pone.0083737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24367611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVyitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&issue=12&author=H.+Wuauthor=H.+Zengauthor=A.+Dongauthor=F.+Liauthor=H.+Heauthor=G.+Senisterraauthor=A.+Seitovaauthor=S.+Duanauthor=P.+J.+Brownauthor=M.+Vedadiauthor=C.+H.+Arrowsmithauthor=M.+Schapira&title=Structure+of+the+catalytic+domain+of+EZH2+reveals+conformational+plasticity+in+cofactor+and+substrate+binding+sites+and+explains+oncogenic+mutations&doi=10.1371%2Fjournal.pone.0083737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations</span></div><div class="casAuthors">Wu, Hong; Zeng, Hong; Dong, Aiping; Li, Fengling; He, Hao; Senisterra, Guillermo; Seitova, Alma; Duan, Shili; Brown, Peter J.; Vedadi, Masoud; Arrowsmith, Cheryl H.; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e83737/1-e83737/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is an important regulator of cellular differentiation and cell type identity.  Overexpression or activating mutations of EZH2, the catalytic component of the PRC2 complex, are linked to hyper-trimethylation of lysine 27 of histone H3 (H3K27me3) in many cancers.  Potent EZH2 inhibitors that reduce levels of H3K27me3 kill mutant lymphoma cells and are efficacious in a mouse xenograft model of malignant rhabdoid tumors.  Unlike most SET domain methyltransferases, EZH2 requires PRC2 components, SUZ12 and EED, for activity, but the mechanism by which catalysis is promoted in the PRC2 complex is unknown.  We solved the 2.0 Å crystal structure of the EZH2 methyltransferase domain revealing that most of the canonical structural features of SET domain methyltransferase structures are conserved.  The site of Me transfer is in a catalytically competent state, and the structure clarifies the structural mechanism underlying oncogenic hyper-trimethylation of H3K27 in tumors harboring mutations at Y641 or A677.  On the other hand, the I-SET and post-SET domains occupy atypical positions relative to the core SET domain resulting in incomplete formation of the cofactor binding site and occlusion of the substrate binding groove.  A novel CXC domain N-terminal to the SET domain may contribute to the apparent inactive conformation.  We propose that protein interactions within the PRC2 complex modulate the trajectory of the post-SET and I-SET domains of EZH2 in favor of a catalytically competent conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNud-MjYOynbVg90H21EOLACvtfcHk0ljr6aDcEtj8bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVyitrs%253D&md5=948041c81ddd5ec5c4b02cdb7213c898</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0083737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0083737%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DSenisterra%26aufirst%3DG.%26aulast%3DSeitova%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DStructure%2520of%2520the%2520catalytic%2520domain%2520of%2520EZH2%2520reveals%2520conformational%2520plasticity%2520in%2520cofactor%2520and%2520substrate%2520binding%2520sites%2520and%2520explains%2520oncogenic%2520mutations%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0083737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekrasov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span> <span> </span><span class="NLM_article-title">Nucleosome binding and histone methyltransferase activity of Drosophila PRC2</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.7400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fsj.embor.7400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15776017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFWjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=348-353&issue=4&author=M.+Nekrasovauthor=B.+Wildauthor=J.+Muller&title=Nucleosome+binding+and+histone+methyltransferase+activity+of+Drosophila+PRC2&doi=10.1038%2Fsj.embor.7400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleosome binding and histone methyltransferase activity of Drosophila PRC2</span></div><div class="casAuthors">Nekrasov, Maxim; Wild, Brigitte; Mueller, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">348-353</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Drosophila Polycomb group protein E(z) is a histone methyltransferase (HMTase) that is essential for maintaining HOX gene silencing during development.  E(z) exists in a multiprotein complex called Polycomb repressive complex 2 (PRC2) that also contains Su(z)12, Esc and Nurf55.  Reconstituted recombinant PRC2 methylates nucleosomes in vitro, but recombinant E(z) on its own shows only poor HMTase activity on nucleosomes.  Here, the authors investigate the function of the PRC2 subunits.  PRC2 binds to nucleosomes in vitro but that individual PRC2 subunits alone do not bind to nucleosomes.  By analyzing PRC2 subcomplexes, the authors show that Su(z)12-Nurf55 is the minimal nucleosome-binding module of PRC2 and that Esc contributes to high-affinity binding of PRC2 nucleosomes.  Nucleosome binding of PRC2 is not sufficient for histone methylation and that only complexes that contain Esc protein show robust HMTase activity.  These observations suggest that different subunits provide mechanistically distinct functions within the PRC2 HMTase: the nucleosome-binding subunits Su(z)12 and Nurf55 anchor the E(z) enzyme on chromatin substrates, whereas Esc is needed to boost enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Jvaz8ZCPZLVg90H21EOLACvtfcHk0ljP9QTGcI9p-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFWjurw%253D&md5=7f553eef608ef68669f075c231db5979</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.7400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.7400376%26sid%3Dliteratum%253Aachs%26aulast%3DNekrasov%26aufirst%3DM.%26aulast%3DWild%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DJ.%26atitle%3DNucleosome%2520binding%2520and%2520histone%2520methyltransferase%2520activity%2520of%2520Drosophila%2520PRC2%26jtitle%3DEMBO%2520Rep.%26date%3D2005%26volume%3D6%26issue%3D4%26spage%3D348%26epage%3D353%26doi%3D10.1038%2Fsj.embor.7400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehani, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monrad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappsilber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerdrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">A model for transmission of the H3K27me3 epigenetic mark</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/ncb1787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fncb1787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18931660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlais7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1291-300&issue=11&author=K.+H.+Hansenauthor=A.+P.+Brackenauthor=D.+Pasiniauthor=N.+Dietrichauthor=S.+S.+Gehaniauthor=A.+Monradauthor=J.+Rappsilberauthor=M.+Lerdrupauthor=K.+Helin&title=A+model+for+transmission+of+the+H3K27me3+epigenetic+mark&doi=10.1038%2Fncb1787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A model for transmission of the H3K27me3 epigenetic mark</span></div><div class="casAuthors">Hansen, Klaus H.; Bracken, Adrian P.; Pasini, Diego; Dietrich, Nikolaj; Gehani, Simmi S.; Monrad, Astrid; Rappsilber, Juri; Lerdrup, Mads; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1291-1300</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Organization of chromatin by epigenetic mechanisms is essential for establishing and maintaining cellular identity in developing and adult organisms.  A key question that remains unresolved about this process is how epigenetic marks are transmitted to the next cell generation during cell division.  Here we provide a model to explain how trimethylated Lys 27 of histone 3 (H3K27me3), which is catalyzed by the EZH2-contg. Polycomb Repressive Complex 2 (PRC2), is maintained in proliferating cells.  We show that the PRC2 complex binds to the H3K27me3 mark and colocalizes with this mark in G1 phase and with sites of ongoing DNA replication.  Efficient binding requires an intact trimeric PRC2 complex contg. EZH2, EED and SUZ12, but is independent of the catalytic SET domain of EZH2.  Using a heterologous reporter system, we show that transient recruitment of the PRC2 complex to chromatin, upstream of the transcriptional start site, is sufficient to maintain repression through endogenous PRC2 during subsequent cell divisions.  Thus, we suggest that once the H3K27me3 is established, it recruits the PRC2 complex to maintain the mark at sites of DNA replication, leading to methylation of H3K27 on the daughter strands during incorporation of newly synthesized histones.  This mechanism ensures maintenance of the H3K27me3 epigenetic mark in proliferating cells, not only during DNA replication when histones synthesized de novo are incorporated, but also outside S phase, thereby preserving chromatin structure and transcriptional programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEAf-769vEd7Vg90H21EOLACvtfcHk0ljP9QTGcI9p-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlais7jK&md5=b2c7c437462df5622e88cc40ac6e15dd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fncb1787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1787%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BH.%26aulast%3DBracken%26aufirst%3DA.%2BP.%26aulast%3DPasini%26aufirst%3DD.%26aulast%3DDietrich%26aufirst%3DN.%26aulast%3DGehani%26aufirst%3DS.%2BS.%26aulast%3DMonrad%26aufirst%3DA.%26aulast%3DRappsilber%26aufirst%3DJ.%26aulast%3DLerdrup%26aufirst%3DM.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DA%2520model%2520for%2520transmission%2520of%2520the%2520H3K27me3%2520epigenetic%2520mark%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2008%26volume%3D10%26issue%3D11%26spage%3D1291%26epage%3D300%26doi%3D10.1038%2Fncb1787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drury, W. J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrotta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span> <span> </span><span class="NLM_article-title">Role of the Polycomb protein EED in the propagation of repressive histone marks</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span> (<span class="NLM_issue">7265</span>),  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nature08398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnature08398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=19767730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=762-767&issue=7265&author=R.+Margueronauthor=N.+Justinauthor=K.+Ohnoauthor=M.+L.+Sharpeauthor=J.+Sonauthor=W.+J.+Druryauthor=P.+Voigtauthor=S.+R.+Martinauthor=W.+R.+Taylorauthor=V.+De+Marcoauthor=V.+Pirrottaauthor=D.+Reinbergauthor=S.+J.+Gamblin&title=Role+of+the+Polycomb+protein+EED+in+the+propagation+of+repressive+histone+marks&doi=10.1038%2Fnature08398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the polycomb protein EED in the propagation of repressive histone marks</span></div><div class="casAuthors">Margueron, Raphael; Justin, Neil; Ohno, Katsuhito; Sharpe, Miriam L.; Son, Jinsook; Drury, William J., III; Voigt, Philipp; Martin, Stephen R.; Taylor, William R.; De Marco, Valeria; Pirrotta, Vincenzo; Reinberg, Danny; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7265</span>),
    <span class="NLM_cas:pages">762-767</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb group proteins have an essential role in the epigenetic maintenance of repressive chromatin states.  The gene-silencing activity of the Polycomb repressive complex 2 (PRC2) depends on its ability to trimethylate lysine 27 of histone H3 (H3K27) by the catalytic SET domain of the EZH2 subunit, and at least two other subunits of the complex: SUZ12 and EED.  Here we show that the carboxy-terminal domain of EED specifically binds to histone tails carrying trimethyl-lysine residues assocd. with repressive chromatin marks, and that this leads to the allosteric activation of the methyltransferase activity of PRC2.  Mutations in EED that prevent it from recognizing repressive trimethyl-lysine marks abolish the activation of PRC2 in vitro and, in Drosophila, reduce global methylation and disrupt development.  These findings suggest a model for the propagation of the H3K27me3 mark that accounts for the maintenance of repressive chromatin domains and for the transmission of a histone modification from mother to daughter cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSke4t5N1P3LVg90H21EOLACvtfcHk0ljP9QTGcI9p-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt73N&md5=63ee782ee42fb9c711a5d2fdf7d4e022</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature08398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08398%26sid%3Dliteratum%253Aachs%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DOhno%26aufirst%3DK.%26aulast%3DSharpe%26aufirst%3DM.%2BL.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DDrury%26aufirst%3DW.%2BJ.%26aulast%3DVoigt%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DS.%2BR.%26aulast%3DTaylor%26aufirst%3DW.%2BR.%26aulast%3DDe%2BMarco%26aufirst%3DV.%26aulast%3DPirrotta%26aufirst%3DV.%26aulast%3DReinberg%26aufirst%3DD.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DRole%2520of%2520the%2520Polycomb%2520protein%2520EED%2520in%2520the%2520propagation%2520of%2520repressive%2520histone%2520marks%26jtitle%3DNature%26date%3D2009%26volume%3D461%26issue%3D7265%26spage%3D762%26epage%3D767%26doi%3D10.1038%2Fnature08398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalantry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, T.</span></span> <span> </span><span class="NLM_article-title">The murine Polycomb group protein EED is required for global histone H3 lysine-27 methylation</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2005.04.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cub.2005.04.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15916951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=942-947&issue=10&author=N.+D.+Montgomeryauthor=D.+Yeeauthor=A.+Chenauthor=S.+Kalantryauthor=S.+J.+Chamberlainauthor=A.+P.+Otteauthor=T.+Magnuson&title=The+murine+Polycomb+group+protein+EED+is+required+for+global+histone+H3+lysine-27+methylation&doi=10.1016%2Fj.cub.2005.04.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation</span></div><div class="casAuthors">Montgomery, Nathan D.; Yee, Della; Chen, Andrew; Kalantry, Sundeep; Chamberlain, Stormy J.; Otte, Arie P.; Magnuson, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">942-947</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PcG proteins mediate heritable transcriptional silencing by generating and recognizing covalent histone modifications.  One conserved PcG complex, PRC2, is composed of several proteins including the histone methyltransferase (HMTase) Ezh2, the WD-repeat protein Eed, and the Zn-finger protein Suz12.  Ezh2 methylates histone H3 on lysine 27 (H3K27) [1-4], which serves as an epigenetic mark mediating silencing.  H3K27 can be mono-, di-, or trimethylated (1mH3K27, 2mH3K27, and 3mH3K27, resp.) [5].  Hence, either PRC2 must be regulated so as to add one Me group to certain nucleosomes but two or three to others, or distinct complexes must be responsible for 1m-, 2m-, and 3mH3K27.  Consistent with the latter possibility, 2mH3K27 and 3mH3K27, but not 1mH3K27, are absent in Suz12-/- embryos, which lack both Suz12 and Ezh2 protein [6].  Mammalian proteins required for 1mH3K27 have not been identified.  Here, authors demonstrate that unlike Suz12 and Ezh2, Eed is required not only for 2m- and 3mH3K27 but also global 1mH3K27.  These results provide a functionally important distinction between PRC2 complex components and implicate Eed in PRC2-independent histone methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh5aUVC-VrdLVg90H21EOLACvtfcHk0lhjHSKEVt4iAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gjt7k%253D&md5=2d378f554b3593f129cf512a04a69b75</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2005.04.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2005.04.051%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DN.%2BD.%26aulast%3DYee%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DKalantry%26aufirst%3DS.%26aulast%3DChamberlain%26aufirst%3DS.%2BJ.%26aulast%3DOtte%26aufirst%3DA.%2BP.%26aulast%3DMagnuson%26aufirst%3DT.%26atitle%3DThe%2520murine%2520Polycomb%2520group%2520protein%2520EED%2520is%2520required%2520for%2520global%2520histone%2520H3%2520lysine-27%2520methylation%26jtitle%3DCurr.%2520Biol.%26date%3D2005%26volume%3D15%26issue%3D10%26spage%3D942%26epage%3D947%26doi%3D10.1016%2Fj.cub.2005.04.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J. R.</span></span> <span> </span><span class="NLM_article-title">Binding of different histone marks differentially regulates the activity and specificity of Polycomb repressive complex 2 (PRC2)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">19266</span>– <span class="NLM_lpage">19271</span>, <span class="refDoi"> DOI: 10.1073/pnas.1008937107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1008937107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20974918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=19266-19271&issue=45&author=C.+Xuauthor=C.+B.+Bianauthor=W.+Yangauthor=M.+Galkaauthor=H.+Ouyangauthor=C.+Chenauthor=W.+Qiuauthor=H.+D.+Liuauthor=A.+E.+Jonesauthor=F.+MacKenzieauthor=P.+Panauthor=S.+S.+C.+Liauthor=H.+B.+Wangauthor=J.+R.+Min&title=Binding+of+different+histone+marks+differentially+regulates+the+activity+and+specificity+of+Polycomb+repressive+complex+2+%28PRC2%29&doi=10.1073%2Fpnas.1008937107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)</span></div><div class="casAuthors">Xu, Chao; Bian, Chuanbing; Yang, Wei; Galka, Marek; Ouyang, Hui; Chen, Chen; Qiu, Wei; Liu, Huadong; Jones, Amanda E.; MacKenzie, Farrell; Pan, Patricia; Li, Shawn Shun-Cheng; Wang, Hengbin; Min, Jinrong</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">19266-19271, S19266/1-S19266/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The polycomb repressive complex 2 (PRC2) is the major methyltransferase for H3K27 methylation, a modification crit. for maintaining repressed gene expression programs throughout development.  It has been previously shown that PRC2 maintains histone methylation patterns during DNA replication in part through its ability to bind to H3K27me3.  However, the mechanism by which PRC2 recognizes H3K27me3 is unclear.  Here we show that the WD40 domain of EED, a PRC2 component, is a methyllysine histone-binding domain.  The crystal structures of apo-EED and EED in complex resp. with five different trimethyllysine histone peptides reveal that EED binds these peptides via the top face of its β-propeller architecture.  The ammonium group of the trimethyllysine is accommodated by an arom. cage formed by three arom. residues, while its aliph. chain is flanked by a fourth arom. residue.  Our structural data provide an explanation for the preferential recognition of the Ala-Arg-Lys-Ser (ARKS) motif-contg. trimethylated H3K27, H3K9, and H1K26 marks by EED over lower methylation states and other histone methyllysine marks.  More importantly, we found that binding of different histone marks by EED differentially regulates the activity and specificity of PRC2.  Whereas the H3K27me3 mark stimulates the histone methyltransferase activity of PRC2, the H1K26me3 mark inhibits PRC2 methyltransferase activity on the nucleosome.  Moreover, H1K26me3 binding switches the specificity of PRC2 from methylating H3K27 to EED.  In addn. to detg. the mol. basis of EED-methyllysine recognition, our work provides the biochem. characterization of how the activity of a histone methyltransferase is oppositely regulated by two histone marks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT9ZyFdoHXqLVg90H21EOLACvtfcHk0lhjHSKEVt4iAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7jM&md5=0814be98c76f9e578a82a50158b66ecb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008937107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008937107%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DC.%2BB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DGalka%26aufirst%3DM.%26aulast%3DOuyang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%2BD.%26aulast%3DJones%26aufirst%3DA.%2BE.%26aulast%3DMacKenzie%26aufirst%3DF.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%2BS.%2BC.%26aulast%3DWang%26aufirst%3DH.%2BB.%26aulast%3DMin%26aufirst%3DJ.%2BR.%26atitle%3DBinding%2520of%2520different%2520histone%2520marks%2520differentially%2520regulates%2520the%2520activity%2520and%2520specificity%2520of%2520Polycomb%2520repressive%2520complex%25202%2520%2528PRC2%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D45%26spage%3D19266%26epage%3D19271%26doi%3D10.1073%2Fpnas.1008937107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, T.</span></span> <span> </span><span class="NLM_article-title">Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency</span>. <i>Stem Cells</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1505</span>, <span class="refDoi"> DOI: 10.1634/stemcells.2008-0102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1634%2Fstemcells.2008-0102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18403752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFGhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1496-1505&issue=6&author=S.+J.+Chamberlainauthor=D.+Yeeauthor=T.+Magnuson&title=Polycomb+repressive+complex+2+is+dispensable+for+maintenance+of+embryonic+stem+cell+pluripotency&doi=10.1634%2Fstemcells.2008-0102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency</span></div><div class="casAuthors">Chamberlain, Stormy J.; Yee, Della; Magnuson, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1496-1505</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) methylates histone H3 tails at lysine 27 and is essential for embryonic development.  The three core components of PRC2, Eed, Ezh2, and Suz12, are also highly expressed in embryonic stem (ES) cells, where they are postulated to repress developmental regulators and thereby prevent differentiation to maintain the pluripotent state.  We performed gene expression and chimera analyses on low- and high-passage Eednull ES cells to det. whether PRC2 is required for the maintenance of pluripotency.  We report here that although developmental regulators are overexpressed in Eednull ES cells, both low- and high-passage cells are functionally pluripotent.  We hypothesize that they are pluripotent because they maintain expression of crit. pluripotency factors.  Given that EED is required for stability of EZH2, the catalytic subunit of the complex, these data suggest that PRC2 is not necessary for the maintenance of the pluripotent state in ES cells.  We propose a pos.-only model of embryonic stem cell maintenance, where pos. regulation of pluripotency factors is sufficient to mediate stem cell pluripotency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKTogaKTDANLVg90H21EOLACvtfcHk0lhjHSKEVt4iAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFGhtb8%253D&md5=0a36228a0af5986f5778df442926c4e8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1634%2Fstemcells.2008-0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Fstemcells.2008-0102%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BJ.%26aulast%3DYee%26aufirst%3DD.%26aulast%3DMagnuson%26aufirst%3DT.%26atitle%3DPolycomb%2520repressive%2520complex%25202%2520is%2520dispensable%2520for%2520maintenance%2520of%2520embryonic%2520stem%2520cell%2520pluripotency%26jtitle%3DStem%2520Cells%26date%3D2008%26volume%3D26%26issue%3D6%26spage%3D1496%26epage%3D1505%26doi%3D10.1634%2Fstemcells.2008-0102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mysliwiec, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span> <span> </span><span class="NLM_article-title">Jumonji modulates Polycomb activity and self-renewal versus differentiation of stem cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2009.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20064376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FhvVeitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2009&pages=1303-1314&issue=7&author=X.+Shenauthor=W.+Kimauthor=Y.+Fujiwaraauthor=M.+D.+Simonauthor=Y.+Liuauthor=M.+R.+Mysliwiecauthor=G.+C.+Yuanauthor=Y.+Leeauthor=S.+H.+Orkin&title=Jumonji+modulates+Polycomb+activity+and+self-renewal+versus+differentiation+of+stem+cells&doi=10.1016%2Fj.cell.2009.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells</span></div><div class="casAuthors">Shen Xiaohua; Kim Woojin; Fujiwara Yuko; Simon Matthew D; Liu Yingchun; Mysliwiec Matthew R; Yuan Guo-Cheng; Lee Youngsook; Orkin Stuart H</div><div class="citationInfo"><span class="NLM_cas:title">Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1303-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trimethylation on histone H3 lysine 27 (H3K27me3) by Polycomb repressive complex 2 (PRC2) regulates the balance between self-renewal and differentiation of embryonic stem cells (ESCs).  The mechanisms controlling the activity and recruitment of PRC2 are largely unknown.  Here we demonstrate that the founding member of the Jumonji family, JMJ (JUMONJI or JARID2), is associated with PRC2, colocalizes with PRC2 and H3K27me3 on chromatin, and modulates PRC2 function.  In vitro JMJ inhibits PRC2 methyltransferase activity, consistent with increased H3K27me3 marks at PRC2 targets in Jmj(-/-) ESCs.  Paradoxically, JMJ is required for efficient binding of PRC2, indicating that the interplay of PRC2 and JMJ fine-tunes deposition of the H3K27me3 mark.  During differentiation, activation of genes marked by H3K27me3 and lineage commitments are delayed in Jmj(-/-) ESCs.  Our results demonstrate that dynamic regulation of Polycomb complex activity orchestrated by JMJ balances self-renewal and differentiation, highlighting the involvement of chromatin dynamics in cell-fate transitions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJgTBYNc3u0kNoizSOkG_FfW6udTcc2eYuiewoQ397o7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FhvVeitA%253D%253D&md5=bc1c94a9bb26b82426869cc5805d9b75</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DSimon%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMysliwiec%26aufirst%3DM.%2BR.%26aulast%3DYuan%26aufirst%3DG.%2BC.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26atitle%3DJumonji%2520modulates%2520Polycomb%2520activity%2520and%2520self-renewal%2520versus%2520differentiation%2520of%2520stem%2520cells%26jtitle%3DCell%26date%3D2009%26volume%3D139%26issue%3D7%26spage%3D1303%26epage%3D1314%26doi%3D10.1016%2Fj.cell.2009.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">A partially disordered region connects gene repression and activation functions of EZH2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">16992</span>– <span class="NLM_lpage">17002</span>, <span class="refDoi"> DOI: 10.1073/pnas.1914866117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1914866117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=32631994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFequ7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=16992-17002&issue=29&author=L.+Jiaoauthor=M.+Shubbarauthor=X.+Yangauthor=Q.+Zhangauthor=S.+Chenauthor=Q.+Wuauthor=Z.+Chenauthor=J.+Rizoauthor=X.+Liu&title=A+partially+disordered+region+connects+gene+repression+and+activation+functions+of+EZH2&doi=10.1073%2Fpnas.1914866117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A partially disordered region connects gene repression and activation functions of EZH2</span></div><div class="casAuthors">Jiao, Lianying; Shubbar, Murtada; Yang, Xin; Zhang, Qi; Chen, Siming; Wu, Qiong; Chen, Zhe; Rizo, Josep; Liu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">16992-17002</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which minimally requires two other subunits, EED and SUZ12, for enzymic activity.  EZH2 has been traditionally known to mediate histone H3K27 trimethylation, a hallmark of silent chromatin.  Emerging evidence indicates that EZH2 also activates gene expression in cancer cells in a context distinct from canonical PRC2.  The mol. mechanism underlying the functional conversion of EZH2 from a gene repressor to an activator is unclear.  Here, we show that EZH2 harbors a hidden, partially disordered transactivation domain (TAD) capable of interacting with components of active transcription machinery, mimicking archetypal acidic activators.  The EZH2 TAD comprises the SRM (Stimulation-Responsive Motif) and SANT1 (SWI3, ADA2, N-CoR, and TFIIIB 1) regions that are normally involved in H3K27 methylation.  The crystal structure of an EZH2-EED binary complex indicates that the EZH2 TAD mediates protein oligomerization in a noncanonical PRC2 context and is entirely sequestered.  The EZH2 TAD can be unlocked by cancer-specific EZH2 phosphorylation events to undergo structural transitions that may enable subsequent transcriptional coactivator binding.  The EZH2 TAD directly interacts with the transcriptional coactivator and histone acetyltransferase p300 and activates gene expression in a p300-dependent manner in cells.  The corresponding TAD may also account for the gene activation function of EZH1, the paralog of EZH2.  Distinct kinase signaling pathways that are known to abnormally convert EZH2 into a gene activator in cancer cells can now be understood in a common structural context of the EZH2 TAD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr7OVG0NaCHrVg90H21EOLACvtfcHk0limN-NfzlSTJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFequ7rL&md5=c138702fd7edf4cc30a22a8b9116c462</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1914866117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1914866117%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DShubbar%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DRizo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DA%2520partially%2520disordered%2520region%2520connects%2520gene%2520repression%2520and%2520activation%2520functions%2520of%2520EZH2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26issue%3D29%26spage%3D16992%26epage%3D17002%26doi%3D10.1073%2Fpnas.1914866117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerenyi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walensky, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span> <span> </span><span class="NLM_article-title">Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.1331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23974116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWktLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=643-650&issue=10&author=W.+Kimauthor=G.+H.+Birdauthor=T.+Neffauthor=G.+Guoauthor=M.+A.+Kerenyiauthor=L.+D.+Walenskyauthor=S.+H.+Orkin&title=Targeted+disruption+of+the+EZH2-EED+complex+inhibits+EZH2-dependent+cancer&doi=10.1038%2Fnchembio.1331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer</span></div><div class="casAuthors">Kim, Woojin; Bird, Gregory H.; Neff, Tobias; Guo, Guoji; Kerenyi, Marc A.; Walensky, Loren D.; Orkin, Stuart H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">643-650</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2) is the histone lysine N-methyltransferase component of the Polycomb repressive complex 2 (PRC2), which, in conjunction with embryonic ectoderm development (EED) and suppressor of zeste 12 homolog, regulates cell lineage detn. and homeostasis.  Enzymic hyperactivity has been linked to aberrant repression of tumor suppressor genes in diverse cancers.  Here, the authors report the development of stabilized α-helix of EZH2 (SAH-EZH2) peptides that selectively inhibit H3 Lys27 trimethylation by dose-responsively disrupting the EZH2-EED complex and reducing EZH2 protein levels, a mechanism distinct from that reported for small-mol. EZH2 inhibitors targeting the enzyme catalytic domain.  MLL-AF9 leukemia cells, which are dependent on PRC2, undergo growth arrest and monocyte-macrophage differentiation upon treatment with SAH-EZH2, consistent with obsd. changes in expression of PRC2-regulated, lineage-specific marker genes.  Thus, by dissocg. the EZH2-EED complex, the authors pharmacol. modulate an epigenetic 'writer' and suppress PRC2-dependent cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofgU19-q6AxLVg90H21EOLACvtfcHk0lipznr0_wUU8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWktLbK&md5=fe40ed4903f710ebe0f30888077fe701</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1331%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%26aulast%3DBird%26aufirst%3DG.%2BH.%26aulast%3DNeff%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DKerenyi%26aufirst%3DM.%2BA.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520EZH2-EED%2520complex%2520inhibits%2520EZH2-dependent%2520cancer%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D10%26spage%3D643%26epage%3D650%26doi%3D10.1038%2Fnchembio.1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Unique structural platforms of SUZ12 dictate distinct classes of PRC2 for chromatin binding</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2018.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29499137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVCntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=840-852&issue=5&author=S.+Chenauthor=L.+Jiaoauthor=M.+Shubbarauthor=X.+Yangauthor=X.+Liu&title=Unique+structural+platforms+of+SUZ12+dictate+distinct+classes+of+PRC2+for+chromatin+binding&doi=10.1016%2Fj.molcel.2018.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding</span></div><div class="casAuthors">Chen, Siming; Jiao, Lianying; Shubbar, Murtada; Yang, Xin; Liu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-852.e5</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Developmentally regulated accessory subunits dictate PRC2 function.  Here, we report the crystal structures of a 120 kDa heterotetrameric complex consisting of Suz12, Rbbp4, Jarid2, and Aebp2 fragments that is minimally active in nucleosome binding and of an inactive binary complex of Suz12 and Rbbp4.  Suz12 contains two unique structural platforms that define distinct classes of PRC2 holo complexes for chromatin binding.  Aebp2 and Phf19 compete for binding of a non-canonical C2 domain of Suz12; Jarid2 and EPOP occupy an overlapped Suz12 surface required for chromatin assocn. of PRC2.  Suz12 and Aebp2 progressively block histone H3K4 binding to Rbbp4, suggesting that Rbbp4 may not be directly involved in PRC2 inhibition by the active H3K4me3 histone mark.  Nucleosome binding enabled by Jarid2 and Aebp2 is in part accounted for by the structures, which also reveal that disruption of the Jarid2-Suz12 interaction may underlie the disease mechanism of an oncogenic chromosomal translocation of Suz12.666.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVsmCE7LlFebVg90H21EOLACvtfcHk0lipznr0_wUU8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVCntb0%253D&md5=33b5e22cb5abdf3d3346e9ec199a666c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DShubbar%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DUnique%2520structural%2520platforms%2520of%2520SUZ12%2520dictate%2520distinct%2520classes%2520of%2520PRC2%2520for%2520chromatin%2520binding%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D69%26issue%3D5%26spage%3D840%26epage%3D852%26doi%3D10.1016%2Fj.molcel.2018.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2004.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15225548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFejurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=57-67&issue=1&author=R.+Caoauthor=Y.+Zhang&title=SUZ12+is+required+for+both+the+histone+methyltransferase+activity+and+the+silencing+function+of+the+EED-EZH2+complex&doi=10.1016%2Fj.molcel.2004.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex</span></div><div class="casAuthors">Cao, Ru; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Recent studies have revealed the intrinsic histone methyltransferase (HMTase) activity of the EED-EZH2 complex and its role in Hox gene silencing, X inactivation, and cancer metastasis.  In this study, we focus on the function of individual components.  We found that the HMTase activity requires a min. of three components - EZH2, EED, and SUZ12 - while AEBP2 is required for optimal enzymic activity.  Using a stable SUZ12 knockdown cell line, we show SUZ12 knockdown results in cell growth defects, which correlate with genome-wide alteration on H3-K27 methylation as well as upregulation of a no. of Hox genes.  Chromatin immunopptn. (ChIP) assay identified a 500 bp region located 4 kb upstream of the HoxA9 transcription initiation site as a SUZ12 binding site, which responds to SUZ12 knockdown and might play an important role in regulating HoxA9 expression.  Thus, our study establishes a crit. role of SUZ12 in H3-lysine 27 methylation and Hox gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWQGRfTk9TrVg90H21EOLACvtfcHk0lipznr0_wUU8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFejurc%253D&md5=4b26382db05fda3e55b5f05dc2e1da9a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DSUZ12%2520is%2520required%2520for%2520both%2520the%2520histone%2520methyltransferase%2520activity%2520and%2520the%2520silencing%2520function%2520of%2520the%2520EED-EZH2%2520complex%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26issue%3D1%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2004.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denchi, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">SUZ12 is essential for mouse development and for EZH2 histone methyltransferase activity</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">4061</span>– <span class="NLM_lpage">4071</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fsj.emboj.7600402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15385962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlCrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=4061-4071&issue=20&author=D.+Pasiniauthor=A.+P.+Brackenauthor=M.+R.+Jensenauthor=E.+L.+Denchiauthor=K.+Helin&title=SUZ12+is+essential+for+mouse+development+and+for+EZH2+histone+methyltransferase+activity&doi=10.1038%2Fsj.emboj.7600402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity</span></div><div class="casAuthors">Pasini, Diego; Bracken, Adrian P.; Jensen, Michael R.; Denchi, Eros Lazzerini; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4061-4071</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SUZ12 is a recently identified Polycomb group (PcG) protein, which together with EZH2 and EED forms different Polycomb repressive complexes (PRC2/3).  These complexes contain histone H3 lysine (K) 27/9 and histone H1 K26 methyltransferase activity specified by the EZH2 SET domain.  Here we show that mice lacking Suz12, like Ezh2 and Eed mutant mice, are not viable and die during early postimplantation stages displaying severe developmental and proliferative defects.  Consistent with this, we demonstrate that SUZ12 is required for proliferation of cells in tissue culture.  Furthermore, we demonstrate that SUZ12 is essential for the activity and stability of the PRC2/3 complexes in mouse embryos, in tissue culture cells and in vitro.  Strikingly, Suz12-deficient embryos show a specific loss of di- and trimethylated H3K27, demonstrating that Suz12 is indeed essential for EZH2 activity in vivo.  In conclusion, our data demonstrate an essential role of SUZ12 in regulating the activity of the PRC2/3 complexes, which are required for regulating proliferation and embryogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Z3ZVmhO_aLVg90H21EOLACvtfcHk0lh5BsaUExluYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlCrs74%253D&md5=297e196b7be06ff22e3359dbc50dba4a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600402%26sid%3Dliteratum%253Aachs%26aulast%3DPasini%26aufirst%3DD.%26aulast%3DBracken%26aufirst%3DA.%2BP.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DDenchi%26aufirst%3DE.%2BL.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DSUZ12%2520is%2520essential%2520for%2520mouse%2520development%2520and%2520for%2520EZH2%2520histone%2520methyltransferase%2520activity%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26issue%3D20%26spage%3D4061%26epage%3D4071%26doi%3D10.1038%2Fsj.emboj.7600402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hojfeldt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laugesen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damhofer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedehus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tvardovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0036-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41594-018-0036-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29483650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrls1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=225-232&issue=3&author=J.+W.+Hojfeldtauthor=A.+Laugesenauthor=B.+M.+Willumsenauthor=H.+Damhoferauthor=L.+Hedehusauthor=A.+Tvardovskiyauthor=F.+Mohammadauthor=O.+N.+Jensenauthor=K.+Helin&title=Accurate+H3K27+methylation+can+be+established+de+novo+by+SUZ12-directed+PRC2&doi=10.1038%2Fs41594-018-0036-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2</span></div><div class="casAuthors">Hojfeldt Jonas W; Laugesen Anne; Damhofer Helene; Hedehus Lin; Mohammad Faizaan; Helin Kristian; Hojfeldt Jonas W; Laugesen Anne; Damhofer Helene; Hedehus Lin; Mohammad Faizaan; Helin Kristian; Willumsen Berthe M; Tvardovskiy Andrey; Jensen Ole N; Tvardovskiy Andrey</div><div class="citationInfo"><span class="NLM_cas:title">Nature structural & molecular biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-232</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) catalyzes methylation on lysine 27 of histone H3 (H3K27) and is required for maintaining transcriptional patterns and cellular identity, but the specification and maintenance of genomic PRC2 binding and H3K27 methylation patterns remain incompletely understood.  Epigenetic mechanisms have been proposed, wherein pre-existing H3K27 methylation directs recruitment and regulates the catalytic activity of PRC2 to support its own maintenance.  Here we investigate whether such mechanisms are required for specifying H3K27 methylation patterns in mouse embryonic stem cells (mESCs).  Through re-expression of PRC2 subunits in PRC2-knockout cells that have lost all H3K27 methylation, we demonstrate that methylation patterns can be accurately established de novo.  We find that regional methylation kinetics correlate with original methylation patterns even in their absence, and specification of the genomic PRC2 binding pattern is retained and specifically dependent on the PRC2 core subunit SUZ12.  Thus, the H3K27 methylation patterns in mESCs are not dependent on self-autonomous epigenetic inheritance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdHZ3bviJkhi86Js-BCLiifW6udTcc2ebLqAk9sGmfnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrls1ejtg%253D%253D&md5=df8a1c6698b11038e75df3d27bd785b7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0036-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0036-6%26sid%3Dliteratum%253Aachs%26aulast%3DHojfeldt%26aufirst%3DJ.%2BW.%26aulast%3DLaugesen%26aufirst%3DA.%26aulast%3DWillumsen%26aufirst%3DB.%2BM.%26aulast%3DDamhofer%26aufirst%3DH.%26aulast%3DHedehus%26aufirst%3DL.%26aulast%3DTvardovskiy%26aufirst%3DA.%26aulast%3DMohammad%26aufirst%3DF.%26aulast%3DJensen%26aufirst%3DO.%2BN.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DAccurate%2520H3K27%2520methylation%2520can%2520be%2520established%2520de%2520novo%2520by%2520SUZ12-directed%2520PRC2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D3%26spage%3D225%26epage%3D232%26doi%3D10.1038%2Fs41594-018-0036-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Polycomb- and methylation-independent roles of EZH2 as a transcription activator</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2808</span>– <span class="NLM_lpage">2820</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.11.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.celrep.2018.11.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30517868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCit7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=2808-2820&issue=10&author=J.+Kimauthor=Y.+Leeauthor=X.+Luauthor=B.+Songauthor=K.+W.+Fongauthor=Q.+Caoauthor=J.+D.+Lichtauthor=J.+C.+Zhaoauthor=J.+Yu&title=Polycomb-+and+methylation-independent+roles+of+EZH2+as+a+transcription+activator&doi=10.1016%2Fj.celrep.2018.11.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator</span></div><div class="casAuthors">Kim, Jung; Lee, Yongik; Lu, Xiaodong; Song, Bing; Fong, Ka-Wing; Cao, Qi; Licht, Jonathan D.; Zhao, Jonathan C.; Yu, Jindan</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2808-2820.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Enhancer of Zeste 2 (EZH2) is the enzymic subunit of Polycomb Repressive Complex 2 (PRC2), which catalyzes histone H3 lysine 27 trimethylation (H3K27me3) at target promoters for gene silencing.  Here, we report that EZH2 activates androgen receptor (AR) gene transcription through direct occupancy at its promoter.  Importantly, this activating role of EZH2 is independent of PRC2 and its methyltransferase activities.  Genome-wide assays revealed extensive EZH2 occupancy at promoters marked by either H3K27ac or H3K27me3, leading to gene activation or repression, resp.  Last, we demonstrate enhanced efficacy of enzymic EZH2 inhibitors when used in combination with AR antagonists in blocking the dual roles of EZH2 and suppressing prostate cancer progression in vitro and in vivo.  Taken together, our study reports EZH2 as a transcriptional activator, a key target of which is AR, and suggests a drug-combinatory approach to treat advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogFd6y_QesoLVg90H21EOLACvtfcHk0lh5BsaUExluYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCit7bL&md5=795cd5933915f46a31e298075abaa247</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.11.035%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DFong%26aufirst%3DK.%2BW.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DPolycomb-%2520and%2520methylation-independent%2520roles%2520of%2520EZH2%2520as%2520a%2520transcription%2520activator%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D25%26issue%3D10%26spage%3D2808%26epage%3D2820%26doi%3D10.1016%2Fj.celrep.2018.11.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatavosian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duc, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phiel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span> <span> </span><span class="NLM_article-title">Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2080</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04455-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41467-018-04455-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29802243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC1MfntlWrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2080&issue=1&author=R.+Tatavosianauthor=H.+N.+Ducauthor=T.+N.+Huynhauthor=D.+Fangauthor=B.+Schmittauthor=X.+Shiauthor=Y.+Dengauthor=C.+Phielauthor=T.+Yaoauthor=Z.+Zhangauthor=H.+Wangauthor=X.+Ren&title=Live-cell+single-molecule+dynamics+of+PcG+proteins+imposed+by+the+DIPG+H3.3K27M+mutation&doi=10.1038%2Fs41467-018-04455-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation</span></div><div class="casAuthors">Tatavosian Roubina; Duc Huy Nguyen; Huynh Thao Ngoc; Wang Haobin; Ren Xiaojun; Fang Dong; Zhang Zhiguo; Schmitt Benjamin; Yao Tingting; Shi Xiaodong; Deng Yiming; Phiel Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2080</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over 80% of diffuse intrinsic pontine gliomas (DIPGs) harbor a point mutation in histone H3.3 where lysine 27 is substituted with methionine (H3.3K27M); however, how the mutation affects kinetics and function of PcG proteins remains elusive.  We demonstrate that H3.3K27M prolongs the residence time and search time of Ezh2, but has no effect on its fraction bound to chromatin.  In contrast, H3.3K27M has no effect on the residence time of Cbx7, but prolongs its search time and decreases its fraction bound to chromatin.  We show that increasing expression of Cbx7 inhibits the proliferation of DIPG cells and prolongs its residence time.  Our results highlight that the residence time of PcG proteins directly correlates with their functions and the search time of PcG proteins is critical for regulating their genomic occupancy.  Together, our data provide mechanisms in which the cancer-causing histone mutation alters the binding and search dynamics of epigenetic complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQs2ntzaadWM3qj_yg7twvpfW6udTcc2ebqx3VDhsmS8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfntlWrtA%253D%253D&md5=f9d46822d925fb966f7841dad2b40ab2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04455-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04455-7%26sid%3Dliteratum%253Aachs%26aulast%3DTatavosian%26aufirst%3DR.%26aulast%3DDuc%26aufirst%3DH.%2BN.%26aulast%3DHuynh%26aufirst%3DT.%2BN.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DSchmitt%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DPhiel%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26atitle%3DLive-cell%2520single-molecule%2520dynamics%2520of%2520PcG%2520proteins%2520imposed%2520by%2520the%2520DIPG%2520H3.3K27M%2520mutation%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D2080%26doi%3D10.1038%2Fs41467-018-04455-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span> <span> </span><span class="NLM_article-title">PRC2 mediated H3K27 methylations in cellular identity and cancer</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2015.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ceb.2015.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26497635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWhsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2015&pages=42-48&author=E.+Conwayauthor=E.+Healyauthor=A.+P.+Bracken&title=PRC2+mediated+H3K27+methylations+in+cellular+identity+and+cancer&doi=10.1016%2Fj.ceb.2015.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">PRC2 mediated H3K27 methylations in cellular identity and cancer</span></div><div class="casAuthors">Conway, Eric; Healy, Evan; Bracken, Adrian P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-48</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Polycomb Repressive Complex 2 (PRC2) is a multiprotein chromatin modifying complex that is essential for vertebrate development and differentiation.  It is composed of a trimeric core of SUZ12, EED and EZH1/2 and is responsible for catalyzing both di-methylation and tri-methylation of Histone H3 at lysine 27 (H3K27me2/3).  Both H3K27 methylations contribute to the role of PRC2 in maintaining cellular identity.  In all cell types, the H3K27me3 modification is assocd. with repression of genes encoding regulators of alternative lineages.  The less well-characterized H3K27me2 modification is ubiquitous throughout the genome and is thought to act like a protective blanket to maintain the repression of non-H3K27me3 assocd. genes and cell-type-specific enhancers of alternative lineages.  Recent cancer genome sequencing studies highlighted that several genes encoding PRC2 components as well as Histone H3 are mutated in multiple cancer types.  Intriguingly, these cancers have changes in the global levels of the H3K27me2 and H3K27me3 modifications as well as genome-wide redistributions.  Exciting new studies suggest that these changes confer context dependent blocks in cellular differentiation and increased vulnerability to aberrant cancer signalling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDF0iuLAc7XrVg90H21EOLACvtfcHk0ljSrLQ4hFqjRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWhsL%252FP&md5=35b6039fde4a6755ea685203fb6334a0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2015.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2015.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DE.%26aulast%3DHealy%26aufirst%3DE.%26aulast%3DBracken%26aufirst%3DA.%2BP.%26atitle%3DPRC2%2520mediated%2520H3K27%2520methylations%2520in%2520cellular%2520identity%2520and%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2015%26volume%3D37%26spage%3D42%26epage%3D48%26doi%3D10.1016%2Fj.ceb.2015.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koche, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheinbay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusbaum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptaszek, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koseki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span> <span> </span><span class="NLM_article-title">Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">10</span>), <span class="NLM_elocation-id">e1000242</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1000242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1371%2Fjournal.pgen.1000242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18974828" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&issue=10&author=M.+Kuauthor=R.+P.+Kocheauthor=E.+Rheinbayauthor=E.+M.+Mendenhallauthor=M.+Endohauthor=T.+S.+Mikkelsenauthor=A.+Presserauthor=C.+Nusbaumauthor=X.+Xieauthor=A.+S.+Chiauthor=M.+Adliauthor=S.+Kasifauthor=L.+M.+Ptaszekauthor=C.+A.+Cowanauthor=E.+S.+Landerauthor=H.+Kosekiauthor=B.+E.+Bernstein&title=Genomewide+analysis+of+PRC1+and+PRC2+occupancy+identifies+two+classes+of+bivalent+domains&doi=10.1371%2Fjournal.pgen.1000242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1000242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1000242%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DM.%26aulast%3DKoche%26aufirst%3DR.%2BP.%26aulast%3DRheinbay%26aufirst%3DE.%26aulast%3DMendenhall%26aufirst%3DE.%2BM.%26aulast%3DEndoh%26aufirst%3DM.%26aulast%3DMikkelsen%26aufirst%3DT.%2BS.%26aulast%3DPresser%26aufirst%3DA.%26aulast%3DNusbaum%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChi%26aufirst%3DA.%2BS.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DKasif%26aufirst%3DS.%26aulast%3DPtaszek%26aufirst%3DL.%2BM.%26aulast%3DCowan%26aufirst%3DC.%2BA.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DKoseki%26aufirst%3DH.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26atitle%3DGenomewide%2520analysis%2520of%2520PRC1%2520and%2520PRC2%2520occupancy%2520identifies%2520two%2520classes%2520of%2520bivalent%2520domains%26jtitle%3DPLoS%2520Genet.%26date%3D2008%26volume%3D4%26issue%3D10%26doi%3D10.1371%2Fjournal.pgen.1000242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>350</i></span> (<span class="NLM_issue">6258</span>),  <span class="NLM_fpage">aac4383</span>, <span class="refDoi"> DOI: 10.1126/science.aac4383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1126%2Fscience.aac4383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26472914" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2015&pages=aac4383&issue=6258&author=L.+Jiaoauthor=X.+Liu&title=Structural+basis+of+histone+H3K27+trimethylation+by+an+active+polycomb+repressive+complex+2&doi=10.1126%2Fscience.aac4383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.aac4383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aac4383%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DStructural%2520basis%2520of%2520histone%2520H3K27%2520trimethylation%2520by%2520an%2520active%2520polycomb%2520repressive%2520complex%25202%26jtitle%3DScience%26date%3D2015%26volume%3D350%26issue%3D6258%26spage%3Daac4383%26doi%3D10.1126%2Fscience.aac4383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scelfo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jammula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barozzi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaldi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, D.</span></span> <span> </span><span class="NLM_article-title">Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2013.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2013.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24289921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKgsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=49-62&issue=1&author=K.+J.+Ferrariauthor=A.+Scelfoauthor=S.+Jammulaauthor=A.+Cuomoauthor=I.+Barozziauthor=A.+Stutzerauthor=W.+Fischleauthor=T.+Bonaldiauthor=D.+Pasini&title=Polycomb-dependent+H3K27me1+and+H3K27me2+regulate+active+transcription+and+enhancer+fidelity&doi=10.1016%2Fj.molcel.2013.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity</span></div><div class="casAuthors">Ferrari, Karin J.; Scelfo, Andrea; Jammula, SriGanesh; Cuomo, Alessandro; Barozzi, Iros; Stutzer, Alexandra; Fischle, Wolfgang; Bonaldi, Tiziana; Pasini, Diego</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-62</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">H3K27me3 is deposited at promoters by the preferential assocn. of Polycomb repressive complex 2 (PRC2) with CpG-rich DNA elements regulating development by repressing gene transcription.  H3K27 is also present in mono- and dimethylated states; however, the functional roles of H3K27me1 and H3K27me2 deposition remain poorly characterized.  Here, we show that PRC2 activity is not only assocd. with H3K27me3 but also regulates all forms of H3K27 methylation in a spatially defined manner, contributing to different genomic functions in mouse embryonic stem cells.  H3K27me1 accumulates within transcribed genes, promotes transcription, and is regulated by Setd2-dependent H3K36me3 deposition.  Contrarily, H3K27me2 is present on approx. 70% of total histone H3 and is distributed in large chromatin domains, exerting protective functions by preventing firing of non-cell-type-specific enhancers.  Considering that only 5%-10% of deregulated genes in PRC2-deficient cells are direct H3K27me3 targets, our data support an active role for all H3K27 methylated forms in regulating transcription and detg. cell identity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwLU-8hWnCibVg90H21EOLACvtfcHk0lj5O7RXAzb2Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKgsrjF&md5=47e9fcbcfdaed6224018c771d1ee13de</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DK.%2BJ.%26aulast%3DScelfo%26aufirst%3DA.%26aulast%3DJammula%26aufirst%3DS.%26aulast%3DCuomo%26aufirst%3DA.%26aulast%3DBarozzi%26aufirst%3DI.%26aulast%3DStutzer%26aufirst%3DA.%26aulast%3DFischle%26aufirst%3DW.%26aulast%3DBonaldi%26aufirst%3DT.%26aulast%3DPasini%26aufirst%3DD.%26atitle%3DPolycomb-dependent%2520H3K27me1%2520and%2520H3K27me2%2520regulate%2520active%2520transcription%2520and%2520enhancer%2520fidelity%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26issue%3D1%26spage%3D49%26epage%3D62%26doi%3D10.1016%2Fj.molcel.2013.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Role of hPHF1 in H3K27 methylation and Hox gene silencing</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1862</span>– <span class="NLM_lpage">1872</span>, <span class="refDoi"> DOI: 10.1128/MCB.01589-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1128%2FMCB.01589-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18086877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1862-1872&issue=5&author=R.+Caoauthor=H.+Wangauthor=J.+Heauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=Y.+Zhang&title=Role+of+hPHF1+in+H3K27+methylation+and+Hox+gene+silencing&doi=10.1128%2FMCB.01589-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hPHF1 in H3K27 methylation and Hox gene silencing</span></div><div class="casAuthors">Cao, Ru; Wang, Hengbin; He, Jin; Erdjument-Bromage, Hediye; Tempst, Paul; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1862-1872</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins are required for maintaining the silent state of the homeotic genes and other important developmental regulators.  The silencing function of the PcG proteins has been linked to their intrinsic histone modifying enzymic activities.  The EED-EZH2 complex, contg. the core subunits EZH2, EED, SUZ12, and RbAp48, functions as a histone H3K27-specific methyltransferase.  Here we describe the identification and characterization of a related EED-EZH2 protein complex which is distinguished from the previous complex by the presence of another PcG protein, hPHF1.  Consistent with the ability of hPHF1 to stimulate the enzymic activity of the core EED-EZH2 complex in vitro, manipulation of mPcl1, the mouse counterpart of hPHF1, in NIH 3T3 cells and cells of the mouse male germ cell line GC1spg results in global alteration of H3K27me2 and H3K27me3 levels and Hox gene expression.  Small interfering RNA-mediated knockdown of mPcl1 affects assocn. of the Eed-Ezh2 complex with certain Hox genes, such as HoxA10, as well as Hox gene expression concomitant with an alteration on the H3K27me2 levels of the corresponding promoters.  Therefore, our results reveal hPHF1 as a component of a novel EED-EZH2 complex and demonstrate its important role in H3K27 methylation and Hox gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbj2dJ_-Si4bVg90H21EOLACvtfcHk0lj5O7RXAzb2Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajtbc%253D&md5=447ec018523c260c0c4e0050405da379</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1128%2FMCB.01589-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01589-07%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DRole%2520of%2520hPHF1%2520in%2520H3K27%2520methylation%2520and%2520Hox%2520gene%2520silencing%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2008%26volume%3D28%26issue%3D5%26spage%3D1862%26epage%3D1872%26doi%3D10.1128%2FMCB.01589-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekrasov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klymenko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraterman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oktaba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stunnenberg, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span> <span> </span><span class="NLM_article-title">Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4078</span>– <span class="NLM_lpage">4088</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fsj.emboj.7601837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17762866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKhtrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=4078-4088&issue=18&author=M.+Nekrasovauthor=T.+Klymenkoauthor=S.+Fratermanauthor=B.+Pappauthor=K.+Oktabaauthor=T.+Kocherauthor=A.+Cohenauthor=H.+G.+Stunnenbergauthor=M.+Wilmauthor=J.+Muller&title=Pcl-PRC2+is+needed+to+generate+high+levels+of+H3-K27+trimethylation+at+Polycomb+target+genes&doi=10.1038%2Fsj.emboj.7601837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes</span></div><div class="casAuthors">Nekrasov, Maxim; Klymenko, Tetyana; Fraterman, Sven; Papp, Bernadett; Oktaba, Katarzyna; Koecher, Thomas; Cohen, Adrian; Stunnenberg, Hendrik G.; Wilm, Matthias; Mueller, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4078-4088</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">PRC2 is thought to be the histone methyltransferase (HMTase) responsible for H3-K27 trimethylation at Polycomb target genes.  Here we report the biochem. purifn. and characterization of a distinct form of Drosophila PRC2 that contains the Polycomb group protein polycomblike (Pcl).  Like PRC2, Pcl-PRC2 is an H3-K27-specific HMTase that mono-, di- and trimethylates H3-K27 in nucleosomes in vitro.  Anal. of Drosophila mutants that lack Pcl unexpectedly reveals that Pcl-PRC2 is required to generate high levels of H3-K27 trimethylation at Polycomb target genes but is dispensable for the genome-wide H3-K27 mono- and dimethylation that is generated by PRC2.  In Pcl mutants, Polycomb target genes become derepressed even though H3-K27 trimethylation at these genes is only reduced and not abolished, and even though targeting of the Polycomb protein complexes PhoRC and PRC1 to Polycomb response elements is not affected.  Pcl-PRC2 is thus the HMTase that generates the high levels of H3-K27 trimethylation in Polycomb target genes that are needed to maintain a Polycomb-repressed chromatin state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVZCMxfevbBLVg90H21EOLACvtfcHk0lj5O7RXAzb2Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKhtrvJ&md5=75db8cee2dc169ccec48065b29d4380e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601837%26sid%3Dliteratum%253Aachs%26aulast%3DNekrasov%26aufirst%3DM.%26aulast%3DKlymenko%26aufirst%3DT.%26aulast%3DFraterman%26aufirst%3DS.%26aulast%3DPapp%26aufirst%3DB.%26aulast%3DOktaba%26aufirst%3DK.%26aulast%3DKocher%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DStunnenberg%26aufirst%3DH.%2BG.%26aulast%3DWilm%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DJ.%26atitle%3DPcl-PRC2%2520is%2520needed%2520to%2520generate%2520high%2520levels%2520of%2520H3-K27%2520trimethylation%2520at%2520Polycomb%2520target%2520genes%26jtitle%3DEMBO%2520J.%26date%3D2007%26volume%3D26%26issue%3D18%26spage%3D4078%26epage%3D4088%26doi%3D10.1038%2Fsj.emboj.7601837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrotta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span> <span> </span><span class="NLM_article-title">EZH2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2731</span>, <span class="refDoi"> DOI: 10.1128/MCB.02017-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1128%2FMCB.02017-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18285464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFWqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=2718-2731&issue=8&author=K.+Sarmaauthor=R.+Margueronauthor=A.+Ivanovauthor=V.+Pirrottaauthor=D.+Reinberg&title=EZH2+requires+PHF1+to+efficiently+catalyze+H3+lysine+27+trimethylation+in+vivo&doi=10.1128%2FMCB.02017-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo</span></div><div class="casAuthors">Sarma, Kavitha; Margueron, Raphael; Ivanov, Alexey; Pirrotta, Vincenzo; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mammalian Polycomblike protein PHF1 was previously shown to interact with the Polycomb group (PcG) protein Ezh2, a histone methyltransferase whose activity is pivotal in sustaining gene repression during development and in adulthood.  As Ezh2 is active only when part of the Polycomb Repressive Complexes (PRC2-PRC4), we examd. the functional role of its interaction with PHF1.  Chromatin immunopptn. expts. revealed that PHF1 resides along with Ezh2 at Ezh2-regulated genes such as the HoxA loci and the non-Hox MYT1 and WNT1 genes.  Knockdown of PHF1 or of Ezh2 led to up-regulated HoxA gene expression.  Interestingly, depletion of PHF1 did correlate with reduced occupancy of Bmi-1, a PRC1 component.  As expected, knockdown of Ezh2 led to reduced levels of its catalytic products H3K27me2/H3K27me3.  However, reduced levels of PHF1 also led to decreased global levels of H3K27me3.  Notably, the levels of H3K27me3 decreased while those of H3K27me2 increased at the up-regulated HoxA loci tested.  Consistent with this, the addn. of PHF1 specifically stimulated the ability of Ezh2 to catalyze H3K27me3 but not H3K27me1/H3K27me2 in vitro.  We conclude that PHF1 modulates the activity of Ezh2 in favor of the repressive H3K27me3 mark.  Thus, we propose that PHF1 is a determinant in PcG-mediated gene repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsiWF9xVC8TbVg90H21EOLACvtfcHk0lg_5xsWpsitRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFWqtrc%253D&md5=ce25d19e315ef42f53c34f199e81cfcb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FMCB.02017-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.02017-07%26sid%3Dliteratum%253Aachs%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DIvanov%26aufirst%3DA.%26aulast%3DPirrotta%26aufirst%3DV.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DEZH2%2520requires%2520PHF1%2520to%2520efficiently%2520catalyze%2520H3%2520lysine%252027%2520trimethylation%2520in%2520vivo%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2008%26volume%3D28%26issue%3D8%26spage%3D2718%26epage%3D2731%26doi%3D10.1128%2FMCB.02017-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnes, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5020</span>– <span class="NLM_lpage">5034</span>, <span class="refDoi"> DOI: 10.7150/thno.34700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.7150%2Fthno.34700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31410199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXoslyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=5020-5034&issue=17&author=L.+Maauthor=Y.+Yanauthor=Y.+Baiauthor=Y.+Yangauthor=Y.+Panauthor=X.+Gangauthor=R.+J.+Karnesauthor=J.+Zhangauthor=Q.+Lvauthor=Q.+Wuauthor=H.+Huang&title=Overcoming+EZH2+inhibitor+resistance+by+taxane+in+PTEN-mutated+cancer&doi=10.7150%2Fthno.34700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer.</span></div><div class="casAuthors">Ma, Linlin; Yan, Yuqian; Bai, Yang; Yang, Yinhui; Pan, Yunqian; Gang, Xiaokun; Karnes, R. Jeffrey; Zhang, Jun; Lv, Qiubo; Wu, Qiang; Huang, Haojie</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5020-5034</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target.  Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulated in human cancers such as prostate cancer although the underlying regulatory mechanisms remain elusive.  Methods: Anal. of EZH2 ChIP-seq and ChIP-on-chip data in various cell types was performed.  ChIP-qPCR, RT-qPCR, and western blot analyses were conducted to det. the mechanism by which EZH2 represses FOXO1 expression.  Results: We demonstrated that EZH2 binds to the FOXO1 gene promoter.  EZH2 represses FOXO1 gene expression at the transcriptional level.  EZH2 protein level inversely correlated with FOXO1 protein expression in prostate cancer patient specimens.  Co-treatment with docetaxel overcame EZH2 inhibitor resistance in PTEN-neg. cancer cells in vitro and in mice.  This effect was largely mediated by docetaxel-induced nuclear localization and activation of FOXO1.  Conclusions: This study identifies FOXO1 as a bona fide repression target of EZH2 and an essential mediator of EZH2 inhibition-induced cell death.  Our findings suggest that EZH2 repression of FOXO1 can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of cancers with PTEN mutation or deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbX_fWJwdq9rVg90H21EOLACvtfcHk0lg_5xsWpsitRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslyqsw%253D%253D&md5=163f9fbcd3bf3728f55eab06bc4c9dad</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.7150%2Fthno.34700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.34700%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DGang%26aufirst%3DX.%26aulast%3DKarnes%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DOvercoming%2520EZH2%2520inhibitor%2520resistance%2520by%2520taxane%2520in%2520PTEN-mutated%2520cancer%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26issue%3D17%26spage%3D5020%26epage%3D5034%26doi%3D10.7150%2Fthno.34700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Role of histone H3 lysine 27 methylation in Polycomb-group silencing</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5595</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1126/science.1076997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1126%2Fscience.1076997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12351676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1039-1043&issue=5595&author=R.+Caoauthor=L.+Wangauthor=H.+Wangauthor=L.+Xiaauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=R.+S.+Jonesauthor=Y.+Zhang&title=Role+of+histone+H3+lysine+27+methylation+in+Polycomb-group+silencing&doi=10.1126%2Fscience.1076997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing</span></div><div class="casAuthors">Cao, Ru; Wang, Liangjun; Wang, Hengbin; Xia, Li; Erdjument-Bromage, Hediye; Tempst, Paul; Jones, Richard S.; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5595</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins play important roles in maintaining the silent state of HOX genes.  Recent studies have implicated histone methylation in long-term gene silencing.  However, a connection between PcG-mediated gene silencing and histone methylation has not been established.  Here the authors report the purifn. and characterization of an EED-EZH2 complex, the human counterpart of the Drosophila ESC-E(Z) complex.  They demonstrate that the complex specifically methylates nucleosomal histone H3 at lysine 27 (H3-K27).  Using chromatin immunopptn. assays, the authors show that H3-K27 methylation colocalizes with, and is dependent on, E(Z) binding at an Ultrabithorax med° (Ubx) Polycomb response element (PRE), and that this methylation correlates with Ubx repression.  Methylation on H3-K27 facilitates binding of Polycomb (PC), a component of the PRC1 complex, to histone H3 amino-terminal tail.  Thus, these studies establish a link between histone methylation and PcG-mediated gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnqusXKZEbLVg90H21EOLACvtfcHk0lg_5xsWpsitRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D&md5=8f24c05ec935c9110b2ff85b65911396</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.1076997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1076997%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DR.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DRole%2520of%2520histone%2520H3%2520lysine%252027%2520methylation%2520in%2520Polycomb-group%2520silencing%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5595%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1076997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czermin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrotta, V.</span></span> <span> </span><span class="NLM_article-title">Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00975-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0092-8674%2802%2900975-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12408863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotlahsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=185-196&issue=2&author=B.+Czerminauthor=R.+Melfiauthor=D.+McCabeauthor=V.+Seitzauthor=A.+Imhofauthor=V.+Pirrotta&title=Drosophila+enhancer+of+Zeste%2FESC+complexes+have+a+histone+H3+methyltransferase+activity+that+marks+chromosomal+Polycomb+sites&doi=10.1016%2FS0092-8674%2802%2900975-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Drosophila Enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites</span></div><div class="casAuthors">Czermin, Birgit; Melfi, Raffaella; McCabe, Donna; Seitz, Volker; Imhof, Axel; Pirrotta, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Enhancer of Zeste, or E(Z), is a Polycomb Group protein essential for the establishment and maintenance of repression of homeotic and other genes.  In the early embryo it is found in a complex that includes ESC and is recruited to Polycomb Response Elements.  We show that this complex contains a methyltransferase activity that methylates lysine 9 and lysine 27 of histone H3, but the activity is lost when the E(Z) SET domain is mutated.  The lysine 9 position is trimethylated and this mark is closely assocd. with Polycomb binding sites on polytene chromosomes but is also found in centric heterochromatin, chromosome 4, and telomeric sites.  Histone H3 methylated in vitro by the E(Z)/ESC complex binds specifically to Polycomb protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwewQaSe63NbVg90H21EOLACvtfcHk0lhjny9GiS7szw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotlahsr8%253D&md5=6fdde52477721e6133b5b0902bd2ed2a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900975-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900975-3%26sid%3Dliteratum%253Aachs%26aulast%3DCzermin%26aufirst%3DB.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DMcCabe%26aufirst%3DD.%26aulast%3DSeitz%26aufirst%3DV.%26aulast%3DImhof%26aufirst%3DA.%26aulast%3DPirrotta%26aufirst%3DV.%26atitle%3DDrosophila%2520enhancer%2520of%2520Zeste%252FESC%2520complexes%2520have%2520a%2520histone%2520H3%2520methyltransferase%2520activity%2520that%2520marks%2520chromosomal%2520Polycomb%2520sites%26jtitle%3DCell%26date%3D2002%26volume%3D111%26issue%3D2%26spage%3D185%26epage%3D196%26doi%3D10.1016%2FS0092-8674%2802%2900975-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmichev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenuwein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span> <span> </span><span class="NLM_article-title">Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(04)00185-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS1097-2765%2804%2900185-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15099518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVyisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=183-193&issue=2&author=A.+Kuzmichevauthor=T.+Jenuweinauthor=P.+Tempstauthor=D.+Reinberg&title=Different+EZH2-containing+complexes+target+methylation+of+histone+H1+or+nucleosomal+histone+H3&doi=10.1016%2FS1097-2765%2804%2900185-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Different Ezh2-containing complexes target methylation of histone H1 or nucleosomal histone H3</span></div><div class="casAuthors">Kuzmichev, Andrei; Jenuwein, Thomas; Tempst, Paul; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-193</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human Enhancer of Zeste homolog (Ezh2) is a histone lysine methyltransferase (HKMT) assocd. with transcriptional repression.  Ezh2 is present in several distinct complexes, one of which, PRC2, we characterized previously.  Here we report an addnl. Ezh2 complex, PRC3.  We show that the Ezh2 complexes exhibit differential targeting of specific histones for lysine methylation dependent upon the context of the histone substrates.  This differential targeting is a function of the assocd. Eed protein within each complex.  We found that Eed protein is present in four isoforms, which represent alternate translation start site usage from the same mRNA.  These Eed isoforms selectively assoc. with distinct Ezh2-contg. complexes with resultant differential targeting of their assocd. HKMT activity toward histone H3-K27 or histone H1-K26.  Our data provide evidence for a novel mechanism regulating the substrate specificity of a chromatin-modifying enzyme through disparate translational products of a regulatory subunit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtSqhDjwyYrVg90H21EOLACvtfcHk0lhjny9GiS7szw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVyisb8%253D&md5=35083f8234ad04a206dcf6e375e0ebd2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2804%2900185-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252804%252900185-6%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmichev%26aufirst%3DA.%26aulast%3DJenuwein%26aufirst%3DT.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DDifferent%2520EZH2-containing%2520complexes%2520target%2520methylation%2520of%2520histone%2520H1%2520or%2520nucleosomal%2520histone%2520H3%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D14%26issue%3D2%26spage%3D183%26epage%3D193%26doi%3D10.1016%2FS1097-2765%2804%2900185-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingston, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J. A.</span></span> <span> </span><span class="NLM_article-title">Histone methyltransferase activity of a Drosophila Polycomb group repressor complex</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00976-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0092-8674%2802%2900976-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12408864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotlahsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=197-208&issue=2&author=J.+Mullerauthor=C.+M.+Hartauthor=N.+J.+Francisauthor=M.+L.+Vargasauthor=A.+Senguptaauthor=B.+Wildauthor=E.+L.+Millerauthor=M.+B.+O%E2%80%99Connorauthor=R.+E.+Kingstonauthor=J.+A.+Simon&title=Histone+methyltransferase+activity+of+a+Drosophila+Polycomb+group+repressor+complex&doi=10.1016%2FS0092-8674%2802%2900976-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Histone methyltransferase activity of a Drosophila polycomb group repressor complex</span></div><div class="casAuthors">Muller, Jurg; Hart, Craig M.; Francis, Nicole J.; Vargas, Marcus L.; Sengupta, Aditya; Wild, Brigitte; Miller, Ellen L.; O'Connor, Michael B.; Kingston, Robert E.; Simon, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins maintain transcriptional repression during development, likely by creating repressive chromatin states.  The Extra Sex Combs (ESC) and Enhancer of Zeste [E(Z)] proteins are partners in an essential PcG complex, but its full compn. and biochem. activities are not known.  A SET domain in E(Z) suggests this complex might methylate histones.  We purified an ESC-E(Z) complex from Drosophila embryos and found four major subunits: ESC, E(Z), NURF-55, and the PcG repressor, SU(Z)12.  A recombinant complex reconstituted from these four subunits methylates lysine-27 of histone H3.  Mutations in the E(Z) SET domain disrupt methyltransferase activity in vitro and HOX gene repression in vivo.  These results identify E(Z) as a PcG protein with enzymic activity and implicate histone methylation in PcG-mediated silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAFZ5Z3wLX7Vg90H21EOLACvtfcHk0lhjny9GiS7szw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotlahsrw%253D&md5=55527bf2dfaf30c62e0baf393b6ee415</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900976-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900976-5%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DHart%26aufirst%3DC.%2BM.%26aulast%3DFrancis%26aufirst%3DN.%2BJ.%26aulast%3DVargas%26aufirst%3DM.%2BL.%26aulast%3DSengupta%26aufirst%3DA.%26aulast%3DWild%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DE.%2BL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BB.%26aulast%3DKingston%26aufirst%3DR.%2BE.%26aulast%3DSimon%26aufirst%3DJ.%2BA.%26atitle%3DHistone%2520methyltransferase%2520activity%2520of%2520a%2520Drosophila%2520Polycomb%2520group%2520repressor%2520complex%26jtitle%3DCell%26date%3D2002%26volume%3D111%26issue%3D2%26spage%3D197%26epage%3D208%26doi%3D10.1016%2FS0092-8674%2802%2900976-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2004.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.gde.2004.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15196462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVKktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=155-164&issue=2&author=R.+Caoauthor=Y.+Zhang&title=The+functions+of+E%28Z%29%2FEZH2-mediated+methylation+of+lysine+27+in+histone+H3&doi=10.1016%2Fj.gde.2004.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3</span></div><div class="casAuthors">Cao, Ru; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) proteins are important for maintaining the silenced state of homeotic genes.  Biochem. and genetic studies in Drosophila and mammalian cells indicate that PcG proteins function in at least two distinct protein complexes: the ESC-E(Z) or EED-EZH2 complex, and the PRC1 complex.  Recent work has shown that at least part of the silencing function of the ESC-E(Z) complex is mediated by its intrinsic activity for methylating histone H3 on lysine 27.  In addn. to being involved in Hox gene silencing, the complex and its assocd. histone methyltransferase activity are important in other biol. processes including X-inactivation, germline development, stem cell pluripotency and cancer metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTnGE_k0TJd7Vg90H21EOLACvtfcHk0lhzLQcUG3cQLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVKktLY%253D&md5=cfe4157f4c953c0473ba341699b6c446</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2004.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2004.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DThe%2520functions%2520of%2520E%2528Z%2529%252FEZH2-mediated%2520methylation%2520of%2520lysine%252027%2520in%2520histone%2520H3%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2004%26volume%3D14%26issue%3D2%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.gde.2004.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laugesen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hojfeldt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms directing PRC2 recruitment and H3K27 methylation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2019.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2019.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30951652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=8-18&issue=1&author=A.+Laugesenauthor=J.+W.+Hojfeldtauthor=K.+Helin&title=Molecular+mechanisms+directing+PRC2+recruitment+and+H3K27+methylation&doi=10.1016%2Fj.molcel.2019.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation</span></div><div class="casAuthors">Laugesen, Anne; Hoejfeldt, Jonas Westergaard; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-18</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The polycomb repressive complex 2 (PRC2) is a chromatin-assocd. methyltransferase catalyzing mono-, di-, and trimethylation of lysine 27 on histone H3 (H3K27).  This activity is required for normal organismal development and maintenance of gene expression patterns to uphold cell identity.  PRC2 function is often deregulated in disease and is a promising candidate for therapeutic targeting in cancer.  In this review, we discuss the mol. mechanisms proposed to take part in modulating PRC2 recruitment and shaping H3K27 methylation patterns across the genome.  This includes consideration of factors influencing PRC2 residence time on chromatin and PRC2 catalytic activity with a focus on the mechanisms giving rise to regional preferences and differential deposition of H3K27 methylation.  We further discuss existing evidence for functional diversity between distinct subsets of PRC2 complexes with the aim of extg. key concepts and highlighting major open questions toward a more complete understanding of PRC2 function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcGQVL8p1vLVg90H21EOLACvtfcHk0lhzLQcUG3cQLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSmtro%253D&md5=ff3e9f3ed45ab516d5c9fe2c5bd64c3d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2019.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2019.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DLaugesen%26aufirst%3DA.%26aulast%3DHojfeldt%26aufirst%3DJ.%2BW.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520directing%2520PRC2%2520recruitment%2520and%2520H3K27%2520methylation%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D74%26issue%3D1%26spage%3D8%26epage%3D18%26doi%3D10.1016%2Fj.molcel.2019.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Histone methylation in DNA repair and clinical practice: new findings during the past 5-years</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2072</span>– <span class="NLM_lpage">2081</span>, <span class="refDoi"> DOI: 10.7150/jca.23427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.7150%2Fjca.23427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29937925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FhtlCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2072-2081&issue=12&author=S.+Weiauthor=C.+Liauthor=Z.+Yinauthor=J.+Wenauthor=H.+Mengauthor=L.+Xueauthor=J.+Wang&title=Histone+methylation+in+DNA+repair+and+clinical+practice%3A+new+findings+during+the+past+5-years&doi=10.7150%2Fjca.23427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Histone methylation in DNA repair and clinical practice: new findings during the past 5-years</span></div><div class="casAuthors">Wei Shuhua; Li Chunxiao; Wen Jie; Meng Hui; Xue Lixiang; Wang Junjie; Yin Zhongnan; Xue Lixiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2072-2081</span>
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    </div><div class="casAbstract">DNA double-strand breaks (DSBs) are highly toxic lesions that can impair cellular homeostasis and genome stability to result in tumorigenesis for inappropriate repair.  Although DSBs are repaired by homologous recombination (HR) or non-homologous end-joining (NHEJ), the related mechanisms are still incompletely unclear.  Indeed, more and more evidences indicate that the methylation of histone lysine has an important role in choosing the pathways of DNA repair.  For example, tri-methylated H3K36 is required for HR repair, while di-methylated H4K20 can recruit 53BP1 for NHEJ repair.  Here, we reviewed the recent progress in the molecular mechanisms by which histone methylation functions in DNA double-strand breaks repair (DSBR).  The insight into the mechanisms of histone methylation repairing DNA damage will supply important cues for clinical cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTusxX5zh2Y9kg6wdEZmT2rfW6udTcc2eb5J9Q88p0Ux7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FhtlCrug%253D%253D&md5=18250c3edb40e0b2d072c60bbfb88faf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.7150%2Fjca.23427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.23427%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DHistone%2520methylation%2520in%2520DNA%2520repair%2520and%2520clinical%2520practice%253A%2520new%2520findings%2520during%2520the%2520past%25205-years%26jtitle%3DJ.%2520Cancer%26date%3D2018%26volume%3D9%26issue%3D12%26spage%3D2072%26epage%3D2081%26doi%3D10.7150%2Fjca.23427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riising, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Maintaining cell identity: PRC2-mediated regulation of transcription and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnrc.2016.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27658528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGgtL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=803-810&issue=12&author=I.+Cometauthor=E.+M.+Riisingauthor=B.+Leblancauthor=K.+Helin&title=Maintaining+cell+identity%3A+PRC2-mediated+regulation+of+transcription+and+cancer&doi=10.1038%2Fnrc.2016.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Maintaining cell identity: PRC2-mediated regulation of transcription and cancer</span></div><div class="casAuthors">Comet, Itys; Riising, Eva M.; Leblanc, Benjamin; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">803-810</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressive complex 2 (PRC2), has attracted broad research attention in the past few years because of its involvement in the development and maintenance of many types of cancer and the use of specific EZH2 inhibitors in clin. trials.  Several observations show that PRC2 can have both oncogenic and tumor-suppressive functions.  We propose that these apparently opposing roles of PRC2 in cancer are a consequence of the mol. function of the complex in maintaining, rather than specifying, the transcriptional repression state of its several thousand target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_illiggfTLVg90H21EOLACvtfcHk0lhs_4VtEth2_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGgtL7N&md5=c491ca235d7751be387730b61b57b94f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.83%26sid%3Dliteratum%253Aachs%26aulast%3DComet%26aufirst%3DI.%26aulast%3DRiising%26aufirst%3DE.%2BM.%26aulast%3DLeblanc%26aufirst%3DB.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DMaintaining%2520cell%2520identity%253A%2520PRC2-mediated%2520regulation%2520of%2520transcription%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26issue%3D12%26spage%3D803%26epage%3D810%26doi%3D10.1038%2Fnrc.2016.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wassef, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span> <span> </span><span class="NLM_article-title">The multiple facets of PRC2 alterations in cancers</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>429</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1993</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2016.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.jmb.2016.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27742591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSit7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=1978-1993&issue=13&author=M.+Wassefauthor=R.+Margueron&title=The+multiple+facets+of+PRC2+alterations+in+cancers&doi=10.1016%2Fj.jmb.2016.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The multiple facets of PRC2 alterations in cancers</span></div><div class="casAuthors">Wassef, M.; Margueron, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1978-1993</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Genome sequencing of large cohorts of tumors has revealed that mutations in genes encoding chromatin regulators are frequent in cancer.  However, the precise contribution of these mutations to tumor development often remains elusive.  Here, we review the current knowledge concerning the alterations of the Polycomb machinery in cancer, with a particular focus on the Polycomb repressive complex 2 (PRC2), a key chromatin modifier involved in the maintenance of transcriptional silencing.  A broad variety of alterations can impair PRC2 activity; yet, overall, only one type of alteration is found in a given class of tumor.  We discuss the potential impact of the various types of PRC2 alterations on gene expression.  We propose that the distinct set of genes regulated by PRC2, depending on tumor etiol., constrain the type of alteration of PRC2 that can fuel tumor development.  Beyond this specificity, we propose that PRC2 and, more generally, chromatin regulators act as gatekeepers of transcriptional integrity, a role that often confers a tumor-suppressive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Fj-RcOKPgLVg90H21EOLACvtfcHk0lhs_4VtEth2_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSit7nK&md5=5a570cb78d98feecd67f5e6c49473e6c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DWassef%26aufirst%3DM.%26aulast%3DMargueron%26aufirst%3DR.%26atitle%3DThe%2520multiple%2520facets%2520of%2520PRC2%2520alterations%2520in%2520cancers%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26issue%3D13%26spage%3D1978%26epage%3D1993%26doi%3D10.1016%2Fj.jmb.2016.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laugesen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Højfeldt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Role of the Polycomb Repressive Complex 2 (PRC2) in transcriptional regulation and cancer</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">a026575</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a026575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fcshperspect.a026575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27449971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1ylsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=a026575&issue=9&author=A.+Laugesenauthor=J.+W.+H%C3%B8jfeldtauthor=K.+Helin&title=Role+of+the+Polycomb+Repressive+Complex+2+%28PRC2%29+in+transcriptional+regulation+and+cancer&doi=10.1101%2Fcshperspect.a026575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer</span></div><div class="casAuthors">Laugesen, Anne; Hoejfeldt, Jonas Westergaard; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">a026575/1-a026575/21</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The chromatin environment is modulated by a machinery of chromatin modifiers, required for the specification and maintenance of cell fate.  Many mutations in the machinery have been linked to the development and progression of cancer.  In this review, we give a brief introduction to Polycomb group (PcG) proteins, their assembly into Polycomb repressive complexes (PRCs) and the normal physiol. roles of these complexes with a focus on the PRC2.  We review the many findings of mutations in the PRC2 coding genes, both loss-offunction and gain-of-function, assocd. with human cancers and discuss potential mol. mechanisms involved in the contribution of PRC2 mutations to cancer development and progression.  Finally, we discuss some of the recent advances in developing and testing drugs targeting the PRC2 as well as emerging results from clin. trials using these drugs in the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfaXQ68AexFbVg90H21EOLACvtfcHk0lhs_4VtEth2_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1ylsLc%253D&md5=f4e4e34f574df73999116c5e257a5f04</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026575%26sid%3Dliteratum%253Aachs%26aulast%3DLaugesen%26aufirst%3DA.%26aulast%3DH%25C3%25B8jfeldt%26aufirst%3DJ.%2BW.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DRole%2520of%2520the%2520Polycomb%2520Repressive%2520Complex%25202%2520%2528PRC2%2529%2520in%2520transcriptional%2520regulation%2520and%2520cancer%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26issue%3D9%26spage%3Da026575%26doi%3D10.1101%2Fcshperspect.a026575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">EZH2, an epigenetic driver of prostate cancer</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1007/s13238-013-2093-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1007%2Fs13238-013-2093-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23636686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12rs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=331-341&issue=5&author=Y.+A.+Yangauthor=J.+Yu&title=EZH2%2C+an+epigenetic+driver+of+prostate+cancer&doi=10.1007%2Fs13238-013-2093-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2, an epigenetic driver of prostate cancer</span></div><div class="casAuthors">Yang, Yeqing Angela; Yu, Jindan</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">331-341</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer.  It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target.  Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches.  This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt28-ADnWJN7Vg90H21EOLACvtfcHk0lhs_4VtEth2_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12rs7s%253D&md5=8039f52b256b1f49259407438bd5f449</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs13238-013-2093-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-013-2093-2%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DEZH2%252C%2520an%2520epigenetic%2520driver%2520of%2520prostate%2520cancer%26jtitle%3DProtein%2520Cell%26date%3D2013%26volume%3D4%26issue%3D5%26spage%3D331%26epage%3D341%26doi%3D10.1007%2Fs13238-013-2093-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beguelin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunting, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezponda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelleher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaknovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchietti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, A. M.</span></span> <span> </span><span class="NLM_article-title">EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ccr.2013.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23680150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslaltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=677-692&issue=5&author=W.+Beguelinauthor=R.+Popovicauthor=M.+Teaterauthor=Y.+Jiangauthor=K.+L.+Buntingauthor=M.+Rosenauthor=H.+Shenauthor=S.+N.+Yangauthor=L.+Wangauthor=T.+Ezpondaauthor=E.+Martinez-Garciaauthor=H.+Zhangauthor=Y.+Zhengauthor=S.+K.+Vermaauthor=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+S.+Van+Allerauthor=R.+G.+Krugerauthor=Y.+Liuauthor=C.+F.+McHughauthor=D.+W.+Scottauthor=Y.+R.+Chungauthor=N.+Kelleherauthor=R.+Shaknovichauthor=C.+L.+Creasyauthor=R.+D.+Gascoyneauthor=K.+K.+Wongauthor=L.+Cerchiettiauthor=R.+L.+Levineauthor=O.+Abdel-Wahabauthor=J.+D.+Lichtauthor=O.+Elementoauthor=A.+M.+Melnick&title=EZH2+is+required+for+germinal+center+formation+and+somatic+EZH2+mutations+promote+lymphoid+transformation&doi=10.1016%2Fj.ccr.2013.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation</span></div><div class="casAuthors">Beguelin, Wendy; Popovic, Relja; Teater, Matt; Jiang, Yanwen; Bunting, Karen L.; Rosen, Monica; Shen, Hao; Yang, Shao Ning; Wang, Ling; Ezponda, Teresa; Martinez-Garcia, Eva; Zhang, Haikuo; Zheng, Yupeng; Verma, Sharad K.; McCabe, Michael T.; Ott, Heidi M.; Van Aller, Glenn S.; Kruger, Ryan G.; Liu, Yan; McHugh, Charles F.; Scott, David W.; Chung, Young Rock; Kelleher, Neil; Shaknovich, Rita; Creasy, Caretha L.; Gascoyne, Randy D.; Wong, Kwok-Kin; Cerchietti, Leandro; Levine, Ross L.; Abdel-Wahab, Omar; Licht, Jonathan D.; Elemento, Olivier; Melnick, Ari M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">677-692</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and targeted by somatic mutations in B cell lymphomas.  Here, we find that EZH2 deletion or pharmacol. inhibition suppresses GC formation and functions.  EZH2 represses proliferation checkpoint genes and helps establish bivalent chromatin domains at key regulatory loci to transiently suppress GC B cell differentiation.  Somatic mutations reinforce these physiol. effects through enhanced silencing of EZH2 targets.  Conditional expression of mutant EZH2 in mice induces GC hyperplasia and accelerated lymphomagenesis in cooperation with BCL2.  GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more differentiated activated B cell (ABC)-type DLBCLs, thus clarifying the therapeutic scope of EZH2 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGRGx_7wvR7Vg90H21EOLACvtfcHk0lg2Wymgh6Fw2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslaltLY%253D&md5=c7a58d41a10c1464eb7ada72b94dfd40</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DBeguelin%26aufirst%3DW.%26aulast%3DPopovic%26aufirst%3DR.%26aulast%3DTeater%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DBunting%26aufirst%3DK.%2BL.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEzponda%26aufirst%3DT.%26aulast%3DMartinez-Garcia%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DScott%26aufirst%3DD.%2BW.%26aulast%3DChung%26aufirst%3DY.%2BR.%26aulast%3DKelleher%26aufirst%3DN.%26aulast%3DShaknovich%26aufirst%3DR.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DMelnick%26aufirst%3DA.%2BM.%26atitle%3DEZH2%2520is%2520required%2520for%2520germinal%2520center%2520formation%2520and%2520somatic%2520EZH2%2520mutations%2520promote%2520lymphoid%2520transformation%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D677%26epage%3D692%26doi%3D10.1016%2Fj.ccr.2013.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morin, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungall, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolcock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchenbauer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimbara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shashkin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlot, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcherpakov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varhol, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smailus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moksa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birol, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. A.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1038/ng.518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fng.518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20081860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=181-185&issue=2&author=R.+D.+Morinauthor=N.+A.+Johnsonauthor=T.+M.+Seversonauthor=A.+J.+Mungallauthor=J.+Anauthor=R.+Goyaauthor=J.+E.+Paulauthor=M.+Boyleauthor=B.+W.+Woolcockauthor=F.+Kuchenbauerauthor=D.+Yapauthor=R.+K.+Humphriesauthor=O.+L.+Griffithauthor=S.+Shahauthor=H.+Zhuauthor=M.+Kimbaraauthor=P.+Shashkinauthor=J.+F.+Charlotauthor=M.+Tcherpakovauthor=R.+Corbettauthor=A.+Tamauthor=R.+Varholauthor=D.+Smailusauthor=M.+Moksaauthor=Y.+Zhaoauthor=A.+Delaneyauthor=H.+Qianauthor=I.+Birolauthor=J.+Scheinauthor=R.+Mooreauthor=R.+Holtauthor=D.+E.+Horsmanauthor=J.+M.+Connorsauthor=S.+Jonesauthor=S.+Aparicioauthor=M.+Hirstauthor=R.+D.+Gascoyneauthor=M.+A.+Marra&title=Somatic+mutations+altering+EZH2+%28Tyr641%29+in+follicular+and+diffuse+large+B-cell+lymphomas+of+germinal-center+origin&doi=10.1038%2Fng.518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span></div><div class="casAuthors">Morin, Ryan D.; Johnson, Nathalie A.; Severson, Tesa M.; Mungall, Andrew J.; An, Jianghong; Goya, Rodrigo; Paul, Jessica E.; Boyle, Merrill; Woolcock, Bruce W.; Kuchenbauer, Florian; Yap, Damian; Humphries, R. Keith; Griffith, Obi L.; Shah, Sohrab; Zhu, Henry; Kimbara, Michelle; Shashkin, Pavel; Charlot, Jean F.; Tcherpakov, Marianna; Corbett, Richard; Tam, Angela; Varhol, Richard; Smailus, Duane; Moksa, Michelle; Zhao, Yongjun; Delaney, Allen; Qian, Hong; Birol, Inanc; Schein, Jacqueline; Moore, Richard; Holt, Robert; Horsman, Doug E.; Connors, Joseph M.; Jones, Steven; Aparicio, Samuel; Hirst, Martin; Gascoyne, Randy D.; Marra, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-185</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells.  Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-κB pathway that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified.  Here the authors report recurrent somatic mutations affecting the polycomb-group oncogene EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27).  After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types, EZH2 is the second histone methyltransferase gene mutated in cancer.  These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs.  The authors' data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymic activity in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvpFnajONCXbVg90H21EOLACvtfcHk0lg2Wymgh6Fw2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D&md5=ab68fe6e8932e720c4e7be82fe35932a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fng.518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.518%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DSeverson%26aufirst%3DT.%2BM.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DPaul%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DWoolcock%26aufirst%3DB.%2BW.%26aulast%3DKuchenbauer%26aufirst%3DF.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DHumphries%26aufirst%3DR.%2BK.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKimbara%26aufirst%3DM.%26aulast%3DShashkin%26aufirst%3DP.%26aulast%3DCharlot%26aufirst%3DJ.%2BF.%26aulast%3DTcherpakov%26aufirst%3DM.%26aulast%3DCorbett%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DVarhol%26aufirst%3DR.%26aulast%3DSmailus%26aufirst%3DD.%26aulast%3DMoksa%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DSchein%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DHolt%26aufirst%3DR.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26atitle%3DSomatic%2520mutations%2520altering%2520EZH2%2520%2528Tyr641%2529%2520in%2520follicular%2520and%2520diffuse%2520large%2520B-cell%2520lymphomas%2520of%2520germinal-center%2520origin%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26issue%3D2%26spage%3D181%26epage%3D185%26doi%3D10.1038%2Fng.518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Cooperation between Polycomb and androgen receptor during oncogenic transformation</span>. <i>Genome Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1101/gr.131508.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fgr.131508.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=22179855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFygtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=322-331&issue=2&author=J.+C.+Zhaoauthor=J.+Yuauthor=C.+Runkleauthor=L.+Wuauthor=M.+Huauthor=D.+Wuauthor=J.+S.+Liuauthor=Q.+Wangauthor=Z.+S.+Qinauthor=J.+Yu&title=Cooperation+between+Polycomb+and+androgen+receptor+during+oncogenic+transformation&doi=10.1101%2Fgr.131508.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cooperation between polycomb and androgen receptor during oncogenic transformation</span></div><div class="casAuthors">Zhao, Jonathan C.; Yu, Jianjun; Runkle, Christine; Wu, Longtao; Hu, Ming; Wu, Dayong; Liu, Jun S.; Wang, Qianben; Qin, Zhaohui S.; Yu, Jindan</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-331</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Androgen receptor (AR) is a hormone-activated transcription factor that plays important roles in prostate development and function, as well as malignant transformation.  The downstream pathways of AR, however, are incompletely understood.  AR has been primarily known as a transcriptional activator inducing prostate-specific gene expression.  Through integrative anal. of genome-wide AR occupancy and androgen-regulated gene expression, here we report AR as a globally acting transcriptional repressor.  This repression is mediated by androgen-responsive elements (ARE) and dictated by Polycomb group protein EZH2 and repressive chromatin remodeling.  In embryonic stem cells, AR-repressed genes are occupied by EZH2 and harbor bivalent H3K4me3 and H3K27me3 modifications that are characteristic of differentiation regulators, the silencing of which maintains the undifferentiated state.  Concordantly, these genes are silenced in castration-resistant prostate cancer rendering a stem cell-like lack of differentiation and tumor progression.  Collectively, our data reveal an unexpected role of AR as a transcriptional repressor inhibiting non-prostatic differentiation and, upon excessive signaling, resulting in cancerous dedifferentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjNol5ZcVfkLVg90H21EOLACvtfcHk0lgU-JundwDTmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFygtrc%253D&md5=debc0ff309b9ee1483b2c03ab7a1f1b4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1101%2Fgr.131508.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.131508.111%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DRunkle%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DQin%26aufirst%3DZ.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DCooperation%2520between%2520Polycomb%2520and%2520androgen%2520receptor%2520during%2520oncogenic%2520transformation%26jtitle%3DGenome%2520Res.%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D322%26epage%3D331%26doi%3D10.1101%2Fgr.131508.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laxman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellaichamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasekaran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrette, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">An integrated network of androgen receptor, Polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ccr.2010.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20478527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslKru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=443-454&issue=5&author=J.+Yuauthor=J.+Yuauthor=R.+S.+Maniauthor=Q.+Caoauthor=C.+J.+Brennerauthor=X.+Caoauthor=X.+Wangauthor=L.+Wuauthor=J.+Liauthor=M.+Huauthor=Y.+Gongauthor=H.+Chengauthor=B.+Laxmanauthor=A.+Vellaichamyauthor=S.+Shankarauthor=Y.+Liauthor=S.+M.+Dhanasekaranauthor=R.+Moreyauthor=T.+Barretteauthor=R.+J.+Lonigroauthor=S.+A.+Tomlinsauthor=S.+Varamballyauthor=Z.+S.+Qinauthor=A.+M.+Chinnaiyan&title=An+integrated+network+of+androgen+receptor%2C+Polycomb%2C+and+TMPRSS2-ERG+gene+fusions+in+prostate+cancer+progression&doi=10.1016%2Fj.ccr.2010.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression</span></div><div class="casAuthors">Yu, Jindan; Yu, Jianjun; Mani, Ram-Shankar; Cao, Qi; Brenner, Chad J.; Cao, Xuhong; Wang, Xiaoju; Wu, Longtao; Li, James; Hu, Ming; Gong, Yusong; Cheng, Hong; Laxman, Bharathi; Vellaichamy, Adaikkalam; Shankar, Sunita; Li, Yong; Dhanasekaran, Saravana M.; Morey, Roger; Barrette, Terrence; Lonigro, Robert J.; Tomlins, Scott A.; Varambally, Sooryanarayana; Qin, Zhaohui S.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">443-454</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS transcription factor ERG occur in approx. 50% of prostate cancers, but how the fusion products regulate prostate cancer remains unclear.  Using chromatin immunopptn. coupled with massively parallel sequencing, we found that ERG disrupts androgen receptor (AR) signaling by inhibiting AR expression, binding to and inhibiting AR activity at gene-specific loci, and inducing repressive epigenetic programs via direct activation of the H3K27 methyltransferase EZH2, a Polycomb group protein.  These findings provide a working model in which TMPRSS2-ERG plays a crit. role in cancer progression by disrupting lineage-specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouYaPEsLZp2bVg90H21EOLACvtfcHk0lgU-JundwDTmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslKru7Y%253D&md5=491eefed71b77076b0fa218a31c226e4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMani%26aufirst%3DR.%2BS.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DBrenner%26aufirst%3DC.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DLaxman%26aufirst%3DB.%26aulast%3DVellaichamy%26aufirst%3DA.%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DDhanasekaran%26aufirst%3DS.%2BM.%26aulast%3DMorey%26aufirst%3DR.%26aulast%3DBarrette%26aufirst%3DT.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DZ.%2BS.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DAn%2520integrated%2520network%2520of%2520androgen%2520receptor%252C%2520Polycomb%252C%2520and%2520TMPRSS2-ERG%2520gene%2520fusions%2520in%2520prostate%2520cancer%2520progression%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26issue%3D5%26spage%3D443%26epage%3D454%26doi%3D10.1016%2Fj.ccr.2010.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laxman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasekaran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2007.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ccr.2007.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17996646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtl2nur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=419-431&issue=5&author=J.+Yuauthor=Q.+Caoauthor=R.+Mehraauthor=B.+Laxmanauthor=J.+Yuauthor=S.+A.+Tomlinsauthor=C.+J.+Creightonauthor=S.+M.+Dhanasekaranauthor=R.+Shenauthor=G.+Chenauthor=D.+S.+Morrisauthor=V.+E.+Marquezauthor=R.+B.+Shahauthor=D.+Ghoshauthor=S.+Varamballyauthor=A.+M.+Chinnaiyan&title=Integrative+genomics+analysis+reveals+silencing+of+beta-adrenergic+signaling+by+polycomb+in+prostate+cancer&doi=10.1016%2Fj.ccr.2007.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative genomics analysis reveals silencing of β-Adrenergic signaling by Polycomb in prostate cancer</span></div><div class="casAuthors">Yu, Jindan; Cao, Qi; Mehra, Rohit; Laxman, Bharathi; Yu, Jianjun; Tomlins, Scott A.; Creighton, Chad J.; Dhanasekaran, Saravana M.; Shen, Ronglai; Chen, Guoan; Morris, David S.; Marquez, Victor E.; Shah, Rajal B.; Ghosh, Debashis; Varambally, Sooryanarayana; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Polycomb group (PcG) protein EZH2 possesses oncogenic properties for which the underlying mechanism is unclear.  We integrated in vitro cell line, in vivo tumor profiling, and genome-wide location data to nominate key targets of EZH2.  One of the candidates identified was ADRB2 (Adrenergic Receptor, Beta-2), a crit. mediator of β-adrenergic signaling.  EZH2 is recruited to the ADRB2 promoter and represses ADRB2 expression.  ADRB2 inhibition confers cell invasion and transforms benign prostate epithelial cells, whereas ADRB2 overexpression counteracts EZH2-mediated oncogenesis.  ADRB2 is underexpressed in metastatic prostate cancer, and clin. localized tumors that express lower levels of ADRB2 exhibit a poor prognosis.  Taken together, we demonstrate the power of integrating multiple diverse genomic data to decipher targets of disease-related genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrU67Cn7lx4rVg90H21EOLACvtfcHk0lgNnB9uFVGQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtl2nur3F&md5=21ac40c21e75e467fbaa9d798ba7c787</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2007.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2007.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DLaxman%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DDhanasekaran%26aufirst%3DS.%2BM.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMorris%26aufirst%3DD.%2BS.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DShah%26aufirst%3DR.%2BB.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DIntegrative%2520genomics%2520analysis%2520reveals%2520silencing%2520of%2520beta-adrenergic%2520signaling%2520by%2520polycomb%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26issue%3D5%26spage%3D419%26epage%3D431%26doi%3D10.1016%2Fj.ccr.2007.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Gise, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, W. T.</span></span> <span> </span><span class="NLM_article-title">PRC2 directly methylates GATA4 and represses its transcriptional activity</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1101/gad.173930.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fgad.173930.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=22215809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlaiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=37-42&issue=1&author=A.+Heauthor=X.+Shenauthor=Q.+Maauthor=J.+Caoauthor=A.+von+Giseauthor=P.+Zhouauthor=G.+Wangauthor=V.+E.+Marquezauthor=S.+H.+Orkinauthor=W.+T.+Pu&title=PRC2+directly+methylates+GATA4+and+represses+its+transcriptional+activity&doi=10.1101%2Fgad.173930.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PRC2 directly methylates GATA4 and represses its transcriptional activity</span></div><div class="casAuthors">He, Aibin; Shen, Xiaohua; Ma, Qing; Cao, Jingjing; von Gise, Alexander; Zhou, Pingzhu; Wang, Gang; Marquez, Victor E.; Orkin, Stuart H.; Pu, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-42</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Polycomb-repressive complex 2 (PRC2) promotes tissue-specific differentiation by depositing trimethylated histone H3 Lys 27 (H3K27me3) epigenetic marks to silence ectopic gene expression programs.  Here, we show that EZH2, the catalytic subunit of PRC2, is required for cardiac morphogenesis.  Both in vitro and in fetal hearts, EZH2 interacted with cardiac transcription factor GATA4 and directly methylated it at Lys 299.  PRC2 methylation of GATA4 attenuated its transcriptional activity by reducing its interaction with and acetylation by p300.  Our results reveal a new mechanism of PRC2-mediated transcriptional repression in which PRC2 methylates a transcription factor to inhibit its transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4-4MX3w79ALVg90H21EOLACvtfcHk0lgNnB9uFVGQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlaiurg%253D&md5=3ab3c7aceb394c49edd0f0af31befbe2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1101%2Fgad.173930.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.173930.111%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3Dvon%2BGise%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DPu%26aufirst%3DW.%2BT.%26atitle%3DPRC2%2520directly%2520methylates%2520GATA4%2520and%2520represses%2520its%2520transcriptional%2520activity%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26issue%3D1%26spage%3D37%26epage%3D42%26doi%3D10.1101%2Fgad.173930.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanulli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teissandier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancelin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Rocha, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loew, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassef, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlina, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span> <span> </span><span class="NLM_article-title">Jarid2 methylation via the PRC2 Complex regulates H3K27me3 deposition during cell differentiation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2014.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25620564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVarsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2015&pages=769-783&issue=5&author=S.+Sanulliauthor=N.+Justinauthor=A.+Teissandierauthor=K.+Ancelinauthor=M.+Portosoauthor=M.+Caronauthor=A.+Michaudauthor=B.+Lombardauthor=S.+T.+da+Rochaauthor=J.+Offerauthor=D.+Loewauthor=N.+Servantauthor=M.+Wassefauthor=F.+Burlinaauthor=S.+J.+Gamblinauthor=E.+Heardauthor=R.+Margueron&title=Jarid2+methylation+via+the+PRC2+Complex+regulates+H3K27me3+deposition+during+cell+differentiation&doi=10.1016%2Fj.molcel.2014.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Jarid2 methylation via the PRC2 complex regulates H3K27me3 deposition during cell differentiation</span></div><div class="casAuthors">Sanulli, Serena; Justin, Neil; Teissandier, Aurelie; Ancelin, Katia; Portoso, Manuela; Caron, Matthieu; Michaud, Audrey; Lombard, Berangere; da Rocha, Simao T.; Offer, John; Loew, Damarys; Servant, Nicolas; Wassef, Michel; Burlina, Fabienne; Gamblin, Steve J.; Heard, Edith; Margueron, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">769-783</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Polycomb Group (PcG) proteins maintain transcriptional repression throughout development, mostly by regulating chromatin structure.  Polycomb Repressive Complex 2 (PRC2), a component of the Polycomb machinery, is responsible for the methylation of histone H3 lysine 27 (H3K27me2/3).  Jarid2 was previously identified as a cofactor of PRC2, regulating PRC2 targeting to chromatin and its enzymic activity.  Deletion of Jarid2 leads to impaired orchestration of gene expression during cell lineage commitment.  Here, we reveal an unexpected crosstalk between Jarid2 and PRC2, with Jarid2 being methylated by PRC2.  This modification is recognized by the Eed core component of PRC2 and triggers an allosteric activation of PRC2's enzymic activity.  We show that Jarid2 methylation is important to promote PRC2 activity at a locus devoid of H3K27me3 and for the correct deposition of this mark during cell differentiation.  Our results uncover a regulation loop where Jarid2 methylation fine-tunes PRC2 activity depending on the chromatin context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9FjHbs3tCbVg90H21EOLACvtfcHk0lhk8cG1QNhy5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVarsL8%253D&md5=aa87be7e8d1af4c9385966c2ff64d009</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DSanulli%26aufirst%3DS.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DTeissandier%26aufirst%3DA.%26aulast%3DAncelin%26aufirst%3DK.%26aulast%3DPortoso%26aufirst%3DM.%26aulast%3DCaron%26aufirst%3DM.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DLombard%26aufirst%3DB.%26aulast%3Dda%2BRocha%26aufirst%3DS.%2BT.%26aulast%3DOffer%26aufirst%3DJ.%26aulast%3DLoew%26aufirst%3DD.%26aulast%3DServant%26aufirst%3DN.%26aulast%3DWassef%26aufirst%3DM.%26aulast%3DBurlina%26aufirst%3DF.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26aulast%3DHeard%26aufirst%3DE.%26aulast%3DMargueron%26aufirst%3DR.%26atitle%3DJarid2%2520methylation%2520via%2520the%2520PRC2%2520Complex%2520regulates%2520H3K27me3%2520deposition%2520during%2520cell%2520differentiation%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D57%26issue%3D5%26spage%3D769%26epage%3D783%26doi%3D10.1016%2Fj.molcel.2014.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. H.</span></span> <span> </span><span class="NLM_article-title">EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2012.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23063525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSjsrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=572-586&issue=4&author=J.+M.+Leeauthor=J.+S.+Leeauthor=H.+Kimauthor=K.+Kimauthor=H.+Parkauthor=J.+Y.+Kimauthor=S.+H.+Leeauthor=I.+S.+Kimauthor=J.+Kimauthor=M.+Leeauthor=C.+H.+Chungauthor=S.+B.+Seoauthor=J.+B.+Yoonauthor=E.+Koauthor=D.+Y.+Nohauthor=K.+I.+Kimauthor=K.+K.+Kimauthor=S.+H.+Baek&title=EZH2+generates+a+methyl+degron+that+is+recognized+by+the+DCAF1%2FDDB1%2FCUL4+E3+ubiquitin+ligase+complex&doi=10.1016%2Fj.molcel.2012.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex</span></div><div class="casAuthors">Lee, Ji Min; Lee, Jason S.; Kim, Hyunkyung; Kim, Kyeongkyu; Park, Hyejin; Kim, Ji-Young; Lee, Seung Hoon; Kim, Ik Soo; Kim, Joomyung; Lee, Minkyoung; Chung, Chin Ha; Seo, Sang-Beom; Yoon, Jong-Bok; Ko, Eunyoung; Noh, Dong-Young; Kim, Keun Il; Kim, Kyeong Kyu; Baek, Sung Hee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">572-586</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Ubiquitination plays a major role in protein degrdn.  Although phosphorylation-dependent ubiquitination is well known for the regulation of protein stability, methylation-dependent ubiquitination machinery has not been characterized.  Here, we provide evidence that methylation-dependent ubiquitination is carried out by damage-specific DNA binding protein 1 (DDB1)/cullin4 (CUL4) E3 ubiquitin ligase complex and a DDB1-CUL4-assocd. factor 1 (DCAF1) adaptor, which recognizes monomethylated substrates.  Mol. modeling and binding affinity studies reveal that the putative chromo domain of DCAF1 directly recognizes monomethylated substrates, whereas crit. binding pocket mutations of the DCAF1 chromo domain ablated the binding from the monomethylated substrates.  Further, we discovered that enhancer of zeste homolog 2 (EZH2) methyltransferase has distinct substrate specificities for histone H3K27 and nonhistones exemplified by an orphan nuclear receptor, RORα.  We propose that EZH2-DCAF1/DDB1/CUL4 represents a previously unrecognized methylation-dependent ubiquitination machinery specifically recognizing "methyl degron"; through this, nonhistone protein stability can be dynamically regulated in a methylation-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCIV6Wfj-iXrVg90H21EOLACvtfcHk0lhk8cG1QNhy5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSjsrzI&md5=0664aa7b7ca69a21f9b0ea4ccb7b4bd2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DI.%2BS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%2BH.%26aulast%3DSeo%26aufirst%3DS.%2BB.%26aulast%3DYoon%26aufirst%3DJ.%2BB.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DNoh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BI.%26aulast%3DKim%26aufirst%3DK.%2BK.%26aulast%3DBaek%26aufirst%3DS.%2BH.%26atitle%3DEZH2%2520generates%2520a%2520methyl%2520degron%2520that%2520is%2520recognized%2520by%2520the%2520DCAF1%252FDDB1%252FCUL4%2520E3%2520ubiquitin%2520ligase%2520complex%26jtitle%3DMol.%2520Cell%26date%3D2012%26volume%3D48%26issue%3D4%26spage%3D572%26epage%3D586%26doi%3D10.1016%2Fj.molcel.2012.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H. S. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessella, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montironi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magi-Galluzzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantoff, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>338</i></span> (<span class="NLM_issue">6113</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1469</span>, <span class="refDoi"> DOI: 10.1126/science.1227604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1126%2Fscience.1227604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23239736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2012&pages=1465-1469&issue=6113&author=K.+X.+Xuauthor=Z.+J.+Wuauthor=A.+C.+Gronerauthor=H.+S.+H.+S.+Heauthor=C.+M.+Caiauthor=R.+T.+Lisauthor=X.+Q.+Wuauthor=E.+C.+Stackauthor=M.+Lodaauthor=T.+Liuauthor=H.+Xuauthor=L.+Catoauthor=J.+E.+Thorntonauthor=R.+I.+Gregoryauthor=C.+Morrisseyauthor=R.+L.+Vessellaauthor=R.+Montironiauthor=C.+Magi-Galluzziauthor=P.+W.+Kantoffauthor=S.+P.+Balkauthor=X.+S.+Liuauthor=M.+Brown&title=EZH2+oncogenic+activity+in+castration-resistant+prostate+cancer+cells+is+Polycomb-independent&doi=10.1126%2Fscience.1227604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent</span></div><div class="casAuthors">Xu, Kexin; Wu, Zhenhua Jeremy; Groner, Anna C.; He, Housheng Hansen; Cai, Changmeng; Lis, Rosina T.; Wu, Xiaoqiu; Stack, Edward C.; Loda, Massimo; Liu, Tao; Xu, Han; Cato, Laura; Thornton, James E.; Gregory, Richard I.; Morrissey, Colm; Vessella, Robert L.; Montironi, Rodolfo; Magi-Galluzzi, Cristina; Kantoff, Philip W.; Balk, Steven P.; Liu, X. Shirley; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">6113</span>),
    <span class="NLM_cas:pages">1465-1469</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Epigenetic regulators represent a promising new class of therapeutic targets for cancer.  Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity.  We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor.  Instead, it involves the ability of EZH2 to act as a coactivator for crit. transcription factors including the androgen receptor.  This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain.  Hence, targeting the non-PRC2 function of EZH2 may have therapeutic efficacy for treating metastatic, hormone-refractory prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOB2b-7A-UaLVg90H21EOLACvtfcHk0lhk8cG1QNhy5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF&md5=98399f2e6a4c9b07121059772650d2d3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscience.1227604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1227604%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%2BX.%26aulast%3DWu%26aufirst%3DZ.%2BJ.%26aulast%3DGroner%26aufirst%3DA.%2BC.%26aulast%3DHe%26aufirst%3DH.%2BS.%2BH.%2BS.%26aulast%3DCai%26aufirst%3DC.%2BM.%26aulast%3DLis%26aufirst%3DR.%2BT.%26aulast%3DWu%26aufirst%3DX.%2BQ.%26aulast%3DStack%26aufirst%3DE.%2BC.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCato%26aufirst%3DL.%26aulast%3DThornton%26aufirst%3DJ.%2BE.%26aulast%3DGregory%26aufirst%3DR.%2BI.%26aulast%3DMorrissey%26aufirst%3DC.%26aulast%3DVessella%26aufirst%3DR.%2BL.%26aulast%3DMontironi%26aufirst%3DR.%26aulast%3DMagi-Galluzzi%26aufirst%3DC.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DEZH2%2520oncogenic%2520activity%2520in%2520castration-resistant%2520prostate%2520cancer%2520cells%2520is%2520Polycomb-independent%26jtitle%3DScience%26date%3D2012%26volume%3D338%26issue%3D6113%26spage%3D1465%26epage%3D1469%26doi%3D10.1126%2Fscience.1227604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasanthakumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, A. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kueh, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gisbergen, K. P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannarella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majewski, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, R. S.</span></span> <span> </span><span class="NLM_article-title">A non-canonical function of EZH2 preserves immune homeostasis</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.15252/embr.201643237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.15252%2Fembr.201643237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28223321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFers7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=619-631&issue=4&author=A.+Vasanthakumarauthor=D.+K.+Xuauthor=A.+T.+L.+Lunauthor=A.+J.+Kuehauthor=K.+P.+J.+M.+van+Gisbergenauthor=N.+Iannarellaauthor=X.+F.+Liauthor=L.+Yuauthor=D.+Wangauthor=B.+R.+G.+Williamsauthor=S.+C.+W.+Leeauthor=I.+J.+Majewskiauthor=D.+I.+Godfreyauthor=G.+K.+Smythauthor=W.+S.+Alexanderauthor=M.+J.+Heroldauthor=A.+Kalliesauthor=S.+L.+Nuttauthor=R.+S.+Allan&title=A+non-canonical+function+of+EZH2+preserves+immune+homeostasis&doi=10.15252%2Fembr.201643237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A non-canonical function of Ezh2 preserves immune homeostasis</span></div><div class="casAuthors">Vasanthakumar, Ajithkumar; Xu, Dakang; Lun, Aaron T. L.; Kueh, Andrew J.; van Gisbergen, Klaas P. J. M.; Iannarella, Nadia; Li, Xiaofang; Yu, Liang; Wang, Die; Williams, Bryan R. G.; Lee, Stanley C. W.; Majewski, Ian J.; Godfrey, Dale I.; Smyth, Gordon K.; Alexander, Warren S.; Herold, Marco J.; Kallies, Axel; Nutt, Stephen L.; Allan, Rhys S.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">619-631</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Enhancer of zeste 2 (Ezh2) mainly methylates lysine 27 of histone-H3 (H3K27me3) as part of the polycomb repressive complex 2 (PRC2) together with Suz12 and Eed.  However, Ezh2 can also modify non-histone substrates, although it is unclear whether this mechanism has a role during development.  Here, we present evidence for a chromatin-independent role of Ezh2 during T-cell development and immune homeostasis.  T-cell-specific depletion of Ezh2 induces a pronounced expansion of natural killer T (NKT) cells, although Ezh2-deficient T cells maintain normal levels of H3K27me3.  In contrast, removal of Suz12 or Eed destabilizes canonical PRC2 function and ablates NKT cell development completely.  We further show that Ezh2 directly methylates the NKT cell lineage defining transcription factor PLZF, leading to its ubiquitination and subsequent degrdn.  Sustained PLZF expression in Ezh2-deficient mice is assocd. with the expansion of a subset of NKT cells that cause immune perturbation.  Taken together, we have identified a chromatin-independent function of Ezh2 that impacts on the development of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8yVKmL-d0c7Vg90H21EOLACvtfcHk0li5Ytzi7rUo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFers7Y%253D&md5=cbc47ab9e46272a6aa281812566e4ea1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.15252%2Fembr.201643237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201643237%26sid%3Dliteratum%253Aachs%26aulast%3DVasanthakumar%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DD.%2BK.%26aulast%3DLun%26aufirst%3DA.%2BT.%2BL.%26aulast%3DKueh%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGisbergen%26aufirst%3DK.%2BP.%2BJ.%2BM.%26aulast%3DIannarella%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%2BF.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DB.%2BR.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BC.%2BW.%26aulast%3DMajewski%26aufirst%3DI.%2BJ.%26aulast%3DGodfrey%26aufirst%3DD.%2BI.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DAlexander%26aufirst%3DW.%2BS.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DKallies%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DS.%2BL.%26aulast%3DAllan%26aufirst%3DR.%2BS.%26atitle%3DA%2520non-canonical%2520function%2520of%2520EZH2%2520preserves%2520immune%2520homeostasis%26jtitle%3DEMBO%2520Rep.%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D619%26epage%3D631%26doi%3D10.15252%2Fembr.201643237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPrie, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merajver, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleer, C. G.</span></span> <span> </span><span class="NLM_article-title">Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2360</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F0008-5472.CAN-10-1933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=21406404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2360-2370&issue=6&author=M.+E.+Gonzalezauthor=M.+L.+DuPrieauthor=H.+Kruegerauthor=S.+D.+Merajverauthor=A.+C.+Venturaauthor=K.+A.+Toyauthor=C.+G.+Kleer&title=Histone+methyltransferase+EZH2+induces+Akt-dependent+genomic+instability+and+BRCA1+inhibition+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-10-1933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer</span></div><div class="casAuthors">Gonzalez, Maria E.; DuPrie, Matthew L.; Krueger, Heather; Merajver, Sofia D.; Ventura, Alejandra C.; Toy, Kathy A.; Kleer, Celina G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2360-2370</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Increased levels of EZH2, a crit. regulator of cellular memory, signal the presence of metastasis and poor outcome in breast cancer patients.  High levels of EZH2 are assocd. with nuclear pleomorphism, lack of estrogen receptor expression, and decreased nuclear levels of BRCA1 tumor suppressor protein in invasive breast carcinomas.  The mechanism by which EZH2 overexpression promotes the growth of poorly differentiated invasive carcinomas remains to be defined.  Here, we show that EZH2 controls the intracellular localization of BRCA1 protein.  Conditional doxycycline-induced upregulation of EZH2 in benign mammary epithelial cells results in nuclear export of BRCA1 protein, aberrant mitoses with extra centrosomes, and genomic instability.  EZH2 inhibition in CAL51 breast cancer cells induces BRCA1 nuclear localization and rescues defects in ploidy and mitosis.  Mechanistically, EZH2 overexpression is sufficient for activation of the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway specifically through activation of Akt isoform 1.  EZH2-induced BRCA1 nuclear export, aneuploidy, and mitotic defects were prevented by treatment with the PI3K inhibitors LY294002 or wortmannin.  Targeted inhibition of Akt-1, Akt-2, and Akt-3 isoforms revealed that the EZH2-induced phenotype requires specific activation of Akt-1.  The relevance of our studies to human breast cancer is highlighted by the finding that high EZH2 protein levels are assocd. with upregulated expression of phospho-Akt-1 (Ser473) and decreased nuclear expression of phospho-BRCA1 (Ser1423) in 39% of invasive breast carcinomas.  These results enable us to pinpoint one mechanism by which EZH2 regulates BRCA1 expression and genomic stability mediated by the PI3K/Akt-1 pathway.  Cancer Res; 71(6); 2360-70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP-z2MC7DxNrVg90H21EOLACvtfcHk0li5Ytzi7rUo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtbg%253D&md5=a6e189f7f529f4f0096df9e57c4aa0da</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1933%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DM.%2BE.%26aulast%3DDuPrie%26aufirst%3DM.%2BL.%26aulast%3DKrueger%26aufirst%3DH.%26aulast%3DMerajver%26aufirst%3DS.%2BD.%26aulast%3DVentura%26aufirst%3DA.%2BC.%26aulast%3DToy%26aufirst%3DK.%2BA.%26aulast%3DKleer%26aufirst%3DC.%2BG.%26atitle%3DHistone%2520methyltransferase%2520EZH2%2520induces%2520Akt-dependent%2520genomic%2520instability%2520and%2520BRCA1%2520inhibition%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26issue%3D6%26spage%3D2360%26epage%3D2370%26doi%3D10.1158%2F0008-5472.CAN-10-1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karuturi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span> <span> </span><span class="NLM_article-title">Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2011.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2011.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=21884980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFeku7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=798-810&issue=5&author=S.+T.+Leeauthor=Z.+Liauthor=Z.+Wuauthor=M.+Aauauthor=P.+Guanauthor=R.+K.+Karuturiauthor=Y.+C.+Liouauthor=Q.+Yu&title=Context-specific+regulation+of+NF-kappaB+target+gene+expression+by+EZH2+in+breast+cancers&doi=10.1016%2Fj.molcel.2011.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers</span></div><div class="casAuthors">Lee, Shuet Theng; Li, Zhimei; Wu, Zhenlong; Aau, Meiyee; Guan, Peiyong; Karuturi, R. K. Murthy; Liou, Yih Cherng; Yu, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">798-810</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Both EZH2 and NF-κB contribute to aggressive breast cancer, yet whether the two oncogenic factors have functional crosstalk in breast cancer is unknown.  Here, we uncover an unexpected role of EZH2 in conferring the constitutive activation of NF-κB target gene expression in ER-neg. basal-like breast cancer cells.  This function of EZH2 is independent of its histone methyltransferase activity but requires the phys. interaction with RelA/RelB to promote the expression of NF-κB targets.  Intriguingly, EZH2 acts oppositely in ER-pos. luminal-like breast cancer cells and represses NF-κB target gene expression by interacting with ER and directing repressive histone methylation on their promoters.  Thus, EZH2 functions as a double-facet mol. in breast cancers, either as a transcriptional activator or repressor of NF-κB targets, depending on the cellular context.  These findings reveal an addnl. mechanism by which EZH2 promotes breast cancer progression and underscore the need for developing context-specific strategy for therapeutic targeting of EZH2 in breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMMWhUS9c9mbVg90H21EOLACvtfcHk0liSygRp5oY9kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFeku7jI&md5=ef7af348dd09e2256df2e29d04f8686b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DAau%26aufirst%3DM.%26aulast%3DGuan%26aufirst%3DP.%26aulast%3DKaruturi%26aufirst%3DR.%2BK.%26aulast%3DLiou%26aufirst%3DY.%2BC.%26aulast%3DYu%26aufirst%3DQ.%26atitle%3DContext-specific%2520regulation%2520of%2520NF-kappaB%2520target%2520gene%2520expression%2520by%2520EZH2%2520in%2520breast%2520cancers%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D43%26issue%3D5%26spage%3D798%26epage%3D810%26doi%3D10.1016%2Fj.molcel.2011.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsherniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haswell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walensky, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. W.</span></span> <span> </span><span class="NLM_article-title">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1038/nm.3968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnm.3968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26552009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1491-1496&issue=12&author=K.+H.+Kimauthor=W.+Kimauthor=T.+P.+Howardauthor=F.+Vazquezauthor=A.+Tsherniakauthor=J.+N.+Wuauthor=W.+Wangauthor=J.+R.+Haswellauthor=L.+D.+Walenskyauthor=W.+C.+Hahnauthor=S.+H.+Orkinauthor=C.+W.+Roberts&title=SWI%2FSNF-mutant+cancers+depend+on+catalytic+and+non-catalytic+activity+of+EZH2&doi=10.1038%2Fnm.3968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span></div><div class="casAuthors">Kim, Kimberly H.; Kim, Woojin; Howard, Thomas P.; Vazquez, Francisca; Tsherniak, Aviad; Wu, Jennifer N.; Wang, Weishan; Haswell, Jeffrey R.; Walensky, Loren D.; Hahn, William C.; Orkin, Stuart H.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1496</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity.  However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown.  Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence.  Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity.  These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymic inhibitors now in clin. development may not fully suppress the oncogenic activity of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjhQKP01U5bVg90H21EOLACvtfcHk0liSygRp5oY9kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK&md5=a30c11fe7ce3c20e982e824105b8d640</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnm.3968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3968%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHoward%26aufirst%3DT.%2BP.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHaswell%26aufirst%3DJ.%2BR.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26atitle%3DSWI%252FSNF-mutant%2520cancers%2520depend%2520on%2520catalytic%2520and%2520non-catalytic%2520activity%2520of%2520EZH2%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D1491%26epage%3D1496%26doi%3D10.1038%2Fnm.3968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weroha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnes, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e99599</span> <span class="refDoi"> DOI: 10.15252/embj.201899599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.15252%2Fembj.201899599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30723117" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&issue=5&author=Y.+Zhaoauthor=L.+Dingauthor=D.+Wangauthor=Z.+Yeauthor=Y.+Heauthor=L.+Maauthor=R.+Zhuauthor=Y.+Panauthor=Q.+Wuauthor=K.+Pangauthor=X.+Houauthor=S.+J.+Werohaauthor=C.+Hanauthor=R.+Colemanauthor=I.+Colemanauthor=R.+J.+Karnesauthor=J.+Zhangauthor=P.+S.+Nelsonauthor=L.+Wangauthor=H.+Huang&title=EZH2+cooperates+with+gain-of-function+p53+mutants+to+promote+cancer+growth+and+metastasis&doi=10.15252%2Fembj.201899599"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.15252%2Fembj.201899599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201899599%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DPang%26aufirst%3DK.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DWeroha%26aufirst%3DS.%2BJ.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DColeman%26aufirst%3DI.%26aulast%3DKarnes%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DP.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DEZH2%2520cooperates%2520with%2520gain-of-function%2520p53%2520mutants%2520to%2520promote%2520cancer%2520growth%2520and%2520metastasis%26jtitle%3DEMBO%2520J.%26date%3D2019%26volume%3D38%26issue%3D5%26doi%3D10.15252%2Fembj.201899599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garapaty-Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span> <span> </span><span class="NLM_article-title">EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1463</span>– <span class="NLM_lpage">1475</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2014.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25457180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1463-1475&issue=11&author=W.+D.+Bradleyauthor=S.+Aroraauthor=J.+Busbyauthor=S.+Balasubramanianauthor=V.+S.+Gehlingauthor=C.+G.+Nasveschukauthor=R.+G.+Vaswaniauthor=C.+C.+Yuanauthor=C.+Hattonauthor=F.+Zhaoauthor=K.+E.+Williamsonauthor=P.+Iyerauthor=J.+Mendezauthor=R.+Campbellauthor=N.+Cantoneauthor=S.+Garapaty-Raoauthor=J.+E.+Audiaauthor=A.+S.+Cookauthor=L.+A.+Dakinauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=D.+L.+Danielsauthor=R.+T.+Cummingsauthor=B.+M.+Bryantauthor=E.+Normantauthor=P.+Trojer&title=EZH2+inhibitor+efficacy+in+non-Hodgkin%E2%80%99s+lymphoma+does+not+require+suppression+of+H3K27+monomethylation&doi=10.1016%2Fj.chembiol.2014.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation</span></div><div class="casAuthors">Bradley, William D.; Arora, Shilpi; Busby, Jennifer; Balasubramanian, Srividya; Gehling, Victor S.; Nasveschuk, Christopher G.; Vaswani, Rishi G.; Yuan, Chih-Chi; Hatton, Charlie; Zhao, Feng; Williamson, Kaylyn E.; Iyer, Priyadarshini; Mendez, Jacqui; Campbell, Robert; Cantone, Nico; Garapaty-Rao, Shivani; Audia, James E.; Cook, Andrew S.; Dakin, Les A.; Albrecht, Brian K.; Harmange, Jean-Christophe; Daniels, Danette L.; Cummings, Richard T.; Bryant, Barbara M.; Normant, Emmanuel; Trojer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1463-1475</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an oncogenic driver in a subset of germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) and follicular lymphoma due to the presence of recurrent, monoallelic mutations in the EZH2 catalytic domain.  These genomic data suggest that targeting the EZH2 MT activity is a valid therapeutic strategy for the treatment of lymphoma patients with EZH2 mutations.  Here we report the identification of highly potent and selective EZH2 small mol. inhibitors, their validation by a cellular thermal shift assay, application across a large cell panel representing various non-Hodgkin's lymphoma (NHL) subtypes, and their efficacy in EZH2 mutant-contg. GCB-DLBCL xenograft models.  Surprisingly, our EZH2 inhibitors selectively affect the turnover of trimethylated, but not monomethylated histone H3 lysine 27 at pharmacol. relevant doses.  Importantly, we find that these inhibitors are broadly efficacious also in NHL models with wild-type EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxrMoLW0OWCbVg90H21EOLACvtfcHk0lj1BaxNsktIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7rE&md5=40b8f604e762dda9420afedede75fd36</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DBusby%26aufirst%3DJ.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DWilliamson%26aufirst%3DK.%2BE.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DMendez%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DGarapaty-Rao%26aufirst%3DS.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DTrojer%26aufirst%3DP.%26atitle%3DEZH2%2520inhibitor%2520efficacy%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520does%2520not%2520require%2520suppression%2520of%2520H3K27%2520monomethylation%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D11%26spage%3D1463%26epage%3D1475%26doi%3D10.1016%2Fj.chembiol.2014.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span> <span> </span><span class="NLM_article-title">Discovery, design, and synthesis of indole-based EZH2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3644</span>– <span class="NLM_lpage">3649</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.06.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2015.06.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26189078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3644-3649&issue=17&author=V.+S.+Gehlingauthor=R.+G.+Vaswaniauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=A.+Gagnonauthor=J.+C.+Harmangeauthor=J.+E.+Audiaauthor=R.+T.+Cummingsauthor=E.+Normantauthor=P.+Trojerauthor=B.+K.+Albrecht&title=Discovery%2C+design%2C+and+synthesis+of+indole-based+EZH2+inhibitors&doi=10.1016%2Fj.bmcl.2015.06.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, design, and synthesis of indole-based EZH2 inhibitors</span></div><div class="casAuthors">Gehling, Victor S.; Vaswani, Rishi G.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Dakin, Les A.; Cook, Andrew S.; Gagnon, Alexandre; Harmange, Jean-Christophe; Audia, James E.; Cummings, Richard T.; Normant, Emmanuel; Trojer, Patrick; Albrecht, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3644-3649</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of small mol. EZH2 inhibitors is described.  Starting from dimethylpyridone HTS hit, a series of indole-based EZH2 inhibitors were identified.  Biochem. potency and microsomal stability were optimized during these studies and afforded compd. (I).  Compd. I demonstrates nanomolar levels of biochem. potency (IC50 = 0.002 μM), cellular potency (EC50 = 0.080 μM), and afforded tumor regression when dosed (200 mpk SC BID) in an EZH2 dependent tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3fNkOZEdBj7Vg90H21EOLACvtfcHk0lj1BaxNsktIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhtrfF&md5=3c8dbee5ab370627568fd48082bf1719</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.056%26sid%3Dliteratum%253Aachs%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DDiscovery%252C%2520design%252C%2520and%2520synthesis%2520of%2520indole-based%2520EZH2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D17%26spage%3D3644%26epage%3D3649%26doi%3D10.1016%2Fj.bmcl.2015.06.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span> <span> </span><span class="NLM_article-title">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1 -(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-Cell lymphomas</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9928</span>– <span class="NLM_lpage">9941</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9928-9941&issue=21&author=R.+G.+Vaswaniauthor=V.+S.+Gehlingauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=N.+Cantoneauthor=R.+T.+Cummingsauthor=E.+Normantauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=P.+Trojerauthor=J.+E.+Audiaauthor=Y.+Zhangauthor=N.+Justinauthor=S.+Chenauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Identification+of+%28R%29-N-%28%284-Methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-2-methyl-1-%281-%281+-%282%2C2%2C2-trifluoroethyl%29piperidin-4-yl%29ethyl%29-1H-indole-3-carboxamide+%28CPI-1205%29%2C+a+potent+and+selective+inhibitor+of+histone+methyltransferase+EZH2%2C+suitable+for+phase+I+clinical+trials+for+B-Cell+lymphomas&doi=10.1021%2Facs.jmedchem.6b01315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span></div><div class="casAuthors">Vaswani, Rishi G.; Gehling, Victor S.; Dakin, Les A.; Cook, Andrew S.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Cantone, Nico; Cummings, Richard T.; Normant, Emmanuel; Bellon, Steven F.; Albrecht, Brian K.; Harmange, Jean-Christophe; Trojer, Patrick; Audia, James E.; Zhang, Ying; Justin, Neil; Chen, Shuyang; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9928-9941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3.  Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis.  EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncol. target for pharmacol. intervention.  Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochem. IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.  This compd. demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clin. trials.  Addnl., we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqnfg3FGdE7Vg90H21EOLACvtfcHk0ljrazsj-iFAvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I&md5=4096fa91399fef88a7ec8aabb5aaee13</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01315%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DIdentification%2520of%2520%2528R%2529-N-%2528%25284-Methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-2-methyl-1-%25281-%25281%2520-%25282%252C2%252C2-trifluoroethyl%2529piperidin-4-yl%2529ethyl%2529-1H-indole-3-carboxamide%2520%2528CPI-1205%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520histone%2520methyltransferase%2520EZH2%252C%2520suitable%2520for%2520phase%2520I%2520clinical%2520trials%2520for%2520B-Cell%2520lymphomas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9928%26epage%3D9941%26doi%3D10.1021%2Facs.jmedchem.6b01315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Roder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&issue=8&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-Roderauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Muller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0liP-wzlObXCOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-Roder%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D8%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taplin, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenfield, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartor, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordquist, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatta, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bupathi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedinsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span> <span> </span><span class="NLM_article-title">Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">CT094</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-CT094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F1538-7445.AM2019-CT094" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=CT094&issue=13%2C+Suppl.&author=M.-E.+Taplinauthor=A.+Hussainauthor=S.+Shahauthor=N.+D.+Shoreauthor=W.+J.+Edenfieldauthor=O.+A.+Sartorauthor=L.+T.+Nordquistauthor=M.+Agrawalauthor=W.+Clarkauthor=D.+R.+Wiseauthor=W.+K.+Ohauthor=M.+T.+Flemingauthor=J.+E.+Butrynskiauthor=G.+S.+Chattaauthor=M.+Bupathiauthor=C.+Lebedinskyauthor=A.+Senderowiczauthor=J.+Liauthor=G.+Colakauthor=D.+Nashauthor=P.+Trojerauthor=W.+D.+Bradleyauthor=J.+Pielauthor=E.+S.+Antonarakis&title=Abstract+CT094%3A+Phase+Ib+results+of+ProSTAR%3A+CPI-1205%2C+EZH2+inhibitor%2C+combined+with+enzalutamide+%28E%29+or+abiraterone%2Fprednisone+%28A%2FP%29+in+patients+with+metastatic+castration-resistant+prostate+cancer+%28mCRPC%29&doi=10.1158%2F1538-7445.AM2019-CT094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-CT094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-CT094%26sid%3Dliteratum%253Aachs%26aulast%3DTaplin%26aufirst%3DM.-E.%26aulast%3DHussain%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DShore%26aufirst%3DN.%2BD.%26aulast%3DEdenfield%26aufirst%3DW.%2BJ.%26aulast%3DSartor%26aufirst%3DO.%2BA.%26aulast%3DNordquist%26aufirst%3DL.%2BT.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DW.%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DOh%26aufirst%3DW.%2BK.%26aulast%3DFleming%26aufirst%3DM.%2BT.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DChatta%26aufirst%3DG.%2BS.%26aulast%3DBupathi%26aufirst%3DM.%26aulast%3DLebedinsky%26aufirst%3DC.%26aulast%3DSenderowicz%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DColak%26aufirst%3DG.%26aulast%3DNash%26aufirst%3DD.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DPiel%26aufirst%3DJ.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26atitle%3DAbstract%2520CT094%253A%2520Phase%2520Ib%2520results%2520of%2520ProSTAR%253A%2520CPI-1205%252C%2520EZH2%2520inhibitor%252C%2520combined%2520with%2520enzalutamide%2520%2528E%2529%2520or%2520abiraterone%252Fprednisone%2520%2528A%252FP%2529%2520in%2520patients%2520with%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520%2528mCRPC%2529%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%252C%2520Suppl%26spage%3DCT094%26doi%3D10.1158%2F1538-7445.AM2019-CT094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toulmonde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coindre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span> <span> </span><span class="NLM_article-title">Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30145-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS1470-2045%2818%2930145-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29650362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlCmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=649-659&issue=5&author=A.+Italianoauthor=J.+C.+Soriaauthor=M.+Toulmondeauthor=J.+M.+Michotauthor=C.+Lucchesiauthor=A.+Vargaauthor=J.+M.+Coindreauthor=S.+J.+Blakemoreauthor=A.+Clawsonauthor=B.+Suttleauthor=A.+A.+McDonaldauthor=M.+Woodruffauthor=S.+Ribichauthor=E.+Hedrickauthor=H.+Keilhackauthor=B.+Thomsonauthor=T.+Owaauthor=R.+A.+Copelandauthor=P.+T.+C.+Hoauthor=V.+Ribrag&title=Tazemetostat%2C+an+EZH2+inhibitor%2C+in+relapsed+or+refractory+B-cell+non-Hodgkin+lymphoma+and+advanced+solid+tumours%3A+a+first-in-human%2C+open-label%2C+phase+1+study&doi=10.1016%2FS1470-2045%2818%2930145-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study</span></div><div class="casAuthors">Italiano, Antoine; Soria, Jean-Charles; Toulmonde, Maud; Michot, Jean-Marie; Lucchesi, Carlo; Varga, Andrea; Coindre, Jean-Michel; Blakemore, Stephen J.; Clawson, Alicia; Suttle, Benjamin; McDonald, Alice A.; Woodruff, Mark; Ribich, Scott; Hedrick, Eric; Keilhack, Heike; Thomson, Blythe; Owa, Takashi; Copeland, Robert A.; Ho, Peter T. C.; Ribrag, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">649-659</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to aberrant histone methylation, oncogenic transformation, and a proliferative dependency on EZH2 activity.  In this first-in-human study, we aimed to investigate the safety, clin. activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of EZH2.  We did an open-label, multicentre, dose-escalation, phase 1 study using a 3 + 3 design with planned cohort expansion at the two highest doses below the maximally tolerated dose.  The study was done at two centers in France: Institut Gustave Roussy (Villejuif, Val de Marne) and Institut Bergonie´ (Bordeaux, Gironde).  Eligible patients had relapsed or refractory B-cell non-Hodgkin lymphoma or an advanced solid tumor and were older than 18 years, with Eastern Cooperative Oncol. Group performance status of 0 or 1, and adequate end-organ function.  Tazemetostat was administered orally from 100 mg twice daily to 1600 mg twice daily in 28-day cycles.  The primary endpoint was to establish the max. tolerated dose or recommended phase 2 dose of tazemetostat, as detd. by dose-limiting toxicities, lab. values, and other safety or pharmacokinetic measures in cycle one according to local investigator assessment.  Safety was assessed in patients who received at least one dose of tazemetostat; antitumor activity was assessed in the intention-to-treat population.  This study is registered with ClinicalTrials.gov, no. NCT01897571.  The phase 1 part of the study is complete, and phase 2 is ongoing.  Between June 13, 2013, and Sept 21, 2016, 64 patients (21 with B-cell non-Hodgkin lymphoma, and 43 with advanced solid tumors) received doses of tazemetostat.  The most common treatment-related adverse events, regardless of attribution, were asthenia (21 [33%] of 64 treatment-related events), anemia (nine [14%]), anorexia (four [6%]), muscle spasms (nine [14%]), nausea (13 [20%]), and vomiting (six [9%]), usually grade 1 or 2 in severity.  A single dose-limiting toxicity of grade 4 thrombocytopenia was identified at the highest dose of 1600 mg twice daily.  No treatment-related deaths occurred; seven (11%) patients had non-treatment-related deaths (one at 200 mg twice daily, four at 400 mg twice daily, and two at 1600 mg twice daily).  The recommended phase 2 dose was detd. to be 800 mg twice daily.  Durable objective responses, including complete responses, were obsd. in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumors.  Tazemetostat showed a favorable safety profile and antitumor activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumors, including epithelioid sarcoma.  Further clin. investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-neg. or SMARCA4-neg. tumors.Epizyme and Eisai.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_63Re30rP1LVg90H21EOLACvtfcHk0lgZpgD9kkkW2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlCmtLo%253D&md5=9c4d4c1d3241c1b5043547acd1ff078f</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930145-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930145-1%26sid%3Dliteratum%253Aachs%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DToulmonde%26aufirst%3DM.%26aulast%3DMichot%26aufirst%3DJ.%2BM.%26aulast%3DLucchesi%26aufirst%3DC.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DCoindre%26aufirst%3DJ.%2BM.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DClawson%26aufirst%3DA.%26aulast%3DSuttle%26aufirst%3DB.%26aulast%3DMcDonald%26aufirst%3DA.%2BA.%26aulast%3DWoodruff%26aufirst%3DM.%26aulast%3DRibich%26aufirst%3DS.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DThomson%26aufirst%3DB.%26aulast%3DOwa%26aufirst%3DT.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DHo%26aufirst%3DP.%2BT.%2BC.%26aulast%3DRibrag%26aufirst%3DV.%26atitle%3DTazemetostat%252C%2520an%2520EZH2%2520inhibitor%252C%2520in%2520relapsed%2520or%2520refractory%2520B-cell%2520non-Hodgkin%2520lymphoma%2520and%2520advanced%2520solid%2520tumours%253A%2520a%2520first-in-human%252C%2520open-label%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26issue%3D5%26spage%3D649%26epage%3D659%26doi%3D10.1016%2FS1470-2045%2818%2930145-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span>; <span class="NLM_string-name">Suttle, B.</span>; <span class="NLM_string-name">Waters, N. L.</span>; <span class="NLM_string-name">Ribrag, V.</span>; <span class="NLM_string-name">Italiano, A.</span>; <span class="NLM_string-name">Michot, J.-M.</span>; <span class="NLM_string-name">Postel-Vinay, S.</span>; <span class="NLM_string-name">Toulmonde, M.</span>; <span class="NLM_string-name">Cousin, S.</span>; <span class="NLM_string-name">Roche, M.</span>; <span class="NLM_string-name">Pimentel, P.</span>; <span class="NLM_string-name">Ho, P.</span></span> <span> </span><span class="NLM_article-title">The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors</span>. Presented at the AACR 107th Annual Meeting, <span class="NLM_year">2016</span>, New Orleans, LA; Abstract CT029.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Smith&author=B.+Suttle&author=N.+L.+Waters&author=V.+Ribrag&author=A.+Italiano&author=J.-M.+Michot&author=S.+Postel-Vinay&author=M.+Toulmonde&author=S.+Cousin&author=M.+Roche&author=P.+Pimentel&author=P.+Ho&title=The+effect+of+tazemetostat+on+CYP3A-mediated+metabolism+of+midazolam+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%26atitle%3DThe%2520effect%2520of%2520tazemetostat%2520on%2520CYP3A-mediated%2520metabolism%2520of%2520midazolam%2520in%2520patients%2520with%2520solid%2520tumors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruderek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levell, J. R.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacologicaleEvaluation of second generation EZH2 inhibitors with long residence time</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1205-1212&author=A.+Khannaauthor=A.+C%C3%B4t%C3%A9author=S.+Aroraauthor=L.+Moineauthor=V.+S.+Gehlingauthor=J.+Brennemanauthor=N.+Cantoneauthor=J.+I.+Stuckeyauthor=S.+Apteauthor=A.+Ramakrishnanauthor=K.+Bruderekauthor=W.+D.+Bradleyauthor=J.+E.+Audiaauthor=R.+T.+Cummingsauthor=R.+J.+Simsauthor=P.+Trojerauthor=J.+R.+Levell&title=Design%2C+synthesis%2C+and+pharmacologicaleEvaluation+of+second+generation+EZH2+inhibitors+with+long+residence+time&doi=10.1021%2Facsmedchemlett.0c00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time</span></div><div class="casAuthors">Khanna, Avinash; Cote, Alexandre; Arora, Shilpi; Moine, Ludivine; Gehling, Victor S.; Brenneman, Jehrod; Cantone, Nico; Stuckey, Jacob I.; Apte, Shruti; Ramakrishnan, Ashwin; Bruderek, Kamil; Bradley, William D.; Audia, James E.; Cummings, Richard T.; Sims, Robert J.; Trojer, Patrick; Levell, Julian R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1205-1212</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27-a transcriptionally repressive post-translational modification (PTM).  EZH2 is commonly mutated in hematol. malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis.  First generation EZH2 inhibitors are beginning to show clin. benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition.  During our medicinal chem. campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time.  Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochem. properties, which have the potential to expand the clin. use of EZH2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx-ixCY_R5KrVg90H21EOLACvtfcHk0lgZpgD9kkkW2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D&md5=e54bac34b75f41d6b82666016df08c1f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00045%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DMoine%26aufirst%3DL.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DBrenneman%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DStuckey%26aufirst%3DJ.%2BI.%26aulast%3DApte%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DA.%26aulast%3DBruderek%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DLevell%26aufirst%3DJ.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacologicaleEvaluation%2520of%2520second%2520generation%2520EZH2%2520inhibitors%2520with%2520long%2520residence%2520time%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1205%26epage%3D1212%26doi%3D10.1021%2Facsmedchemlett.0c00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardayfio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">21360</span>– <span class="NLM_lpage">21365</span>, <span class="refDoi"> DOI: 10.1073/pnas.1210371110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1210371110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23236167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21360-21365&issue=52&author=W.+Qiauthor=H.+Chanauthor=L.+Tengauthor=L.+Liauthor=S.+Chuaiauthor=R.+Zhangauthor=J.+Zengauthor=M.+Liauthor=H.+Fanauthor=Y.+Linauthor=J.+Guauthor=O.+Ardayfioauthor=J.+H.+Zhangauthor=X.+Yanauthor=J.+Fangauthor=Y.+Miauthor=M.+Zhangauthor=T.+Zhouauthor=G.+Fengauthor=Z.+Chenauthor=G.+Liauthor=T.+Yangauthor=K.+Zhaoauthor=X.+Liuauthor=Z.+Yuauthor=C.+X.+Luauthor=P.+Atadjaauthor=E.+Li&title=Selective+inhibition+of+EZH2+by+a+small+molecule+inhibitor+blocks+tumor+cells+proliferation&doi=10.1073%2Fpnas.1210371110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation</span></div><div class="casAuthors">Qi, Wei; Chan, Homan; Teng, Lin; Li, Ling; Chuai, Shannon; Zhang, Ruipeng; Zeng, Jue; Li, Min; Fan, Hong; Lin, Ying; Gu, Justin; Ardayfio, Ophelia; Zhang, Ji-Hu; Yan, Xiaoxia; Fang, Jialuo; Mi, Yuan; Zhang, Man; Zhou, Tao; Feng, Grace; Chen, Zijun; Li, Guobin; Yang, Teddy; Zhao, Kehao; Liu, Xianghui; Yu, Zhengtian; Lu, Chris X.; Atadja, Peter; Li, En</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21360-21365, S21360/1-S21360/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ezh2 (Enhancer of zeste homolog 2) protein is the enzymic component of the Polycomb repressive complex 2 (PRC2), which represses gene expression by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation and differentiation during embryonic development.  Recently, hot-spot mutations of Ezh2 were identified in diffused large B-cell lymphomas and follicular lymphomas.  To investigate if tumor growth is dependent on the enzymic activity of Ezh2, the authors developed a potent and selective small mol. inhibitor, EI1, which inhibits the enzymic activity of Ezh2 through direct binding to the enzyme and competing with the Me group donor S-Adenosyl methionine.  EI1-treated cells exhibit genome-wide loss of H3K27 methylation and activation of PRC2 target genes.  Furthermore, inhibition of Ezh2 by EI1 in diffused large B-cell lymphomas cells carrying the Y641 mutations results in decreased proliferation, cell cycle arrest, and apoptosis.  These results provide strong validation of Ezh2 as a potential therapeutic target for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR1oWnCAdMmrVg90H21EOLACvtfcHk0liuhyfWjG7N4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSnsA%253D%253D&md5=b85578201119e39887e323aad25d959b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1210371110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1210371110%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChuai%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DArdayfio%26aufirst%3DO.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DC.%2BX.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DE.%26atitle%3DSelective%2520inhibition%2520of%2520EZH2%2520by%2520a%2520small%2520molecule%2520inhibitor%2520blocks%2520tumor%2520cells%2520proliferation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D52%26spage%3D21360%26epage%3D21365%26doi%3D10.1073%2Fpnas.1210371110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satalkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shete, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severance, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span> <span> </span><span class="NLM_article-title">Novel 3-methylindoline inhibitors of EZH2: design, synthesis and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2016.11.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27923618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWmtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=217-222&issue=2&author=A.+Ansariauthor=S.+Satalkarauthor=V.+Patilauthor=A.+S.+Sheteauthor=S.+Kaurauthor=A.+Guptaauthor=S.+Singhauthor=M.+Rajaauthor=D.+L.+Severanceauthor=S.+Bernalesauthor=S.+Chakravartyauthor=D.+T.+Hungauthor=S.+M.+Phamauthor=F.+J.+Herreraauthor=R.+Rai&title=Novel+3-methylindoline+inhibitors+of+EZH2%3A+design%2C+synthesis+and+SAR&doi=10.1016%2Fj.bmcl.2016.11.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR</span></div><div class="casAuthors">Ansari, Amantullah; Satalkar, Sharad; Patil, Varshavekumar; Shete, Amit S.; Kaur, Simranjeet; Gupta, Ashu; Singh, Siddhartha; Raja, Mohd.; Severance, Daniel L.; Bernales, Sebastian; Chakravarty, Sarvajit; Hung, David T.; Pham, Son M.; Herrera, Francisco J.; Rai, Roopa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-222</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">EZH2 (enhancer of zeste homolog 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27).  Dysregulation of EZH2 activity is assocd. with several human cancers and therefore EZH2 inhibition has emerged as a promising therapeutic target.  Several small mol. EZH2 inhibitors with different chemotypes have been reported in the literature, many of which use a bicyclic heteroaryl core.  Herein, we report the design and synthesis of EZH2 inhibitors contg. an indoline core, such as I.  Partial satn. of an indole to an indoline provided lead compds. with nanomolar activity against EZH2, while also improving soly. and oxidative metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoExJWdsv7qhrVg90H21EOLACvtfcHk0liuhyfWjG7N4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWmtLvN&md5=7bfc9701f14188d45807afc0dcde1c50</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.080%26sid%3Dliteratum%253Aachs%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSatalkar%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DShete%26aufirst%3DA.%2BS.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DRaja%26aufirst%3DM.%26aulast%3DSeverance%26aufirst%3DD.%2BL.%26aulast%3DBernales%26aufirst%3DS.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DHung%26aufirst%3DD.%2BT.%26aulast%3DPham%26aufirst%3DS.%2BM.%26aulast%3DHerrera%26aufirst%3DF.%2BJ.%26aulast%3DRai%26aufirst%3DR.%26atitle%3DNovel%25203-methylindoline%2520inhibitors%2520of%2520EZH2%253A%2520design%252C%2520synthesis%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D2%26spage%3D217%26epage%3D222%26doi%3D10.1016%2Fj.bmcl.2016.11.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liuhyfWjG7N4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneeringer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacks, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span> <span> </span><span class="NLM_article-title">A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.1084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23023262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVaqtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=890-896&issue=11&author=S.+K.+Knutsonauthor=T.+J.+Wigleauthor=N.+M.+Warholicauthor=C.+J.+Sneeringerauthor=C.+J.+Allainauthor=C.+R.+Klausauthor=J.+D.+Sacksauthor=A.+Raimondiauthor=C.+R.+Majerauthor=J.+Songauthor=M.+P.+Scottauthor=L.+Jinauthor=J.+J.+Smithauthor=E.+J.+Olhavaauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=V.+M.+Richonauthor=R.+A.+Copelandauthor=H.+Keilhackauthor=R.+M.+Pollockauthor=K.+W.+Kuntz&title=A+selective+inhibitor+of+EZH2+blocks+H3K27+methylation+and+kills+mutant+lymphoma+cells&doi=10.1038%2Fnchembio.1084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells</span></div><div class="casAuthors">Knutson, Sarah K.; Wigle, Tim J.; Warholic, Natalie M.; Sneeringer, Christopher J.; Allain, Christina J.; Klaus, Christine R.; Sacks, Joelle D.; Raimondi, Alejandra; Majer, Christina R.; Song, Jeffrey; Scott, Margaret Porter; Jin, Lei; Smith, Jesse J.; Olhava, Edward J.; Chesworth, Richard; Moyer, Mikel P.; Richon, Victoria M.; Copeland, Robert A.; Keilhack, Heike; Pollock, Roy M.; Kuntz, Kevin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">890-896</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27).  Point mutations of EZH2 at Tyr 641 and Ala 677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation.  Here the authors report the discovery of EPZ005687, a potent inhibitor of EZH2 (Ki of 24 nM).  EPZ005687 has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1.  The compd. reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr 641 or Ala 677 mutant cells, with minimal effects on the proliferation of wild-type cells.  These data suggest that genetic alteration of EZH2 (for example, mutations at Tyr 641 or Ala 677) results in a crit. dependency on enzymic activity for proliferation (i.e., the equiv. of oncogene addiction), thus portending the clin. use of EZH2 inhibitors for cancers in which EZH2 is genetically altered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohlduVbTgWJrVg90H21EOLACvtfcHk0ljku3F6FgsJaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVaqtrvP&md5=a9ad7a41505e3fd4aa087d9f5dae8825</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1084%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DSneeringer%26aufirst%3DC.%2BJ.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DSacks%26aufirst%3DJ.%2BD.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26atitle%3DA%2520selective%2520inhibitor%2520of%2520EZH2%2520blocks%2520H3K27%2520methylation%2520and%2520kills%2520mutant%2520lymphoma%2520cells%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D11%26spage%3D890%26epage%3D896%26doi%3D10.1038%2Fnchembio.1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federation, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Raedt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter-Sprie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainson, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cichowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F2159-8290.CD-16-0164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27312177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKrt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1006-1021&issue=9&author=H.+Zhangauthor=J.+Qiauthor=J.+M.+Reyesauthor=L.+Liauthor=P.+K.+Raoauthor=F.+Liauthor=C.+Y.+Linauthor=J.+A.+Perryauthor=M.+A.+Lawlorauthor=A.+Federationauthor=T.+De+Raedtauthor=Y.+Y.+Liauthor=Y.+Liuauthor=M.+A.+Duarteauthor=Y.+Zhangauthor=G.+S.+Herter-Sprieauthor=E.+Kikuchiauthor=J.+Carreteroauthor=C.+M.+Perouauthor=J.+B.+Reibelauthor=J.+Paulkauthor=R.+T.+Bronsonauthor=H.+Watanabeauthor=C.+F.+Brainsonauthor=C.+F.+Kimauthor=P.+S.+Hammermanauthor=M.+Brownauthor=K.+Cichowskiauthor=H.+Longauthor=J.+E.+Bradnerauthor=K.+K.+Wong&title=Oncogenic+deregulation+of+EZH2+as+an+opportunity+for+targeted+therapy+in+lung+cancer&doi=10.1158%2F2159-8290.CD-16-0164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer</span></div><div class="casAuthors">Zhang, Haikuo; Qi, Jun; Reyes, Jaime M.; Li, Lewyn; Rao, Prakash K.; Li, Fugen; Lin, Charles Y.; Perry, Jennifer A.; Lawlor, Matthew A.; Federation, Alexander; De Raedt, Thomas; Li, Yvonne Y.; Liu, Yan; Duarte, Melissa A.; Zhang, Yanxi; Herter-Sprie, Grit S.; Kikuchi, Eiki; Carretero, Julian; Perou, Charles M.; Reibel, Jacob B.; Paulk, Joshiawa; Bronson, Roderick T.; Watanabe, Hideo; Brainson, Christine Fillmore; Kim, Carla F.; Hammerman, Peter S.; Brown, Myles; Cichowski, Karen; Long, Henry; Bradner, James E.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1006-1021</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks.  Overexpression of EZH2 is commonly obsd. in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive.  Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma.  Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation.  As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression.  To target EZH2-dependent cancers, we developed a potent open-source EZH2 inhibitor, JQEZ5, that promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a subset of lung cancer.  Significance: EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity.  Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojSYdBWV-BlrVg90H21EOLACvtfcHk0ljku3F6FgsJaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKrt73K&md5=e67b20c867007aed77c08d858bd4d788</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0164%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DReyes%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DRao%26aufirst%3DP.%2BK.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26aulast%3DLawlor%26aufirst%3DM.%2BA.%26aulast%3DFederation%26aufirst%3DA.%26aulast%3DDe%2BRaedt%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDuarte%26aufirst%3DM.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DKikuchi%26aufirst%3DE.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DReibel%26aufirst%3DJ.%2BB.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DBrainson%26aufirst%3DC.%2BF.%26aulast%3DKim%26aufirst%3DC.%2BF.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCichowski%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DOncogenic%2520deregulation%2520of%2520EZH2%2520as%2520an%2520opportunity%2520for%2520targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D9%26spage%3D1006%26epage%3D1021%26doi%3D10.1158%2F2159-8290.CD-16-0164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konze, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macnevin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rougie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattenden, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1324</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1021/cb400133j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400133j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1324-1334&issue=6&author=K.+D.+Konzeauthor=A.+Maauthor=F.+Liauthor=D.+Barsyte-Lovejoyauthor=T.+Partonauthor=C.+J.+Macnevinauthor=F.+Liuauthor=C.+Gaoauthor=X.+P.+Huangauthor=E.+Kuznetsovaauthor=M.+Rougieauthor=A.+Jiangauthor=S.+G.+Pattendenauthor=J.+L.+Norrisauthor=L.+I.+Jamesauthor=B.+L.+Rothauthor=P.+J.+Brownauthor=S.+V.+Fryeauthor=C.+H.+Arrowsmithauthor=K.+M.+Hahnauthor=G.+G.+Wangauthor=M.+Vedadiauthor=J.+Jin&title=An+orally+bioavailable+chemical+probe+of+the+lysine+methyltransferases+EZH2+and+EZH1&doi=10.1021%2Fcb400133j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1</span></div><div class="casAuthors">Konze, Kyle D.; Ma, Anqi; Li, Fengling; Barsyte-Lovejoy, Dalia; Parton, Trevor; MacNevin, Christopher J.; Liu, Feng; Gao, Cen; Huang, Xi-Ping; Kuznetsova, Ekaterina; Rougie, Marie; Jiang, Alice; Pattenden, Samantha G.; Norris, Jacqueline L.; James, Lindsey I.; Roth, Bryan L.; Brown, Peter J.; Frye, Stephen V.; Arrowsmith, Cheryl H.; Hahn, Klaus M.; Wang, Gang Greg; Vedadi, Masoud; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1324-1334</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EZH2 or EZH1 is the catalytic subunit of the polycomb repressive complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27).  The trimethylation of H3K27 (H3K27me3) is a transcriptionally repressive post-translational modification.  Overexpression of EZH2 and hypertrimethylation of H3K27 have been implicated in a no. of cancers.  Several selective inhibitors of EZH2 have been reported recently.  Herein we disclose UNC1999, the first orally bioavailable inhibitor that has high in vitro potency for wild-type and mutant EZH2 as well as EZH1, a closely related H3K27 methyltransferase that shares 96% sequence identity with EZH2 in their resp. catalytic domains.  UNC1999 was highly selective for EZH2 and EZH1 over a broad range of epigenetic and non-epigenetic targets, competitive with the cofactor SAM and non-competitive with the peptide substrate.  This inhibitor potently reduced H3K27me3 levels in cells and selectively killed diffused large B cell lymphoma cell lines harboring the EZH2Y641N mutant.  Importantly, UNC1999 was orally bioavailable in mice, making this inhibitor a valuable tool for investigating the role of EZH2 and EZH1 in chronic animal studies.  We also designed and synthesized UNC2400, a close analog of UNC1999 with potency >1,000-fold lower than that of UNC1999 as a neg. control for cell-based studies.  Finally, we created a biotin-tagged UNC1999 (UNC2399), which enriched EZH2 in pull-down studies, and a UNC1999-dye conjugate (UNC2239) for co-localization studies with EZH2 in live cells.  Taken together, these compds. represent a set of useful tools for the biomedical community to investigate the role of EZH2 and EZH1 in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzhUO0iAe8BbVg90H21EOLACvtfcHk0lgre2DGsRZ5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsrk%253D&md5=311d77f5f0cc0b9e2610d8d002a6709c</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fcb400133j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400133j%26sid%3Dliteratum%253Aachs%26aulast%3DKonze%26aufirst%3DK.%2BD.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DParton%26aufirst%3DT.%26aulast%3DMacnevin%26aufirst%3DC.%2BJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DKuznetsova%26aufirst%3DE.%26aulast%3DRougie%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DPattenden%26aufirst%3DS.%2BG.%26aulast%3DNorris%26aufirst%3DJ.%2BL.%26aulast%3DJames%26aufirst%3DL.%2BI.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DHahn%26aufirst%3DK.%2BM.%26aulast%3DWang%26aufirst%3DG.%2BG.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DAn%2520orally%2520bioavailable%2520chemical%2520probe%2520of%2520the%2520lysine%2520methyltransferases%2520EZH2%2520and%2520EZH1%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26issue%3D6%26spage%3D1324%26epage%3D1334%26doi%3D10.1021%2Fcb400133j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uesugi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter-Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uenaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F1535-7163.MCT-13-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24563539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=842-854&issue=4&author=S.+K.+Knutsonauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=N.+M.+Warholicauthor=K.+C.+Huangauthor=Y.+Xiaoauthor=T.+Kadowakiauthor=M.+Uesugiauthor=G.+Kuznetsovauthor=N.+Kumarauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+Porter-Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=T.+Uenakaauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=A.+Yokoiauthor=H.+Keilhack&title=Selective+inhibition+of+EZH2+by+EPZ-6438+leads+to+potent+antitumor+activity+in+EZH2-mutant+non-Hodgkin+lymphoma&doi=10.1158%2F1535-7163.MCT-13-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span></div><div class="casAuthors">Knutson, Sarah K.; Kawano, Satoshi; Minoshima, Yukinori; Warholic, Natalie M.; Huang, Kuan-Chun; Xiao, Yonghong; Kadowaki, Tadashi; Uesugi, Mai; Kuznetsov, Galina; Kumar, Namita; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Waters, Nigel J.; Smith, Jesse J.; Porter-Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Uenaka, Toshimitsu; Pollock, Roy M.; Kuntz, Kevin W.; Yokoi, Akira; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-854</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL).  These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymic activity in these cancers.  We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small mol. inhibitors of EZH2.  Although both compds. are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals.  Here, we characterize the activity of EPZ-6438 in preclin. models of NHL.  EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concn.- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells.  Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations.  Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues.  Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compd. treatment in two EZH2-mutant xenograft models.  These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.  Mol Cancer Ther; 13(4); 842-54. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2o1v5F3GzLVg90H21EOLACvtfcHk0lgre2DGsRZ5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D&md5=89354e9453dcd7430978d1a6c5ee5846</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0773%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DHuang%26aufirst%3DK.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DUesugi%26aufirst%3DM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DSelective%2520inhibition%2520of%2520EZH2%2520by%2520EPZ-6438%2520leads%2520to%2520potent%2520antitumor%2520activity%2520in%2520EZH2-mutant%2520non-Hodgkin%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D842%26epage%3D854%26doi%3D10.1158%2F1535-7163.MCT-13-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pietra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquenne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span> <span> </span><span class="NLM_article-title">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span> (<span class="NLM_issue">7427</span>),  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/nature11606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnature11606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23051747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=108-112&issue=7427&author=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+Ganjiauthor=S.+Korenchukauthor=C.+Thompsonauthor=G.+S.+Van+Allerauthor=Y.+Liuauthor=A.+P.+Gravesauthor=A.+Della+Pietraauthor=E.+Diazauthor=L.+V.+LaFranceauthor=M.+Mellingerauthor=C.+Duquenneauthor=X.+R.+Tianauthor=R.+G.+Krugerauthor=C.+F.+McHughauthor=M.+Brandtauthor=W.+H.+Millerauthor=D.+Dhanakauthor=S.+K.+Vermaauthor=P.+J.+Tumminoauthor=C.+L.+Creasy&title=EZH2+inhibition+as+a+therapeutic+strategy+for+lymphoma+with+EZH2-activating+mutations&doi=10.1038%2Fnature11606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span></div><div class="casAuthors">McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; Della Pietra, Anthony , III; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7427</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In eukaryotes, post-translational modification of histones is crit. for regulation of chromatin structure and gene expression.  EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).  EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumor types.  Addnl., somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.  The Y641 residue is the most frequently mutated residue, with up to 22% of germinal center B-cell DLBCL and follicular lymphoma harbouring mutations at this site.  These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes.  However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.  Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-mol. inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.  GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.  Together, these data demonstrate that pharmacol. inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxw5cLmW3Lc7Vg90H21EOLACvtfcHk0lgqMOI6leNFzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL&md5=a1dff99556de004c48aae88bc45dffab</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnature11606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11606%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DMellinger%26aufirst%3DM.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DX.%2BR.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DEZH2%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520lymphoma%2520with%2520EZH2-activating%2520mutations%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7427%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature11606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span> <span> </span><span class="NLM_article-title">Many paths to methyltransfer: a chronicle of convergence</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(03)00090-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0968-0004%2803%2900090-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12826405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=329-335&issue=6&author=H.+L.+Schubertauthor=R.+M.+Blumenthalauthor=X.+Cheng&title=Many+paths+to+methyltransfer%3A+a+chronicle+of+convergence&doi=10.1016%2FS0968-0004%2803%2900090-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Many paths to methyltransfer: a chronicle of convergence</span></div><div class="casAuthors">Schubert, Heidi L.; Blumenthal, Robert M.; Cheng, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">329-335</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  S-adenosyl-L-methionine (AdoMet) dependent methyltransferases (MTases) are involved in biosynthesis, signal transduction, protein repair, chromatin regulation and gene silencing.  Five different structural folds (I-V) have been described that bind AdoMet and catalyze Me transfer to diverse substrates, although the great majority of known MTases have the Class I fold.  Even within a particular MTase class the amino-acid sequence similarity can be as low as 10%.  Thus, the structural and catalytic requirements for Me transfer from AdoMet appear to be remarkably flexible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXf7A-x2vdrVg90H21EOLACvtfcHk0lgqMOI6leNFzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCmsrw%253D&md5=7e6760df484f7d8d68dbd53533333620</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2803%2900090-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252803%252900090-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchubert%26aufirst%3DH.%2BL.%26aulast%3DBlumenthal%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DX.%26atitle%3DMany%2520paths%2520to%2520methyltransfer%253A%2520a%2520chronicle%2520of%2520convergence%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2003%26volume%3D28%26issue%3D6%26spage%3D329%26epage%3D335%26doi%3D10.1016%2FS0968-0004%2803%2900090-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquenne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newlander, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeril, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherzer, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machutta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span> <span> </span><span class="NLM_article-title">Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1096</span>, <span class="refDoi"> DOI: 10.1021/ml3003346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3003346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChs77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1091-1096&issue=12&author=S.+K.+Vermaauthor=X.+Tianauthor=L.+V.+LaFranceauthor=C.+Duquenneauthor=D.+P.+Suarezauthor=K.+A.+Newlanderauthor=S.+P.+Romerilauthor=J.+L.+Burgessauthor=S.+W.+Grantauthor=J.+A.+Brackleyauthor=A.+P.+Gravesauthor=D.+A.+Scherzerauthor=A.+Shuauthor=C.+Thompsonauthor=H.+M.+Ottauthor=G.+S.+Allerauthor=C.+A.+Machuttaauthor=E.+Diazauthor=Y.+Jiangauthor=N.+W.+Johnsonauthor=S.+D.+Knightauthor=R.+G.+Krugerauthor=M.+T.+McCabeauthor=D.+Dhanakauthor=P.+J.+Tumminoauthor=C.+L.+Creasyauthor=W.+H.+Miller&title=Identification+of+potent%2C+selective%2C+cell-active+inhibitors+of+the+histone+lysine+methyltransferase+EZH2&doi=10.1021%2Fml3003346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2</span></div><div class="casAuthors">Verma, Sharad K.; Tian, Xinrong; LaFrance, Louis V.; Duquenne, Celine; Suarez, Dominic P.; Newlander, Kenneth A.; Romeril, Stuart P.; Burgess, Joelle L.; Grant, Seth W.; Brackley, James A.; Graves, Alan P.; Scherzer, Daryl A.; Shu, Art; Thompson, Christine; Ott, Heidi M.; Van Aller, Glenn S.; Machutta, Carl A.; Diaz, Elsie; Jiang, Yong; Johnson, Neil W.; Knight, Steven D.; Kruger, Ryan G.; McCabe, Michael T.; Dhanak, Dashyant; Tummino, Peter J.; Creasy, Caretha L.; Miller, William H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1091-1096</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a crit. role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer.  As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, S-(S'-adenosyl)-L-methionine (SAM)-competitive, and cell-active EZH2 inhibitors, including GSK926 I (R1 = Me, R2 = Q) and GSK343 I (R1 = n-Pr, R2 = Q1).  These compds. are small mol. chem. tools that would be useful to further explore the biol. of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8NUzf0zjo0bVg90H21EOLACvtfcHk0li_YKZAt1qyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChs77K&md5=a6540bb712ee52cba05bd0b074d8b26a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fml3003346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3003346%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DSuarez%26aufirst%3DD.%2BP.%26aulast%3DNewlander%26aufirst%3DK.%2BA.%26aulast%3DRomeril%26aufirst%3DS.%2BP.%26aulast%3DBurgess%26aufirst%3DJ.%2BL.%26aulast%3DGrant%26aufirst%3DS.%2BW.%26aulast%3DBrackley%26aufirst%3DJ.%2BA.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DScherzer%26aufirst%3DD.%2BA.%26aulast%3DShu%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DAller%26aufirst%3DG.%2BS.%26aulast%3DMachutta%26aufirst%3DC.%2BA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DN.%2BW.%26aulast%3DKnight%26aufirst%3DS.%2BD.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26atitle%3DIdentification%2520of%2520potent%252C%2520selective%252C%2520cell-active%2520inhibitors%2520of%2520the%2520histone%2520lysine%2520methyltransferase%2520EZH2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D1091%26epage%3D1096%26doi%3D10.1021%2Fml3003346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter-Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneeringer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">The importance of being Me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01501</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01501" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XotF2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1556-1564&issue=4&author=K.+W.+Kuntzauthor=J.+E.+Campbellauthor=H.+Keilhackauthor=R.+M.+Pollockauthor=S.+K.+Knutsonauthor=M.+Porter-Scottauthor=V.+M.+Richonauthor=C.+J.+Sneeringerauthor=T.+J.+Wigleauthor=C.+J.+Allainauthor=C.+R.+Majerauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=R.+Chesworth&title=The+importance+of+being+Me%3A+magic+methyls%2C+methyltransferase+inhibitors%2C+and+the+discovery+of+tazemetostat&doi=10.1021%2Facs.jmedchem.5b01501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat</span></div><div class="casAuthors">Kuntz, Kevin W.; Campbell, John E.; Keilhack, Heike; Pollock, Roy M.; Knutson, Sarah K.; Porter-Scott, Margaret; Richon, Victoria M.; Sneeringer, Chris J.; Wigle, Tim J.; Allain, Christina J.; Majer, Christina R.; Moyer, Mikel P.; Copeland, Robert A.; Chesworth, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1556-1564</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Posttranslational methylation of histones plays a crit. role in gene regulation.  Misregulation of histone methylation can lead to oncogenic transformation.  Enhancer of Zeste homolog 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers.  Tazemetostat, an EHZ2 inhibitor in clin. development, has shown activity in both preclin. models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors.  Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clin. development.  The importance of several Me groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryASbIgMDxAbVg90H21EOLACvtfcHk0li_YKZAt1qyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotF2qsA%253D%253D&md5=a26ccc4a0109f57fbb64f7fded8965a1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01501%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DSneeringer%26aufirst%3DC.%2BJ.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26atitle%3DThe%2520importance%2520of%2520being%2520Me%253A%2520magic%2520methyls%252C%2520methyltransferase%2520inhibitors%252C%2520and%2520the%2520discovery%2520of%2520tazemetostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D4%26spage%3D1556%26epage%3D1564%26doi%3D10.1021%2Facs.jmedchem.5b01501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span> <span> </span><span class="NLM_article-title">Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7922</span>– <span class="NLM_lpage">7927</span>, <span class="refDoi"> DOI: 10.1073/pnas.1303800110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1303800110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23620515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFGrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=7922-7927&issue=19&author=S.+K.+Knutsonauthor=N.+M.+Warholicauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=M.+Porter+Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=H.+Keilhack&title=Durable+tumor+regression+in+genetically+altered+malignant+rhabdoid+tumors+by+inhibition+of+methyltransferase+EZH2&doi=10.1073%2Fpnas.1303800110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2</span></div><div class="casAuthors">Knutson, Sarah K.; Warholic, Natalie M.; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Scott, Margaret Porter; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Pollock, Roy M.; Kuntz, Kevin W.; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7922-7927, S7922/1-S7922/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Inactivation of the switch/sucrose nonfermentable complex component SMARCB1 is extremely prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tumors.  This alteration is hypothesized to confer oncogenic dependency on EZH2 in these cancers.  The authors report the discovery of a potent, selective, and orally bioavailable small-mol. inhibitor of EZH2 enzymic activity, (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide).  The compd. induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.  Treatment of xenograft-bearing mice with (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide) leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation.  These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymic activity and portend the utility of EZH2-targeted drugs for the treatment of these genetically defined cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWRIJfPhwLA7Vg90H21EOLACvtfcHk0li_YKZAt1qyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFGrurw%253D&md5=c2c6470d48a13ab8343db0a09465ba42</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1303800110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1303800110%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DPorter%2BScott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DDurable%2520tumor%2520regression%2520in%2520genetically%2520altered%2520malignant%2520rhabdoid%2520tumors%2520by%2520inhibition%2520of%2520methyltransferase%2520EZH2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D19%26spage%3D7922%26epage%3D7927%26doi%3D10.1073%2Fpnas.1303800110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span>; <span class="NLM_string-name">Sammons, M.</span>; <span class="NLM_string-name">Favours, E.</span>; <span class="NLM_string-name">Wu, J.</span>; <span class="NLM_string-name">Kurmashev, D.</span>; <span class="NLM_string-name">Cosmopoulos, K.</span>; <span class="NLM_string-name">Keilhack, H.</span>; <span class="NLM_string-name">Klaus, C. R.</span>; <span class="NLM_string-name">Houghton, P. J.</span>; <span class="NLM_string-name">Smith, M. A.</span></span>, <span> </span><span class="NLM_article-title">Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program</span>.  <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">64</span> (<span class="NLM_issue">3</span>), <span class="refDoi"> DOI: 10.1002/pbc.26218</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1002%2Fpbc.26218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&issue=3&author=R.+T.+Kurmasheva&author=M.+Sammons&author=E.+Favours&author=J.+Wu&author=D.+Kurmashev&author=K.+Cosmopoulos&author=H.+Keilhack&author=C.+R.+Klaus&author=P.+J.+Houghton&author=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+tazemetostat+%28EPZ-6438%29%2C+a+novel+EZH2+inhibitor%2C+by+the+Pediatric+Preclinical+Testing+Program&doi=10.1002%2Fpbc.26218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fpbc.26218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.26218%26sid%3Dliteratum%253Aachs%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520tazemetostat%2520%2528EPZ-6438%2529%252C%2520a%2520novel%2520EZH2%2520inhibitor%252C%2520by%2520the%2520Pediatric%2520Preclinical%2520Testing%2520Program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2017%26volume%3D64%26issue%3D3%26doi%3D10.1002%2Fpbc.26218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">EPZ011989, a potent, orally-available EZH2 inhibitor with robust in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslelsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=491-495&issue=5&author=J.+E.+Campbellauthor=K.+W.+Kuntzauthor=S.+K.+Knutsonauthor=N.+M.+Warholicauthor=H.+Keilhackauthor=T.+J.+Wigleauthor=A.+Raimondiauthor=C.+R.+Klausauthor=N.+Riouxauthor=A.+Yokoiauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=H.+W.+Choiauthor=M.+Porter+Scottauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copeland&title=EPZ011989%2C+a+potent%2C+orally-available+EZH2+inhibitor+with+robust+in+vivo+activity&doi=10.1021%2Facsmedchemlett.5b00037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity</span></div><div class="casAuthors">Campbell, John E.; Kuntz, Kevin W.; Knutson, Sarah K.; Warholic, Natalie M.; Keilhack, Heike; Wigle, Tim J.; Raimondi, Alejandra; Klaus, Christine R.; Rioux, Nathalie; Yokoi, Akira; Kawano, Satoshi; Minoshima, Yukinori; Choi, Hyeong-Wook; Porter Scott, Margaret; Waters, Nigel J.; Smith, Jesse J.; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">491-495</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications.  The ability of the scientific community to explore fully the spectrum of EZH2-assocd. pathobiol. has been hampered by the lack of in vivo-active tool compds. for this enzyme.  Here the authors report the discovery and characterization of EPZ011989, a potent, selective, orally bioavailable inhibitor of EZH2 with useful pharmacokinetic properties.  EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenograft model of human B cell lymphoma.  Hence, this compd. represents a powerful tool for the expanded exploration of EZH2 activity in biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqfVfbr3kS67Vg90H21EOLACvtfcHk0ljLay7hYNEEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslelsL8%253D&md5=21fa182b2474678f663459a9dc2878e6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00037%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DRioux%26aufirst%3DN.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DH.%2BW.%26aulast%3DPorter%2BScott%26aufirst%3DM.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DEPZ011989%252C%2520a%2520potent%252C%2520orally-available%2520EZH2%2520inhibitor%2520with%2520robust%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D491%26epage%3D495%26doi%3D10.1021%2Facsmedchemlett.5b00037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of EBI-2511: a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslyqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=98-102&issue=2&author=B.+Luauthor=X.+D.+Shenauthor=L.+Zhangauthor=D.+Liuauthor=C.+H.+Zhangauthor=J.+S.+Caoauthor=R.+Shenauthor=J.+Y.+Zhangauthor=D.+Wangauthor=H.+Wanauthor=Z.+B.+Xuauthor=M.+H.+Hoauthor=M.+S.+Zhangauthor=L.+S.+Zhangauthor=F.+Heauthor=W.+K.+Tao&title=Discovery+of+EBI-2511%3A+a+highly+potent+and+orally+active+EZH2+inhibitor+for+the+treatment+of+Non-Hodgkin%E2%80%99s+Lymphoma&doi=10.1021%2Facsmedchemlett.7b00437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma</span></div><div class="casAuthors">Lu, Biao; Shen, Xiaodong; Zhang, Lei; Liu, Dong; Zhang, Caihua; Cao, Jingsong; Shen, Ru; Zhang, Jiayin; Wang, Dan; Wan, Hong; Xu, Zhibin; Ho, Ming-Hsun; Zhang, Minsheng; Zhang, Lianshan; He, Feng; Tao, Weikang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of benzofuran derived EZH2 inhibitors were discovered through a scaffold hopping approach based on the clin. compd. of EPZ-6438.  Further rational structure-activity relationship exploration and optimization led to the discovery of more potent EZH2 inhibitors with oral bioavailability in mice and rats.  A lead compd. EBI-2511 (compd. 34) demonstrated excellent in vivo efficacy in Pfeiffer tumor Xenograft models in mouse and is under preclin. development for the treatment of cancers assocd. with EZH2 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAjNckZVf2n7Vg90H21EOLACvtfcHk0ljLay7hYNEEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslyqsbc%253D&md5=ce0c8e7f336ddb14b15b82c80c23f02e</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00437%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DX.%2BD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DCao%26aufirst%3DJ.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%2BB.%26aulast%3DHo%26aufirst%3DM.%2BH.%26aulast%3DZhang%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DL.%2BS.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DW.%2BK.%26atitle%3DDiscovery%2520of%2520EBI-2511%253A%2520a%2520highly%2520potent%2520and%2520orally%2520active%2520EZH2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D98%26epage%3D102%26doi%3D10.1021%2Facsmedchemlett.7b00437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryskin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of Enhancer of Zeste Homolog 2 (EZH2) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8306</span>– <span class="NLM_lpage">8325</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8306-8325&issue=18&author=P.+P.+Kungauthor=E.+Ruiauthor=S.+Bergqvistauthor=P.+Binghamauthor=J.+Braganzaauthor=M.+Collinsauthor=M.+Cuiauthor=W.+Diehlauthor=D.+Dinhauthor=C.+Fanauthor=V.+R.+Fantinauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=S.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=G.+Liauthor=K.+A.+Maegleyauthor=I.+McAlpineauthor=L.+Nguyenauthor=S.+Ninkovicauthor=M.+Ornelasauthor=M.+Ryskinauthor=S.+Scalesauthor=S.+Suttonauthor=J.+Tatlockauthor=D.+Verhelleauthor=F.+Wangauthor=P.+Wellsauthor=M.+Wythesauthor=S.+Yamazakiauthor=B.+Yipauthor=X.+Yuauthor=L.+Zehnderauthor=W.+G.+Zhangauthor=R.+A.+Rollinsauthor=M.+Edwards&title=Design+and+synthesis+of+pyridone-containing+3%2C4-dihydroisoquinoline-1%282H%29-ones+as+a+novel+class+of+Enhancer+of+Zeste+Homolog+2+%28EZH2%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors</span></div><div class="casAuthors">Kung, Pei-Pei; Rui, Eugene; Bergqvist, Simon; Bingham, Patrick; Braganza, John; Collins, Michael; Cui, Mei; Diehl, Wade; Dinh, Dac; Fan, Connie; Fantin, Valeria R.; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kephart, Susan; Krivacic, Cody; Kumpf, Robert A.; Li, Gary; Maegley, Karen A.; McAlpine, Indrawan; Nguyen, Lisa; Ninkovic, Sacha; Ornelas, Martha; Ryskin, Michael; Scales, Stephanie; Sutton, Scott; Tatlock, John; Verhelle, Dominique; Wang, Fen; Wells, Peter; Wythes, Martin; Yamazaki, Shinji; Yip, Brian; Yu, Xiu; Zehnder, Luke; Zhang, Wei-Guo; Rollins, Robert A.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8306-8325</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted Ph ring joined to a dimethylpyridone moiety via an amide linkage has been designed.  A preferential amide torsion that improved the binding properties of the compds. was identified for this series via computational anal.  Cyclization of the amide linker resulted in a six-membered lactam analog, compd. I.  This transformation significantly improved the ligand efficiency/potency of the cyclized compd. relative to its acyclic analog.  Addnl. optimization of the lactam-contg. EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compd. II.  Compd. II displayed improved LipE and on-target potency in both biochem. and cellular readouts relative to compd. I.  Inhibitor II also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50CIrIhlikrVg90H21EOLACvtfcHk0lgo9JALWkymyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM&md5=eb6f2b053e5ba2c2d214d847ad8d9f1f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00515%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DRui%26aufirst%3DE.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBraganza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%26aulast%3DRyskin%26aufirst%3DM.%26aulast%3DScales%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520pyridone-containing%25203%252C4-dihydroisoquinoline-1%25282H%2529-ones%2520as%2520a%2520novel%2520class%2520of%2520Enhancer%2520of%2520Zeste%2520Homolog%25202%2520%2528EZH2%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D18%26spage%3D8306%26epage%3D8325%26doi%3D10.1021%2Facs.jmedchem.6b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grantner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamphavong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of orally bioavailable Enhancer of Zeste Homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01375</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01375" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=650-665&issue=3&author=P.+P.+Kungauthor=P.+Binghamauthor=A.+Broounauthor=M.+Collinsauthor=Y.+L.+Dengauthor=D.+Dinhauthor=C.+Fanauthor=K.+S.+Gajiwalaauthor=R.+Grantnerauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=R.+Kaniaauthor=S.+E.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=P.+Khamphavongauthor=M.+Krausauthor=W.+Liuauthor=K.+A.+Maegleyauthor=L.+Nguyenauthor=S.+Renauthor=D.+Richterauthor=R.+A.+Rollinsauthor=N.+Sachauthor=S.+Sharmaauthor=J.+Sherrillauthor=J.+Spanglerauthor=A.+E.+Stewartauthor=S.+Suttonauthor=S.+Uryuauthor=D.+Verhelleauthor=H.+Wangauthor=S.+Wangauthor=M.+Wythesauthor=S.+Xinauthor=S.+Yamazakiauthor=H.+Zhuauthor=J.+Zhuauthor=L.+Zehnderauthor=M.+Edwards&title=Optimization+of+orally+bioavailable+Enhancer+of+Zeste+Homolog+2+%28EZH2%29+inhibitors+using+ligand+and+property-based+design+strategies%3A+identification+of+development+candidate+%28R%29-5%2C8-Dichloro-7-%28methoxy%28oxetan-3-yl%29methyl%29-2-%28%284-methoxy-6-methyl-2-oxo-1%2C2-+dihydropyridin-3-yl%29methyl%29-3%2C4-dihydroisoquinolin-1%282H%29-one+%28PF-06821497%29&doi=10.1021%2Facs.jmedchem.7b01375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)</span></div><div class="casAuthors">Kung, Pei-Pei; Bingham, Patrick; Brooun, Alexei; Collins, Michael; Deng, Ya-Li; Dinh, Dac; Fan, Connie; Gajiwala, Ketan S.; Grantner, Rita; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kania, Robert; Kephart, Susan E.; Krivacic, Cody; Kumpf, Robert A.; Khamphavong, Penney; Kraus, Manfred; Liu, Wei; Maegley, Karen A.; Nguyen, Lisa; Ren, Shijian; Richter, Dan; Rollins, Robert A.; Sach, Neal; Sharma, Shikhar; Sherrill, John; Spangler, Jillian; Stewart, Albert E.; Sutton, Scott; Uryu, Sean; Verhelle, Dominique; Wang, Hui; Wang, Shuiwang; Wythes, Martin; Xin, Shuibo; Yamazaki, Shinji; Zhu, Huichun; Zhu, JinJiang; Zehnder, Luke; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochem.-property-based strategies to address metabolic stability and thermodn. soly. issues assocd. with previous lead compd. (I).  The new inhibitors incorporated an Sp3 hybridized carbon atom at the 7-position of the lactam moiety present in lead compd. (I) as a replacement for a dimethylisoxazole group.  This transformation enabled optimization of the physicochem. properties and potency compared to compd. (I).  Anal. of relationships between calcd. log D (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single mol.  Compd. 23a (5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one) exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497).  A crystal structure of 23a in complex with the three-protein PRC2 complex enabled understanding of the key structural features required for optimal binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro0-Aa0AZgXLVg90H21EOLACvtfcHk0lgo9JALWkymyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF&md5=96ff75b96f5eea2dc82013a6bad8096b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01375%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DGrantner%26aufirst%3DR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DKhamphavong%26aufirst%3DP.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSherrill%26aufirst%3DJ.%26aulast%3DSpangler%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520orally%2520bioavailable%2520Enhancer%2520of%2520Zeste%2520Homolog%25202%2520%2528EZH2%2529%2520inhibitors%2520using%2520ligand%2520and%2520property-based%2520design%2520strategies%253A%2520identification%2520of%2520development%2520candidate%2520%2528R%2529-5%252C8-Dichloro-7-%2528methoxy%2528oxetan-3-yl%2529methyl%2529-2-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-%2520dihydropyridin-3-yl%2529methyl%2529-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2520%2528PF-06821497%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1021%2Facs.jmedchem.7b01375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garapaty-Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1021/ml400494b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400494b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=378-383&issue=4&author=C.+G.+Nasveschukauthor=A.+Gagnonauthor=S.+Garapaty-Raoauthor=S.+Balasubramanianauthor=R.+Campbellauthor=C.+Leeauthor=F.+Zhaoauthor=L.+Bergeronauthor=R.+Cummingsauthor=P.+Trojerauthor=J.+E.+Audiaauthor=B.+K.+Albrechtauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+tetramethylpiperidinyl+benzamides+as+inhibitors+of+EZH2&doi=10.1021%2Fml400494b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2</span></div><div class="casAuthors">Nasveschuk, Christopher G.; Gagnon, Alexandre; Garapaty-Rao, Shivani; Balasubramanian, Srividya; Campbell, Robert; Lee, Christina; Zhao, Feng; Bergeron, Louise; Cummings, Richard; Trojer, Patrick; Audia, James E.; Albrecht, Brian K.; Harmange, Jean-Christophe P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">378-383</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification and development of a novel series of small mol. Enhancer of Zeste Homolog 2 (EZH2) inhibitors is described.  A concise and modular synthesis enabled the rapid development of structure-activity relationships, which led to the identification of I as a potent, SAM-competitive inhibitor of EZH2 that dose-dependently decreased global H3K27me3 in KARPAS-422 lymphoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-T4S47cYnxrVg90H21EOLACvtfcHk0lh1Ti_Q3kTo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjtw%253D%253D&md5=059381c9e416ee50fb37a8cf3ccef239</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fml400494b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400494b%26sid%3Dliteratum%253Aachs%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DGarapaty-Rao%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520tetramethylpiperidinyl%2520benzamides%2520as%2520inhibitors%2520of%2520EZH2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D4%26spage%3D378%26epage%3D383%26doi%3D10.1021%2Fml400494b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garapaty-Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span> <span> </span><span class="NLM_article-title">Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24183969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1329-1339&issue=11&author=S.+Garapaty-Raoauthor=C.+Nasveschukauthor=A.+Gagnonauthor=E.+Y.+Chanauthor=P.+Sandyauthor=J.+Busbyauthor=S.+Balasubramanianauthor=R.+Campbellauthor=F.+Zhaoauthor=L.+Bergeronauthor=J.+E.+Audiaauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=R.+Cummingsauthor=P.+Trojer&title=Identification+of+EZH2+and+EZH1+small+molecule+inhibitors+with+selective+impact+on+diffuse+large+B+cell+lymphoma+cell+growth&doi=10.1016%2Fj.chembiol.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth</span></div><div class="casAuthors">Garapaty-Rao, Shivani; Nasveschuk, Christopher; Gagnon, Alexandre; Chan, Eric Y.; Sandy, Peter; Busby, Jennifer; Balasubramanian, Srividya; Campbell, Robert; Zhao, Feng; Bergeron, Louise; Audia, James E.; Albrecht, Brian K.; Harmange, Jean-Christophe; Cummings, Richard; Trojer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1329-1339</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due to its prevalent overexpression in malignant diseases, including late stage prostate and breast cancers.  The dependency of cancer cells on EZH2 activity is also predicated by recurrent missense mutations residing in the catalytic domain of EZH2 that have been identified in subtypes of diffuse large B cell lymphoma, follicular lymphoma and melanoma.  Herein, we report the identification of a highly selective small mol. inhibitor series of EZH2 and EZH1.  These compds. inhibit wild-type and mutant versions of EZH2 with nanomolar potency, suppress global histone H3-lysine 27 methylation, affect gene expression, and cause selective proliferation defects.  These compds. represent a structurally distinct EZH2 inhibitor chemotype for the exploration of the role of Polycomb Repressive Complex 2-mediated H3K27 methylation in various biol. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNGhFRO6LRbVg90H21EOLACvtfcHk0lh1Ti_Q3kTo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmtrrP&md5=6079ba01ae1f1964ac1d8108aa5e1227</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DGarapaty-Rao%26aufirst%3DS.%26aulast%3DNasveschuk%26aufirst%3DC.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DE.%2BY.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBusby%26aufirst%3DJ.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DTrojer%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520EZH2%2520and%2520EZH1%2520small%2520molecule%2520inhibitors%2520with%2520selective%2520impact%2520on%2520diffuse%2520large%2520B%2520cell%2520lymphoma%2520cell%2520growth%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26issue%3D11%26spage%3D1329%26epage%3D1339%26doi%3D10.1016%2Fj.chembiol.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span> <span> </span><span class="NLM_article-title">SAH derived potent and selective EZH2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2015.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25746813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVWjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1532-1537&issue=7&author=P.+P.+Kungauthor=B.+Huangauthor=L.+Zehnderauthor=J.+Tatlockauthor=P.+Binghamauthor=C.+Krivacicauthor=K.+Gajiwalaauthor=W.+Diehlauthor=X.+Yuauthor=K.+A.+Maegley&title=SAH+derived+potent+and+selective+EZH2+inhibitors&doi=10.1016%2Fj.bmcl.2015.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">SAH derived potent and selective EZH2 inhibitors</span></div><div class="casAuthors">Kung, Pei-Pei; Huang, Buwen; Zehnder, Luke; Tatlock, John; Bingham, Patrick; Krivacic, Cody; Gajiwala, Ketan; Diehl, Wade; Yu, Xiu; Maegley, Karen A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1532-1537</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel enhancer of zeste homolog 2 (EZH2) inhibitors was designed based on the chem. structure of the histone methyltransferase (HMT) inhibitor SAH (S-adenosyl-L-homocysteine).  These nucleoside-based EZH2 inhibitors blocked the methylation of nucleosomes at H3K27 in biochem. assays employing both WT PRC2 complex as well as a Y641N mutant PRC2 complex.  The most potent compd., 27, displayed IC50's against both complexes of 270 nM and 70 nM, resp.  To our knowledge, compd. 27 is the most potent SAH-derived inhibitor of the EZH2 PRC2 complex yet identified.  This compd. also displayed improved potency, lipophilic efficiency (LipE), and selectivity profile against other lysine methyltransferases compared with SAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD6-bRuJKI9LVg90H21EOLACvtfcHk0lj05lk6-DMeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVWjsrk%253D&md5=c223e65ceadad748c164b6bbcb38b3df</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26atitle%3DSAH%2520derived%2520potent%2520and%2520selective%2520EZH2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D7%26spage%3D1532%26epage%3D1537%26doi%3D10.1016%2Fj.bmcl.2015.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvaraju, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comess, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">The, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima-Fernandes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinge, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliushchev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petros, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweis, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigelow, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senisterra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindley, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasinski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappano, W. N.</span></span> <span> </span><span class="NLM_article-title">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.2306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28135237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=389-395&issue=4&author=Y.+Heauthor=S.+Selvarajuauthor=M.+L.+Curtinauthor=C.+G.+Jakobauthor=H.+Zhuauthor=K.+M.+Comessauthor=B.+Shawauthor=J.+Theauthor=E.+Lima-Fernandesauthor=M.+M.+Szewczykauthor=D.+Chengauthor=K.+L.+Klingeauthor=H.+Q.+Liauthor=M.+Pliushchevauthor=M.+A.+Algireauthor=D.+Maagauthor=J.+Guoauthor=J.+Dietrichauthor=S.+C.+Panchalauthor=A.+M.+Petrosauthor=R.+F.+Sweisauthor=M.+Torrentauthor=L.+J.+Bigelowauthor=G.+Senisterraauthor=F.+Liauthor=S.+Kennedyauthor=Q.+Wuauthor=D.+J.+Osterlingauthor=D.+J.+Lindleyauthor=W.+Gaoauthor=S.+Galasinskiauthor=D.+Barsyte-Lovejoyauthor=M.+Vedadiauthor=F.+G.+Buchananauthor=C.+H.+Arrowsmithauthor=G.+G.+Chiangauthor=C.+Sunauthor=W.+N.+Pappano&title=The+EED+protein-protein+interaction+inhibitor+A-395+inactivates+the+PRC2+complex&doi=10.1038%2Fnchembio.2306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span></div><div class="casAuthors">He, Yupeng; Selvaraju, Sujatha; Curtin, Michael L.; Jakob, Clarissa G.; Zhu, Haizhong; Comess, Kenneth M.; Shaw, Bailin; The, Juliana; Lima-Fernandes, Evelyne; Szewczyk, Magdalena M.; Cheng, Dong; Klinge, Kelly L.; Li, Huan-Qiu; Pliushchev, Marina; Algire, Mikkel A.; Maag, David; Guo, Jun; Dietrich, Justin; Panchal, Sanjay C.; Petros, Andrew M.; Sweis, Ramzi F.; Torrent, Maricel; Bigelow, Lance J.; Senisterra, Guillermo; Li, Fengling; Kennedy, Steven; Wu, Qin; Osterling, Donald J.; Lindley, David J.; Gao, Wenqing; Galasinski, Scott; Barsyte-Lovejoy, Dalia; Vedadi, Masoud; Buchanan, Fritz G.; Arrowsmith, Cheryl H.; Chiang, Gary G.; Sun, Chaohong; Pappano, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is a regulator of epigenetic states required for development and homeostasis.  PRC2 trimethylates histone H3 at lysine 27 (H3K27me3), which leads to gene silencing, and is dysregulated in many cancers.  The embryonic ectoderm development (EED) protein is an essential subunit of PRC2 that has both a scaffolding function and an H3K27me3-binding function.  Here we report the identification of A-395, a potent antagonist of the H3K27me3 binding functions of EED.  Structural studies demonstrate that A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2.  Phenotypic effects obsd. in vitro and in vivo are similar to those of known PRC2 enzymic inhibitors; however, A-395 retains potent activity against cell lines resistant to the catalytic inhibitors.  A-395 represents a first-in-class antagonist of PRC2 protein-protein interactions (PPI) for use as a chem. probe to investigate the roles of EED-contg. protein complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5rHeR_Z5mLVg90H21EOLACvtfcHk0lj05lk6-DMeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D&md5=d41eee098ed123f8c7f50babe93d7692</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2306%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DSelvaraju%26aufirst%3DS.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DJakob%26aufirst%3DC.%2BG.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DComess%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DB.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DLima-Fernandes%26aufirst%3DE.%26aulast%3DSzewczyk%26aufirst%3DM.%2BM.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DKlinge%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DPliushchev%26aufirst%3DM.%26aulast%3DAlgire%26aufirst%3DM.%2BA.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DSweis%26aufirst%3DR.%2BF.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DBigelow%26aufirst%3DL.%2BJ.%26aulast%3DSenisterra%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DLindley%26aufirst%3DD.%2BJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DGalasinski%26aufirst%3DS.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBuchanan%26aufirst%3DF.%2BG.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPappano%26aufirst%3DW.%2BN.%26atitle%3DThe%2520EED%2520protein-protein%2520interaction%2520inhibitor%2520A-395%2520inactivates%2520the%2520PRC2%2520complex%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D389%26epage%3D395%26doi%3D10.1038%2Fnchembio.2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanacci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cambillau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5108</span>– <span class="NLM_lpage">5113</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508200103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.0508200103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=16549795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsVGltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5108-5113&issue=13&author=E.+Minskaiaauthor=T.+Hertzigauthor=A.+E.+Gorbalenyaauthor=V.+Campanacciauthor=C.+Cambillauauthor=B.+Canardauthor=J.+Ziebuhr&title=Discovery+of+an+RNA+virus+3%27-%3E5%27+exoribonuclease+that+is+critically+involved+in+coronavirus+RNA+synthesis&doi=10.1073%2Fpnas.0508200103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an RNA virus 3'→5' exoribonuclease that is critically involved in coronavirus RNA synthesis</span></div><div class="casAuthors">Minskaia, Ekaterina; Hertzig, Tobias; Gorbalenya, Alexander E.; Campanacci, Valerie; Cambillau, Christian; Canard, Bruno; Ziebuhr, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5108-5113</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Replication of the giant RNA genome of severe acute respiratory syndrome (SARS) coronavirus (CoV) and synthesis of as many as eight subgenomic (sg) mRNAs are mediated by a viral replicase-transcriptase of outstanding complexity that includes an essential endoribonuclease activity.  Here, we show that the CoV replicative machinery, unlike that of other RNA viruses, also uses an exoribonuclease (ExoN) activity, which is assocd. with nonstructural protein (nsp) 14.  Bacterially expressed forms of SARS-CoV nsp14 were shown to act on both ssRNAs and dsRNAs in a 3'→5' direction.  The activity depended on residues that are conserved in the DEDD exonuclease superfamily.  The protein did not hydrolyze DNA or ribose-2'-O-methylated RNA substrates and required divalent metal ions for activity.  A range of 5'-labeled ssRNA substrates were processed to final products of ≈8-12 nucleotides.  When part of dsRNA or in the presence of nonlabeled dsRNA, the 5'-labeled RNA substrates were processed to significantly smaller products, indicating that binding to dsRNA in cis or trans modulates the exonucleolytic activity of nsp14.  Characterization of human CoV 229E ExoN active-site mutants revealed severe defects in viral RNA synthesis, and no viable virus could be recovered.  Besides strongly reduced genome replication, specific defects in sg RNA synthesis, such as aberrant sizes of specific sg RNAs and changes in the molar ratios between individual sg RNA species, were obsd.  Taken together, the study identifies an RNA virus ExoN activity that is involved in the synthesis of multiple RNAs from the exceptionally large genomic RNA templates of CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6SF6y0gH--rVg90H21EOLACvtfcHk0ljQaH9gOrRMgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsVGltr0%253D&md5=bdf193d90a45d6b9433dbdd4d74d4a4f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508200103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508200103%26sid%3Dliteratum%253Aachs%26aulast%3DMinskaia%26aufirst%3DE.%26aulast%3DHertzig%26aufirst%3DT.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DCampanacci%26aufirst%3DV.%26aulast%3DCambillau%26aufirst%3DC.%26aulast%3DCanard%26aufirst%3DB.%26aulast%3DZiebuhr%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520an%2520RNA%2520virus%25203%2527-%253E5%2527%2520exoribonuclease%2520that%2520is%2520critically%2520involved%2520in%2520coronavirus%2520RNA%2520synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D13%26spage%3D5108%26epage%3D5113%26doi%3D10.1073%2Fpnas.0508200103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibaja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Vash, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejtar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span> <span> </span><span class="NLM_article-title">Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/onc.2015.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fonc.2015.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25893294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=558-566&issue=5&author=V.+Gibajaauthor=F.+Shenauthor=J.+Harariauthor=J.+Kornauthor=D.+Ruddyauthor=V.+Saenz-Vashauthor=H.+Zhaiauthor=T.+Rejtarauthor=C.+G.+Parisauthor=Z.+Yuauthor=M.+Liraauthor=D.+Kingauthor=W.+Qiauthor=N.+Keenauthor=A.+Q.+Hassanauthor=H.+M.+Chan&title=Development+of+secondary+mutations+in+wild-type+and+mutant+EZH2+alleles+cooperates+to+confer+resistance+to+EZH2+inhibitors&doi=10.1038%2Fonc.2015.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors</span></div><div class="casAuthors">Gibaja, V.; Shen, F.; Harari, J.; Korn, J.; Ruddy, D.; Saenz-Vash, V.; Zhai, H.; Rejtar, T.; Paris, C. G.; Yu, Z.; Lira, M.; King, D.; Qi, W.; Keen, N.; Hassan, A. Q.; Chan, H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">558-566</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) is frequently dysregulated in cancers, and gain-of-function (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas.  Small-mol. inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entered clin. trials.  Here, we developed models of acquired resistance to EZH2 inhibitor EI1 with EZH2-mutated lymphoma cells.  Resistance was generated by secondary mutations in both wild-type (WT) and GOF Y641N EZH2 alleles.  These EZH2 mutants retained the substrate specificity of their predecessor complexes but became refractory to biochem. inhibition by EZH2 inhibitors.  Resistant cells were able to maintain a high level of H3K27Me3 in the presence of inhibitors.  Interestingly, mutation of EZH2 WT alone generated an intermediate resistance phenotype, which is consistent with a previously proposed model of cooperation between EZH2 WT and Y641N mutants to promote tumorigenesis.  In addn., the findings presented here have implications for the clin. translation of EZH2 inhibitors and underscore the need to develop novel EZH2 inhibitors to target potential resistance emerging in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUaTpSYCtEf7Vg90H21EOLACvtfcHk0ljQaH9gOrRMgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt74%253D&md5=fcfebb482305effcb67f258ce8c589e8</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.114%26sid%3Dliteratum%253Aachs%26aulast%3DGibaja%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DHarari%26aufirst%3DJ.%26aulast%3DKorn%26aufirst%3DJ.%26aulast%3DRuddy%26aufirst%3DD.%26aulast%3DSaenz-Vash%26aufirst%3DV.%26aulast%3DZhai%26aufirst%3DH.%26aulast%3DRejtar%26aufirst%3DT.%26aulast%3DParis%26aufirst%3DC.%2BG.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLira%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DD.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26atitle%3DDevelopment%2520of%2520secondary%2520mutations%2520in%2520wild-type%2520and%2520mutant%2520EZH2%2520alleles%2520cooperates%2520to%2520confer%2520resistance%2520to%2520EZH2%2520inhibitors%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D5%26spage%3D558%26epage%3D566%26doi%3D10.1038%2Fonc.2015.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalvez, F.</span></span> <span> </span><span class="NLM_article-title">Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">32646</span>– <span class="NLM_lpage">32655</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.18632%2Foncotarget.5066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26360609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC283htF2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=32646-32655&issue=32&author=T.+Bakerauthor=S.+Nerleauthor=J.+Pritchardauthor=B.+Zhaoauthor=V.+M.+Riveraauthor=A.+Garnerauthor=F.+Gonzalvez&title=Acquisition+of+a+single+EZH2+D1+domain+mutation+confers+acquired+resistance+to+EZH2-targeted+inhibitors&doi=10.18632%2Foncotarget.5066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors</span></div><div class="casAuthors">Baker Theresa; Nerle Sujata; Pritchard Justin; Zhao Boyang; Rivera Victor M; Garner Andrew; Gonzalvez Francois</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">32646-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although targeted therapies have revolutionized cancer treatment, overcoming acquired resistance remains a major clinical challenge.  EZH2 inhibitors (EZH2i), EPZ-6438 and GSK126, are currently in the early stages of clinical evaluation and the first encouraging signs of efficacy have recently emerged in the clinic.  To anticipate mechanisms of resistance to EZH2i, we used a forward genetic platform combining a mutagenesis screen with next generation sequencing technology and identified a hotspot of secondary mutations in the EZH2 D1 domain (Y111 and I109).  Y111D mutation within the WT or A677G EZH2 allele conferred robust resistance to both EPZ-6438 and GSK126, but it only drove a partial resistance within the Y641F allele.  EZH2 mutants required histone methyltransferase (HMT) catalytic activity and the polycomb repressive complex 2 (PRC2) components, SUZ12 and EED, to drive drug resistance.  Furthermore, D1 domain mutations not only blocked the ability of EZH2i to bind to WT and A677G mutant, but also abrogated drug binding to the Y641F mutant.  These data provide the first cellular validation of the mechanistic model underpinning the oncogenic function of WT and mutant EZH2.  Importantly, our findings suggest that acquired-resistance to EZH2i may arise in WT and mutant EZH2 patients through a single mutation that remains targetable by second generation EZH2i.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrjQ7fThFnJ75XHngOXiV_fW6udTcc2ebsJbsWAb-Xhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htF2msw%253D%253D&md5=c1af5705275e07526267d5d322cf3fac</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5066%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DT.%26aulast%3DNerle%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DGarner%26aufirst%3DA.%26aulast%3DGonzalvez%26aufirst%3DF.%26atitle%3DAcquisition%2520of%2520a%2520single%2520EZH2%2520D1%2520domain%2520mutation%2520confers%2520acquired%2520resistance%2520to%2520EZH2-targeted%2520inhibitors%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D32%26spage%3D32646%26epage%3D32655%26doi%3D10.18632%2Foncotarget.5066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span> <span> </span><span class="NLM_article-title">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.2304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28135235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=381-388&issue=4&author=W.+Qiauthor=K.+Zhaoauthor=J.+Guauthor=Y.+Huangauthor=Y.+Wangauthor=H.+Zhangauthor=M.+Zhangauthor=J.+Zhangauthor=Z.+Yuauthor=L.+Liauthor=L.+Tengauthor=S.+Chuaiauthor=C.+Zhangauthor=M.+Zhaoauthor=H.+Chanauthor=Z.+Chenauthor=D.+Fangauthor=Q.+Feiauthor=L.+Fengauthor=L.+Fengauthor=Y.+Gaoauthor=H.+Geauthor=X.+Geauthor=G.+Liauthor=A.+Lingelauthor=Y.+Linauthor=Y.+Liuauthor=F.+Luoauthor=M.+Shiauthor=L.+Wangauthor=Z.+Wangauthor=Y.+Yuauthor=J.+Zengauthor=C.+Zengauthor=L.+Zhangauthor=Q.+Zhangauthor=S.+Zhouauthor=C.+Oyangauthor=P.+Atadjaauthor=E.+Li&title=An+allosteric+PRC2+inhibitor+targeting+the+H3K27me3+binding+pocket+of+EED&doi=10.1038%2Fnchembio.2304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span></div><div class="casAuthors">Qi, Wei; Zhao, Kehao; Gu, Justin; Huang, Ying; Wang, Youzhen; Zhang, Hailong; Zhang, Man; Zhang, Jeff; Yu, Zhengtian; Li, Ling; Teng, Lin; Chuai, Shannon; Zhang, Chao; Zhao, Mengxi; Chan, Ho Man; Chen, Zijun; Fang, Douglas; Fei, Qi; Feng, Leying; Feng, Lijian; Gao, Yuan; Ge, Hui; Ge, Xinjian; Li, Guobin; Lingel, Andreas; Lin, Ying; Liu, Yueqin; Luo, Fangjun; Shi, Minlong; Wang, Long; Wang, Zhaofu; Yu, Yanyan; Zeng, Jue; Zeng, Chenhui; Zhang, Lijun; Zhang, Qiong; Zhou, Shaolian; Oyang, Counde; Atadja, Peter; Li, En</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) consists of three core subunits, EZH2, EED and SUZ12, and plays pivotal roles in transcriptional regulation.  The catalytic subunit EZH2 methylates histone H3 lysine 27 (H3K27), and its activity is further enhanced by the binding of EED to trimethylated H3K27 (H3K27me3).  Small-mol. inhibitors that compete with the cofactor S-adenosylmethionine (SAM) have been reported.  Here we report the discovery of EED226, a potent and selective PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED.  EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity.  EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors.  Interestingly, EED226 also effectively inhibits PRC2 contg. a mutant EZH2 protein resistant to SAM-competitive inhibitors.  Together, we show that EED226 inhibits PRC2 activity via an allosteric mechanism and offers an opportunity for treatment of PRC2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjpXExCMohI7Vg90H21EOLACvtfcHk0ljneigpOcSnPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D&md5=62d10723685450ca7ffd599a61134d42</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2304%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DChuai%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DFei%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DOyang%26aufirst%3DC.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DE.%26atitle%3DAn%2520allosteric%2520PRC2%2520inhibitor%2520targeting%2520the%2520H3K27me3%2520binding%2520pocket%2520of%2520EED%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D381%26epage%3D388%26doi%3D10.1038%2Fnchembio.2304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliushchev, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarris, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvaraju, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweis, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span> <span> </span><span class="NLM_article-title">SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1583</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2017.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28254486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Oju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1576-1583&issue=7&author=M.+L.+Curtinauthor=M.+A.+Pliushchevauthor=H.-Q.+Liauthor=M.+Torrentauthor=J.+D.+Dietrichauthor=C.+G.+Jakobauthor=H.+Zhuauthor=H.+Zhaoauthor=Y.+Wangauthor=Z.+Jiauthor=R.+F.+Clarkauthor=K.+A.+Sarrisauthor=S.+Selvarajuauthor=B.+Shawauthor=M.+A.+Algireauthor=Y.+Heauthor=P.+L.+Richardsonauthor=R.+F.+Sweisauthor=C.+Sunauthor=G.+G.+Chiangauthor=M.+R.+Michaelides&title=SAR+of+amino+pyrrolidines+as+potent+and+novel+protein-protein+interaction+inhibitors+of+the+PRC2+complex+through+EED+binding&doi=10.1016%2Fj.bmcl.2017.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding</span></div><div class="casAuthors">Curtin, Michael L.; Pliushchev, Marina A.; Li, Huan-Qiu; Torrent, Maricel; Dietrich, Justin D.; Jakob, Clarissa G.; Zhu, Haizhong; Zhao, Hongyu; Wang, Ying; Ji, Zhiqin; Clark, Richard F.; Sarris, Kathy A.; Selvaraju, Sujatha; Shaw, Bailin; Algire, Mikkel A.; He, Yupeng; Richardson, Paul L.; Sweis, Ramzi F.; Sun, Chaohong; Chiang, Gary G.; Michaelides, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1576-1583</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we disclose SAR studies of a series of dimethylamino pyrrolidines which we recently reported as novel inhibitors of the PRC2 complex through disruption of EED/H3K27me3 binding.  Modification of the indole and benzyl moieties of screening hit 1 provided analogs with substantially improved binding and cellular activities.  This work culminated in the identification of compd. 2, our nanomolar proof-of-concept (PoC) inhibitor which provided on-target tumor growth inhibition in a mouse xenograft model.  X-ray crystal structures of several inhibitors bound in the EED active-site are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkdonJy6cBnbVg90H21EOLACvtfcHk0ljneigpOcSnPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Oju7s%253D&md5=3396f3f4c2d3944237cfde004ac4204b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DPliushchev%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DH.-Q.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DJ.%2BD.%26aulast%3DJakob%26aufirst%3DC.%2BG.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DClark%26aufirst%3DR.%2BF.%26aulast%3DSarris%26aufirst%3DK.%2BA.%26aulast%3DSelvaraju%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DB.%26aulast%3DAlgire%26aufirst%3DM.%2BA.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DRichardson%26aufirst%3DP.%2BL.%26aulast%3DSweis%26aufirst%3DR.%2BF.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DSAR%2520of%2520amino%2520pyrrolidines%2520as%2520potent%2520and%2520novel%2520protein-protein%2520interaction%2520inhibitors%2520of%2520the%2520PRC2%2520complex%2520through%2520EED%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D7%26spage%3D1576%26epage%3D1583%26doi%3D10.1016%2Fj.bmcl.2017.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of first-in-class, potent, and orally bioavailable embryonic ectoderm development (EED) inhibitor with robust anticancer efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2215</span>– <span class="NLM_lpage">2226</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2215-2226&issue=6&author=Y.+Huangauthor=J.+Zhangauthor=Z.+Yuauthor=H.+Zhangauthor=Y.+Wangauthor=A.+Lingelauthor=W.+Qiauthor=J.+Guauthor=K.+Zhaoauthor=M.+D.+Shultzauthor=L.+Wangauthor=X.+Fuauthor=Y.+Sunauthor=Q.+Zhangauthor=X.+Jiangauthor=J.+Zhangauthor=C.+Zhangauthor=L.+Liauthor=J.+Zengauthor=L.+Fengauthor=C.+Zhangauthor=Y.+Liuauthor=M.+Zhangauthor=L.+Zhangauthor=M.+Zhaoauthor=Z.+Gaoauthor=X.+Liuauthor=D.+Fangauthor=H.+Guoauthor=Y.+Miauthor=T.+Gabrielauthor=M.+P.+Dillonauthor=P.+Atadjaauthor=C.+Oyang&title=Discovery+of+first-in-class%2C+potent%2C+and+orally+bioavailable+embryonic+ectoderm+development+%28EED%29+inhibitor+with+robust+anticancer+efficacy&doi=10.1021%2Facs.jmedchem.6b01576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy</span></div><div class="casAuthors">Huang, Ying; Zhang, Jeff; Yu, Zhengtian; Zhang, Hailong; Wang, Youzhen; Lingel, Andreas; Qi, Wei; Gu, Justin; Zhao, Kehao; Shultz, Michael D.; Wang, Long; Fu, Xingnian; Sun, Yongfeng; Zhang, Qiong; Jiang, Xiangqing; Zhang, Jiangwei; Zhang, Chunye; Li, Ling; Zeng, Jue; Feng, Lijian; Zhang, Chao; Liu, Yueqin; Zhang, Man; Zhang, Lijun; Zhao, Mengxi; Gao, Zhenting; Liu, Xianghui; Fang, Douglas; Guo, Haibing; Mi, Yuan; Gabriel, Tobias; Dillon, Michael P.; Atadja, Peter; Oyang, Counde</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2215-2226</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression and somatic heterozygous mutations of EZH2, the catalytic subunit Polycomb repressive complex 2 (PRC2), are assocd. with several tumor types.  EZH2 inhibitor, EPZ-6438 (Tazemetostat), demonstrated clin. efficacy in patients with acceptable safety profile as monotherapy.  EED, another subunit of PRC2 complex, is essential for its histone methyltransferase activity through direct binding to trimethylated lysine 27 on histone 3 (H3K27Me3).  Herein the authors disclose the discovery of a first-in-class potent, selective and orally bioavailable EED inhibitor EED226 (compd. 43).  Guided by x-ray crystallog., compd. 43 discovered by fragmentation and regrowth of Compd. (I), a PRC2 HTS hit that directly binds EED.  Scaffold hopping followed by ensuing multi-parameter optimization led to the discovery compd. 43.  Compd. 43 induces robust and sustained tumor regression in EZH2MUT pre-clin. DLBCL model.  For the first time specific and direct inhibition of EED can be effective as an anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRnKW75ksfdbVg90H21EOLACvtfcHk0ljqK3e1EGUjuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKisLo%253D&md5=c53a43e71d22a315b99f39929f666744</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01576%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DOyang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520first-in-class%252C%2520potent%252C%2520and%2520orally%2520bioavailable%2520embryonic%2520ectoderm%2520development%2520%2528EED%2529%2520inhibitor%2520with%2520robust%2520anticancer%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D6%26spage%3D2215%26epage%3D2226%26doi%3D10.1021%2Facs.jmedchem.6b01576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span> <span> </span><span class="NLM_article-title">An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5587</span>– <span class="NLM_lpage">5596</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-0428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F0008-5472.CAN-19-0428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31395608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1KitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=5587-5596&issue=21&author=H.+Dongauthor=S.+Liuauthor=X.+Zhangauthor=S.+Chenauthor=L.+Kangauthor=Y.+Chenauthor=S.+Maauthor=X.+Fuauthor=Y.+Liuauthor=H.+Zhangauthor=B.+Zou&title=An+allosteric+PRC2+inhibitor+targeting+EED+suppresses+tumor+progression+by+modulating+the+immune+response&doi=10.1158%2F0008-5472.CAN-19-0428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response</span></div><div class="casAuthors">Dong, Hongping; Liu, Shaojun; Zhang, Xuejie; Chen, Sheng; Kang, Lijing; Chen, Yanni; Ma, Shichao; Fu, Xianlei; Liu, Yanchao; Zhang, Hailong; Zou, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5587-5596</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant activity of polycomb repressive complex 2 (PRC2) is involved in a wide range of human cancer progression.  The WD40 repeat-contg. protein EED is a core component of PRC2 and enhances PRC2 activity through interaction with H3K27me3.  In this study, we report the discovery of a class of pyrimidone compds., represented by BR-001 as potent allosteric inhibitors of PRC2.  X-ray co-crystallog. showed that BR-001 directly binds EED in the H3K27me3-binding pocket.  BR-001 displayed antitumor potency in vitro and in vivo.  In Karpas422 and Pfeiffer xenograft mouse models, twice daily oral dosing with BR-001 resulted in robust anti-tumor activity.  BR-001 was also efficacious in syngeneic CT26 colon tumor-bearing mice; oral dosing of 30 mg/kg of BR-001 led to 59.3% tumor growth suppression and increased frequency of effector CD8+ T-cell infiltrates in tumors.  Pharmacodynamic anal. revealed that CXCL10 was highly upregulated, suggesting that CXCL10 triggers the trafficking of CD8+ T cells toward tumor sites.  Our results demonstrate for the first time that inhibition of EED modulates the tumor immune microenvironment to induce regression of colon tumors and therefore has the potential to be used in combination with immune-oncol. therapy.  Significance: BR-001, a potent inhibitor of the EED subunit of the PRC2 complex, suppresses tumor progression by modulating the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriYcNHbku1ZbVg90H21EOLACvtfcHk0ljqK3e1EGUjuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1KitL8%253D&md5=51331eac62193271e40ea4b9246a348c</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-0428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-0428%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DB.%26atitle%3DAn%2520allosteric%2520PRC2%2520inhibitor%2520targeting%2520EED%2520suppresses%2520tumor%2520progression%2520by%2520modulating%2520the%2520immune%2520response%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D21%26spage%3D5587%26epage%3D5596%26doi%3D10.1158%2F0008-5472.CAN-19-0428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.08.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2018.08.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30220457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslahs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=186-199&issue=1&author=X.+Huangauthor=J.+Yanauthor=M.+Zhangauthor=Y.+Wangauthor=Y.+Chenauthor=X.+Fuauthor=R.+Weiauthor=X.+L.+Zhengauthor=Z.+Liuauthor=X.+Zhangauthor=H.+Yangauthor=B.+Haoauthor=Y.+Y.+Shenauthor=Y.+Suauthor=X.+Congauthor=M.+Huangauthor=M.+Tanauthor=J.+Dingauthor=M.+Geng&title=Targeting+epigenetic+crosstalk+as+a+therapeutic+strategy+for+EZH2-aberrant+solid+tumors&doi=10.1016%2Fj.cell.2018.08.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors</span></div><div class="casAuthors">Huang, Xun; Yan, Juan; Zhang, Min; Wang, Yafang; Chen, Yi; Fu, Xuhong; Wei, Rongrui; Zheng, Xing-ling; Liu, Zhiwei; Zhang, Xiong; Yang, Hong; Hao, Bingbing; Shen, Yan-yan; Su, Yi; Cong, Xiaoji; Huang, Min; Tan, Minjia; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-199.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clin. benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematol. malignancies.  We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i.  We report here oncogenic transcriptional reprogramming mediated by MLL1's interaction with the p300/CBP complex, which directs H3K27me loss to reciprocal H3K27ac gain and restricts EZH2i response.  Concurrent inhibition of H3K27me and H3K27ac results in transcriptional repression and MAPK pathway dependency in cancer subsets.  In preclin. models encompassing a broad spectrum of EZH2-aberrant solid tumors, a combination of EZH2 and BRD4 inhibitors, or a triple-combination including MAPK inhibition display robust efficacy with very tolerable toxicity.  Our results suggest an attractive precision treatment strategy for EZH2-aberrant tumors on the basis of tumor-intrinsic MLL1 expression and concurrent inhibition of epigenetic crosstalk and feedback MAPK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgroiKQYI5RLVg90H21EOLACvtfcHk0ljqK3e1EGUjuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslahs7%252FM&md5=1879411de33f088e3c197d6175e02e18</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.08.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.08.058%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DX.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHao%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%2BY.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DCong%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DTargeting%2520epigenetic%2520crosstalk%2520as%2520a%2520therapeutic%2520strategy%2520for%2520EZH2-aberrant%2520solid%2520tumors%26jtitle%3DCell%26date%3D2018%26volume%3D175%26issue%3D1%26spage%3D186%26epage%3D199%26doi%3D10.1016%2Fj.cell.2018.08.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rej, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrunak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawacki, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">EEDi-5285: an exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic ectoderm development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">7252</span>– <span class="NLM_lpage">7267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1arsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=7252-7267&issue=13&author=R.+K.+Rejauthor=C.+Wangauthor=J.+Luauthor=M.+Wangauthor=E.+Petrunakauthor=K.+P.+Zawackiauthor=D.+McEachernauthor=E.+Fernandez-Salasauthor=C.+Y.+Yangauthor=L.+Wangauthor=R.+Liauthor=K.+Chinnaswamyauthor=B.+Wenauthor=D.+Sunauthor=J.+Stuckeyauthor=Y.+Zhouauthor=J.+Chenauthor=G.+Tangauthor=S.+Wang&title=EEDi-5285%3A+an+exceptionally+potent%2C+efficacious%2C+and+orally+active+small-molecule+inhibitor+of+embryonic+ectoderm+development&doi=10.1021%2Facs.jmedchem.0c00479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development</span></div><div class="casAuthors">Rej, Rohan Kalyan; Wang, Changwei; Lu, Jianfeng; Wang, Mi; Petrunak, Elyse; Zawacki, Kaitlin P.; McEachern, Donna; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Lu; Li, Ruiting; Chinnaswamy, Krishnapriya; Wen, Bo; Sun, Duxin; Stuckey, Jeanne; Zhou, Yunlong; Chen, Jianyong; Tang, Guozhi; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7252-7267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of embryonic ectoderm development (EED) is a new cancer therapeutic strategy.  Herein, we report our discovery of EEDi-5285 as an exceptionally potent, efficacious, and orally active EED inhibitor.  EEDi-5285 binds to the EED protein with an IC50 value of 0.2 nM and inhibits cell growth with IC50 values of 20 pM and 0.5 nM in the Pfeiffer and KARPAS422 lymphoma cell lines, resp., carrying an EZH2 mutation.  EEDi-5285 is approx. 100 times more potent than EED226 in binding to EED and >300 times more potent than EED226 in inhibition of cell growth in the KARPAS422 cell line.  EEDi-5285 has excellent pharmacokinetics and achieves complete and durable tumor regression in the KARPAS422 xenograft model in mice with oral administration.  The cocrystal structure of EEDi-5285 in a complex with EED defines the precise structural basis for their high binding affinity.  EEDi-5285 is the most potent and efficacious EED inhibitor reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiIQoP1xeDu7Vg90H21EOLACvtfcHk0lhBWyMADP-0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1arsL7J&md5=8438554230a2258e3d4d7748a090bc7f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00479%26sid%3Dliteratum%253Aachs%26aulast%3DRej%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DPetrunak%26aufirst%3DE.%26aulast%3DZawacki%26aufirst%3DK.%2BP.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DEEDi-5285%253A%2520an%2520exceptionally%2520potent%252C%2520efficacious%252C%2520and%2520orally%2520active%2520small-molecule%2520inhibitor%2520of%2520embryonic%2520ectoderm%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D13%26spage%3D7252%26epage%3D7267%26doi%3D10.1021%2Facs.jmedchem.0c00479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisserier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajapeyee, N.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">2125</span>– <span class="NLM_lpage">2137</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-08-804344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1182%2Fblood-2017-08-804344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29572378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFenurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2125-2137&issue=19&author=M.+Bisserierauthor=N.+Wajapeyee&title=Mechanisms+of+resistance+to+EZH2+inhibitors+in+diffuse+large+B-cell+lymphomas&doi=10.1182%2Fblood-2017-08-804344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas</span></div><div class="casAuthors">Bisserier, Malik; Wajapeyee, Narendra</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2125-2137</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Resistance to targeted therapies has become increasingly prevalent.  We noted that resistance to different targeted therapies occurs by largely common mechanisms.  In this study, we used this information for identifying the mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphoma (DLBCL) harboring EZH2 mutations.  We discovered that EZH2 inhibitor-resistant DLBCL cells showed activation of the insulin-like growth factor 1 receptor (IGF-1R), MEK, and PI3K pathways.  Constitutive activation of IGF-1R, MEK, or PI3K pathways was sufficient to confer resistance to EZH2 inhibitors in DLBCL.  The activation of the PI3K/AKT andMAPK pathways decreased TNFSF10 and BAD expression through a FOXO3-dependent mechanism, which was required for the antitumor effects of EZH2i GSK126.  We also identified multiple acquired mutations in EZH2 inhibitor-resistant DLBCL cell lines.  Acquired EZH2 mutations that confer resistance to EZH2 inhibitors prevent EZH2 inhibitor binding to the EZH2 mutants.  Notably, EZH2 inhibitor GSK126- and EPZ-6438-resistant DLBCL cells remained sensitive to the EZH2 inhibitor UNC1999 and embryonic ectoderm development protein inhibitor EED226, which provides an opportunity to treat DLBCLs that are resistant to these drugs.  Collectively, our results underpin the importance for developing a unified approach for forestalling drug resistance by prospectively considering lessons learned from the use of different targeted therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8bPfbf3K8qrVg90H21EOLACvtfcHk0lhBWyMADP-0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFenurrO&md5=e1e626bc16271b40be809c7587279cff</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-08-804344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-08-804344%26sid%3Dliteratum%253Aachs%26aulast%3DBisserier%26aufirst%3DM.%26aulast%3DWajapeyee%26aufirst%3DN.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EZH2%2520inhibitors%2520in%2520diffuse%2520large%2520B-cell%2520lymphomas%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26issue%3D19%26spage%3D2125%26epage%3D2137%26doi%3D10.1182%2Fblood-2017-08-804344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D. E.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of EED binders allosterically inhibiting the epigenetic Polycomb Repressive Complex 2 (PRC2) methyltransferase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaiurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=415-427&issue=1&author=A.+Lingelauthor=M.+Sendzikauthor=Y.+Huangauthor=M.+D.+Shultzauthor=J.+Cantwellauthor=M.+P.+Dillonauthor=X.+Fuauthor=J.+Fullerauthor=T.+Gabrielauthor=J.+Guauthor=X.+Jiangauthor=L.+Liauthor=F.+Liangauthor=M.+McKennaauthor=W.+Qiauthor=W.+Raoauthor=X.+Shengauthor=W.+Shuauthor=J.+Suttonauthor=B.+Taftauthor=L.+Wangauthor=J.+Zengauthor=H.+Zhangauthor=M.+Zhangauthor=K.+Zhaoauthor=M.+Lindvallauthor=D.+E.+Bussiere&title=Structure-guided+design+of+EED+binders+allosterically+inhibiting+the+epigenetic+Polycomb+Repressive+Complex+2+%28PRC2%29+methyltransferase&doi=10.1021%2Facs.jmedchem.6b01473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase</span></div><div class="casAuthors">Lingel, Andreas; Sendzik, Martin; Huang, Ying; Shultz, Michael D.; Cantwell, John; Dillon, Michael P.; Fu, Xingnian; Fuller, John; Gabriel, Tobias; Gu, Justin; Jiang, Xiangqing; Li, Ling; Liang, Fang; McKenna, Maureen; Qi, Wei; Rao, Weijun; Sheng, Xijun; Shu, Wei; Sutton, James; Taft, Benjamin; Wang, Long; Zeng, Jue; Zhang, Hailong; Zhang, Maya; Zhao, Kehao; Lindvall, Mika; Bussiere, Dirksen E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">415-427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PRC2 is a multisubunit methyltransferase involved in epigenetic regulation of early embryonic development and cell growth.  The catalytic subunit EZH2 methylates primarily lysine 27 of histone H3, leading to chromatin compaction and repression of tumor suppressor genes.  Inhibiting this activity by small mols. targeting EZH2 was shown to result in antitumor efficacy.  Here, the authors describe for the first time the optimization of a chem. series representing a new class of PRC2 inhibitors which acts allosterically via the trimethyllysine pocket of the noncatalytic EED subunit.  Deconstruction of a larger and complex screening hit to a simple fragment-sized mol. followed by structure-guided regrowth and careful property modulation were employed to yield compds. which achieve sub-micromolar inhibition in functional assays and cellular activity.  The resulting mols. can serve as a simplified entry point for lead optimization and can be utilized to study this new mechanism of PRC2 inhibition and the assocd. biol. in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRo2rkeTDLibVg90H21EOLACvtfcHk0liU75DAvJOcQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaiurrF&md5=3aec108471439f4ac99728a57b4eaf8e</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01473%26sid%3Dliteratum%253Aachs%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DFuller%26aufirst%3DJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DMcKenna%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DX.%26aulast%3DShu%26aufirst%3DW.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DTaft%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%2BE.%26atitle%3DStructure-guided%2520design%2520of%2520EED%2520binders%2520allosterically%2520inhibiting%2520the%2520epigenetic%2520Polycomb%2520Repressive%2520Complex%25202%2520%2528PRC2%2529%2520methyltransferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D1%26spage%3D415%26epage%3D427%26doi%3D10.1021%2Facs.jmedchem.6b01473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardayfio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and molecular basis of a diverse set of Polycomb repressive complex 2 inhibitors recognition by EED</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e0169855</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0169855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1371%2Fjournal.pone.0169855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28072869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFyjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&issue=1&author=L.+Liauthor=H.+Zhangauthor=M.+Zhangauthor=M.+Zhaoauthor=L.+Fengauthor=X.+Luoauthor=Z.+Gaoauthor=Y.+Huangauthor=O.+Ardayfioauthor=J.-H.+Zhangauthor=Y.+Linauthor=H.+Fanauthor=Y.+Miauthor=G.+Liauthor=L.+Liuauthor=L.+Fengauthor=F.+Luoauthor=L.+Tengauthor=W.+Qiauthor=J.+Ottlauthor=A.+Lingelauthor=D.+E.+Bussiereauthor=Z.+Yuauthor=P.+Atadjaauthor=C.+Luauthor=E.+Liauthor=J.+Guauthor=K.+Zhao&title=Discovery+and+molecular+basis+of+a+diverse+set+of+Polycomb+repressive+complex+2+inhibitors+recognition+by+EED&doi=10.1371%2Fjournal.pone.0169855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and molecular basis of a diverse set of polycomb repressive complex 2 inhibitors recognition by EED</span></div><div class="casAuthors">Li, Ling; Zhang, Hailong; Zhang, Man; Zhao, Mengxi; Feng, Lijian; Luo, Xiao; Gao, Zhenting; Huang, Ying; Ardayfio, Ophelia; Zhang, Ji-Hu; Lin, Ying; Fan, Hong; Mi, Yuan; Li, Guobin; Liu, Lei; Feng, Leying; Luo, Fangjun; Teng, Lin; Qi, Wei; Ottl, Johannes; Lingel, Andreas; Bussiere, Dirksen E.; Yu, Zhengtian; Atadja, Peter; Lu, Chris; Li, En; Gu, Justin; Zhao, Kehao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0169855/1-e0169855/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2), a histone H3 lysine 27 methyltransferase, plays a key role in gene regulation and is a known epigenetics drug target for cancer therapy.  The WD40 domain-contg. protein EED is the regulatory subunit of PRC2.  It binds to the tri-methylated lysine 27 of the histone H3 (H3K27me3), and through which stimulates the activity of PRC2 allosterically.  Recently, we disclosed a novel PRC2 inhibitor EED226 which binds to the K27me3-pocket on EED and showed strong antitumor activity in xenograft mice model.  Here, we further report the identification and validation of four other EED binders along with EED162, the parental compd. of EED226.  The crystal structures for all these five compds. in complex with EED revealed a common deep pocket induced by the binding of this diverse set of compds.  This pocket was created after significant conformational rearrangement of the arom. cage residues (Y365, Y148 and F97) in the H3K27me3 binding pocket of EED, the width of which was delineated by the side chains of these rearranged residues.  In addn., all five compds. interact with the Arg367 at the bottom of the pocket.  Each compd. also displays unique features in its interaction with EED, suggesting the dynamics of the H3K27me3 pocket in accommodating the binding of different compds.  Our results provide structural insights for rational design of novel EED binder for the inhibition of PRC2 complex activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBpGXyLD21irVg90H21EOLACvtfcHk0liU75DAvJOcQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFyjsb8%253D&md5=69c8c6b0f83866296d21f5fd23927c3e</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0169855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0169855%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DArdayfio%26aufirst%3DO.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DOttl%26aufirst%3DJ.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%2BE.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520molecular%2520basis%2520of%2520a%2520diverse%2520set%2520of%2520Polycomb%2520repressive%2520complex%25202%2520inhibitors%2520recognition%2520by%2520EED%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D1%26doi%3D10.1371%2Fjournal.pone.0169855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnash, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">The, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholensky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worley, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptidomimetic ligands of EED as allosteric inhibitors of PRC2</span>. <i>ACS Comb. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1021/acscombsci.6b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscombsci.6b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=161-172&issue=3&author=K.+D.+Barnashauthor=J.+Theauthor=J.+L.+Norris-Drouinauthor=S.+H.+Cholenskyauthor=B.+M.+Worleyauthor=F.+Liauthor=J.+I.+Stuckeyauthor=P.+J.+Brownauthor=M.+Vedadiauthor=C.+H.+Arrowsmithauthor=S.+V.+Fryeauthor=L.+I.+James&title=Discovery+of+peptidomimetic+ligands+of+EED+as+allosteric+inhibitors+of+PRC2&doi=10.1021%2Facscombsci.6b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2</span></div><div class="casAuthors">Barnash, Kimberly D.; The, Juliana; Norris-Drouin, Jacqueline L.; Cholensky, Stephanie H.; Worley, Beau M.; Li, Fengling; Stuckey, Jacob I.; Brown, Peter J.; Vedadi, Masoud; Arrowsmith, Cheryl H.; Frye, Stephen V.; James, Lindsey I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Combinatorial Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-172</span>CODEN:
                <span class="NLM_cas:coden">ACSCCC</span>;
        ISSN:<span class="NLM_cas:issn">2156-8944</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The function of EED within Polycomb repressive complex 2 (PRC2) is mediated by a complex network of protein-protein interactions.  Allosteric activation of PRC2 by binding of methylated proteins to EED's arom. cage is essential for full catalytic activity, but details of this regulation are not fully understood.  EED's recognition of the product of PRC2 activity, histone H3 lysine 27 trimethylation (H3K27me3), stimulates PRC2 methyltransferase activity at adjacent nucleosomes leading to H3K27me3 propagation and, ultimately, gene repression.  By coupling combinatorial chem. and structure-based design, we optimized a low affinity methylated Jarid2 peptide to a smaller, more potent peptidomimetic ligand (Kd = 1.14 ± 0.14 μM) of the arom. cage of EED.  Our strategy illustrates the effectiveness of applying combinatorial chem. to achieve both ligand potency and property optimization.  Furthermore, the resulting ligands, UNC5114 and UNC5115, demonstrate that targeted disruption of EED's reader function can lead to allosteric inhibition of PRC2 catalytic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwOqOVJ8hSD7Vg90H21EOLACvtfcHk0liU75DAvJOcQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWgsrw%253D&md5=0e7da46fc40d89f4095ac979374338fc</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facscombsci.6b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscombsci.6b00174%26sid%3Dliteratum%253Aachs%26aulast%3DBarnash%26aufirst%3DK.%2BD.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%2BL.%26aulast%3DCholensky%26aufirst%3DS.%2BH.%26aulast%3DWorley%26aufirst%3DB.%2BM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DStuckey%26aufirst%3DJ.%2BI.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DJames%26aufirst%3DL.%2BI.%26atitle%3DDiscovery%2520of%2520peptidomimetic%2520ligands%2520of%2520EED%2520as%2520allosteric%2520inhibitors%2520of%2520PRC2%26jtitle%3DACS%2520Comb.%2520Sci.%26date%3D2017%26volume%3D19%26issue%3D3%26spage%3D161%26epage%3D172%26doi%3D10.1021%2Facscombsci.6b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnash, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">The, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelberg, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective activators of PRC2 mutant EED-I363M</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">6524</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-43005-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41598-019-43005-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31024026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fptlajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=6524&issue=1&author=J.+L.+Suhauthor=K.+D.+Barnashauthor=T.+M.+Abramyanauthor=F.+Liauthor=J.+Theauthor=I.+A.+Engelbergauthor=M.+Vedadiauthor=P.+J.+Brownauthor=D.+B.+Kireevauthor=C.+H.+Arrowsmithauthor=L.+I.+Jamesauthor=S.+V.+Frye&title=Discovery+of+selective+activators+of+PRC2+mutant+EED-I363M&doi=10.1038%2Fs41598-019-43005-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective activators of PRC2 mutant EED-I363M</span></div><div class="casAuthors">Suh Junghyun L; Barnash Kimberly D; Abramyan Tigran M; Engelberg Isabelle A; Kireev Dmitri B; James Lindsey I; Frye Stephen V; Barnash Kimberly D; Li Fengling; The Juliana; Vedadi Masoud; Brown Peter J; Arrowsmith Cheryl H; Arrowsmith Cheryl H</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6524</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many common disease-causing mutations result in loss-of-function (LOF) of the proteins in which they occur.  LOF mutations have proven recalcitrant to pharmacologic intervention, presenting a challenge for the development of targeted therapeutics.  Polycomb repressive complex 2 (PRC2), which contains core subunits (EZH2, EED, and SUZ12), regulates gene activity by trimethylation of histone 3 lysine 27.  The dysregulation of PRC2 catalytic activity by mutations has been implicated in cancer and other diseases.  Among the mutations that cause PRC2 malfunction, an I363M LOF mutation of EED has been identified in myeloid disorders, where it prevents allosteric activation of EZH2 catalysis.  We describe structure-based design and computational simulations of ligands created to ameliorate this LOF.  Notably, these compounds selectively stimulate the catalytic activity of PRC2-EED-I363M over wildtype-PRC2.  Overall, this work demonstrates the feasibility of developing targeted therapeutics for PRC2-EED-I363M that act as allosteric agonists, potentially correcting this LOF mutant phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy_y3UKz_BfTQLBVDQn4bCfW6udTcc2eaTZW6rLk_zoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fptlajtg%253D%253D&md5=92fb9e3260bdc49440a1b803c833ed9e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-43005-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-43005-z%26sid%3Dliteratum%253Aachs%26aulast%3DSuh%26aufirst%3DJ.%2BL.%26aulast%3DBarnash%26aufirst%3DK.%2BD.%26aulast%3DAbramyan%26aufirst%3DT.%2BM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DEngelberg%26aufirst%3DI.%2BA.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DKireev%26aufirst%3DD.%2BB.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DJames%26aufirst%3DL.%2BI.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26atitle%3DDiscovery%2520of%2520selective%2520activators%2520of%2520PRC2%2520mutant%2520EED-I363M%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D6524%26doi%3D10.1038%2Fs41598-019-43005-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Z.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span> <span> </span><span class="NLM_article-title">Propagation of trimethylated H3K27 regulated by Polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">10370</span>– <span class="NLM_lpage">10375</span>, <span class="refDoi"> DOI: 10.1073/pnas.1600070113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1600070113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27578866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVegs7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=10370-10375&issue=37&author=T.+Uedaauthor=Y.+Nakataauthor=A.+Nagamachiauthor=N.+Yamasakiauthor=A.+Kanaiauthor=Y.+Seraauthor=M.+Sasakiauthor=H.+Matsuiauthor=Z.-i.+Hondaauthor=H.+Odaauthor=L.+Wolffauthor=T.+Inabaauthor=H.+Honda&title=Propagation+of+trimethylated+H3K27+regulated+by+Polycomb+protein+EED+is+required+for+embryogenesis%2C+hematopoietic+maintenance%2C+and+tumor+suppression&doi=10.1073%2Fpnas.1600070113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Propagation of trimethylated H3K27 regulated by polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression</span></div><div class="casAuthors">Ueda, Takeshi; Nakata, Yuichiro; Nagamachi, Akiko; Yamasaki, Norimasa; Kanai, Akinori; Sera, Yasuyuki; Sasaki, Masato; Matsui, Hirotaka; Honda, Zen-ichiro; Oda, Hideaki; Wolff, Linda; Inaba, Toshiya; Honda, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">10370-10375</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) catalyzes the monomethylation, dimethylation, and trimethylation of histone H3 Lys27 (H3K27) and acts as a central epigenetic regulator that marks the repressive chromatin domain.  Embryonic ectoderm development (EED), an essential component of PRC2, interacts with trimethylated H3K27 (H3K27me3) through the arom. cage structure composed of its three arom. amino acids, Phe97, Trp364, and Tyr365.  This interaction allosterically activates the histone methyltransferase activity of PRC2 and thereby propagates repressive histone marks.  In this study, we report the anal. of knock-in mice harboring the myeloid disorder-assocd. EED Ile363Met (I363M) mutation, analogous to the EED arom. cage mutants.  The I363M homozygotes displayed a remarkable and preferential redn. of H3K27me3 and died at mid-gestation.  The heterozygotes increased the clonogenic capacity and bone marrow repopulating activity of hematopoietic stem/progenitor cells (HSPCs) and were susceptible to leukemia.  Lgals3, a PRC2 target gene encoding a multifunctional galactose-binding lectin, was derepressed in I363M heterozygotes, which enhanced the stemness of HSPCs.  Thus, our work provides in vivo evidence that the structural integrity of EED to H3K27me3 propagation is crit., esp. for embryonic development and hematopoietic homeostasis, and that its perturbation increases the predisposition to hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLX-SDuRygrVg90H21EOLACvtfcHk0lhC8RXsi7-ctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVegs7rN&md5=3770f9cd696a1a69424f38326d25007f</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1600070113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1600070113%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DNakata%26aufirst%3DY.%26aulast%3DNagamachi%26aufirst%3DA.%26aulast%3DYamasaki%26aufirst%3DN.%26aulast%3DKanai%26aufirst%3DA.%26aulast%3DSera%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DHonda%26aufirst%3DZ.-i.%26aulast%3DOda%26aufirst%3DH.%26aulast%3DWolff%26aufirst%3DL.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DH.%26atitle%3DPropagation%2520of%2520trimethylated%2520H3K27%2520regulated%2520by%2520Polycomb%2520protein%2520EED%2520is%2520required%2520for%2520embryogenesis%252C%2520hematopoietic%2520maintenance%252C%2520and%2520tumor%2520suppression%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D37%26spage%3D10370%26epage%3D10375%26doi%3D10.1073%2Fpnas.1600070113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Z. i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span> <span> </span><span class="NLM_article-title">EED mutants impair Polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2557</span>– <span class="NLM_lpage">2560</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fleu.2012.146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=22733077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVChs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2557-2560&issue=12&author=T.+Uedaauthor=M.+Sanadaauthor=H.+Matsuiauthor=N.+Yamasakiauthor=Z.+i.+Hondaauthor=L.+Y.+Shihauthor=H.+Moriauthor=T.+Inabaauthor=S.+Ogawaauthor=H.+Honda&title=EED+mutants+impair+Polycomb+repressive+complex+2+in+myelodysplastic+syndrome+and+related+neoplasms.&doi=10.1038%2Fleu.2012.146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms</span></div><div class="casAuthors">Ueda, T.; Sanada, M.; Matsui, H.; Yamasaki, N.; Honda, Z.-I.; Shih, L.-Y.; Mori, H.; Inaba, T.; Ogawa, S.; Honda, H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2557-2560</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This paper describes EED mutants impair Polycomb recessive complex 2 (PRC2) in myelodysplastic syndrome and related neoplasms.  The six mutated forms of EED displayed functional defects involving changes: (i) protein stability, (ii) interaction with EZH2 and/or (iii) binding to H3K27me3, thereby impairing PRC2 function.  Recurrent mutations in PRC2 may constitute a new mol.-based disease category of myeloid malignancies are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN5kgOaBYnbbVg90H21EOLACvtfcHk0lhC8RXsi7-ctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVChs73I&md5=a830e98f1f7e09c77be26e653442d198</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.146%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DYamasaki%26aufirst%3DN.%26aulast%3DHonda%26aufirst%3DZ.%2Bi.%26aulast%3DShih%26aufirst%3DL.%2BY.%26aulast%3DMori%26aufirst%3DH.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DHonda%26aufirst%3DH.%26atitle%3DEED%2520mutants%2520impair%2520Polycomb%2520repressive%2520complex%25202%2520in%2520myelodysplastic%2520syndrome%2520and%2520related%2520neoplasms.%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D12%26spage%3D2557%26epage%3D2560%26doi%3D10.1038%2Fleu.2012.146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of Polycomb repressive complex 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9512</span>– <span class="NLM_lpage">9521</span>, <span class="refDoi"> DOI: 10.1021/jm501230c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501230c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9512-9521&issue=22&author=X.+Kongauthor=L.+Chenauthor=L.+Jiaoauthor=X.+Jiangauthor=F.+Lianauthor=J.+Luauthor=K.+Zhuauthor=D.+Duauthor=J.+Liuauthor=H.+Dingauthor=N.+Zhangauthor=J.+Shenauthor=M.+Zhengauthor=K.+Chenauthor=X.+Liuauthor=H.+Jiangauthor=C.+Luo&title=Astemizole+arrests+the+proliferation+of+cancer+cells+by+disrupting+the+EZH2-EED+interaction+of+Polycomb+repressive+complex+2&doi=10.1021%2Fjm501230c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2</span></div><div class="casAuthors">Kong, Xiangqian; Chen, Limin; Jiao, Lianying; Jiang, Xiangrui; Lian, Fulin; Lu, Junyan; Zhu, Kongkai; Du, Daohai; Liu, Jingqiu; Ding, Hong; Zhang, Naixia; Shen, Jingshan; Zheng, Mingyue; Chen, Kaixian; Liu, Xin; Jiang, Hualiang; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9512-9521</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb Repressive Complex 2 (PRC2) modulates the chromatin structure and transcriptional repression by trimethylation lysine 27 of histone H3 (H3K27me3), a process that necessitates the protein-protein interaction (PPI) between the catalytic subunit EZH2 and EED.  Deregulated PRC2 is intimately involved in tumorigenesis and progression, making it an invaluable target for epigenetic cancer therapy.  However, until now, there have been no reported small mol. compds. targeting the EZH2-EED interactions.  In the present study, we identified astemizole, an FDA-approved drug, as a small mol. inhibitor of the EZH2-EED interaction of PRC2.  The disruption of the EZH2-EED interaction by astemizole destabilizes the PRC2 complex and inhibits its methyltransferase activity in cancer cells.  Multiple lines of evidence have demonstrated that astemizole arrests the proliferation of PRC2-driven lymphomas primarily by disabling the PRC2 complex.  Our findings demonstrate the chem. tractability of the difficult PPI target by a small mol. compd., highlighting the therapeutic promise for PRC2-driven human cancers via targeted destruction of the EZH2-EED complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUoHR0GppdWLVg90H21EOLACvtfcHk0lg1LKcjtSP8MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nO&md5=9aa407fe354ba7e272bdfb6c6445f7f3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm501230c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501230c%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLian%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DAstemizole%2520arrests%2520the%2520proliferation%2520of%2520cancer%2520cells%2520by%2520disrupting%2520the%2520EZH2-EED%2520interaction%2520of%2520Polycomb%2520repressive%2520complex%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D22%26spage%3D9512%26epage%3D9521%26doi%3D10.1021%2Fjm501230c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">13049</span>– <span class="NLM_lpage">13059</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.18632%2Foncotarget.3790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25944687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC2MfgvFGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=13049-13059&issue=15&author=H.+Chenauthor=S.+Gaoauthor=J.+Liauthor=D.+Liuauthor=C.+Shengauthor=C.+Yaoauthor=W.+Jiangauthor=J.+Wuauthor=S.+Chenauthor=W.+Huang&title=Wedelolactone+disrupts+the+interaction+of+EZH2-EED+complex+and+inhibits+PRC2-dependent+cancer&doi=10.18632%2Foncotarget.3790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer</span></div><div class="casAuthors">Chen Huiming; Gao Shijuan; Li Jiandong; Liu Dong; Sheng Chunjie; Yao Chen; Jiang Wei; Wu Jiaoxiang; Chen Shuai; Huang Wenlin; Chen Huiming; Yao Chen; Wu Jiaoxiang; Chen Shuai; Huang Wenlin; Huang Wenlin</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">13049-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2), which is responsible for the trimethylation of H3K27 (H3K27me3), plays a part in tumorigenesis, development and/or maintenance of adult tissue specificity.  The pivotal role of PRC2 in cancer makes it a therapeutic target for epigenetic cancer therapy.  However, natural compounds targeting the enhancer of zeste homolog 2 (EZH2) - embryonic ectoderm development (EED) interaction to disable PRC2 complex are scarcely reported.  Here, we reported the screening and identification of natural compounds which could disrupt the EZH2-EED interaction.  One of these compounds, wedelolactone, binds to EED with a high affinity (KD = 2.82 μM), blocks the EZH2-EED interaction in vitro, induces the degradation of PRC2 core components and modulates the expression of detected PRC2 downstream targets and cancer-related genes.  Furthermore, some PRC2-dependent cancer cells undergone growth arrest upon treatment with wedelolactone.  Thus, wedelolactone and its derivatives which target the EZH2-EED interaction could be candidates for the treatment of PRC2-dependent cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVWfUI8TyID75XHngOXiV_fW6udTcc2eYywYmpuvr21Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfgvFGiuw%253D%253D&md5=409700e2287c7af5ed9ea2a504b5675f</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3790%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DWedelolactone%2520disrupts%2520the%2520interaction%2520of%2520EZH2-EED%2520complex%2520and%2520inhibits%2520PRC2-dependent%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D15%26spage%3D13049%26epage%3D13059%26doi%3D10.18632%2Foncotarget.3790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostic, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in selective and irreversible covalent ligand development and validation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1486</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2019.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31631011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1486-1500&issue=11&author=T.+Zhangauthor=J.+M.+Hatcherauthor=M.+Tengauthor=N.+S.+Grayauthor=M.+Kostic&title=Recent+advances+in+selective+and+irreversible+covalent+ligand+development+and+validation&doi=10.1016%2Fj.chembiol.2019.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation</span></div><div class="casAuthors">Zhang, Tinghu; Hatcher, John M.; Teng, Mingxing; Gray, Nathanael S.; Kostic, Milka</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1486-1500</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Some of the most widely used drugs, such as aspirin and penicillin, are covalent drugs.  Covalent binding can improve potency, selectivity, and duration of the effects, but the intrinsic reactivity represents a potential liability and may result in idiosyncratic toxicity.  For decades, the cons were believed to outweigh the pros, and covalent targeting was deprioritized in drug discovery.  Recently, several covalent inhibitors have been approved for cancer treatment, thus rebooting the field.  In this review, we briefly reflect on the history of selective covalent targeting, and provide a comprehensive overview of emerging developments from a chem. biol. stand-point.  Our discussion will reflect on efforts to validate irreversible covalent ligands, expand the scope of targets, and discover new ligands and warheads.  We conclude with a brief commentary of remaining limitations and emerging opportunities in selective covalent targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc9UIuWjfX97Vg90H21EOLACvtfcHk0lg5r3ljLrfgrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO&md5=ce957a868ca27f545243d28e60dc5868</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKostic%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520selective%2520and%2520irreversible%2520covalent%2520ligand%2520development%2520and%2520validation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D11%26spage%3D1486%26epage%3D1500%26doi%3D10.1016%2Fj.chembiol.2019.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span> <span> </span><span class="NLM_article-title">A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.15252/embj.201694058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.15252%2Fembj.201694058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28320739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=1243-1260&issue=9&author=X.+Wangauthor=W.+Caoauthor=J.+Zhangauthor=M.+Yanauthor=Q.+Xuauthor=X.+Wuauthor=L.+Wanauthor=Z.+Zhangauthor=C.+Zhangauthor=X.+Qinauthor=M.+Xiaoauthor=D.+Yeauthor=Y.+Liuauthor=Z.+Hanauthor=S.+Wangauthor=L.+Maoauthor=W.+Weiauthor=W.+Chen&title=A+covalently+bound+inhibitor+triggers+EZH2+degradation+through+CHIP-mediated+ubiquitination&doi=10.15252%2Fembj.201694058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination</span></div><div class="casAuthors">Wang, Xu; Cao, Wei; Zhang, Jianjun; Yan, Ming; Xu, Qin; Wu, Xiangbing; Wan, Lixin; Zhang, Zhiyuan; Zhang, Chenping; Qin, Xing; Xiao, Meng; Ye, Dongxia; Liu, Yuyang; Han, Zeguang; Wang, Shaomeng; Mao, Li; Wei, Wenyi; Chen, Wantao</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1243-1260</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2) has been characterized as a crit. oncogene and a promising drug target in human malignant tumors.  The current EZH2 inhibitors strongly suppress the enhanced enzymic function of mutant EZH2 in some lymphomas.  However, the recent identification of a PRC2- and methyltransferase-independent role of EZH2 indicates that a complete suppression of all oncogenic functions of EZH2 is needed.  Here, we report a unique EZH2-targeting strategy by identifying a gambogenic acid (GNA) deriv. as a novel agent that specifically and covalently bound to Cys668 within the EZH2-SET domain, triggering EZH2 degrdn. through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.  This class of inhibitors significantly suppressed H3K27Me3 and effectively reactivated polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes.  Moreover, the novel inhibitors significantly suppressed tumor growth in an EZH2-dependent manner, and tumors bearing a non-GNA-interacting C668S-EZH2 mutation exhibited resistance to the inhibitors.  Together, our results identify the inhibition of the signaling pathway that governs GNA-mediated destruction of EZH2 as a promising anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRQknSdWy5T7Vg90H21EOLACvtfcHk0lg5r3ljLrfgrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D&md5=b9b8a266537e2922648784d9cd4edf02</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.15252%2Fembj.201694058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201694058%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26atitle%3DA%2520covalently%2520bound%2520inhibitor%2520triggers%2520EZH2%2520degradation%2520through%2520CHIP-mediated%2520ubiquitination%26jtitle%3DEMBO%2520J.%26date%3D2017%26volume%3D36%26issue%3D9%26spage%3D1243%26epage%3D1260%26doi%3D10.15252%2Fembj.201694058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratikopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rialdi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class EZH2 selective degrader</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0421-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41589-019-0421-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31819273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCht7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=214-222&issue=2&author=A.+Maauthor=E.+Stratikopoulosauthor=K.+S.+Parkauthor=J.+Weiauthor=T.+C.+Martinauthor=X.+Yangauthor=M.+Schwarzauthor=V.+Leshchenkoauthor=A.+Rialdiauthor=B.+Daleauthor=A.+Laganaauthor=E.+Guccioneauthor=S.+Parekhauthor=R.+Parsonsauthor=J.+Jin&title=Discovery+of+a+first-in-class+EZH2+selective+degrader&doi=10.1038%2Fs41589-019-0421-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a first-in-class EZH2 selective degrader</span></div><div class="casAuthors">Ma, Anqi; Stratikopoulos, Elias; Park, Kwang-Su; Wei, Jieli; Martin, Tiphaine C.; Yang, Xiaobao; Schwarz, Megan; Leshchenko, Violetta; Rialdi, Alexander; Dale, Brandon; Lagana, Alessandro; Guccione, Ernesto; Parekh, Samir; Parsons, Ramon; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-222</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The enhancer of zeste homolog 2 (EZH2) is the main enzymic subunit of the PRC2 complex, which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3) to promote transcriptional silencing.  EZH2 is overexpressed in multiple types of cancer including triple-neg. breast cancer (TNBC), and high expression levels correlate with poor prognosis.  Several EZH2 inhibitors, which inhibit the methyltransferase activity of EZH2, have shown promise in treating sarcoma and follicular lymphoma in clinics.  However, EZH2 inhibitors are ineffective at blocking proliferation of TNBC cells, even though they effectively reduce the H3K27me3 mark.  Using a hydrophobic tagging approach, we generated MS1943, a first-in-class EZH2 selective degrader that effectively reduces EZH2 levels in cells.  Importantly, MS1943 has a profound cytotoxic effect in multiple TNBC cells, while sparing normal cells, and is efficacious in vivo, suggesting that pharmacol. degrdn. of EZH2 can be advantageous for treating the cancers that are dependent on EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPb6bK3v_gQrVg90H21EOLACvtfcHk0lg5r3ljLrfgrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCht7zJ&md5=e1ccae457eba9b298f8b0e583bbaa833</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0421-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0421-4%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DA.%26aulast%3DStratikopoulos%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DK.%2BS.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DT.%2BC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DLeshchenko%26aufirst%3DV.%26aulast%3DRialdi%26aufirst%3DA.%26aulast%3DDale%26aufirst%3DB.%26aulast%3DLagana%26aufirst%3DA.%26aulast%3DGuccione%26aufirst%3DE.%26aulast%3DParekh%26aufirst%3DS.%26aulast%3DParsons%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520EZH2%2520selective%2520degrader%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26issue%3D2%26spage%3D214%26epage%3D222%26doi%3D10.1038%2Fs41589-019-0421-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konze, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meslamani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaniskan, H. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7617</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00855</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00855" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmtr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7617-7633&issue=16&author=X.+Yangauthor=F.+Liauthor=K.+D.+Konzeauthor=J.+Meslamaniauthor=A.+Maauthor=P.+J.+Brownauthor=M.+M.+Zhouauthor=C.+H.+Arrowsmithauthor=H.+U.+Kaniskanauthor=M.+Vedadiauthor=J.+Jin&title=Structure-activity+relationship+studies+for+Enhancer+of+Zeste+Homologue+2+%28EZH2%29+and+Enhancer+of+Zeste+Homologue+1+%28EZH1%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors</span></div><div class="casAuthors">Yang, Xiaobao; Li, Fengling; Konze, Kyle D.; Meslamani, Jamel; Ma, Anqi; Brown, Peter J.; Zhou, Ming-Ming; Arrowsmith, Cheryl H.; Kaniskan, H. Umit; Vedadi, Masoud; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7617-7633</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EZH2 or EZH1 (enhancer of zeste homolog 2 or 1) is the catalytic subunit of polycomb repressive complex 2 (PRC2) that catalyzes methylation of histone H3 lysine 27 (H3K27).  PRC2 hyperactivity and/or hypertrimethylation of H3K27 are assocd. with numerous human cancers, therefore inhibition of PRC2 complex has emerged as a promising therapeutic approach.  Recent studies have shown that EZH2 and EZH1 are not functionally redundant and inhibition of both EZH2 and EZH1 is necessary to block the progression of certain cancers such as MLL (mixed-lineage leukemia)-rearranged leukemias.  Despite the significant advances in discovery of EZH2 inhibitors, there has not been a systematic structure-activity relation (SAR) study to investigate the selectivity between EZH2 and EZH1 inhibition.  Here, the authors report the authors SAR studies that focus on modifications to various regions of the EZH2/1 inhibitor UNC1999 (5) to investigate the impact of the structural changes on EZH2 and EZH1 inhibition and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7AOr5A2kOH7Vg90H21EOLACvtfcHk0ljQie-qcJhttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmtr3P&md5=14d5dba978adc28baaf2b781ae9a1541</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00855%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKonze%26aufirst%3DK.%2BD.%26aulast%3DMeslamani%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DZhou%26aufirst%3DM.%2BM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DKaniskan%26aufirst%3DH.%2BU.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%2520studies%2520for%2520Enhancer%2520of%2520Zeste%2520Homologue%25202%2520%2528EZH2%2529%2520and%2520Enhancer%2520of%2520Zeste%2520Homologue%25201%2520%2528EZH1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D16%26spage%3D7617%26epage%3D7633%26doi%3D10.1021%2Facs.jmedchem.6b00855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmusson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Donovan, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloecher, A.</span></span> <span> </span><span class="NLM_article-title">EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2019.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31786184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1KqsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=41-46&issue=1&author=J.+H.+Hsuauthor=T.+Rasmussonauthor=J.+Robinsonauthor=F.+Pachlauthor=J.+Readauthor=S.+Kawatkarauthor=D.+H.+O%27Donovanauthor=S.+Bagalauthor=E.+Codeauthor=P.+Rawlinsauthor=A.+Argyrouauthor=R.+Tomlinsonauthor=N.+Gaoauthor=X.+Zhuauthor=E.+Chiarparinauthor=K.+Jacquesauthor=M.+Shenauthor=H.+Woodsauthor=E.+Bednarskiauthor=D.+M.+Wilsonauthor=L.+Drewauthor=M.+P.+Castaldiauthor=S.+Fawellauthor=A.+Bloecher&title=EED-targeted+PROTACs+degrade+EED%2C+EZH2%2C+and+SUZ12+in+the+PRC2+complex&doi=10.1016%2Fj.chembiol.2019.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex</span></div><div class="casAuthors">Hsu, Jessie Hao-Ru; Rasmusson, Timothy; Robinson, James; Pachl, Fiona; Read, Jon; Kawatkar, Sameer; O' Donovan, Daniel H.; Bagal, Sharan; Code, Erin; Rawlins, Philip; Argyrou, Argyrides; Tomlinson, Ronald; Gao, Ning; Zhu, Xiahui; Chiarparin, Elisabetta; Jacques, Kelly; Shen, Minhui; Woods, Haley; Bednarski, Emma; Wilson, David M.; Drew, Lisa; Castaldi, M. Paola; Fawell, Stephen; Bloecher, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-46.e17</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Deregulation of the PRC2 complex, comprised of the core subunits EZH2, SUZ12, and EED, drives aberrant hypermethylation of H3K27 and tumorigenicity of many cancers.  Although inhibitors of EZH2 have shown promising clin. activity, preclin. data suggest that resistance can be acquired through secondary mutations in EZH2 that abrogate drug target engagement.  To address these limitations, we have designed several hetero-bifunctional PROTACs (proteolysis-targeting chimera) to efficiently target EED for elimination.  Our PROTACs bind to EED (pKD ~ 9.0) and promote ternary complex formation with the E3 ubiquitin ligase.  The PROTACs potently inhibit PRC2 enzyme activity (pIC50 ~ 8.1) and induce rapid degrdn. of not only EED but also EZH2 and SUZ12 within the PRC2 complex.  Furthermore, the PROTACs selectively inhibit proliferation of PRC2-dependent cancer cells (half maximal growth inhibition [GI50] = 49-58 nM).  In summary, our data demonstrate a therapeutic modality to target PRC2-dependent cancer through a PROTAC-mediated degrdn. mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WGn283nfDLVg90H21EOLACvtfcHk0ljQie-qcJhttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1KqsrnO&md5=791238d7d1423f4a715529cfa14bfb65</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DJ.%2BH.%26aulast%3DRasmusson%26aufirst%3DT.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DO%2527Donovan%26aufirst%3DD.%2BH.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DCode%26aufirst%3DE.%26aulast%3DRawlins%26aufirst%3DP.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DTomlinson%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DJacques%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DH.%26aulast%3DBednarski%26aufirst%3DE.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DCastaldi%26aufirst%3DM.%2BP.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DBloecher%26aufirst%3DA.%26atitle%3DEED-targeted%2520PROTACs%2520degrade%2520EED%252C%2520EZH2%252C%2520and%2520SUZ12%2520in%2520the%2520PRC2%2520complex%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D41%26epage%3D46%26doi%3D10.1016%2Fj.chembiol.2019.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potjewyd, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rectenwald, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholensky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span> <span> </span><span class="NLM_article-title">Degradation of Polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2019.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31831267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlOmt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=47-56&issue=1&author=F.+Potjewydauthor=A.+W.+Turnerauthor=J.+Beriauthor=J.+M.+Rectenwaldauthor=J.+L.+Norris-Drouinauthor=S.+H.+Cholenskyauthor=D.+M.+Margolisauthor=K.+H.+Pearceauthor=L.+E.+Herringauthor=L.+I.+James&title=Degradation+of+Polycomb+repressive+complex+2+with+an+EED-targeted+bivalent+chemical+degrader&doi=10.1016%2Fj.chembiol.2019.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader</span></div><div class="casAuthors">Potjewyd, Frances; Turner, Anne-Marie W.; Beri, Joshua; Rectenwald, Justin M.; Norris-Drouin, Jacqueline L.; Cholensky, Stephanie H.; Margolis, David M.; Pearce, Kenneth H.; Herring, Laura E.; James, Lindsey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-56.e15</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein degrdn. via the use of bivalent chem. degraders provides an alternative strategy to block protein function and assess the biol. roles of putative drug targets.  This approach capitalizes on the advantages of small-mol. inhibitors while moving beyond the restrictions of traditional pharmacol.  Here, we report a chem. degrader (UNC6852) that targets polycomb repressive complex 2 (PRC2).  UNC6852 contains an EED226-derived ligand and a ligand for VHL which bind to the WD40 arom. cage of EED and CRL2VHL, resp., to induce proteasomal degrdn. of PRC2 components, EED, EZH2, and SUZ12.  Degrdn. of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B cell lymphoma (DLBCL) cells contg. EZH2 gain-of-function mutations.  UNC6852 degrades both wild-type and mutant EZH2, and addnl. displays anti-proliferative effects in this cancer model system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF3p-HFdD9KLVg90H21EOLACvtfcHk0ljQie-qcJhttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlOmt7bM&md5=7d9ca2726bad4e40003310951edc09d4</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DPotjewyd%26aufirst%3DF.%26aulast%3DTurner%26aufirst%3DA.%2BW.%26aulast%3DBeri%26aufirst%3DJ.%26aulast%3DRectenwald%26aufirst%3DJ.%2BM.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%2BL.%26aulast%3DCholensky%26aufirst%3DS.%2BH.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26aulast%3DPearce%26aufirst%3DK.%2BH.%26aulast%3DHerring%26aufirst%3DL.%2BE.%26aulast%3DJames%26aufirst%3DL.%2BI.%26atitle%3DDegradation%2520of%2520Polycomb%2520repressive%2520complex%25202%2520with%2520an%2520EED-targeted%2520bivalent%2520chemical%2520degrader%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.chembiol.2019.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">A Polycomb repression signature in metastatic prostate cancer predicts cancer outcome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10657</span>– <span class="NLM_lpage">10663</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F0008-5472.CAN-07-2498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18006806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=10657-10663&issue=22&author=J.+Yuauthor=J.+Yuauthor=D.+R.+Rhodesauthor=S.+A.+Tomlinsauthor=X.+Caoauthor=G.+Chenauthor=R.+Mehraauthor=X.+Wangauthor=D.+Ghoshauthor=R.+B.+Shahauthor=S.+Varamballyauthor=K.+J.+Pientaauthor=A.+M.+Chinnaiyan&title=A+Polycomb+repression+signature+in+metastatic+prostate+cancer+predicts+cancer+outcome&doi=10.1158%2F0008-5472.CAN-07-2498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome</span></div><div class="casAuthors">Yu, Jindan; Yu, Jianjun; Rhodes, Daniel R.; Tomlins, Scott A.; Cao, Xuhong; Chen, Guoan; Mehra, Rohit; Wang, Xiaoju; Ghosh, Debashis; Shah, Rajal B.; Varambally, Sooryanarayana; Pienta, Kenneth J.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10657-10663</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Polycomb Group (PcG) protein EZH2 is a crit. component of a multiprotein complex that methylates Lys27 of histone 3 (H3K27), which consequently leads to the repression of target gene expression.  We have previously reported that EZH2 is overexpressed in metastatic prostate cancer and is a marker of aggressive diseases in clin. localized solid tumors.  However, the global set of genes directly regulated by PcG in tumors is largely unknown, and thus how PcG mediates tumor progression remains unclear.  Herein we mapped genome-wide H3K27 methylation in aggressive, disseminated human prostate cancer tissues.  Integrative anal. revealed that a significant subset of these genes are also targets of PcG in embryonic stem cells, and their repression in tumors is assocd. with poor prognosis.  By stepwise cross-validation, we developed a "Polycomb repression signature" composed of 14 direct targets of PcG in metastatic tumors.  Notably, solid tumor subtypes in which this gene signature is repressed show poor clin. outcome in multiple microarray data sets of tumors including breast and prostate cancer.  Taken together, our results show a fingerprint of PcG-mediated transcriptional repression in metastatic prostate cancer that is reminiscent of stem cells and assocd. with cancer progression.  Therefore, PcG proteins play a central role in the epigenetic silencing of target genes and functionally link stem cells, metastasis, and cancer survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVnXl_rXgadbVg90H21EOLACvtfcHk0libXVVC1CrvxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7rO&md5=27bcf577683e5be369d74bfd380b267d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2498%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DRhodes%26aufirst%3DD.%2BR.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DShah%26aufirst%3DR.%2BB.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DA%2520Polycomb%2520repression%2520signature%2520in%2520metastatic%2520prostate%2520cancer%2520predicts%2520cancer%2520outcome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D22%26spage%3D10657%26epage%3D10663%26doi%3D10.1158%2F0008-5472.CAN-07-2498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maneiro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shchepinova, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kounde, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span> <span> </span><span class="NLM_article-title">Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1021/acschembio.0c00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.0c00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1306-1312&issue=6&author=M.+A.+Maneiroauthor=N.+Forteauthor=M.+M.+Shchepinovaauthor=C.+S.+Koundeauthor=V.+Chudasamaauthor=J.+R.+Bakerauthor=E.+W.+Tate&title=Antibody-PROTAC+conjugates+enable+HER2-dependent+targeted+protein+degradation+of+BRD4&doi=10.1021%2Facschembio.0c00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4</span></div><div class="casAuthors">Maneiro, Maria; Forte, Nafsika; Shchepinova, Maria M.; Kounde, Cyrille S.; Chudasama, Vijay; Baker, James Richard; Tate, Edward W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-1312</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting protein degrdn. with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery.  Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity and do not discriminate between cells of different types.  Here, we describe a strategy for selective protein degrdn. in a specific cell type.  We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internalization, releasing the active PROTAC and inducing catalytic protein degrdn.  We show that 3 selectively targets bromodomain-contg. protein 4 (BRD4) for degrdn. only in HER2 pos. breast cancer cell lines, while sparing HER2 neg. cells.  Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 pos. cells, leading to the release of active PROTAC in quantities sufficient to induce potent BRD4 degrdn.  These studies demonstrate proof-of-concept for tissue-specific BRD4 degrdn., overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPwGNLaGmRbbVg90H21EOLACvtfcHk0libXVVC1CrvxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D&md5=544b53e54d3f0696f0b425c3f6e48e46</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facschembio.0c00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.0c00285%26sid%3Dliteratum%253Aachs%26aulast%3DManeiro%26aufirst%3DM.%2BA.%26aulast%3DForte%26aufirst%3DN.%26aulast%3DShchepinova%26aufirst%3DM.%2BM.%26aulast%3DKounde%26aufirst%3DC.%2BS.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DTate%26aufirst%3DE.%2BW.%26atitle%3DAntibody-PROTAC%2520conjugates%2520enable%2520HER2-dependent%2520targeted%2520protein%2520degradation%2520of%2520BRD4%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D1306%26epage%3D1312%26doi%3D10.1021%2Facschembio.0c00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Daohai Du, Dandan Xu, Licheng Zhu, Giulia Stazi, Clemens Zwergel, Yanli Liu, Zhongyuan Luo, Yuanqing Li, Yuanyuan Zhang, Kongkai Zhu, Yiluan Ding, Jingqiu Liu, Shijie Fan, Kaiyan Zhao, Naixia Zhang, Xiangqian Kong, Hualiang Jiang, Kaixian Chen, Kehao Zhao, Sergio Valente, Jinrong Min, Wenhu Duan, <span class="NLM_string-name hlFld-ContribAuthor">Cheng Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8194-8207. <a href="https://doi.org/10.1021/acs.jmedchem.0c02261" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02261%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BDevelopment%252Bof%252BSmall-Molecule%252BPRC2%252BInhibitors%252BTargeting%252BEZH2%2525E2%252580%252593EED%252BInteraction%26aulast%3DDu%26aufirst%3DDaohai%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30122020%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D8194%26epage%3D8207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhang, Deqin Rong, Bingbing Li, <span class="NLM_string-name hlFld-ContribAuthor">Yuanxiang Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7900-7925. <a href="https://doi.org/10.1021/acs.jmedchem.0c02055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BEpigenetic%252BRegulators%252Bwith%252BCovalent%252BSmall-Molecule%252BInhibitors%26aulast%3DZhang%26aufirst%3DYi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D18022021%26volume%3D64%26issue%3D12%26spage%3D7900%26epage%3D7925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su H.  Park</span>, <span class="hlFld-ContribAuthor ">Ka-Wing  Fong</span>, <span class="hlFld-ContribAuthor ">Ezinne  Mong</span>, <span class="hlFld-ContribAuthor ">M. Cynthia  Martin</span>, <span class="hlFld-ContribAuthor ">Gary E.  Schiltz</span>, <span class="hlFld-ContribAuthor ">Jindan  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Going beyond Polycomb: EZH2 functions in prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2021,</strong> <em>276 </em><a href="https://doi.org/10.1038/s41388-021-01982-4" title="DOI URL">https://doi.org/10.1038/s41388-021-01982-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-021-01982-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-021-01982-4%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DGoing%252Bbeyond%252BPolycomb%25253A%252BEZH2%252Bfunctions%252Bin%252Bprostate%252Bcancer%26aulast%3DPark%26aufirst%3DSu%2BH.%26date%3D2021%26date%3D2021%26volume%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Peter  Svensson</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Epigenetics to Cure HIV-1: Lessons From (and for) Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular and Infection Microbiology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fcimb.2021.668637" title="DOI URL">https://doi.org/10.3389/fcimb.2021.668637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcimb.2021.668637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcimb.2021.668637%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520and%2520Infection%2520Microbiology%26atitle%3DTargeting%252BEpigenetics%252Bto%252BCure%252BHIV-1%25253A%252BLessons%252BFrom%252B%252528and%252Bfor%252529%252BCancer%252BTreatment%26aulast%3DSvensson%26aufirst%3DJ.%2BPeter%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Davidovich</span>, <span class="hlFld-ContribAuthor ">Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2021,</strong> <em>49 </em>
                                    (2)
                                     , 591-607. <a href="https://doi.org/10.1042/BST20200238" title="DOI URL">https://doi.org/10.1042/BST20200238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20200238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20200238%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DAllosteric%252Bregulation%252Bof%252Bhistone%252Blysine%252Bmethyltransferases%25253A%252Bfrom%252Bcontext-specific%252Bregulation%252Bto%252Bselective%252Bdrugs%26aulast%3DDavidovich%26aufirst%3DChen%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D2%26spage%3D591%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0048.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of various strategies to target PRC2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (Top) Structures of significant EZH2 catalytic inhibitors. (Bottom) Crystal structure of inhibitor (<b>13</b>) bound to EZH2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6">5LS6</a>) (salmon) with key hydrogen bonds shown in red. Also shown is EZH2 ligand <i>S</i>-adenosyl-<span class="smallcaps smallerCapital">l</span>-homocysteine (SAH, <b>14</b>) (shown in gray) overlaid with the 5LS6 structure. Bound pose of SAH is taken from crystal structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HYN">5HYN</a>. Overlay shows the partial occupancy of the SAH site by pyridone-based EZH2 inhibitor <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of CPI-905 and CPI-360.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Initial design strategy incorporating the structural combination of <b>17</b> and <b>15</b> (CPI-905) which led to the identification of potent EZH2 inhibitor <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR-based elaboration of compound <b>20</b> leading to optimized EZH2 inhibitor <b>23</b> (CPI-169).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Chemical structure of <b>4</b> (CPI-1205). (B) Chemical structure of derivative <b>13</b> in which the CF<sub>3</sub> group was modified to a CF<sub>2</sub>CH<sub>3</sub>. (C) Cocrystal structure of <b>13</b> bound to human PRC2 with key interactions between the pyridone and W624 backbone residues shown with yellow dotted lines (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6">5LS6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Lead optimization of <b>4</b> (CPI-1205) to increase residence time which led to identification of EZH2 inhibitor <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structure of Novartis EZH2 inhibitor <b>7</b> (El1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SAR leading to <b>8</b> (EPZ-5687).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure of JQEZ5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Lead optimization development of <b>10</b> (UNC1999) based on potent EZH2 inhibitor <b>8</b> (EPZ-5687).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of initial GSK hit compound <b>34</b> (GSK-A) and optimized EZH2 inhibitor <b>3</b> (GSK126).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0013.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of <b>35</b> (GSK926) and <b>36</b> (GSK343).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0014.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Initial hit compound <b>37</b> and SAR leading to inhibitor <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0015.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure of <b>1</b> (tazemetostat, EPZ-6438).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0016.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure of <b>45</b> (EPZ011989<b>)</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0017.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Initial design for the benzofuran-derived EZH2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0018.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Initial EZH2 SAR development by Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0019.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of EZH2 inhibitors developed at Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0020.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Cocrystal structure of <b>5</b> (PF06821497) in complex with EZH2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R">4W2R</a>). Hydrogen bonds are shown in dotted yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0021.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Initial SAR development of non-pyridone containing EZH2 inhibitor series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0022.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. SAR exploration of oligonucleosomes as EZH2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0023.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. SAR optimization leading to A-395.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0024.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Cocrystal structure of <b>74</b> (A-395) in complex with EED (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JZG">3JZG</a>). Dashed yellow lines indicate hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0025.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures of EED inhibitors EED226, BR-001, and MAK683.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0026.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (Left) X-ray crystal structure of <b>76</b> (EED226) bound to EED. Important ligand–protein and ligand–water interactions are shown with a yellow dotted line. (Right) Position of <b>76</b> binding to EED relative to the overall protein, indicating the location of the terminal sulfone group which points out toward solvent (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GSA">5GSA</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0027.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Initial structure-guided design from EED226 to inhibitor <b>80</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0028.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. SAR modifications of the core and tail leading to <b>87</b> (EEDi-5285).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0029.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Medicinal chemistry strategy for the development of the Novartis EED inhibitor <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0030.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. X-ray crystal structure of <b>93</b> bound to EED (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U5H">5U5H</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0031.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures of peptides derived from Jarid<sub>114–118</sub> that act as allosteric inhibitors or activators of PRC2 activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0032.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures of EZH2-EED inhibitor <b>99</b> (astemizole), EED inhibitor <b>100</b> (wedelolactone), and covalent PRC2 inhibitors <b>101</b> (gambogenic acid) and derivative <b>102</b> (GNA002).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0033.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of EZH2 hydrophobic tag degrader <b>103</b> (MS1943), EZH2 catalytic inhibitor <b>105</b> (C24), and hydrophobic tag moiety <b>104</b> (AM41-44A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0034.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Chemical structures of EED PROTACs based on EED inhibitor <b>76</b> (EED226).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/medium/jm0c01344_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0035.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structure of reported EED PROTAC degrader by UNC (<b>109</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01344/20201218/images/large/jm0c01344_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01344&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48321" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48321" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 109 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitges, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusty, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraju, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiwazian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly-Hartig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoma, N. H.</span></span> <span> </span><span class="NLM_article-title">Histone methylation by PRC2 is inhibited by active chromatin marks</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2011.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2011.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=21549310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=330-341&issue=3&author=F.+W.+Schmitgesauthor=A.+B.+Prustyauthor=M.+Fatyauthor=A.+Stutzerauthor=G.+M.+Lingarajuauthor=J.+Aiwazianauthor=R.+Sackauthor=D.+Hessauthor=L.+Liauthor=S.+Zhouauthor=R.+D.+Bunkerauthor=U.+Wirthauthor=T.+Bouwmeesterauthor=A.+Bauerauthor=N.+Ly-Hartigauthor=K.+Zhaoauthor=H.+Chanauthor=J.+Guauthor=H.+Gutauthor=W.+Fischleauthor=J.+Mullerauthor=N.+H.+Thoma&title=Histone+methylation+by+PRC2+is+inhibited+by+active+chromatin+marks&doi=10.1016%2Fj.molcel.2011.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Methylation by PRC2 Is Inhibited by Active Chromatin Marks</span></div><div class="casAuthors">Schmitges, Frank W.; Prusty, Archana B.; Faty, Mahamadou; Stuetzer, Alexandra; Lingaraju, Gondichatnahalli M.; Aiwazian, Jonathan; Sack, Ragna; Hess, Daniel; Li, Ling; Zhou, Shaolian; Bunker, Richard D.; Wirth, Urs; Bouwmeester, Tewis; Bauer, Andreas; Ly-Hartig, Nga; Zhao, Kehao; Chan, Homan; Gu, Justin; Gut, Heinz; Fischle, Wolfgang; Mueller, Juerg; Thomae, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-341</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Polycomb repressive complex 2 (PRC2) confers transcriptional repression through histone H3 lysine 27 trimethylation (H3K27me3).  Here, we examd. how PRC2 is modulated by histone modifications assocd. with transcriptionally active chromatin.  We provide the mol. basis of histone H3 N terminus recognition by the PRC2 Nurf55-Su(z)12 submodule.  Binding of H3 is lost if lysine 4 in H3 is trimethylated.  We find that H3K4me3 inhibits PRC2 activity in an allosteric fashion assisted by the Su(z)12 C terminus.  In addn. to H3K4me3, PRC2 is inhibited by H3K36me2/3 (i.e., both H3K36me2 and H3K36me3).  Direct PRC2 inhibition by H3K4me3 and H3K36me2/3 active marks is conserved in humans, mouse, and fly, rendering transcriptionally active chromatin refractory to PRC2 H3K27 trimethylation.  While inhibition is present in plant PRC2, it can be modulated through exchange of the Su(z)12 subunit.  Inhibition by active chromatin marks, coupled to stimulation by transcriptionally repressive H3K27me3, enables PRC2 to autonomously template repressive H3K27me3 without overwriting active chromatin domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnXPqq7hTWOLVg90H21EOLACvtfcHk0lh-mbtvVHUkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVyiurc%253D&md5=ac62c56650a4a4ede3c9c1491d3da6af</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitges%26aufirst%3DF.%2BW.%26aulast%3DPrusty%26aufirst%3DA.%2BB.%26aulast%3DFaty%26aufirst%3DM.%26aulast%3DStutzer%26aufirst%3DA.%26aulast%3DLingaraju%26aufirst%3DG.%2BM.%26aulast%3DAiwazian%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DBunker%26aufirst%3DR.%2BD.%26aulast%3DWirth%26aufirst%3DU.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DLy-Hartig%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DFischle%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DThoma%26aufirst%3DN.%2BH.%26atitle%3DHistone%2520methylation%2520by%2520PRC2%2520is%2520inhibited%2520by%2520active%2520chromatin%2520marks%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D42%26issue%3D3%26spage%3D330%26epage%3D341%26doi%3D10.1016%2Fj.molcel.2011.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuettengruber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chourrout, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vervoort, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, G.</span></span> <span> </span><span class="NLM_article-title">Genome regulation by Polycomb and trithorax proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2007.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17320510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12isr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=735-745&issue=4&author=B.+Schuettengruberauthor=D.+Chourroutauthor=M.+Vervoortauthor=B.+Leblancauthor=G.+Cavalli&title=Genome+regulation+by+Polycomb+and+trithorax+proteins&doi=10.1016%2Fj.cell.2007.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Genome regulation by polycomb and trithorax proteins</span></div><div class="casAuthors">Schuettengruber, Bernd; Chourrout, Daniel; Vervoort, Michel; Leblanc, Benjamin; Cavalli, Giacomo</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">735-745</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) and trithorax group (trxG) proteins are crit. regulators of numerous developmental genes.  To silence or activate gene expression, resp., PcG and trxG proteins bind to specific regions of DNA and direct the posttranslational modification of histones.  Recent work suggests that PcG proteins regulate the nuclear organization of their target genes and that PcG-mediated gene silencing involves noncoding RNAs and the RNAi machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAySqV0OrdULVg90H21EOLACvtfcHk0lh-mbtvVHUkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12isr8%253D&md5=dc79b73ed4d2d5f1b11bb3e357997bff</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DSchuettengruber%26aufirst%3DB.%26aulast%3DChourrout%26aufirst%3DD.%26aulast%3DVervoort%26aufirst%3DM.%26aulast%3DLeblanc%26aufirst%3DB.%26aulast%3DCavalli%26aufirst%3DG.%26atitle%3DGenome%2520regulation%2520by%2520Polycomb%2520and%2520trithorax%2520proteins%26jtitle%3DCell%26date%3D2007%26volume%3D128%26issue%3D4%26spage%3D735%26epage%3D745%26doi%3D10.1016%2Fj.cell.2007.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span> <span> </span><span class="NLM_article-title">Understanding the words of chromatin regulation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2009.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=19167321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Kitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=200-206&issue=2&author=J.+I.+Wuauthor=J.+Lessardauthor=G.+R.+Crabtree&title=Understanding+the+words+of+chromatin+regulation&doi=10.1016%2Fj.cell.2009.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the words of chromatin regulation</span></div><div class="casAuthors">Wu, Jiang I.; Lessard, Julie; Crabtree, Gerald R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-206</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent studies indicate that chromatin regulatory complexes produce biol. specificity in the way that letters produce meanings by combinations into words.  A combinatorial assembly of chromatin regulatory complexes may be crit. for maximizing the information content provided by arrays of histone modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ4fG29930ubVg90H21EOLACvtfcHk0li-4npgwcya1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Kitbc%253D&md5=6180d642563b24be264d1c2acfc9abb8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BI.%26aulast%3DLessard%26aufirst%3DJ.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26atitle%3DUnderstanding%2520the%2520words%2520of%2520chromatin%2520regulation%26jtitle%3DCell%26date%3D2009%26volume%3D136%26issue%3D2%26spage%3D200%26epage%3D206%26doi%3D10.1016%2Fj.cell.2009.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, V.</span></span> <span> </span><span class="NLM_article-title">Polycomb, epigenomes, and control of cell identity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(03)00157-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0092-8674%2803%2900157-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12628181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFykuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=599-606&issue=5&author=V.+Orlando&title=Polycomb%2C+epigenomes%2C+and+control+of+cell+identity&doi=10.1016%2FS0092-8674%2803%2900157-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb, epigenomes, and control of cell identity</span></div><div class="casAuthors">Orlando, Valerio</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">599-606</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  In development, cell identity is maintained by epigenetic functions that prevent changes in cell type-specific transcription programs.  Recent insights into gene silencing mechanisms by Polycomb group (PcG) and trithorax group (trxG) proteins reveal that the memory system involves a concerted process of chromatin modification, blocking of RNA polymerase II, and synthesis of noncoding RNA.  Remarkably, cell memory is regulated by a balance between repressors and activators that maintains both transcription status and at the same time the possibility of switching to a different state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh_WxAV7icnLVg90H21EOLACvtfcHk0li-4npgwcya1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFykuro%253D&md5=1e6ea2b704929d93fb9e156ad243d6a3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900157-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900157-0%26sid%3Dliteratum%253Aachs%26aulast%3DOrlando%26aufirst%3DV.%26atitle%3DPolycomb%252C%2520epigenomes%252C%2520and%2520control%2520of%2520cell%2520identity%26jtitle%3DCell%26date%3D2003%26volume%3D112%26issue%3D5%26spage%3D599%26epage%3D606%26doi%3D10.1016%2FS0092-8674%2803%2900157-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmichev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span> <span> </span><span class="NLM_article-title">Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2893</span>– <span class="NLM_lpage">2905</span>, <span class="refDoi"> DOI: 10.1101/gad.1035902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fgad.1035902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12435631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVejsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=2893-2905&issue=22&author=A.+Kuzmichevauthor=K.+Nishiokaauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=D.+Reinberg&title=Histone+methyltransferase+activity+associated+with+a+human+multiprotein+complex+containing+the+Enhancer+of+Zeste+protein&doi=10.1101%2Fgad.1035902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein</span></div><div class="casAuthors">Kuzmichev, Andrei; Nishioka, Kenichi; Erdjument-Bromage, Hediye; Tempst, Paul; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2893-2905</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Enhancer of Zeste [E(z)] is a Polycomb-group transcriptional repressor and one of the founding members of the family of SET domain-contg. proteins.  Several SET-domain proteins possess intrinsic histone methyltransferase (HMT) activity.  However, recombinant E(z) protein was found to be inactive in a HMT assay.  Here we report the isolation of a multiprotein E(z) complex that contains extra sex combs, suppressor of zeste-12 [Su(z)12], and the histone binding proteins RbAp46/RbAp48.  This complex, which we termed Polycomb repressive complex (PRC) 2, possesses HMT activity with specificity for Lys 9 (K9) and Lys 27 (K27) of histone H3.  The HMT activity of PRC2 is dependent on an intact SET domain in the E(z) protein.  We hypothesize that transcriptional repression by the E(z) protein involves methylation-dependent recruitment of PRC1.  The presence of Su(z)12, a strong suppressor of position effect variegation, in PRC2 suggests that PRC2 may play a widespread role in heterochromatin-mediated silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxD09IiaeCvLVg90H21EOLACvtfcHk0li-4npgwcya1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVejsLY%253D&md5=b61767bc9b30b403f5fc7bb202281da1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1101%2Fgad.1035902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1035902%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmichev%26aufirst%3DA.%26aulast%3DNishioka%26aufirst%3DK.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DHistone%2520methyltransferase%2520activity%2520associated%2520with%2520a%2520human%2520multiprotein%2520complex%2520containing%2520the%2520Enhancer%2520of%2520Zeste%2520protein%26jtitle%3DGenes%2520Dev.%26date%3D2002%26volume%3D16%26issue%3D22%26spage%3D2893%26epage%3D2905%26doi%3D10.1101%2Fgad.1035902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senisterra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span> <span> </span><span class="NLM_article-title">Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e83737</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0083737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1371%2Fjournal.pone.0083737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24367611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVyitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&issue=12&author=H.+Wuauthor=H.+Zengauthor=A.+Dongauthor=F.+Liauthor=H.+Heauthor=G.+Senisterraauthor=A.+Seitovaauthor=S.+Duanauthor=P.+J.+Brownauthor=M.+Vedadiauthor=C.+H.+Arrowsmithauthor=M.+Schapira&title=Structure+of+the+catalytic+domain+of+EZH2+reveals+conformational+plasticity+in+cofactor+and+substrate+binding+sites+and+explains+oncogenic+mutations&doi=10.1371%2Fjournal.pone.0083737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations</span></div><div class="casAuthors">Wu, Hong; Zeng, Hong; Dong, Aiping; Li, Fengling; He, Hao; Senisterra, Guillermo; Seitova, Alma; Duan, Shili; Brown, Peter J.; Vedadi, Masoud; Arrowsmith, Cheryl H.; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e83737/1-e83737/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is an important regulator of cellular differentiation and cell type identity.  Overexpression or activating mutations of EZH2, the catalytic component of the PRC2 complex, are linked to hyper-trimethylation of lysine 27 of histone H3 (H3K27me3) in many cancers.  Potent EZH2 inhibitors that reduce levels of H3K27me3 kill mutant lymphoma cells and are efficacious in a mouse xenograft model of malignant rhabdoid tumors.  Unlike most SET domain methyltransferases, EZH2 requires PRC2 components, SUZ12 and EED, for activity, but the mechanism by which catalysis is promoted in the PRC2 complex is unknown.  We solved the 2.0 Å crystal structure of the EZH2 methyltransferase domain revealing that most of the canonical structural features of SET domain methyltransferase structures are conserved.  The site of Me transfer is in a catalytically competent state, and the structure clarifies the structural mechanism underlying oncogenic hyper-trimethylation of H3K27 in tumors harboring mutations at Y641 or A677.  On the other hand, the I-SET and post-SET domains occupy atypical positions relative to the core SET domain resulting in incomplete formation of the cofactor binding site and occlusion of the substrate binding groove.  A novel CXC domain N-terminal to the SET domain may contribute to the apparent inactive conformation.  We propose that protein interactions within the PRC2 complex modulate the trajectory of the post-SET and I-SET domains of EZH2 in favor of a catalytically competent conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNud-MjYOynbVg90H21EOLACvtfcHk0liJaCdnZY2DVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVyitrs%253D&md5=948041c81ddd5ec5c4b02cdb7213c898</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0083737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0083737%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DSenisterra%26aufirst%3DG.%26aulast%3DSeitova%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DStructure%2520of%2520the%2520catalytic%2520domain%2520of%2520EZH2%2520reveals%2520conformational%2520plasticity%2520in%2520cofactor%2520and%2520substrate%2520binding%2520sites%2520and%2520explains%2520oncogenic%2520mutations%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0083737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekrasov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span> <span> </span><span class="NLM_article-title">Nucleosome binding and histone methyltransferase activity of Drosophila PRC2</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.7400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fsj.embor.7400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15776017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFWjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=348-353&issue=4&author=M.+Nekrasovauthor=B.+Wildauthor=J.+Muller&title=Nucleosome+binding+and+histone+methyltransferase+activity+of+Drosophila+PRC2&doi=10.1038%2Fsj.embor.7400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleosome binding and histone methyltransferase activity of Drosophila PRC2</span></div><div class="casAuthors">Nekrasov, Maxim; Wild, Brigitte; Mueller, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">348-353</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Drosophila Polycomb group protein E(z) is a histone methyltransferase (HMTase) that is essential for maintaining HOX gene silencing during development.  E(z) exists in a multiprotein complex called Polycomb repressive complex 2 (PRC2) that also contains Su(z)12, Esc and Nurf55.  Reconstituted recombinant PRC2 methylates nucleosomes in vitro, but recombinant E(z) on its own shows only poor HMTase activity on nucleosomes.  Here, the authors investigate the function of the PRC2 subunits.  PRC2 binds to nucleosomes in vitro but that individual PRC2 subunits alone do not bind to nucleosomes.  By analyzing PRC2 subcomplexes, the authors show that Su(z)12-Nurf55 is the minimal nucleosome-binding module of PRC2 and that Esc contributes to high-affinity binding of PRC2 nucleosomes.  Nucleosome binding of PRC2 is not sufficient for histone methylation and that only complexes that contain Esc protein show robust HMTase activity.  These observations suggest that different subunits provide mechanistically distinct functions within the PRC2 HMTase: the nucleosome-binding subunits Su(z)12 and Nurf55 anchor the E(z) enzyme on chromatin substrates, whereas Esc is needed to boost enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Jvaz8ZCPZLVg90H21EOLACvtfcHk0liJaCdnZY2DVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFWjurw%253D&md5=7f553eef608ef68669f075c231db5979</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.7400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.7400376%26sid%3Dliteratum%253Aachs%26aulast%3DNekrasov%26aufirst%3DM.%26aulast%3DWild%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DJ.%26atitle%3DNucleosome%2520binding%2520and%2520histone%2520methyltransferase%2520activity%2520of%2520Drosophila%2520PRC2%26jtitle%3DEMBO%2520Rep.%26date%3D2005%26volume%3D6%26issue%3D4%26spage%3D348%26epage%3D353%26doi%3D10.1038%2Fsj.embor.7400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehani, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monrad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappsilber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerdrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">A model for transmission of the H3K27me3 epigenetic mark</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/ncb1787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fncb1787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18931660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlais7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1291-300&issue=11&author=K.+H.+Hansenauthor=A.+P.+Brackenauthor=D.+Pasiniauthor=N.+Dietrichauthor=S.+S.+Gehaniauthor=A.+Monradauthor=J.+Rappsilberauthor=M.+Lerdrupauthor=K.+Helin&title=A+model+for+transmission+of+the+H3K27me3+epigenetic+mark&doi=10.1038%2Fncb1787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A model for transmission of the H3K27me3 epigenetic mark</span></div><div class="casAuthors">Hansen, Klaus H.; Bracken, Adrian P.; Pasini, Diego; Dietrich, Nikolaj; Gehani, Simmi S.; Monrad, Astrid; Rappsilber, Juri; Lerdrup, Mads; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1291-1300</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Organization of chromatin by epigenetic mechanisms is essential for establishing and maintaining cellular identity in developing and adult organisms.  A key question that remains unresolved about this process is how epigenetic marks are transmitted to the next cell generation during cell division.  Here we provide a model to explain how trimethylated Lys 27 of histone 3 (H3K27me3), which is catalyzed by the EZH2-contg. Polycomb Repressive Complex 2 (PRC2), is maintained in proliferating cells.  We show that the PRC2 complex binds to the H3K27me3 mark and colocalizes with this mark in G1 phase and with sites of ongoing DNA replication.  Efficient binding requires an intact trimeric PRC2 complex contg. EZH2, EED and SUZ12, but is independent of the catalytic SET domain of EZH2.  Using a heterologous reporter system, we show that transient recruitment of the PRC2 complex to chromatin, upstream of the transcriptional start site, is sufficient to maintain repression through endogenous PRC2 during subsequent cell divisions.  Thus, we suggest that once the H3K27me3 is established, it recruits the PRC2 complex to maintain the mark at sites of DNA replication, leading to methylation of H3K27 on the daughter strands during incorporation of newly synthesized histones.  This mechanism ensures maintenance of the H3K27me3 epigenetic mark in proliferating cells, not only during DNA replication when histones synthesized de novo are incorporated, but also outside S phase, thereby preserving chromatin structure and transcriptional programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEAf-769vEd7Vg90H21EOLACvtfcHk0liJaCdnZY2DVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlais7jK&md5=b2c7c437462df5622e88cc40ac6e15dd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fncb1787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1787%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BH.%26aulast%3DBracken%26aufirst%3DA.%2BP.%26aulast%3DPasini%26aufirst%3DD.%26aulast%3DDietrich%26aufirst%3DN.%26aulast%3DGehani%26aufirst%3DS.%2BS.%26aulast%3DMonrad%26aufirst%3DA.%26aulast%3DRappsilber%26aufirst%3DJ.%26aulast%3DLerdrup%26aufirst%3DM.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DA%2520model%2520for%2520transmission%2520of%2520the%2520H3K27me3%2520epigenetic%2520mark%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2008%26volume%3D10%26issue%3D11%26spage%3D1291%26epage%3D300%26doi%3D10.1038%2Fncb1787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drury, W. J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrotta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span> <span> </span><span class="NLM_article-title">Role of the Polycomb protein EED in the propagation of repressive histone marks</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span> (<span class="NLM_issue">7265</span>),  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nature08398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnature08398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=19767730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=762-767&issue=7265&author=R.+Margueronauthor=N.+Justinauthor=K.+Ohnoauthor=M.+L.+Sharpeauthor=J.+Sonauthor=W.+J.+Druryauthor=P.+Voigtauthor=S.+R.+Martinauthor=W.+R.+Taylorauthor=V.+De+Marcoauthor=V.+Pirrottaauthor=D.+Reinbergauthor=S.+J.+Gamblin&title=Role+of+the+Polycomb+protein+EED+in+the+propagation+of+repressive+histone+marks&doi=10.1038%2Fnature08398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the polycomb protein EED in the propagation of repressive histone marks</span></div><div class="casAuthors">Margueron, Raphael; Justin, Neil; Ohno, Katsuhito; Sharpe, Miriam L.; Son, Jinsook; Drury, William J., III; Voigt, Philipp; Martin, Stephen R.; Taylor, William R.; De Marco, Valeria; Pirrotta, Vincenzo; Reinberg, Danny; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7265</span>),
    <span class="NLM_cas:pages">762-767</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb group proteins have an essential role in the epigenetic maintenance of repressive chromatin states.  The gene-silencing activity of the Polycomb repressive complex 2 (PRC2) depends on its ability to trimethylate lysine 27 of histone H3 (H3K27) by the catalytic SET domain of the EZH2 subunit, and at least two other subunits of the complex: SUZ12 and EED.  Here we show that the carboxy-terminal domain of EED specifically binds to histone tails carrying trimethyl-lysine residues assocd. with repressive chromatin marks, and that this leads to the allosteric activation of the methyltransferase activity of PRC2.  Mutations in EED that prevent it from recognizing repressive trimethyl-lysine marks abolish the activation of PRC2 in vitro and, in Drosophila, reduce global methylation and disrupt development.  These findings suggest a model for the propagation of the H3K27me3 mark that accounts for the maintenance of repressive chromatin domains and for the transmission of a histone modification from mother to daughter cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSke4t5N1P3LVg90H21EOLACvtfcHk0liJ349tisQIqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt73N&md5=63ee782ee42fb9c711a5d2fdf7d4e022</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature08398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08398%26sid%3Dliteratum%253Aachs%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DOhno%26aufirst%3DK.%26aulast%3DSharpe%26aufirst%3DM.%2BL.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DDrury%26aufirst%3DW.%2BJ.%26aulast%3DVoigt%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DS.%2BR.%26aulast%3DTaylor%26aufirst%3DW.%2BR.%26aulast%3DDe%2BMarco%26aufirst%3DV.%26aulast%3DPirrotta%26aufirst%3DV.%26aulast%3DReinberg%26aufirst%3DD.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DRole%2520of%2520the%2520Polycomb%2520protein%2520EED%2520in%2520the%2520propagation%2520of%2520repressive%2520histone%2520marks%26jtitle%3DNature%26date%3D2009%26volume%3D461%26issue%3D7265%26spage%3D762%26epage%3D767%26doi%3D10.1038%2Fnature08398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalantry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, T.</span></span> <span> </span><span class="NLM_article-title">The murine Polycomb group protein EED is required for global histone H3 lysine-27 methylation</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2005.04.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cub.2005.04.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15916951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=942-947&issue=10&author=N.+D.+Montgomeryauthor=D.+Yeeauthor=A.+Chenauthor=S.+Kalantryauthor=S.+J.+Chamberlainauthor=A.+P.+Otteauthor=T.+Magnuson&title=The+murine+Polycomb+group+protein+EED+is+required+for+global+histone+H3+lysine-27+methylation&doi=10.1016%2Fj.cub.2005.04.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation</span></div><div class="casAuthors">Montgomery, Nathan D.; Yee, Della; Chen, Andrew; Kalantry, Sundeep; Chamberlain, Stormy J.; Otte, Arie P.; Magnuson, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">942-947</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PcG proteins mediate heritable transcriptional silencing by generating and recognizing covalent histone modifications.  One conserved PcG complex, PRC2, is composed of several proteins including the histone methyltransferase (HMTase) Ezh2, the WD-repeat protein Eed, and the Zn-finger protein Suz12.  Ezh2 methylates histone H3 on lysine 27 (H3K27) [1-4], which serves as an epigenetic mark mediating silencing.  H3K27 can be mono-, di-, or trimethylated (1mH3K27, 2mH3K27, and 3mH3K27, resp.) [5].  Hence, either PRC2 must be regulated so as to add one Me group to certain nucleosomes but two or three to others, or distinct complexes must be responsible for 1m-, 2m-, and 3mH3K27.  Consistent with the latter possibility, 2mH3K27 and 3mH3K27, but not 1mH3K27, are absent in Suz12-/- embryos, which lack both Suz12 and Ezh2 protein [6].  Mammalian proteins required for 1mH3K27 have not been identified.  Here, authors demonstrate that unlike Suz12 and Ezh2, Eed is required not only for 2m- and 3mH3K27 but also global 1mH3K27.  These results provide a functionally important distinction between PRC2 complex components and implicate Eed in PRC2-independent histone methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh5aUVC-VrdLVg90H21EOLACvtfcHk0liJ349tisQIqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gjt7k%253D&md5=2d378f554b3593f129cf512a04a69b75</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2005.04.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2005.04.051%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DN.%2BD.%26aulast%3DYee%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DKalantry%26aufirst%3DS.%26aulast%3DChamberlain%26aufirst%3DS.%2BJ.%26aulast%3DOtte%26aufirst%3DA.%2BP.%26aulast%3DMagnuson%26aufirst%3DT.%26atitle%3DThe%2520murine%2520Polycomb%2520group%2520protein%2520EED%2520is%2520required%2520for%2520global%2520histone%2520H3%2520lysine-27%2520methylation%26jtitle%3DCurr.%2520Biol.%26date%3D2005%26volume%3D15%26issue%3D10%26spage%3D942%26epage%3D947%26doi%3D10.1016%2Fj.cub.2005.04.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J. R.</span></span> <span> </span><span class="NLM_article-title">Binding of different histone marks differentially regulates the activity and specificity of Polycomb repressive complex 2 (PRC2)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">19266</span>– <span class="NLM_lpage">19271</span>, <span class="refDoi"> DOI: 10.1073/pnas.1008937107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1008937107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20974918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=19266-19271&issue=45&author=C.+Xuauthor=C.+B.+Bianauthor=W.+Yangauthor=M.+Galkaauthor=H.+Ouyangauthor=C.+Chenauthor=W.+Qiuauthor=H.+D.+Liuauthor=A.+E.+Jonesauthor=F.+MacKenzieauthor=P.+Panauthor=S.+S.+C.+Liauthor=H.+B.+Wangauthor=J.+R.+Min&title=Binding+of+different+histone+marks+differentially+regulates+the+activity+and+specificity+of+Polycomb+repressive+complex+2+%28PRC2%29&doi=10.1073%2Fpnas.1008937107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)</span></div><div class="casAuthors">Xu, Chao; Bian, Chuanbing; Yang, Wei; Galka, Marek; Ouyang, Hui; Chen, Chen; Qiu, Wei; Liu, Huadong; Jones, Amanda E.; MacKenzie, Farrell; Pan, Patricia; Li, Shawn Shun-Cheng; Wang, Hengbin; Min, Jinrong</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">19266-19271, S19266/1-S19266/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The polycomb repressive complex 2 (PRC2) is the major methyltransferase for H3K27 methylation, a modification crit. for maintaining repressed gene expression programs throughout development.  It has been previously shown that PRC2 maintains histone methylation patterns during DNA replication in part through its ability to bind to H3K27me3.  However, the mechanism by which PRC2 recognizes H3K27me3 is unclear.  Here we show that the WD40 domain of EED, a PRC2 component, is a methyllysine histone-binding domain.  The crystal structures of apo-EED and EED in complex resp. with five different trimethyllysine histone peptides reveal that EED binds these peptides via the top face of its β-propeller architecture.  The ammonium group of the trimethyllysine is accommodated by an arom. cage formed by three arom. residues, while its aliph. chain is flanked by a fourth arom. residue.  Our structural data provide an explanation for the preferential recognition of the Ala-Arg-Lys-Ser (ARKS) motif-contg. trimethylated H3K27, H3K9, and H1K26 marks by EED over lower methylation states and other histone methyllysine marks.  More importantly, we found that binding of different histone marks by EED differentially regulates the activity and specificity of PRC2.  Whereas the H3K27me3 mark stimulates the histone methyltransferase activity of PRC2, the H1K26me3 mark inhibits PRC2 methyltransferase activity on the nucleosome.  Moreover, H1K26me3 binding switches the specificity of PRC2 from methylating H3K27 to EED.  In addn. to detg. the mol. basis of EED-methyllysine recognition, our work provides the biochem. characterization of how the activity of a histone methyltransferase is oppositely regulated by two histone marks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT9ZyFdoHXqLVg90H21EOLACvtfcHk0li1jF-GwfB8ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7jM&md5=0814be98c76f9e578a82a50158b66ecb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008937107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008937107%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DC.%2BB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DGalka%26aufirst%3DM.%26aulast%3DOuyang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%2BD.%26aulast%3DJones%26aufirst%3DA.%2BE.%26aulast%3DMacKenzie%26aufirst%3DF.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%2BS.%2BC.%26aulast%3DWang%26aufirst%3DH.%2BB.%26aulast%3DMin%26aufirst%3DJ.%2BR.%26atitle%3DBinding%2520of%2520different%2520histone%2520marks%2520differentially%2520regulates%2520the%2520activity%2520and%2520specificity%2520of%2520Polycomb%2520repressive%2520complex%25202%2520%2528PRC2%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D45%26spage%3D19266%26epage%3D19271%26doi%3D10.1073%2Fpnas.1008937107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, T.</span></span> <span> </span><span class="NLM_article-title">Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency</span>. <i>Stem Cells</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1505</span>, <span class="refDoi"> DOI: 10.1634/stemcells.2008-0102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1634%2Fstemcells.2008-0102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18403752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFGhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1496-1505&issue=6&author=S.+J.+Chamberlainauthor=D.+Yeeauthor=T.+Magnuson&title=Polycomb+repressive+complex+2+is+dispensable+for+maintenance+of+embryonic+stem+cell+pluripotency&doi=10.1634%2Fstemcells.2008-0102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency</span></div><div class="casAuthors">Chamberlain, Stormy J.; Yee, Della; Magnuson, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1496-1505</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) methylates histone H3 tails at lysine 27 and is essential for embryonic development.  The three core components of PRC2, Eed, Ezh2, and Suz12, are also highly expressed in embryonic stem (ES) cells, where they are postulated to repress developmental regulators and thereby prevent differentiation to maintain the pluripotent state.  We performed gene expression and chimera analyses on low- and high-passage Eednull ES cells to det. whether PRC2 is required for the maintenance of pluripotency.  We report here that although developmental regulators are overexpressed in Eednull ES cells, both low- and high-passage cells are functionally pluripotent.  We hypothesize that they are pluripotent because they maintain expression of crit. pluripotency factors.  Given that EED is required for stability of EZH2, the catalytic subunit of the complex, these data suggest that PRC2 is not necessary for the maintenance of the pluripotent state in ES cells.  We propose a pos.-only model of embryonic stem cell maintenance, where pos. regulation of pluripotency factors is sufficient to mediate stem cell pluripotency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKTogaKTDANLVg90H21EOLACvtfcHk0li1jF-GwfB8ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFGhtb8%253D&md5=0a36228a0af5986f5778df442926c4e8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1634%2Fstemcells.2008-0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Fstemcells.2008-0102%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BJ.%26aulast%3DYee%26aufirst%3DD.%26aulast%3DMagnuson%26aufirst%3DT.%26atitle%3DPolycomb%2520repressive%2520complex%25202%2520is%2520dispensable%2520for%2520maintenance%2520of%2520embryonic%2520stem%2520cell%2520pluripotency%26jtitle%3DStem%2520Cells%26date%3D2008%26volume%3D26%26issue%3D6%26spage%3D1496%26epage%3D1505%26doi%3D10.1634%2Fstemcells.2008-0102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mysliwiec, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span> <span> </span><span class="NLM_article-title">Jumonji modulates Polycomb activity and self-renewal versus differentiation of stem cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2009.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20064376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FhvVeitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2009&pages=1303-1314&issue=7&author=X.+Shenauthor=W.+Kimauthor=Y.+Fujiwaraauthor=M.+D.+Simonauthor=Y.+Liuauthor=M.+R.+Mysliwiecauthor=G.+C.+Yuanauthor=Y.+Leeauthor=S.+H.+Orkin&title=Jumonji+modulates+Polycomb+activity+and+self-renewal+versus+differentiation+of+stem+cells&doi=10.1016%2Fj.cell.2009.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells</span></div><div class="casAuthors">Shen Xiaohua; Kim Woojin; Fujiwara Yuko; Simon Matthew D; Liu Yingchun; Mysliwiec Matthew R; Yuan Guo-Cheng; Lee Youngsook; Orkin Stuart H</div><div class="citationInfo"><span class="NLM_cas:title">Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1303-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trimethylation on histone H3 lysine 27 (H3K27me3) by Polycomb repressive complex 2 (PRC2) regulates the balance between self-renewal and differentiation of embryonic stem cells (ESCs).  The mechanisms controlling the activity and recruitment of PRC2 are largely unknown.  Here we demonstrate that the founding member of the Jumonji family, JMJ (JUMONJI or JARID2), is associated with PRC2, colocalizes with PRC2 and H3K27me3 on chromatin, and modulates PRC2 function.  In vitro JMJ inhibits PRC2 methyltransferase activity, consistent with increased H3K27me3 marks at PRC2 targets in Jmj(-/-) ESCs.  Paradoxically, JMJ is required for efficient binding of PRC2, indicating that the interplay of PRC2 and JMJ fine-tunes deposition of the H3K27me3 mark.  During differentiation, activation of genes marked by H3K27me3 and lineage commitments are delayed in Jmj(-/-) ESCs.  Our results demonstrate that dynamic regulation of Polycomb complex activity orchestrated by JMJ balances self-renewal and differentiation, highlighting the involvement of chromatin dynamics in cell-fate transitions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJgTBYNc3u0kNoizSOkG_FfW6udTcc2eaK-I0duccKPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FhvVeitA%253D%253D&md5=bc1c94a9bb26b82426869cc5805d9b75</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DSimon%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMysliwiec%26aufirst%3DM.%2BR.%26aulast%3DYuan%26aufirst%3DG.%2BC.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26atitle%3DJumonji%2520modulates%2520Polycomb%2520activity%2520and%2520self-renewal%2520versus%2520differentiation%2520of%2520stem%2520cells%26jtitle%3DCell%26date%3D2009%26volume%3D139%26issue%3D7%26spage%3D1303%26epage%3D1314%26doi%3D10.1016%2Fj.cell.2009.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">A partially disordered region connects gene repression and activation functions of EZH2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">16992</span>– <span class="NLM_lpage">17002</span>, <span class="refDoi"> DOI: 10.1073/pnas.1914866117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1914866117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=32631994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFequ7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=16992-17002&issue=29&author=L.+Jiaoauthor=M.+Shubbarauthor=X.+Yangauthor=Q.+Zhangauthor=S.+Chenauthor=Q.+Wuauthor=Z.+Chenauthor=J.+Rizoauthor=X.+Liu&title=A+partially+disordered+region+connects+gene+repression+and+activation+functions+of+EZH2&doi=10.1073%2Fpnas.1914866117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A partially disordered region connects gene repression and activation functions of EZH2</span></div><div class="casAuthors">Jiao, Lianying; Shubbar, Murtada; Yang, Xin; Zhang, Qi; Chen, Siming; Wu, Qiong; Chen, Zhe; Rizo, Josep; Liu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">16992-17002</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which minimally requires two other subunits, EED and SUZ12, for enzymic activity.  EZH2 has been traditionally known to mediate histone H3K27 trimethylation, a hallmark of silent chromatin.  Emerging evidence indicates that EZH2 also activates gene expression in cancer cells in a context distinct from canonical PRC2.  The mol. mechanism underlying the functional conversion of EZH2 from a gene repressor to an activator is unclear.  Here, we show that EZH2 harbors a hidden, partially disordered transactivation domain (TAD) capable of interacting with components of active transcription machinery, mimicking archetypal acidic activators.  The EZH2 TAD comprises the SRM (Stimulation-Responsive Motif) and SANT1 (SWI3, ADA2, N-CoR, and TFIIIB 1) regions that are normally involved in H3K27 methylation.  The crystal structure of an EZH2-EED binary complex indicates that the EZH2 TAD mediates protein oligomerization in a noncanonical PRC2 context and is entirely sequestered.  The EZH2 TAD can be unlocked by cancer-specific EZH2 phosphorylation events to undergo structural transitions that may enable subsequent transcriptional coactivator binding.  The EZH2 TAD directly interacts with the transcriptional coactivator and histone acetyltransferase p300 and activates gene expression in a p300-dependent manner in cells.  The corresponding TAD may also account for the gene activation function of EZH1, the paralog of EZH2.  Distinct kinase signaling pathways that are known to abnormally convert EZH2 into a gene activator in cancer cells can now be understood in a common structural context of the EZH2 TAD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr7OVG0NaCHrVg90H21EOLACvtfcHk0lhtOCCAnSuZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFequ7rL&md5=c138702fd7edf4cc30a22a8b9116c462</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1914866117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1914866117%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DShubbar%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DRizo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DA%2520partially%2520disordered%2520region%2520connects%2520gene%2520repression%2520and%2520activation%2520functions%2520of%2520EZH2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26issue%3D29%26spage%3D16992%26epage%3D17002%26doi%3D10.1073%2Fpnas.1914866117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerenyi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walensky, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span> <span> </span><span class="NLM_article-title">Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.1331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23974116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWktLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=643-650&issue=10&author=W.+Kimauthor=G.+H.+Birdauthor=T.+Neffauthor=G.+Guoauthor=M.+A.+Kerenyiauthor=L.+D.+Walenskyauthor=S.+H.+Orkin&title=Targeted+disruption+of+the+EZH2-EED+complex+inhibits+EZH2-dependent+cancer&doi=10.1038%2Fnchembio.1331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer</span></div><div class="casAuthors">Kim, Woojin; Bird, Gregory H.; Neff, Tobias; Guo, Guoji; Kerenyi, Marc A.; Walensky, Loren D.; Orkin, Stuart H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">643-650</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2) is the histone lysine N-methyltransferase component of the Polycomb repressive complex 2 (PRC2), which, in conjunction with embryonic ectoderm development (EED) and suppressor of zeste 12 homolog, regulates cell lineage detn. and homeostasis.  Enzymic hyperactivity has been linked to aberrant repression of tumor suppressor genes in diverse cancers.  Here, the authors report the development of stabilized α-helix of EZH2 (SAH-EZH2) peptides that selectively inhibit H3 Lys27 trimethylation by dose-responsively disrupting the EZH2-EED complex and reducing EZH2 protein levels, a mechanism distinct from that reported for small-mol. EZH2 inhibitors targeting the enzyme catalytic domain.  MLL-AF9 leukemia cells, which are dependent on PRC2, undergo growth arrest and monocyte-macrophage differentiation upon treatment with SAH-EZH2, consistent with obsd. changes in expression of PRC2-regulated, lineage-specific marker genes.  Thus, by dissocg. the EZH2-EED complex, the authors pharmacol. modulate an epigenetic 'writer' and suppress PRC2-dependent cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofgU19-q6AxLVg90H21EOLACvtfcHk0lhtOCCAnSuZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWktLbK&md5=fe40ed4903f710ebe0f30888077fe701</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1331%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%26aulast%3DBird%26aufirst%3DG.%2BH.%26aulast%3DNeff%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DKerenyi%26aufirst%3DM.%2BA.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520EZH2-EED%2520complex%2520inhibits%2520EZH2-dependent%2520cancer%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D10%26spage%3D643%26epage%3D650%26doi%3D10.1038%2Fnchembio.1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Unique structural platforms of SUZ12 dictate distinct classes of PRC2 for chromatin binding</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2018.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29499137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVCntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=840-852&issue=5&author=S.+Chenauthor=L.+Jiaoauthor=M.+Shubbarauthor=X.+Yangauthor=X.+Liu&title=Unique+structural+platforms+of+SUZ12+dictate+distinct+classes+of+PRC2+for+chromatin+binding&doi=10.1016%2Fj.molcel.2018.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding</span></div><div class="casAuthors">Chen, Siming; Jiao, Lianying; Shubbar, Murtada; Yang, Xin; Liu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-852.e5</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Developmentally regulated accessory subunits dictate PRC2 function.  Here, we report the crystal structures of a 120 kDa heterotetrameric complex consisting of Suz12, Rbbp4, Jarid2, and Aebp2 fragments that is minimally active in nucleosome binding and of an inactive binary complex of Suz12 and Rbbp4.  Suz12 contains two unique structural platforms that define distinct classes of PRC2 holo complexes for chromatin binding.  Aebp2 and Phf19 compete for binding of a non-canonical C2 domain of Suz12; Jarid2 and EPOP occupy an overlapped Suz12 surface required for chromatin assocn. of PRC2.  Suz12 and Aebp2 progressively block histone H3K4 binding to Rbbp4, suggesting that Rbbp4 may not be directly involved in PRC2 inhibition by the active H3K4me3 histone mark.  Nucleosome binding enabled by Jarid2 and Aebp2 is in part accounted for by the structures, which also reveal that disruption of the Jarid2-Suz12 interaction may underlie the disease mechanism of an oncogenic chromosomal translocation of Suz12.666.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVsmCE7LlFebVg90H21EOLACvtfcHk0lhtOCCAnSuZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVCntb0%253D&md5=33b5e22cb5abdf3d3346e9ec199a666c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DShubbar%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DUnique%2520structural%2520platforms%2520of%2520SUZ12%2520dictate%2520distinct%2520classes%2520of%2520PRC2%2520for%2520chromatin%2520binding%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D69%26issue%3D5%26spage%3D840%26epage%3D852%26doi%3D10.1016%2Fj.molcel.2018.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2004.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15225548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFejurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=57-67&issue=1&author=R.+Caoauthor=Y.+Zhang&title=SUZ12+is+required+for+both+the+histone+methyltransferase+activity+and+the+silencing+function+of+the+EED-EZH2+complex&doi=10.1016%2Fj.molcel.2004.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex</span></div><div class="casAuthors">Cao, Ru; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Recent studies have revealed the intrinsic histone methyltransferase (HMTase) activity of the EED-EZH2 complex and its role in Hox gene silencing, X inactivation, and cancer metastasis.  In this study, we focus on the function of individual components.  We found that the HMTase activity requires a min. of three components - EZH2, EED, and SUZ12 - while AEBP2 is required for optimal enzymic activity.  Using a stable SUZ12 knockdown cell line, we show SUZ12 knockdown results in cell growth defects, which correlate with genome-wide alteration on H3-K27 methylation as well as upregulation of a no. of Hox genes.  Chromatin immunopptn. (ChIP) assay identified a 500 bp region located 4 kb upstream of the HoxA9 transcription initiation site as a SUZ12 binding site, which responds to SUZ12 knockdown and might play an important role in regulating HoxA9 expression.  Thus, our study establishes a crit. role of SUZ12 in H3-lysine 27 methylation and Hox gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWQGRfTk9TrVg90H21EOLACvtfcHk0lgmGEsUrxsZSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFejurc%253D&md5=4b26382db05fda3e55b5f05dc2e1da9a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DSUZ12%2520is%2520required%2520for%2520both%2520the%2520histone%2520methyltransferase%2520activity%2520and%2520the%2520silencing%2520function%2520of%2520the%2520EED-EZH2%2520complex%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26issue%3D1%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2004.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denchi, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">SUZ12 is essential for mouse development and for EZH2 histone methyltransferase activity</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">4061</span>– <span class="NLM_lpage">4071</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fsj.emboj.7600402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15385962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlCrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=4061-4071&issue=20&author=D.+Pasiniauthor=A.+P.+Brackenauthor=M.+R.+Jensenauthor=E.+L.+Denchiauthor=K.+Helin&title=SUZ12+is+essential+for+mouse+development+and+for+EZH2+histone+methyltransferase+activity&doi=10.1038%2Fsj.emboj.7600402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity</span></div><div class="casAuthors">Pasini, Diego; Bracken, Adrian P.; Jensen, Michael R.; Denchi, Eros Lazzerini; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4061-4071</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SUZ12 is a recently identified Polycomb group (PcG) protein, which together with EZH2 and EED forms different Polycomb repressive complexes (PRC2/3).  These complexes contain histone H3 lysine (K) 27/9 and histone H1 K26 methyltransferase activity specified by the EZH2 SET domain.  Here we show that mice lacking Suz12, like Ezh2 and Eed mutant mice, are not viable and die during early postimplantation stages displaying severe developmental and proliferative defects.  Consistent with this, we demonstrate that SUZ12 is required for proliferation of cells in tissue culture.  Furthermore, we demonstrate that SUZ12 is essential for the activity and stability of the PRC2/3 complexes in mouse embryos, in tissue culture cells and in vitro.  Strikingly, Suz12-deficient embryos show a specific loss of di- and trimethylated H3K27, demonstrating that Suz12 is indeed essential for EZH2 activity in vivo.  In conclusion, our data demonstrate an essential role of SUZ12 in regulating the activity of the PRC2/3 complexes, which are required for regulating proliferation and embryogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Z3ZVmhO_aLVg90H21EOLACvtfcHk0lgmGEsUrxsZSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlCrs74%253D&md5=297e196b7be06ff22e3359dbc50dba4a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600402%26sid%3Dliteratum%253Aachs%26aulast%3DPasini%26aufirst%3DD.%26aulast%3DBracken%26aufirst%3DA.%2BP.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DDenchi%26aufirst%3DE.%2BL.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DSUZ12%2520is%2520essential%2520for%2520mouse%2520development%2520and%2520for%2520EZH2%2520histone%2520methyltransferase%2520activity%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26issue%3D20%26spage%3D4061%26epage%3D4071%26doi%3D10.1038%2Fsj.emboj.7600402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hojfeldt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laugesen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damhofer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedehus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tvardovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0036-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41594-018-0036-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29483650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrls1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=225-232&issue=3&author=J.+W.+Hojfeldtauthor=A.+Laugesenauthor=B.+M.+Willumsenauthor=H.+Damhoferauthor=L.+Hedehusauthor=A.+Tvardovskiyauthor=F.+Mohammadauthor=O.+N.+Jensenauthor=K.+Helin&title=Accurate+H3K27+methylation+can+be+established+de+novo+by+SUZ12-directed+PRC2&doi=10.1038%2Fs41594-018-0036-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2</span></div><div class="casAuthors">Hojfeldt Jonas W; Laugesen Anne; Damhofer Helene; Hedehus Lin; Mohammad Faizaan; Helin Kristian; Hojfeldt Jonas W; Laugesen Anne; Damhofer Helene; Hedehus Lin; Mohammad Faizaan; Helin Kristian; Willumsen Berthe M; Tvardovskiy Andrey; Jensen Ole N; Tvardovskiy Andrey</div><div class="citationInfo"><span class="NLM_cas:title">Nature structural & molecular biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-232</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) catalyzes methylation on lysine 27 of histone H3 (H3K27) and is required for maintaining transcriptional patterns and cellular identity, but the specification and maintenance of genomic PRC2 binding and H3K27 methylation patterns remain incompletely understood.  Epigenetic mechanisms have been proposed, wherein pre-existing H3K27 methylation directs recruitment and regulates the catalytic activity of PRC2 to support its own maintenance.  Here we investigate whether such mechanisms are required for specifying H3K27 methylation patterns in mouse embryonic stem cells (mESCs).  Through re-expression of PRC2 subunits in PRC2-knockout cells that have lost all H3K27 methylation, we demonstrate that methylation patterns can be accurately established de novo.  We find that regional methylation kinetics correlate with original methylation patterns even in their absence, and specification of the genomic PRC2 binding pattern is retained and specifically dependent on the PRC2 core subunit SUZ12.  Thus, the H3K27 methylation patterns in mESCs are not dependent on self-autonomous epigenetic inheritance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdHZ3bviJkhi86Js-BCLiifW6udTcc2eYGxBcEgIDUvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrls1ejtg%253D%253D&md5=df8a1c6698b11038e75df3d27bd785b7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0036-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0036-6%26sid%3Dliteratum%253Aachs%26aulast%3DHojfeldt%26aufirst%3DJ.%2BW.%26aulast%3DLaugesen%26aufirst%3DA.%26aulast%3DWillumsen%26aufirst%3DB.%2BM.%26aulast%3DDamhofer%26aufirst%3DH.%26aulast%3DHedehus%26aufirst%3DL.%26aulast%3DTvardovskiy%26aufirst%3DA.%26aulast%3DMohammad%26aufirst%3DF.%26aulast%3DJensen%26aufirst%3DO.%2BN.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DAccurate%2520H3K27%2520methylation%2520can%2520be%2520established%2520de%2520novo%2520by%2520SUZ12-directed%2520PRC2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D3%26spage%3D225%26epage%3D232%26doi%3D10.1038%2Fs41594-018-0036-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Polycomb- and methylation-independent roles of EZH2 as a transcription activator</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2808</span>– <span class="NLM_lpage">2820</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.11.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.celrep.2018.11.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30517868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCit7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=2808-2820&issue=10&author=J.+Kimauthor=Y.+Leeauthor=X.+Luauthor=B.+Songauthor=K.+W.+Fongauthor=Q.+Caoauthor=J.+D.+Lichtauthor=J.+C.+Zhaoauthor=J.+Yu&title=Polycomb-+and+methylation-independent+roles+of+EZH2+as+a+transcription+activator&doi=10.1016%2Fj.celrep.2018.11.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator</span></div><div class="casAuthors">Kim, Jung; Lee, Yongik; Lu, Xiaodong; Song, Bing; Fong, Ka-Wing; Cao, Qi; Licht, Jonathan D.; Zhao, Jonathan C.; Yu, Jindan</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2808-2820.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Enhancer of Zeste 2 (EZH2) is the enzymic subunit of Polycomb Repressive Complex 2 (PRC2), which catalyzes histone H3 lysine 27 trimethylation (H3K27me3) at target promoters for gene silencing.  Here, we report that EZH2 activates androgen receptor (AR) gene transcription through direct occupancy at its promoter.  Importantly, this activating role of EZH2 is independent of PRC2 and its methyltransferase activities.  Genome-wide assays revealed extensive EZH2 occupancy at promoters marked by either H3K27ac or H3K27me3, leading to gene activation or repression, resp.  Last, we demonstrate enhanced efficacy of enzymic EZH2 inhibitors when used in combination with AR antagonists in blocking the dual roles of EZH2 and suppressing prostate cancer progression in vitro and in vivo.  Taken together, our study reports EZH2 as a transcriptional activator, a key target of which is AR, and suggests a drug-combinatory approach to treat advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogFd6y_QesoLVg90H21EOLACvtfcHk0lgcQ0Eovj9PFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCit7bL&md5=795cd5933915f46a31e298075abaa247</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.11.035%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DFong%26aufirst%3DK.%2BW.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DPolycomb-%2520and%2520methylation-independent%2520roles%2520of%2520EZH2%2520as%2520a%2520transcription%2520activator%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D25%26issue%3D10%26spage%3D2808%26epage%3D2820%26doi%3D10.1016%2Fj.celrep.2018.11.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatavosian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duc, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phiel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span> <span> </span><span class="NLM_article-title">Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2080</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04455-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41467-018-04455-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29802243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC1MfntlWrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2080&issue=1&author=R.+Tatavosianauthor=H.+N.+Ducauthor=T.+N.+Huynhauthor=D.+Fangauthor=B.+Schmittauthor=X.+Shiauthor=Y.+Dengauthor=C.+Phielauthor=T.+Yaoauthor=Z.+Zhangauthor=H.+Wangauthor=X.+Ren&title=Live-cell+single-molecule+dynamics+of+PcG+proteins+imposed+by+the+DIPG+H3.3K27M+mutation&doi=10.1038%2Fs41467-018-04455-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation</span></div><div class="casAuthors">Tatavosian Roubina; Duc Huy Nguyen; Huynh Thao Ngoc; Wang Haobin; Ren Xiaojun; Fang Dong; Zhang Zhiguo; Schmitt Benjamin; Yao Tingting; Shi Xiaodong; Deng Yiming; Phiel Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2080</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over 80% of diffuse intrinsic pontine gliomas (DIPGs) harbor a point mutation in histone H3.3 where lysine 27 is substituted with methionine (H3.3K27M); however, how the mutation affects kinetics and function of PcG proteins remains elusive.  We demonstrate that H3.3K27M prolongs the residence time and search time of Ezh2, but has no effect on its fraction bound to chromatin.  In contrast, H3.3K27M has no effect on the residence time of Cbx7, but prolongs its search time and decreases its fraction bound to chromatin.  We show that increasing expression of Cbx7 inhibits the proliferation of DIPG cells and prolongs its residence time.  Our results highlight that the residence time of PcG proteins directly correlates with their functions and the search time of PcG proteins is critical for regulating their genomic occupancy.  Together, our data provide mechanisms in which the cancer-causing histone mutation alters the binding and search dynamics of epigenetic complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQs2ntzaadWM3qj_yg7twvpfW6udTcc2eaNXlBjSEpQZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfntlWrtA%253D%253D&md5=f9d46822d925fb966f7841dad2b40ab2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04455-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04455-7%26sid%3Dliteratum%253Aachs%26aulast%3DTatavosian%26aufirst%3DR.%26aulast%3DDuc%26aufirst%3DH.%2BN.%26aulast%3DHuynh%26aufirst%3DT.%2BN.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DSchmitt%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DPhiel%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26atitle%3DLive-cell%2520single-molecule%2520dynamics%2520of%2520PcG%2520proteins%2520imposed%2520by%2520the%2520DIPG%2520H3.3K27M%2520mutation%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D2080%26doi%3D10.1038%2Fs41467-018-04455-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span> <span> </span><span class="NLM_article-title">PRC2 mediated H3K27 methylations in cellular identity and cancer</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2015.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ceb.2015.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26497635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWhsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2015&pages=42-48&author=E.+Conwayauthor=E.+Healyauthor=A.+P.+Bracken&title=PRC2+mediated+H3K27+methylations+in+cellular+identity+and+cancer&doi=10.1016%2Fj.ceb.2015.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">PRC2 mediated H3K27 methylations in cellular identity and cancer</span></div><div class="casAuthors">Conway, Eric; Healy, Evan; Bracken, Adrian P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-48</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Polycomb Repressive Complex 2 (PRC2) is a multiprotein chromatin modifying complex that is essential for vertebrate development and differentiation.  It is composed of a trimeric core of SUZ12, EED and EZH1/2 and is responsible for catalyzing both di-methylation and tri-methylation of Histone H3 at lysine 27 (H3K27me2/3).  Both H3K27 methylations contribute to the role of PRC2 in maintaining cellular identity.  In all cell types, the H3K27me3 modification is assocd. with repression of genes encoding regulators of alternative lineages.  The less well-characterized H3K27me2 modification is ubiquitous throughout the genome and is thought to act like a protective blanket to maintain the repression of non-H3K27me3 assocd. genes and cell-type-specific enhancers of alternative lineages.  Recent cancer genome sequencing studies highlighted that several genes encoding PRC2 components as well as Histone H3 are mutated in multiple cancer types.  Intriguingly, these cancers have changes in the global levels of the H3K27me2 and H3K27me3 modifications as well as genome-wide redistributions.  Exciting new studies suggest that these changes confer context dependent blocks in cellular differentiation and increased vulnerability to aberrant cancer signalling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDF0iuLAc7XrVg90H21EOLACvtfcHk0lhS6qijaf0_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWhsL%252FP&md5=35b6039fde4a6755ea685203fb6334a0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2015.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2015.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DE.%26aulast%3DHealy%26aufirst%3DE.%26aulast%3DBracken%26aufirst%3DA.%2BP.%26atitle%3DPRC2%2520mediated%2520H3K27%2520methylations%2520in%2520cellular%2520identity%2520and%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2015%26volume%3D37%26spage%3D42%26epage%3D48%26doi%3D10.1016%2Fj.ceb.2015.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koche, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheinbay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusbaum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptaszek, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koseki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span> <span> </span><span class="NLM_article-title">Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">10</span>), <span class="NLM_elocation-id">e1000242</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1000242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1371%2Fjournal.pgen.1000242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18974828" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&issue=10&author=M.+Kuauthor=R.+P.+Kocheauthor=E.+Rheinbayauthor=E.+M.+Mendenhallauthor=M.+Endohauthor=T.+S.+Mikkelsenauthor=A.+Presserauthor=C.+Nusbaumauthor=X.+Xieauthor=A.+S.+Chiauthor=M.+Adliauthor=S.+Kasifauthor=L.+M.+Ptaszekauthor=C.+A.+Cowanauthor=E.+S.+Landerauthor=H.+Kosekiauthor=B.+E.+Bernstein&title=Genomewide+analysis+of+PRC1+and+PRC2+occupancy+identifies+two+classes+of+bivalent+domains&doi=10.1371%2Fjournal.pgen.1000242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1000242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1000242%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DM.%26aulast%3DKoche%26aufirst%3DR.%2BP.%26aulast%3DRheinbay%26aufirst%3DE.%26aulast%3DMendenhall%26aufirst%3DE.%2BM.%26aulast%3DEndoh%26aufirst%3DM.%26aulast%3DMikkelsen%26aufirst%3DT.%2BS.%26aulast%3DPresser%26aufirst%3DA.%26aulast%3DNusbaum%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChi%26aufirst%3DA.%2BS.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DKasif%26aufirst%3DS.%26aulast%3DPtaszek%26aufirst%3DL.%2BM.%26aulast%3DCowan%26aufirst%3DC.%2BA.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DKoseki%26aufirst%3DH.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26atitle%3DGenomewide%2520analysis%2520of%2520PRC1%2520and%2520PRC2%2520occupancy%2520identifies%2520two%2520classes%2520of%2520bivalent%2520domains%26jtitle%3DPLoS%2520Genet.%26date%3D2008%26volume%3D4%26issue%3D10%26doi%3D10.1371%2Fjournal.pgen.1000242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>350</i></span> (<span class="NLM_issue">6258</span>),  <span class="NLM_fpage">aac4383</span>, <span class="refDoi"> DOI: 10.1126/science.aac4383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1126%2Fscience.aac4383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26472914" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2015&pages=aac4383&issue=6258&author=L.+Jiaoauthor=X.+Liu&title=Structural+basis+of+histone+H3K27+trimethylation+by+an+active+polycomb+repressive+complex+2&doi=10.1126%2Fscience.aac4383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.aac4383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aac4383%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DStructural%2520basis%2520of%2520histone%2520H3K27%2520trimethylation%2520by%2520an%2520active%2520polycomb%2520repressive%2520complex%25202%26jtitle%3DScience%26date%3D2015%26volume%3D350%26issue%3D6258%26spage%3Daac4383%26doi%3D10.1126%2Fscience.aac4383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scelfo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jammula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barozzi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaldi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, D.</span></span> <span> </span><span class="NLM_article-title">Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2013.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2013.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24289921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKgsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=49-62&issue=1&author=K.+J.+Ferrariauthor=A.+Scelfoauthor=S.+Jammulaauthor=A.+Cuomoauthor=I.+Barozziauthor=A.+Stutzerauthor=W.+Fischleauthor=T.+Bonaldiauthor=D.+Pasini&title=Polycomb-dependent+H3K27me1+and+H3K27me2+regulate+active+transcription+and+enhancer+fidelity&doi=10.1016%2Fj.molcel.2013.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity</span></div><div class="casAuthors">Ferrari, Karin J.; Scelfo, Andrea; Jammula, SriGanesh; Cuomo, Alessandro; Barozzi, Iros; Stutzer, Alexandra; Fischle, Wolfgang; Bonaldi, Tiziana; Pasini, Diego</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-62</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">H3K27me3 is deposited at promoters by the preferential assocn. of Polycomb repressive complex 2 (PRC2) with CpG-rich DNA elements regulating development by repressing gene transcription.  H3K27 is also present in mono- and dimethylated states; however, the functional roles of H3K27me1 and H3K27me2 deposition remain poorly characterized.  Here, we show that PRC2 activity is not only assocd. with H3K27me3 but also regulates all forms of H3K27 methylation in a spatially defined manner, contributing to different genomic functions in mouse embryonic stem cells.  H3K27me1 accumulates within transcribed genes, promotes transcription, and is regulated by Setd2-dependent H3K36me3 deposition.  Contrarily, H3K27me2 is present on approx. 70% of total histone H3 and is distributed in large chromatin domains, exerting protective functions by preventing firing of non-cell-type-specific enhancers.  Considering that only 5%-10% of deregulated genes in PRC2-deficient cells are direct H3K27me3 targets, our data support an active role for all H3K27 methylated forms in regulating transcription and detg. cell identity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwLU-8hWnCibVg90H21EOLACvtfcHk0lhS6qijaf0_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKgsrjF&md5=47e9fcbcfdaed6224018c771d1ee13de</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DK.%2BJ.%26aulast%3DScelfo%26aufirst%3DA.%26aulast%3DJammula%26aufirst%3DS.%26aulast%3DCuomo%26aufirst%3DA.%26aulast%3DBarozzi%26aufirst%3DI.%26aulast%3DStutzer%26aufirst%3DA.%26aulast%3DFischle%26aufirst%3DW.%26aulast%3DBonaldi%26aufirst%3DT.%26aulast%3DPasini%26aufirst%3DD.%26atitle%3DPolycomb-dependent%2520H3K27me1%2520and%2520H3K27me2%2520regulate%2520active%2520transcription%2520and%2520enhancer%2520fidelity%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26issue%3D1%26spage%3D49%26epage%3D62%26doi%3D10.1016%2Fj.molcel.2013.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Role of hPHF1 in H3K27 methylation and Hox gene silencing</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1862</span>– <span class="NLM_lpage">1872</span>, <span class="refDoi"> DOI: 10.1128/MCB.01589-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1128%2FMCB.01589-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18086877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1862-1872&issue=5&author=R.+Caoauthor=H.+Wangauthor=J.+Heauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=Y.+Zhang&title=Role+of+hPHF1+in+H3K27+methylation+and+Hox+gene+silencing&doi=10.1128%2FMCB.01589-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hPHF1 in H3K27 methylation and Hox gene silencing</span></div><div class="casAuthors">Cao, Ru; Wang, Hengbin; He, Jin; Erdjument-Bromage, Hediye; Tempst, Paul; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1862-1872</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins are required for maintaining the silent state of the homeotic genes and other important developmental regulators.  The silencing function of the PcG proteins has been linked to their intrinsic histone modifying enzymic activities.  The EED-EZH2 complex, contg. the core subunits EZH2, EED, SUZ12, and RbAp48, functions as a histone H3K27-specific methyltransferase.  Here we describe the identification and characterization of a related EED-EZH2 protein complex which is distinguished from the previous complex by the presence of another PcG protein, hPHF1.  Consistent with the ability of hPHF1 to stimulate the enzymic activity of the core EED-EZH2 complex in vitro, manipulation of mPcl1, the mouse counterpart of hPHF1, in NIH 3T3 cells and cells of the mouse male germ cell line GC1spg results in global alteration of H3K27me2 and H3K27me3 levels and Hox gene expression.  Small interfering RNA-mediated knockdown of mPcl1 affects assocn. of the Eed-Ezh2 complex with certain Hox genes, such as HoxA10, as well as Hox gene expression concomitant with an alteration on the H3K27me2 levels of the corresponding promoters.  Therefore, our results reveal hPHF1 as a component of a novel EED-EZH2 complex and demonstrate its important role in H3K27 methylation and Hox gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbj2dJ_-Si4bVg90H21EOLACvtfcHk0lgPzej3CVoBMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajtbc%253D&md5=447ec018523c260c0c4e0050405da379</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1128%2FMCB.01589-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01589-07%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DRole%2520of%2520hPHF1%2520in%2520H3K27%2520methylation%2520and%2520Hox%2520gene%2520silencing%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2008%26volume%3D28%26issue%3D5%26spage%3D1862%26epage%3D1872%26doi%3D10.1128%2FMCB.01589-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekrasov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klymenko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraterman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oktaba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stunnenberg, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span> <span> </span><span class="NLM_article-title">Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4078</span>– <span class="NLM_lpage">4088</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fsj.emboj.7601837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17762866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKhtrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=4078-4088&issue=18&author=M.+Nekrasovauthor=T.+Klymenkoauthor=S.+Fratermanauthor=B.+Pappauthor=K.+Oktabaauthor=T.+Kocherauthor=A.+Cohenauthor=H.+G.+Stunnenbergauthor=M.+Wilmauthor=J.+Muller&title=Pcl-PRC2+is+needed+to+generate+high+levels+of+H3-K27+trimethylation+at+Polycomb+target+genes&doi=10.1038%2Fsj.emboj.7601837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes</span></div><div class="casAuthors">Nekrasov, Maxim; Klymenko, Tetyana; Fraterman, Sven; Papp, Bernadett; Oktaba, Katarzyna; Koecher, Thomas; Cohen, Adrian; Stunnenberg, Hendrik G.; Wilm, Matthias; Mueller, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4078-4088</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">PRC2 is thought to be the histone methyltransferase (HMTase) responsible for H3-K27 trimethylation at Polycomb target genes.  Here we report the biochem. purifn. and characterization of a distinct form of Drosophila PRC2 that contains the Polycomb group protein polycomblike (Pcl).  Like PRC2, Pcl-PRC2 is an H3-K27-specific HMTase that mono-, di- and trimethylates H3-K27 in nucleosomes in vitro.  Anal. of Drosophila mutants that lack Pcl unexpectedly reveals that Pcl-PRC2 is required to generate high levels of H3-K27 trimethylation at Polycomb target genes but is dispensable for the genome-wide H3-K27 mono- and dimethylation that is generated by PRC2.  In Pcl mutants, Polycomb target genes become derepressed even though H3-K27 trimethylation at these genes is only reduced and not abolished, and even though targeting of the Polycomb protein complexes PhoRC and PRC1 to Polycomb response elements is not affected.  Pcl-PRC2 is thus the HMTase that generates the high levels of H3-K27 trimethylation in Polycomb target genes that are needed to maintain a Polycomb-repressed chromatin state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVZCMxfevbBLVg90H21EOLACvtfcHk0lgPzej3CVoBMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKhtrvJ&md5=75db8cee2dc169ccec48065b29d4380e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601837%26sid%3Dliteratum%253Aachs%26aulast%3DNekrasov%26aufirst%3DM.%26aulast%3DKlymenko%26aufirst%3DT.%26aulast%3DFraterman%26aufirst%3DS.%26aulast%3DPapp%26aufirst%3DB.%26aulast%3DOktaba%26aufirst%3DK.%26aulast%3DKocher%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DStunnenberg%26aufirst%3DH.%2BG.%26aulast%3DWilm%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DJ.%26atitle%3DPcl-PRC2%2520is%2520needed%2520to%2520generate%2520high%2520levels%2520of%2520H3-K27%2520trimethylation%2520at%2520Polycomb%2520target%2520genes%26jtitle%3DEMBO%2520J.%26date%3D2007%26volume%3D26%26issue%3D18%26spage%3D4078%26epage%3D4088%26doi%3D10.1038%2Fsj.emboj.7601837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrotta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span> <span> </span><span class="NLM_article-title">EZH2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2731</span>, <span class="refDoi"> DOI: 10.1128/MCB.02017-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1128%2FMCB.02017-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18285464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFWqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=2718-2731&issue=8&author=K.+Sarmaauthor=R.+Margueronauthor=A.+Ivanovauthor=V.+Pirrottaauthor=D.+Reinberg&title=EZH2+requires+PHF1+to+efficiently+catalyze+H3+lysine+27+trimethylation+in+vivo&doi=10.1128%2FMCB.02017-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo</span></div><div class="casAuthors">Sarma, Kavitha; Margueron, Raphael; Ivanov, Alexey; Pirrotta, Vincenzo; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mammalian Polycomblike protein PHF1 was previously shown to interact with the Polycomb group (PcG) protein Ezh2, a histone methyltransferase whose activity is pivotal in sustaining gene repression during development and in adulthood.  As Ezh2 is active only when part of the Polycomb Repressive Complexes (PRC2-PRC4), we examd. the functional role of its interaction with PHF1.  Chromatin immunopptn. expts. revealed that PHF1 resides along with Ezh2 at Ezh2-regulated genes such as the HoxA loci and the non-Hox MYT1 and WNT1 genes.  Knockdown of PHF1 or of Ezh2 led to up-regulated HoxA gene expression.  Interestingly, depletion of PHF1 did correlate with reduced occupancy of Bmi-1, a PRC1 component.  As expected, knockdown of Ezh2 led to reduced levels of its catalytic products H3K27me2/H3K27me3.  However, reduced levels of PHF1 also led to decreased global levels of H3K27me3.  Notably, the levels of H3K27me3 decreased while those of H3K27me2 increased at the up-regulated HoxA loci tested.  Consistent with this, the addn. of PHF1 specifically stimulated the ability of Ezh2 to catalyze H3K27me3 but not H3K27me1/H3K27me2 in vitro.  We conclude that PHF1 modulates the activity of Ezh2 in favor of the repressive H3K27me3 mark.  Thus, we propose that PHF1 is a determinant in PcG-mediated gene repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsiWF9xVC8TbVg90H21EOLACvtfcHk0lizcK-EKK1SjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFWqtrc%253D&md5=ce25d19e315ef42f53c34f199e81cfcb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FMCB.02017-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.02017-07%26sid%3Dliteratum%253Aachs%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DIvanov%26aufirst%3DA.%26aulast%3DPirrotta%26aufirst%3DV.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DEZH2%2520requires%2520PHF1%2520to%2520efficiently%2520catalyze%2520H3%2520lysine%252027%2520trimethylation%2520in%2520vivo%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2008%26volume%3D28%26issue%3D8%26spage%3D2718%26epage%3D2731%26doi%3D10.1128%2FMCB.02017-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnes, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5020</span>– <span class="NLM_lpage">5034</span>, <span class="refDoi"> DOI: 10.7150/thno.34700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.7150%2Fthno.34700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31410199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXoslyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=5020-5034&issue=17&author=L.+Maauthor=Y.+Yanauthor=Y.+Baiauthor=Y.+Yangauthor=Y.+Panauthor=X.+Gangauthor=R.+J.+Karnesauthor=J.+Zhangauthor=Q.+Lvauthor=Q.+Wuauthor=H.+Huang&title=Overcoming+EZH2+inhibitor+resistance+by+taxane+in+PTEN-mutated+cancer&doi=10.7150%2Fthno.34700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer.</span></div><div class="casAuthors">Ma, Linlin; Yan, Yuqian; Bai, Yang; Yang, Yinhui; Pan, Yunqian; Gang, Xiaokun; Karnes, R. Jeffrey; Zhang, Jun; Lv, Qiubo; Wu, Qiang; Huang, Haojie</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5020-5034</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target.  Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulated in human cancers such as prostate cancer although the underlying regulatory mechanisms remain elusive.  Methods: Anal. of EZH2 ChIP-seq and ChIP-on-chip data in various cell types was performed.  ChIP-qPCR, RT-qPCR, and western blot analyses were conducted to det. the mechanism by which EZH2 represses FOXO1 expression.  Results: We demonstrated that EZH2 binds to the FOXO1 gene promoter.  EZH2 represses FOXO1 gene expression at the transcriptional level.  EZH2 protein level inversely correlated with FOXO1 protein expression in prostate cancer patient specimens.  Co-treatment with docetaxel overcame EZH2 inhibitor resistance in PTEN-neg. cancer cells in vitro and in mice.  This effect was largely mediated by docetaxel-induced nuclear localization and activation of FOXO1.  Conclusions: This study identifies FOXO1 as a bona fide repression target of EZH2 and an essential mediator of EZH2 inhibition-induced cell death.  Our findings suggest that EZH2 repression of FOXO1 can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of cancers with PTEN mutation or deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbX_fWJwdq9rVg90H21EOLACvtfcHk0lgqNFWMX4Wglg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslyqsw%253D%253D&md5=163f9fbcd3bf3728f55eab06bc4c9dad</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.7150%2Fthno.34700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.34700%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DGang%26aufirst%3DX.%26aulast%3DKarnes%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DOvercoming%2520EZH2%2520inhibitor%2520resistance%2520by%2520taxane%2520in%2520PTEN-mutated%2520cancer%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26issue%3D17%26spage%3D5020%26epage%3D5034%26doi%3D10.7150%2Fthno.34700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Role of histone H3 lysine 27 methylation in Polycomb-group silencing</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5595</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1126/science.1076997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1126%2Fscience.1076997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12351676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1039-1043&issue=5595&author=R.+Caoauthor=L.+Wangauthor=H.+Wangauthor=L.+Xiaauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=R.+S.+Jonesauthor=Y.+Zhang&title=Role+of+histone+H3+lysine+27+methylation+in+Polycomb-group+silencing&doi=10.1126%2Fscience.1076997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing</span></div><div class="casAuthors">Cao, Ru; Wang, Liangjun; Wang, Hengbin; Xia, Li; Erdjument-Bromage, Hediye; Tempst, Paul; Jones, Richard S.; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5595</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins play important roles in maintaining the silent state of HOX genes.  Recent studies have implicated histone methylation in long-term gene silencing.  However, a connection between PcG-mediated gene silencing and histone methylation has not been established.  Here the authors report the purifn. and characterization of an EED-EZH2 complex, the human counterpart of the Drosophila ESC-E(Z) complex.  They demonstrate that the complex specifically methylates nucleosomal histone H3 at lysine 27 (H3-K27).  Using chromatin immunopptn. assays, the authors show that H3-K27 methylation colocalizes with, and is dependent on, E(Z) binding at an Ultrabithorax med° (Ubx) Polycomb response element (PRE), and that this methylation correlates with Ubx repression.  Methylation on H3-K27 facilitates binding of Polycomb (PC), a component of the PRC1 complex, to histone H3 amino-terminal tail.  Thus, these studies establish a link between histone methylation and PcG-mediated gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnqusXKZEbLVg90H21EOLACvtfcHk0lh5dRFzG8kxhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D&md5=8f24c05ec935c9110b2ff85b65911396</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.1076997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1076997%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DR.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DRole%2520of%2520histone%2520H3%2520lysine%252027%2520methylation%2520in%2520Polycomb-group%2520silencing%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5595%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1076997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czermin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrotta, V.</span></span> <span> </span><span class="NLM_article-title">Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00975-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0092-8674%2802%2900975-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12408863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotlahsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=185-196&issue=2&author=B.+Czerminauthor=R.+Melfiauthor=D.+McCabeauthor=V.+Seitzauthor=A.+Imhofauthor=V.+Pirrotta&title=Drosophila+enhancer+of+Zeste%2FESC+complexes+have+a+histone+H3+methyltransferase+activity+that+marks+chromosomal+Polycomb+sites&doi=10.1016%2FS0092-8674%2802%2900975-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Drosophila Enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites</span></div><div class="casAuthors">Czermin, Birgit; Melfi, Raffaella; McCabe, Donna; Seitz, Volker; Imhof, Axel; Pirrotta, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Enhancer of Zeste, or E(Z), is a Polycomb Group protein essential for the establishment and maintenance of repression of homeotic and other genes.  In the early embryo it is found in a complex that includes ESC and is recruited to Polycomb Response Elements.  We show that this complex contains a methyltransferase activity that methylates lysine 9 and lysine 27 of histone H3, but the activity is lost when the E(Z) SET domain is mutated.  The lysine 9 position is trimethylated and this mark is closely assocd. with Polycomb binding sites on polytene chromosomes but is also found in centric heterochromatin, chromosome 4, and telomeric sites.  Histone H3 methylated in vitro by the E(Z)/ESC complex binds specifically to Polycomb protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwewQaSe63NbVg90H21EOLACvtfcHk0lh5dRFzG8kxhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotlahsr8%253D&md5=6fdde52477721e6133b5b0902bd2ed2a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900975-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900975-3%26sid%3Dliteratum%253Aachs%26aulast%3DCzermin%26aufirst%3DB.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DMcCabe%26aufirst%3DD.%26aulast%3DSeitz%26aufirst%3DV.%26aulast%3DImhof%26aufirst%3DA.%26aulast%3DPirrotta%26aufirst%3DV.%26atitle%3DDrosophila%2520enhancer%2520of%2520Zeste%252FESC%2520complexes%2520have%2520a%2520histone%2520H3%2520methyltransferase%2520activity%2520that%2520marks%2520chromosomal%2520Polycomb%2520sites%26jtitle%3DCell%26date%3D2002%26volume%3D111%26issue%3D2%26spage%3D185%26epage%3D196%26doi%3D10.1016%2FS0092-8674%2802%2900975-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmichev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenuwein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinberg, D.</span></span> <span> </span><span class="NLM_article-title">Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(04)00185-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS1097-2765%2804%2900185-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15099518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVyisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=183-193&issue=2&author=A.+Kuzmichevauthor=T.+Jenuweinauthor=P.+Tempstauthor=D.+Reinberg&title=Different+EZH2-containing+complexes+target+methylation+of+histone+H1+or+nucleosomal+histone+H3&doi=10.1016%2FS1097-2765%2804%2900185-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Different Ezh2-containing complexes target methylation of histone H1 or nucleosomal histone H3</span></div><div class="casAuthors">Kuzmichev, Andrei; Jenuwein, Thomas; Tempst, Paul; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-193</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human Enhancer of Zeste homolog (Ezh2) is a histone lysine methyltransferase (HKMT) assocd. with transcriptional repression.  Ezh2 is present in several distinct complexes, one of which, PRC2, we characterized previously.  Here we report an addnl. Ezh2 complex, PRC3.  We show that the Ezh2 complexes exhibit differential targeting of specific histones for lysine methylation dependent upon the context of the histone substrates.  This differential targeting is a function of the assocd. Eed protein within each complex.  We found that Eed protein is present in four isoforms, which represent alternate translation start site usage from the same mRNA.  These Eed isoforms selectively assoc. with distinct Ezh2-contg. complexes with resultant differential targeting of their assocd. HKMT activity toward histone H3-K27 or histone H1-K26.  Our data provide evidence for a novel mechanism regulating the substrate specificity of a chromatin-modifying enzyme through disparate translational products of a regulatory subunit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtSqhDjwyYrVg90H21EOLACvtfcHk0ljAOpluNriOBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVyisb8%253D&md5=35083f8234ad04a206dcf6e375e0ebd2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2804%2900185-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252804%252900185-6%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmichev%26aufirst%3DA.%26aulast%3DJenuwein%26aufirst%3DT.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DDifferent%2520EZH2-containing%2520complexes%2520target%2520methylation%2520of%2520histone%2520H1%2520or%2520nucleosomal%2520histone%2520H3%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D14%26issue%3D2%26spage%3D183%26epage%3D193%26doi%3D10.1016%2FS1097-2765%2804%2900185-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingston, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J. A.</span></span> <span> </span><span class="NLM_article-title">Histone methyltransferase activity of a Drosophila Polycomb group repressor complex</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00976-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0092-8674%2802%2900976-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12408864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotlahsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=197-208&issue=2&author=J.+Mullerauthor=C.+M.+Hartauthor=N.+J.+Francisauthor=M.+L.+Vargasauthor=A.+Senguptaauthor=B.+Wildauthor=E.+L.+Millerauthor=M.+B.+O%E2%80%99Connorauthor=R.+E.+Kingstonauthor=J.+A.+Simon&title=Histone+methyltransferase+activity+of+a+Drosophila+Polycomb+group+repressor+complex&doi=10.1016%2FS0092-8674%2802%2900976-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Histone methyltransferase activity of a Drosophila polycomb group repressor complex</span></div><div class="casAuthors">Muller, Jurg; Hart, Craig M.; Francis, Nicole J.; Vargas, Marcus L.; Sengupta, Aditya; Wild, Brigitte; Miller, Ellen L.; O'Connor, Michael B.; Kingston, Robert E.; Simon, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins maintain transcriptional repression during development, likely by creating repressive chromatin states.  The Extra Sex Combs (ESC) and Enhancer of Zeste [E(Z)] proteins are partners in an essential PcG complex, but its full compn. and biochem. activities are not known.  A SET domain in E(Z) suggests this complex might methylate histones.  We purified an ESC-E(Z) complex from Drosophila embryos and found four major subunits: ESC, E(Z), NURF-55, and the PcG repressor, SU(Z)12.  A recombinant complex reconstituted from these four subunits methylates lysine-27 of histone H3.  Mutations in the E(Z) SET domain disrupt methyltransferase activity in vitro and HOX gene repression in vivo.  These results identify E(Z) as a PcG protein with enzymic activity and implicate histone methylation in PcG-mediated silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAFZ5Z3wLX7Vg90H21EOLACvtfcHk0ljAOpluNriOBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotlahsrw%253D&md5=55527bf2dfaf30c62e0baf393b6ee415</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900976-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900976-5%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DHart%26aufirst%3DC.%2BM.%26aulast%3DFrancis%26aufirst%3DN.%2BJ.%26aulast%3DVargas%26aufirst%3DM.%2BL.%26aulast%3DSengupta%26aufirst%3DA.%26aulast%3DWild%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DE.%2BL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BB.%26aulast%3DKingston%26aufirst%3DR.%2BE.%26aulast%3DSimon%26aufirst%3DJ.%2BA.%26atitle%3DHistone%2520methyltransferase%2520activity%2520of%2520a%2520Drosophila%2520Polycomb%2520group%2520repressor%2520complex%26jtitle%3DCell%26date%3D2002%26volume%3D111%26issue%3D2%26spage%3D197%26epage%3D208%26doi%3D10.1016%2FS0092-8674%2802%2900976-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2004.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.gde.2004.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=15196462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVKktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=155-164&issue=2&author=R.+Caoauthor=Y.+Zhang&title=The+functions+of+E%28Z%29%2FEZH2-mediated+methylation+of+lysine+27+in+histone+H3&doi=10.1016%2Fj.gde.2004.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3</span></div><div class="casAuthors">Cao, Ru; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) proteins are important for maintaining the silenced state of homeotic genes.  Biochem. and genetic studies in Drosophila and mammalian cells indicate that PcG proteins function in at least two distinct protein complexes: the ESC-E(Z) or EED-EZH2 complex, and the PRC1 complex.  Recent work has shown that at least part of the silencing function of the ESC-E(Z) complex is mediated by its intrinsic activity for methylating histone H3 on lysine 27.  In addn. to being involved in Hox gene silencing, the complex and its assocd. histone methyltransferase activity are important in other biol. processes including X-inactivation, germline development, stem cell pluripotency and cancer metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTnGE_k0TJd7Vg90H21EOLACvtfcHk0liSYg6ZzlCImA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVKktLY%253D&md5=cfe4157f4c953c0473ba341699b6c446</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2004.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2004.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DThe%2520functions%2520of%2520E%2528Z%2529%252FEZH2-mediated%2520methylation%2520of%2520lysine%252027%2520in%2520histone%2520H3%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2004%26volume%3D14%26issue%3D2%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.gde.2004.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laugesen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hojfeldt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms directing PRC2 recruitment and H3K27 methylation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2019.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2019.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30951652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=8-18&issue=1&author=A.+Laugesenauthor=J.+W.+Hojfeldtauthor=K.+Helin&title=Molecular+mechanisms+directing+PRC2+recruitment+and+H3K27+methylation&doi=10.1016%2Fj.molcel.2019.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation</span></div><div class="casAuthors">Laugesen, Anne; Hoejfeldt, Jonas Westergaard; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-18</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The polycomb repressive complex 2 (PRC2) is a chromatin-assocd. methyltransferase catalyzing mono-, di-, and trimethylation of lysine 27 on histone H3 (H3K27).  This activity is required for normal organismal development and maintenance of gene expression patterns to uphold cell identity.  PRC2 function is often deregulated in disease and is a promising candidate for therapeutic targeting in cancer.  In this review, we discuss the mol. mechanisms proposed to take part in modulating PRC2 recruitment and shaping H3K27 methylation patterns across the genome.  This includes consideration of factors influencing PRC2 residence time on chromatin and PRC2 catalytic activity with a focus on the mechanisms giving rise to regional preferences and differential deposition of H3K27 methylation.  We further discuss existing evidence for functional diversity between distinct subsets of PRC2 complexes with the aim of extg. key concepts and highlighting major open questions toward a more complete understanding of PRC2 function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcGQVL8p1vLVg90H21EOLACvtfcHk0liSYg6ZzlCImA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSmtro%253D&md5=ff3e9f3ed45ab516d5c9fe2c5bd64c3d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2019.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2019.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DLaugesen%26aufirst%3DA.%26aulast%3DHojfeldt%26aufirst%3DJ.%2BW.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520directing%2520PRC2%2520recruitment%2520and%2520H3K27%2520methylation%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D74%26issue%3D1%26spage%3D8%26epage%3D18%26doi%3D10.1016%2Fj.molcel.2019.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Histone methylation in DNA repair and clinical practice: new findings during the past 5-years</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2072</span>– <span class="NLM_lpage">2081</span>, <span class="refDoi"> DOI: 10.7150/jca.23427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.7150%2Fjca.23427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29937925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FhtlCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2072-2081&issue=12&author=S.+Weiauthor=C.+Liauthor=Z.+Yinauthor=J.+Wenauthor=H.+Mengauthor=L.+Xueauthor=J.+Wang&title=Histone+methylation+in+DNA+repair+and+clinical+practice%3A+new+findings+during+the+past+5-years&doi=10.7150%2Fjca.23427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Histone methylation in DNA repair and clinical practice: new findings during the past 5-years</span></div><div class="casAuthors">Wei Shuhua; Li Chunxiao; Wen Jie; Meng Hui; Xue Lixiang; Wang Junjie; Yin Zhongnan; Xue Lixiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2072-2081</span>
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    </div><div class="casAbstract">DNA double-strand breaks (DSBs) are highly toxic lesions that can impair cellular homeostasis and genome stability to result in tumorigenesis for inappropriate repair.  Although DSBs are repaired by homologous recombination (HR) or non-homologous end-joining (NHEJ), the related mechanisms are still incompletely unclear.  Indeed, more and more evidences indicate that the methylation of histone lysine has an important role in choosing the pathways of DNA repair.  For example, tri-methylated H3K36 is required for HR repair, while di-methylated H4K20 can recruit 53BP1 for NHEJ repair.  Here, we reviewed the recent progress in the molecular mechanisms by which histone methylation functions in DNA double-strand breaks repair (DSBR).  The insight into the mechanisms of histone methylation repairing DNA damage will supply important cues for clinical cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTusxX5zh2Y9kg6wdEZmT2rfW6udTcc2ebNxAPMBbdNYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FhtlCrug%253D%253D&md5=18250c3edb40e0b2d072c60bbfb88faf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.7150%2Fjca.23427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.23427%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DHistone%2520methylation%2520in%2520DNA%2520repair%2520and%2520clinical%2520practice%253A%2520new%2520findings%2520during%2520the%2520past%25205-years%26jtitle%3DJ.%2520Cancer%26date%3D2018%26volume%3D9%26issue%3D12%26spage%3D2072%26epage%3D2081%26doi%3D10.7150%2Fjca.23427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riising, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Maintaining cell identity: PRC2-mediated regulation of transcription and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnrc.2016.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27658528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGgtL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=803-810&issue=12&author=I.+Cometauthor=E.+M.+Riisingauthor=B.+Leblancauthor=K.+Helin&title=Maintaining+cell+identity%3A+PRC2-mediated+regulation+of+transcription+and+cancer&doi=10.1038%2Fnrc.2016.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Maintaining cell identity: PRC2-mediated regulation of transcription and cancer</span></div><div class="casAuthors">Comet, Itys; Riising, Eva M.; Leblanc, Benjamin; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">803-810</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressive complex 2 (PRC2), has attracted broad research attention in the past few years because of its involvement in the development and maintenance of many types of cancer and the use of specific EZH2 inhibitors in clin. trials.  Several observations show that PRC2 can have both oncogenic and tumor-suppressive functions.  We propose that these apparently opposing roles of PRC2 in cancer are a consequence of the mol. function of the complex in maintaining, rather than specifying, the transcriptional repression state of its several thousand target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_illiggfTLVg90H21EOLACvtfcHk0lhJlby4UKgNAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGgtL7N&md5=c491ca235d7751be387730b61b57b94f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.83%26sid%3Dliteratum%253Aachs%26aulast%3DComet%26aufirst%3DI.%26aulast%3DRiising%26aufirst%3DE.%2BM.%26aulast%3DLeblanc%26aufirst%3DB.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DMaintaining%2520cell%2520identity%253A%2520PRC2-mediated%2520regulation%2520of%2520transcription%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26issue%3D12%26spage%3D803%26epage%3D810%26doi%3D10.1038%2Fnrc.2016.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wassef, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span> <span> </span><span class="NLM_article-title">The multiple facets of PRC2 alterations in cancers</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>429</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1993</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2016.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.jmb.2016.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27742591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSit7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=1978-1993&issue=13&author=M.+Wassefauthor=R.+Margueron&title=The+multiple+facets+of+PRC2+alterations+in+cancers&doi=10.1016%2Fj.jmb.2016.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The multiple facets of PRC2 alterations in cancers</span></div><div class="casAuthors">Wassef, M.; Margueron, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1978-1993</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Genome sequencing of large cohorts of tumors has revealed that mutations in genes encoding chromatin regulators are frequent in cancer.  However, the precise contribution of these mutations to tumor development often remains elusive.  Here, we review the current knowledge concerning the alterations of the Polycomb machinery in cancer, with a particular focus on the Polycomb repressive complex 2 (PRC2), a key chromatin modifier involved in the maintenance of transcriptional silencing.  A broad variety of alterations can impair PRC2 activity; yet, overall, only one type of alteration is found in a given class of tumor.  We discuss the potential impact of the various types of PRC2 alterations on gene expression.  We propose that the distinct set of genes regulated by PRC2, depending on tumor etiol., constrain the type of alteration of PRC2 that can fuel tumor development.  Beyond this specificity, we propose that PRC2 and, more generally, chromatin regulators act as gatekeepers of transcriptional integrity, a role that often confers a tumor-suppressive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Fj-RcOKPgLVg90H21EOLACvtfcHk0liIMMWdT-QKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSit7nK&md5=5a570cb78d98feecd67f5e6c49473e6c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DWassef%26aufirst%3DM.%26aulast%3DMargueron%26aufirst%3DR.%26atitle%3DThe%2520multiple%2520facets%2520of%2520PRC2%2520alterations%2520in%2520cancers%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26issue%3D13%26spage%3D1978%26epage%3D1993%26doi%3D10.1016%2Fj.jmb.2016.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laugesen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Højfeldt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Role of the Polycomb Repressive Complex 2 (PRC2) in transcriptional regulation and cancer</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">a026575</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a026575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fcshperspect.a026575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27449971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1ylsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=a026575&issue=9&author=A.+Laugesenauthor=J.+W.+H%C3%B8jfeldtauthor=K.+Helin&title=Role+of+the+Polycomb+Repressive+Complex+2+%28PRC2%29+in+transcriptional+regulation+and+cancer&doi=10.1101%2Fcshperspect.a026575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer</span></div><div class="casAuthors">Laugesen, Anne; Hoejfeldt, Jonas Westergaard; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">a026575/1-a026575/21</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The chromatin environment is modulated by a machinery of chromatin modifiers, required for the specification and maintenance of cell fate.  Many mutations in the machinery have been linked to the development and progression of cancer.  In this review, we give a brief introduction to Polycomb group (PcG) proteins, their assembly into Polycomb repressive complexes (PRCs) and the normal physiol. roles of these complexes with a focus on the PRC2.  We review the many findings of mutations in the PRC2 coding genes, both loss-offunction and gain-of-function, assocd. with human cancers and discuss potential mol. mechanisms involved in the contribution of PRC2 mutations to cancer development and progression.  Finally, we discuss some of the recent advances in developing and testing drugs targeting the PRC2 as well as emerging results from clin. trials using these drugs in the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfaXQ68AexFbVg90H21EOLACvtfcHk0liIMMWdT-QKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1ylsLc%253D&md5=f4e4e34f574df73999116c5e257a5f04</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026575%26sid%3Dliteratum%253Aachs%26aulast%3DLaugesen%26aufirst%3DA.%26aulast%3DH%25C3%25B8jfeldt%26aufirst%3DJ.%2BW.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DRole%2520of%2520the%2520Polycomb%2520Repressive%2520Complex%25202%2520%2528PRC2%2529%2520in%2520transcriptional%2520regulation%2520and%2520cancer%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26issue%3D9%26spage%3Da026575%26doi%3D10.1101%2Fcshperspect.a026575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">EZH2, an epigenetic driver of prostate cancer</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1007/s13238-013-2093-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1007%2Fs13238-013-2093-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23636686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12rs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=331-341&issue=5&author=Y.+A.+Yangauthor=J.+Yu&title=EZH2%2C+an+epigenetic+driver+of+prostate+cancer&doi=10.1007%2Fs13238-013-2093-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2, an epigenetic driver of prostate cancer</span></div><div class="casAuthors">Yang, Yeqing Angela; Yu, Jindan</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">331-341</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer.  It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target.  Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches.  This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt28-ADnWJN7Vg90H21EOLACvtfcHk0liIMMWdT-QKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12rs7s%253D&md5=8039f52b256b1f49259407438bd5f449</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs13238-013-2093-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-013-2093-2%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DEZH2%252C%2520an%2520epigenetic%2520driver%2520of%2520prostate%2520cancer%26jtitle%3DProtein%2520Cell%26date%3D2013%26volume%3D4%26issue%3D5%26spage%3D331%26epage%3D341%26doi%3D10.1007%2Fs13238-013-2093-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beguelin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunting, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezponda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelleher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaknovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchietti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, A. M.</span></span> <span> </span><span class="NLM_article-title">EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ccr.2013.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23680150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslaltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=677-692&issue=5&author=W.+Beguelinauthor=R.+Popovicauthor=M.+Teaterauthor=Y.+Jiangauthor=K.+L.+Buntingauthor=M.+Rosenauthor=H.+Shenauthor=S.+N.+Yangauthor=L.+Wangauthor=T.+Ezpondaauthor=E.+Martinez-Garciaauthor=H.+Zhangauthor=Y.+Zhengauthor=S.+K.+Vermaauthor=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+S.+Van+Allerauthor=R.+G.+Krugerauthor=Y.+Liuauthor=C.+F.+McHughauthor=D.+W.+Scottauthor=Y.+R.+Chungauthor=N.+Kelleherauthor=R.+Shaknovichauthor=C.+L.+Creasyauthor=R.+D.+Gascoyneauthor=K.+K.+Wongauthor=L.+Cerchiettiauthor=R.+L.+Levineauthor=O.+Abdel-Wahabauthor=J.+D.+Lichtauthor=O.+Elementoauthor=A.+M.+Melnick&title=EZH2+is+required+for+germinal+center+formation+and+somatic+EZH2+mutations+promote+lymphoid+transformation&doi=10.1016%2Fj.ccr.2013.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation</span></div><div class="casAuthors">Beguelin, Wendy; Popovic, Relja; Teater, Matt; Jiang, Yanwen; Bunting, Karen L.; Rosen, Monica; Shen, Hao; Yang, Shao Ning; Wang, Ling; Ezponda, Teresa; Martinez-Garcia, Eva; Zhang, Haikuo; Zheng, Yupeng; Verma, Sharad K.; McCabe, Michael T.; Ott, Heidi M.; Van Aller, Glenn S.; Kruger, Ryan G.; Liu, Yan; McHugh, Charles F.; Scott, David W.; Chung, Young Rock; Kelleher, Neil; Shaknovich, Rita; Creasy, Caretha L.; Gascoyne, Randy D.; Wong, Kwok-Kin; Cerchietti, Leandro; Levine, Ross L.; Abdel-Wahab, Omar; Licht, Jonathan D.; Elemento, Olivier; Melnick, Ari M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">677-692</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and targeted by somatic mutations in B cell lymphomas.  Here, we find that EZH2 deletion or pharmacol. inhibition suppresses GC formation and functions.  EZH2 represses proliferation checkpoint genes and helps establish bivalent chromatin domains at key regulatory loci to transiently suppress GC B cell differentiation.  Somatic mutations reinforce these physiol. effects through enhanced silencing of EZH2 targets.  Conditional expression of mutant EZH2 in mice induces GC hyperplasia and accelerated lymphomagenesis in cooperation with BCL2.  GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more differentiated activated B cell (ABC)-type DLBCLs, thus clarifying the therapeutic scope of EZH2 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGRGx_7wvR7Vg90H21EOLACvtfcHk0liiPh-gT9It8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslaltLY%253D&md5=c7a58d41a10c1464eb7ada72b94dfd40</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DBeguelin%26aufirst%3DW.%26aulast%3DPopovic%26aufirst%3DR.%26aulast%3DTeater%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DBunting%26aufirst%3DK.%2BL.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEzponda%26aufirst%3DT.%26aulast%3DMartinez-Garcia%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DScott%26aufirst%3DD.%2BW.%26aulast%3DChung%26aufirst%3DY.%2BR.%26aulast%3DKelleher%26aufirst%3DN.%26aulast%3DShaknovich%26aufirst%3DR.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DMelnick%26aufirst%3DA.%2BM.%26atitle%3DEZH2%2520is%2520required%2520for%2520germinal%2520center%2520formation%2520and%2520somatic%2520EZH2%2520mutations%2520promote%2520lymphoid%2520transformation%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D677%26epage%3D692%26doi%3D10.1016%2Fj.ccr.2013.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morin, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungall, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolcock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchenbauer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimbara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shashkin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlot, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcherpakov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varhol, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smailus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moksa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birol, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. A.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1038/ng.518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fng.518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20081860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=181-185&issue=2&author=R.+D.+Morinauthor=N.+A.+Johnsonauthor=T.+M.+Seversonauthor=A.+J.+Mungallauthor=J.+Anauthor=R.+Goyaauthor=J.+E.+Paulauthor=M.+Boyleauthor=B.+W.+Woolcockauthor=F.+Kuchenbauerauthor=D.+Yapauthor=R.+K.+Humphriesauthor=O.+L.+Griffithauthor=S.+Shahauthor=H.+Zhuauthor=M.+Kimbaraauthor=P.+Shashkinauthor=J.+F.+Charlotauthor=M.+Tcherpakovauthor=R.+Corbettauthor=A.+Tamauthor=R.+Varholauthor=D.+Smailusauthor=M.+Moksaauthor=Y.+Zhaoauthor=A.+Delaneyauthor=H.+Qianauthor=I.+Birolauthor=J.+Scheinauthor=R.+Mooreauthor=R.+Holtauthor=D.+E.+Horsmanauthor=J.+M.+Connorsauthor=S.+Jonesauthor=S.+Aparicioauthor=M.+Hirstauthor=R.+D.+Gascoyneauthor=M.+A.+Marra&title=Somatic+mutations+altering+EZH2+%28Tyr641%29+in+follicular+and+diffuse+large+B-cell+lymphomas+of+germinal-center+origin&doi=10.1038%2Fng.518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span></div><div class="casAuthors">Morin, Ryan D.; Johnson, Nathalie A.; Severson, Tesa M.; Mungall, Andrew J.; An, Jianghong; Goya, Rodrigo; Paul, Jessica E.; Boyle, Merrill; Woolcock, Bruce W.; Kuchenbauer, Florian; Yap, Damian; Humphries, R. Keith; Griffith, Obi L.; Shah, Sohrab; Zhu, Henry; Kimbara, Michelle; Shashkin, Pavel; Charlot, Jean F.; Tcherpakov, Marianna; Corbett, Richard; Tam, Angela; Varhol, Richard; Smailus, Duane; Moksa, Michelle; Zhao, Yongjun; Delaney, Allen; Qian, Hong; Birol, Inanc; Schein, Jacqueline; Moore, Richard; Holt, Robert; Horsman, Doug E.; Connors, Joseph M.; Jones, Steven; Aparicio, Samuel; Hirst, Martin; Gascoyne, Randy D.; Marra, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-185</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells.  Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-κB pathway that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified.  Here the authors report recurrent somatic mutations affecting the polycomb-group oncogene EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27).  After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types, EZH2 is the second histone methyltransferase gene mutated in cancer.  These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs.  The authors' data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymic activity in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvpFnajONCXbVg90H21EOLACvtfcHk0lhSC694T6GXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D&md5=ab68fe6e8932e720c4e7be82fe35932a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fng.518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.518%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DSeverson%26aufirst%3DT.%2BM.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DPaul%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DWoolcock%26aufirst%3DB.%2BW.%26aulast%3DKuchenbauer%26aufirst%3DF.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DHumphries%26aufirst%3DR.%2BK.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKimbara%26aufirst%3DM.%26aulast%3DShashkin%26aufirst%3DP.%26aulast%3DCharlot%26aufirst%3DJ.%2BF.%26aulast%3DTcherpakov%26aufirst%3DM.%26aulast%3DCorbett%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DVarhol%26aufirst%3DR.%26aulast%3DSmailus%26aufirst%3DD.%26aulast%3DMoksa%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DSchein%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DHolt%26aufirst%3DR.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26atitle%3DSomatic%2520mutations%2520altering%2520EZH2%2520%2528Tyr641%2529%2520in%2520follicular%2520and%2520diffuse%2520large%2520B-cell%2520lymphomas%2520of%2520germinal-center%2520origin%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26issue%3D2%26spage%3D181%26epage%3D185%26doi%3D10.1038%2Fng.518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Cooperation between Polycomb and androgen receptor during oncogenic transformation</span>. <i>Genome Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1101/gr.131508.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fgr.131508.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=22179855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFygtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=322-331&issue=2&author=J.+C.+Zhaoauthor=J.+Yuauthor=C.+Runkleauthor=L.+Wuauthor=M.+Huauthor=D.+Wuauthor=J.+S.+Liuauthor=Q.+Wangauthor=Z.+S.+Qinauthor=J.+Yu&title=Cooperation+between+Polycomb+and+androgen+receptor+during+oncogenic+transformation&doi=10.1101%2Fgr.131508.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cooperation between polycomb and androgen receptor during oncogenic transformation</span></div><div class="casAuthors">Zhao, Jonathan C.; Yu, Jianjun; Runkle, Christine; Wu, Longtao; Hu, Ming; Wu, Dayong; Liu, Jun S.; Wang, Qianben; Qin, Zhaohui S.; Yu, Jindan</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-331</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Androgen receptor (AR) is a hormone-activated transcription factor that plays important roles in prostate development and function, as well as malignant transformation.  The downstream pathways of AR, however, are incompletely understood.  AR has been primarily known as a transcriptional activator inducing prostate-specific gene expression.  Through integrative anal. of genome-wide AR occupancy and androgen-regulated gene expression, here we report AR as a globally acting transcriptional repressor.  This repression is mediated by androgen-responsive elements (ARE) and dictated by Polycomb group protein EZH2 and repressive chromatin remodeling.  In embryonic stem cells, AR-repressed genes are occupied by EZH2 and harbor bivalent H3K4me3 and H3K27me3 modifications that are characteristic of differentiation regulators, the silencing of which maintains the undifferentiated state.  Concordantly, these genes are silenced in castration-resistant prostate cancer rendering a stem cell-like lack of differentiation and tumor progression.  Collectively, our data reveal an unexpected role of AR as a transcriptional repressor inhibiting non-prostatic differentiation and, upon excessive signaling, resulting in cancerous dedifferentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjNol5ZcVfkLVg90H21EOLACvtfcHk0lig9iGEImls5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFygtrc%253D&md5=debc0ff309b9ee1483b2c03ab7a1f1b4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1101%2Fgr.131508.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.131508.111%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DRunkle%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DQin%26aufirst%3DZ.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DCooperation%2520between%2520Polycomb%2520and%2520androgen%2520receptor%2520during%2520oncogenic%2520transformation%26jtitle%3DGenome%2520Res.%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D322%26epage%3D331%26doi%3D10.1101%2Fgr.131508.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laxman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellaichamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasekaran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrette, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">An integrated network of androgen receptor, Polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ccr.2010.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=20478527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslKru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=443-454&issue=5&author=J.+Yuauthor=J.+Yuauthor=R.+S.+Maniauthor=Q.+Caoauthor=C.+J.+Brennerauthor=X.+Caoauthor=X.+Wangauthor=L.+Wuauthor=J.+Liauthor=M.+Huauthor=Y.+Gongauthor=H.+Chengauthor=B.+Laxmanauthor=A.+Vellaichamyauthor=S.+Shankarauthor=Y.+Liauthor=S.+M.+Dhanasekaranauthor=R.+Moreyauthor=T.+Barretteauthor=R.+J.+Lonigroauthor=S.+A.+Tomlinsauthor=S.+Varamballyauthor=Z.+S.+Qinauthor=A.+M.+Chinnaiyan&title=An+integrated+network+of+androgen+receptor%2C+Polycomb%2C+and+TMPRSS2-ERG+gene+fusions+in+prostate+cancer+progression&doi=10.1016%2Fj.ccr.2010.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression</span></div><div class="casAuthors">Yu, Jindan; Yu, Jianjun; Mani, Ram-Shankar; Cao, Qi; Brenner, Chad J.; Cao, Xuhong; Wang, Xiaoju; Wu, Longtao; Li, James; Hu, Ming; Gong, Yusong; Cheng, Hong; Laxman, Bharathi; Vellaichamy, Adaikkalam; Shankar, Sunita; Li, Yong; Dhanasekaran, Saravana M.; Morey, Roger; Barrette, Terrence; Lonigro, Robert J.; Tomlins, Scott A.; Varambally, Sooryanarayana; Qin, Zhaohui S.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">443-454</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS transcription factor ERG occur in approx. 50% of prostate cancers, but how the fusion products regulate prostate cancer remains unclear.  Using chromatin immunopptn. coupled with massively parallel sequencing, we found that ERG disrupts androgen receptor (AR) signaling by inhibiting AR expression, binding to and inhibiting AR activity at gene-specific loci, and inducing repressive epigenetic programs via direct activation of the H3K27 methyltransferase EZH2, a Polycomb group protein.  These findings provide a working model in which TMPRSS2-ERG plays a crit. role in cancer progression by disrupting lineage-specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouYaPEsLZp2bVg90H21EOLACvtfcHk0lig9iGEImls5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslKru7Y%253D&md5=491eefed71b77076b0fa218a31c226e4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMani%26aufirst%3DR.%2BS.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DBrenner%26aufirst%3DC.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DLaxman%26aufirst%3DB.%26aulast%3DVellaichamy%26aufirst%3DA.%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DDhanasekaran%26aufirst%3DS.%2BM.%26aulast%3DMorey%26aufirst%3DR.%26aulast%3DBarrette%26aufirst%3DT.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DZ.%2BS.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DAn%2520integrated%2520network%2520of%2520androgen%2520receptor%252C%2520Polycomb%252C%2520and%2520TMPRSS2-ERG%2520gene%2520fusions%2520in%2520prostate%2520cancer%2520progression%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26issue%3D5%26spage%3D443%26epage%3D454%26doi%3D10.1016%2Fj.ccr.2010.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laxman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasekaran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2007.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.ccr.2007.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17996646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtl2nur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=419-431&issue=5&author=J.+Yuauthor=Q.+Caoauthor=R.+Mehraauthor=B.+Laxmanauthor=J.+Yuauthor=S.+A.+Tomlinsauthor=C.+J.+Creightonauthor=S.+M.+Dhanasekaranauthor=R.+Shenauthor=G.+Chenauthor=D.+S.+Morrisauthor=V.+E.+Marquezauthor=R.+B.+Shahauthor=D.+Ghoshauthor=S.+Varamballyauthor=A.+M.+Chinnaiyan&title=Integrative+genomics+analysis+reveals+silencing+of+beta-adrenergic+signaling+by+polycomb+in+prostate+cancer&doi=10.1016%2Fj.ccr.2007.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative genomics analysis reveals silencing of β-Adrenergic signaling by Polycomb in prostate cancer</span></div><div class="casAuthors">Yu, Jindan; Cao, Qi; Mehra, Rohit; Laxman, Bharathi; Yu, Jianjun; Tomlins, Scott A.; Creighton, Chad J.; Dhanasekaran, Saravana M.; Shen, Ronglai; Chen, Guoan; Morris, David S.; Marquez, Victor E.; Shah, Rajal B.; Ghosh, Debashis; Varambally, Sooryanarayana; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Polycomb group (PcG) protein EZH2 possesses oncogenic properties for which the underlying mechanism is unclear.  We integrated in vitro cell line, in vivo tumor profiling, and genome-wide location data to nominate key targets of EZH2.  One of the candidates identified was ADRB2 (Adrenergic Receptor, Beta-2), a crit. mediator of β-adrenergic signaling.  EZH2 is recruited to the ADRB2 promoter and represses ADRB2 expression.  ADRB2 inhibition confers cell invasion and transforms benign prostate epithelial cells, whereas ADRB2 overexpression counteracts EZH2-mediated oncogenesis.  ADRB2 is underexpressed in metastatic prostate cancer, and clin. localized tumors that express lower levels of ADRB2 exhibit a poor prognosis.  Taken together, we demonstrate the power of integrating multiple diverse genomic data to decipher targets of disease-related genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrU67Cn7lx4rVg90H21EOLACvtfcHk0ljmA86VfwzGPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtl2nur3F&md5=21ac40c21e75e467fbaa9d798ba7c787</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2007.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2007.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DLaxman%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DDhanasekaran%26aufirst%3DS.%2BM.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMorris%26aufirst%3DD.%2BS.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DShah%26aufirst%3DR.%2BB.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DIntegrative%2520genomics%2520analysis%2520reveals%2520silencing%2520of%2520beta-adrenergic%2520signaling%2520by%2520polycomb%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26issue%3D5%26spage%3D419%26epage%3D431%26doi%3D10.1016%2Fj.ccr.2007.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Gise, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, W. T.</span></span> <span> </span><span class="NLM_article-title">PRC2 directly methylates GATA4 and represses its transcriptional activity</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1101/gad.173930.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1101%2Fgad.173930.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=22215809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlaiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=37-42&issue=1&author=A.+Heauthor=X.+Shenauthor=Q.+Maauthor=J.+Caoauthor=A.+von+Giseauthor=P.+Zhouauthor=G.+Wangauthor=V.+E.+Marquezauthor=S.+H.+Orkinauthor=W.+T.+Pu&title=PRC2+directly+methylates+GATA4+and+represses+its+transcriptional+activity&doi=10.1101%2Fgad.173930.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PRC2 directly methylates GATA4 and represses its transcriptional activity</span></div><div class="casAuthors">He, Aibin; Shen, Xiaohua; Ma, Qing; Cao, Jingjing; von Gise, Alexander; Zhou, Pingzhu; Wang, Gang; Marquez, Victor E.; Orkin, Stuart H.; Pu, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-42</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Polycomb-repressive complex 2 (PRC2) promotes tissue-specific differentiation by depositing trimethylated histone H3 Lys 27 (H3K27me3) epigenetic marks to silence ectopic gene expression programs.  Here, we show that EZH2, the catalytic subunit of PRC2, is required for cardiac morphogenesis.  Both in vitro and in fetal hearts, EZH2 interacted with cardiac transcription factor GATA4 and directly methylated it at Lys 299.  PRC2 methylation of GATA4 attenuated its transcriptional activity by reducing its interaction with and acetylation by p300.  Our results reveal a new mechanism of PRC2-mediated transcriptional repression in which PRC2 methylates a transcription factor to inhibit its transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4-4MX3w79ALVg90H21EOLACvtfcHk0ljmA86VfwzGPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlaiurg%253D&md5=3ab3c7aceb394c49edd0f0af31befbe2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1101%2Fgad.173930.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.173930.111%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3Dvon%2BGise%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DPu%26aufirst%3DW.%2BT.%26atitle%3DPRC2%2520directly%2520methylates%2520GATA4%2520and%2520represses%2520its%2520transcriptional%2520activity%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26issue%3D1%26spage%3D37%26epage%3D42%26doi%3D10.1101%2Fgad.173930.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanulli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teissandier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancelin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Rocha, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loew, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassef, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlina, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margueron, R.</span></span> <span> </span><span class="NLM_article-title">Jarid2 methylation via the PRC2 Complex regulates H3K27me3 deposition during cell differentiation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2014.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25620564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVarsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2015&pages=769-783&issue=5&author=S.+Sanulliauthor=N.+Justinauthor=A.+Teissandierauthor=K.+Ancelinauthor=M.+Portosoauthor=M.+Caronauthor=A.+Michaudauthor=B.+Lombardauthor=S.+T.+da+Rochaauthor=J.+Offerauthor=D.+Loewauthor=N.+Servantauthor=M.+Wassefauthor=F.+Burlinaauthor=S.+J.+Gamblinauthor=E.+Heardauthor=R.+Margueron&title=Jarid2+methylation+via+the+PRC2+Complex+regulates+H3K27me3+deposition+during+cell+differentiation&doi=10.1016%2Fj.molcel.2014.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Jarid2 methylation via the PRC2 complex regulates H3K27me3 deposition during cell differentiation</span></div><div class="casAuthors">Sanulli, Serena; Justin, Neil; Teissandier, Aurelie; Ancelin, Katia; Portoso, Manuela; Caron, Matthieu; Michaud, Audrey; Lombard, Berangere; da Rocha, Simao T.; Offer, John; Loew, Damarys; Servant, Nicolas; Wassef, Michel; Burlina, Fabienne; Gamblin, Steve J.; Heard, Edith; Margueron, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">769-783</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Polycomb Group (PcG) proteins maintain transcriptional repression throughout development, mostly by regulating chromatin structure.  Polycomb Repressive Complex 2 (PRC2), a component of the Polycomb machinery, is responsible for the methylation of histone H3 lysine 27 (H3K27me2/3).  Jarid2 was previously identified as a cofactor of PRC2, regulating PRC2 targeting to chromatin and its enzymic activity.  Deletion of Jarid2 leads to impaired orchestration of gene expression during cell lineage commitment.  Here, we reveal an unexpected crosstalk between Jarid2 and PRC2, with Jarid2 being methylated by PRC2.  This modification is recognized by the Eed core component of PRC2 and triggers an allosteric activation of PRC2's enzymic activity.  We show that Jarid2 methylation is important to promote PRC2 activity at a locus devoid of H3K27me3 and for the correct deposition of this mark during cell differentiation.  Our results uncover a regulation loop where Jarid2 methylation fine-tunes PRC2 activity depending on the chromatin context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9FjHbs3tCbVg90H21EOLACvtfcHk0lh-IpUTDfe68A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVarsL8%253D&md5=aa87be7e8d1af4c9385966c2ff64d009</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DSanulli%26aufirst%3DS.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DTeissandier%26aufirst%3DA.%26aulast%3DAncelin%26aufirst%3DK.%26aulast%3DPortoso%26aufirst%3DM.%26aulast%3DCaron%26aufirst%3DM.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DLombard%26aufirst%3DB.%26aulast%3Dda%2BRocha%26aufirst%3DS.%2BT.%26aulast%3DOffer%26aufirst%3DJ.%26aulast%3DLoew%26aufirst%3DD.%26aulast%3DServant%26aufirst%3DN.%26aulast%3DWassef%26aufirst%3DM.%26aulast%3DBurlina%26aufirst%3DF.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26aulast%3DHeard%26aufirst%3DE.%26aulast%3DMargueron%26aufirst%3DR.%26atitle%3DJarid2%2520methylation%2520via%2520the%2520PRC2%2520Complex%2520regulates%2520H3K27me3%2520deposition%2520during%2520cell%2520differentiation%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D57%26issue%3D5%26spage%3D769%26epage%3D783%26doi%3D10.1016%2Fj.molcel.2014.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. H.</span></span> <span> </span><span class="NLM_article-title">EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2012.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23063525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSjsrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=572-586&issue=4&author=J.+M.+Leeauthor=J.+S.+Leeauthor=H.+Kimauthor=K.+Kimauthor=H.+Parkauthor=J.+Y.+Kimauthor=S.+H.+Leeauthor=I.+S.+Kimauthor=J.+Kimauthor=M.+Leeauthor=C.+H.+Chungauthor=S.+B.+Seoauthor=J.+B.+Yoonauthor=E.+Koauthor=D.+Y.+Nohauthor=K.+I.+Kimauthor=K.+K.+Kimauthor=S.+H.+Baek&title=EZH2+generates+a+methyl+degron+that+is+recognized+by+the+DCAF1%2FDDB1%2FCUL4+E3+ubiquitin+ligase+complex&doi=10.1016%2Fj.molcel.2012.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex</span></div><div class="casAuthors">Lee, Ji Min; Lee, Jason S.; Kim, Hyunkyung; Kim, Kyeongkyu; Park, Hyejin; Kim, Ji-Young; Lee, Seung Hoon; Kim, Ik Soo; Kim, Joomyung; Lee, Minkyoung; Chung, Chin Ha; Seo, Sang-Beom; Yoon, Jong-Bok; Ko, Eunyoung; Noh, Dong-Young; Kim, Keun Il; Kim, Kyeong Kyu; Baek, Sung Hee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">572-586</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Ubiquitination plays a major role in protein degrdn.  Although phosphorylation-dependent ubiquitination is well known for the regulation of protein stability, methylation-dependent ubiquitination machinery has not been characterized.  Here, we provide evidence that methylation-dependent ubiquitination is carried out by damage-specific DNA binding protein 1 (DDB1)/cullin4 (CUL4) E3 ubiquitin ligase complex and a DDB1-CUL4-assocd. factor 1 (DCAF1) adaptor, which recognizes monomethylated substrates.  Mol. modeling and binding affinity studies reveal that the putative chromo domain of DCAF1 directly recognizes monomethylated substrates, whereas crit. binding pocket mutations of the DCAF1 chromo domain ablated the binding from the monomethylated substrates.  Further, we discovered that enhancer of zeste homolog 2 (EZH2) methyltransferase has distinct substrate specificities for histone H3K27 and nonhistones exemplified by an orphan nuclear receptor, RORα.  We propose that EZH2-DCAF1/DDB1/CUL4 represents a previously unrecognized methylation-dependent ubiquitination machinery specifically recognizing "methyl degron"; through this, nonhistone protein stability can be dynamically regulated in a methylation-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCIV6Wfj-iXrVg90H21EOLACvtfcHk0li8h-4CSZ1klA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSjsrzI&md5=0664aa7b7ca69a21f9b0ea4ccb7b4bd2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DI.%2BS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%2BH.%26aulast%3DSeo%26aufirst%3DS.%2BB.%26aulast%3DYoon%26aufirst%3DJ.%2BB.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DNoh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BI.%26aulast%3DKim%26aufirst%3DK.%2BK.%26aulast%3DBaek%26aufirst%3DS.%2BH.%26atitle%3DEZH2%2520generates%2520a%2520methyl%2520degron%2520that%2520is%2520recognized%2520by%2520the%2520DCAF1%252FDDB1%252FCUL4%2520E3%2520ubiquitin%2520ligase%2520complex%26jtitle%3DMol.%2520Cell%26date%3D2012%26volume%3D48%26issue%3D4%26spage%3D572%26epage%3D586%26doi%3D10.1016%2Fj.molcel.2012.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H. S. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessella, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montironi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magi-Galluzzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantoff, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>338</i></span> (<span class="NLM_issue">6113</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1469</span>, <span class="refDoi"> DOI: 10.1126/science.1227604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1126%2Fscience.1227604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23239736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2012&pages=1465-1469&issue=6113&author=K.+X.+Xuauthor=Z.+J.+Wuauthor=A.+C.+Gronerauthor=H.+S.+H.+S.+Heauthor=C.+M.+Caiauthor=R.+T.+Lisauthor=X.+Q.+Wuauthor=E.+C.+Stackauthor=M.+Lodaauthor=T.+Liuauthor=H.+Xuauthor=L.+Catoauthor=J.+E.+Thorntonauthor=R.+I.+Gregoryauthor=C.+Morrisseyauthor=R.+L.+Vessellaauthor=R.+Montironiauthor=C.+Magi-Galluzziauthor=P.+W.+Kantoffauthor=S.+P.+Balkauthor=X.+S.+Liuauthor=M.+Brown&title=EZH2+oncogenic+activity+in+castration-resistant+prostate+cancer+cells+is+Polycomb-independent&doi=10.1126%2Fscience.1227604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent</span></div><div class="casAuthors">Xu, Kexin; Wu, Zhenhua Jeremy; Groner, Anna C.; He, Housheng Hansen; Cai, Changmeng; Lis, Rosina T.; Wu, Xiaoqiu; Stack, Edward C.; Loda, Massimo; Liu, Tao; Xu, Han; Cato, Laura; Thornton, James E.; Gregory, Richard I.; Morrissey, Colm; Vessella, Robert L.; Montironi, Rodolfo; Magi-Galluzzi, Cristina; Kantoff, Philip W.; Balk, Steven P.; Liu, X. Shirley; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">6113</span>),
    <span class="NLM_cas:pages">1465-1469</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Epigenetic regulators represent a promising new class of therapeutic targets for cancer.  Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity.  We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor.  Instead, it involves the ability of EZH2 to act as a coactivator for crit. transcription factors including the androgen receptor.  This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain.  Hence, targeting the non-PRC2 function of EZH2 may have therapeutic efficacy for treating metastatic, hormone-refractory prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOB2b-7A-UaLVg90H21EOLACvtfcHk0li8h-4CSZ1klA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF&md5=98399f2e6a4c9b07121059772650d2d3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscience.1227604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1227604%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%2BX.%26aulast%3DWu%26aufirst%3DZ.%2BJ.%26aulast%3DGroner%26aufirst%3DA.%2BC.%26aulast%3DHe%26aufirst%3DH.%2BS.%2BH.%2BS.%26aulast%3DCai%26aufirst%3DC.%2BM.%26aulast%3DLis%26aufirst%3DR.%2BT.%26aulast%3DWu%26aufirst%3DX.%2BQ.%26aulast%3DStack%26aufirst%3DE.%2BC.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCato%26aufirst%3DL.%26aulast%3DThornton%26aufirst%3DJ.%2BE.%26aulast%3DGregory%26aufirst%3DR.%2BI.%26aulast%3DMorrissey%26aufirst%3DC.%26aulast%3DVessella%26aufirst%3DR.%2BL.%26aulast%3DMontironi%26aufirst%3DR.%26aulast%3DMagi-Galluzzi%26aufirst%3DC.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DEZH2%2520oncogenic%2520activity%2520in%2520castration-resistant%2520prostate%2520cancer%2520cells%2520is%2520Polycomb-independent%26jtitle%3DScience%26date%3D2012%26volume%3D338%26issue%3D6113%26spage%3D1465%26epage%3D1469%26doi%3D10.1126%2Fscience.1227604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasanthakumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, A. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kueh, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gisbergen, K. P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannarella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majewski, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, R. S.</span></span> <span> </span><span class="NLM_article-title">A non-canonical function of EZH2 preserves immune homeostasis</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.15252/embr.201643237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.15252%2Fembr.201643237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28223321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFers7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=619-631&issue=4&author=A.+Vasanthakumarauthor=D.+K.+Xuauthor=A.+T.+L.+Lunauthor=A.+J.+Kuehauthor=K.+P.+J.+M.+van+Gisbergenauthor=N.+Iannarellaauthor=X.+F.+Liauthor=L.+Yuauthor=D.+Wangauthor=B.+R.+G.+Williamsauthor=S.+C.+W.+Leeauthor=I.+J.+Majewskiauthor=D.+I.+Godfreyauthor=G.+K.+Smythauthor=W.+S.+Alexanderauthor=M.+J.+Heroldauthor=A.+Kalliesauthor=S.+L.+Nuttauthor=R.+S.+Allan&title=A+non-canonical+function+of+EZH2+preserves+immune+homeostasis&doi=10.15252%2Fembr.201643237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A non-canonical function of Ezh2 preserves immune homeostasis</span></div><div class="casAuthors">Vasanthakumar, Ajithkumar; Xu, Dakang; Lun, Aaron T. L.; Kueh, Andrew J.; van Gisbergen, Klaas P. J. M.; Iannarella, Nadia; Li, Xiaofang; Yu, Liang; Wang, Die; Williams, Bryan R. G.; Lee, Stanley C. W.; Majewski, Ian J.; Godfrey, Dale I.; Smyth, Gordon K.; Alexander, Warren S.; Herold, Marco J.; Kallies, Axel; Nutt, Stephen L.; Allan, Rhys S.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">619-631</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Enhancer of zeste 2 (Ezh2) mainly methylates lysine 27 of histone-H3 (H3K27me3) as part of the polycomb repressive complex 2 (PRC2) together with Suz12 and Eed.  However, Ezh2 can also modify non-histone substrates, although it is unclear whether this mechanism has a role during development.  Here, we present evidence for a chromatin-independent role of Ezh2 during T-cell development and immune homeostasis.  T-cell-specific depletion of Ezh2 induces a pronounced expansion of natural killer T (NKT) cells, although Ezh2-deficient T cells maintain normal levels of H3K27me3.  In contrast, removal of Suz12 or Eed destabilizes canonical PRC2 function and ablates NKT cell development completely.  We further show that Ezh2 directly methylates the NKT cell lineage defining transcription factor PLZF, leading to its ubiquitination and subsequent degrdn.  Sustained PLZF expression in Ezh2-deficient mice is assocd. with the expansion of a subset of NKT cells that cause immune perturbation.  Taken together, we have identified a chromatin-independent function of Ezh2 that impacts on the development of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8yVKmL-d0c7Vg90H21EOLACvtfcHk0ljt_dJY0X-Ccg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFers7Y%253D&md5=cbc47ab9e46272a6aa281812566e4ea1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.15252%2Fembr.201643237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201643237%26sid%3Dliteratum%253Aachs%26aulast%3DVasanthakumar%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DD.%2BK.%26aulast%3DLun%26aufirst%3DA.%2BT.%2BL.%26aulast%3DKueh%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGisbergen%26aufirst%3DK.%2BP.%2BJ.%2BM.%26aulast%3DIannarella%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%2BF.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DB.%2BR.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BC.%2BW.%26aulast%3DMajewski%26aufirst%3DI.%2BJ.%26aulast%3DGodfrey%26aufirst%3DD.%2BI.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DAlexander%26aufirst%3DW.%2BS.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DKallies%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DS.%2BL.%26aulast%3DAllan%26aufirst%3DR.%2BS.%26atitle%3DA%2520non-canonical%2520function%2520of%2520EZH2%2520preserves%2520immune%2520homeostasis%26jtitle%3DEMBO%2520Rep.%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D619%26epage%3D631%26doi%3D10.15252%2Fembr.201643237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPrie, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merajver, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleer, C. G.</span></span> <span> </span><span class="NLM_article-title">Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2360</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F0008-5472.CAN-10-1933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=21406404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2360-2370&issue=6&author=M.+E.+Gonzalezauthor=M.+L.+DuPrieauthor=H.+Kruegerauthor=S.+D.+Merajverauthor=A.+C.+Venturaauthor=K.+A.+Toyauthor=C.+G.+Kleer&title=Histone+methyltransferase+EZH2+induces+Akt-dependent+genomic+instability+and+BRCA1+inhibition+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-10-1933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer</span></div><div class="casAuthors">Gonzalez, Maria E.; DuPrie, Matthew L.; Krueger, Heather; Merajver, Sofia D.; Ventura, Alejandra C.; Toy, Kathy A.; Kleer, Celina G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2360-2370</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Increased levels of EZH2, a crit. regulator of cellular memory, signal the presence of metastasis and poor outcome in breast cancer patients.  High levels of EZH2 are assocd. with nuclear pleomorphism, lack of estrogen receptor expression, and decreased nuclear levels of BRCA1 tumor suppressor protein in invasive breast carcinomas.  The mechanism by which EZH2 overexpression promotes the growth of poorly differentiated invasive carcinomas remains to be defined.  Here, we show that EZH2 controls the intracellular localization of BRCA1 protein.  Conditional doxycycline-induced upregulation of EZH2 in benign mammary epithelial cells results in nuclear export of BRCA1 protein, aberrant mitoses with extra centrosomes, and genomic instability.  EZH2 inhibition in CAL51 breast cancer cells induces BRCA1 nuclear localization and rescues defects in ploidy and mitosis.  Mechanistically, EZH2 overexpression is sufficient for activation of the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway specifically through activation of Akt isoform 1.  EZH2-induced BRCA1 nuclear export, aneuploidy, and mitotic defects were prevented by treatment with the PI3K inhibitors LY294002 or wortmannin.  Targeted inhibition of Akt-1, Akt-2, and Akt-3 isoforms revealed that the EZH2-induced phenotype requires specific activation of Akt-1.  The relevance of our studies to human breast cancer is highlighted by the finding that high EZH2 protein levels are assocd. with upregulated expression of phospho-Akt-1 (Ser473) and decreased nuclear expression of phospho-BRCA1 (Ser1423) in 39% of invasive breast carcinomas.  These results enable us to pinpoint one mechanism by which EZH2 regulates BRCA1 expression and genomic stability mediated by the PI3K/Akt-1 pathway.  Cancer Res; 71(6); 2360-70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP-z2MC7DxNrVg90H21EOLACvtfcHk0ljt_dJY0X-Ccg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtbg%253D&md5=a6e189f7f529f4f0096df9e57c4aa0da</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1933%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DM.%2BE.%26aulast%3DDuPrie%26aufirst%3DM.%2BL.%26aulast%3DKrueger%26aufirst%3DH.%26aulast%3DMerajver%26aufirst%3DS.%2BD.%26aulast%3DVentura%26aufirst%3DA.%2BC.%26aulast%3DToy%26aufirst%3DK.%2BA.%26aulast%3DKleer%26aufirst%3DC.%2BG.%26atitle%3DHistone%2520methyltransferase%2520EZH2%2520induces%2520Akt-dependent%2520genomic%2520instability%2520and%2520BRCA1%2520inhibition%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26issue%3D6%26spage%3D2360%26epage%3D2370%26doi%3D10.1158%2F0008-5472.CAN-10-1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karuturi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span> <span> </span><span class="NLM_article-title">Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2011.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.molcel.2011.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=21884980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFeku7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=798-810&issue=5&author=S.+T.+Leeauthor=Z.+Liauthor=Z.+Wuauthor=M.+Aauauthor=P.+Guanauthor=R.+K.+Karuturiauthor=Y.+C.+Liouauthor=Q.+Yu&title=Context-specific+regulation+of+NF-kappaB+target+gene+expression+by+EZH2+in+breast+cancers&doi=10.1016%2Fj.molcel.2011.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers</span></div><div class="casAuthors">Lee, Shuet Theng; Li, Zhimei; Wu, Zhenlong; Aau, Meiyee; Guan, Peiyong; Karuturi, R. K. Murthy; Liou, Yih Cherng; Yu, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">798-810</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Both EZH2 and NF-κB contribute to aggressive breast cancer, yet whether the two oncogenic factors have functional crosstalk in breast cancer is unknown.  Here, we uncover an unexpected role of EZH2 in conferring the constitutive activation of NF-κB target gene expression in ER-neg. basal-like breast cancer cells.  This function of EZH2 is independent of its histone methyltransferase activity but requires the phys. interaction with RelA/RelB to promote the expression of NF-κB targets.  Intriguingly, EZH2 acts oppositely in ER-pos. luminal-like breast cancer cells and represses NF-κB target gene expression by interacting with ER and directing repressive histone methylation on their promoters.  Thus, EZH2 functions as a double-facet mol. in breast cancers, either as a transcriptional activator or repressor of NF-κB targets, depending on the cellular context.  These findings reveal an addnl. mechanism by which EZH2 promotes breast cancer progression and underscore the need for developing context-specific strategy for therapeutic targeting of EZH2 in breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMMWhUS9c9mbVg90H21EOLACvtfcHk0ljSwhpDr-T67Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFeku7jI&md5=ef7af348dd09e2256df2e29d04f8686b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DAau%26aufirst%3DM.%26aulast%3DGuan%26aufirst%3DP.%26aulast%3DKaruturi%26aufirst%3DR.%2BK.%26aulast%3DLiou%26aufirst%3DY.%2BC.%26aulast%3DYu%26aufirst%3DQ.%26atitle%3DContext-specific%2520regulation%2520of%2520NF-kappaB%2520target%2520gene%2520expression%2520by%2520EZH2%2520in%2520breast%2520cancers%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D43%26issue%3D5%26spage%3D798%26epage%3D810%26doi%3D10.1016%2Fj.molcel.2011.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsherniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haswell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walensky, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. W.</span></span> <span> </span><span class="NLM_article-title">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1038/nm.3968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnm.3968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26552009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1491-1496&issue=12&author=K.+H.+Kimauthor=W.+Kimauthor=T.+P.+Howardauthor=F.+Vazquezauthor=A.+Tsherniakauthor=J.+N.+Wuauthor=W.+Wangauthor=J.+R.+Haswellauthor=L.+D.+Walenskyauthor=W.+C.+Hahnauthor=S.+H.+Orkinauthor=C.+W.+Roberts&title=SWI%2FSNF-mutant+cancers+depend+on+catalytic+and+non-catalytic+activity+of+EZH2&doi=10.1038%2Fnm.3968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span></div><div class="casAuthors">Kim, Kimberly H.; Kim, Woojin; Howard, Thomas P.; Vazquez, Francisca; Tsherniak, Aviad; Wu, Jennifer N.; Wang, Weishan; Haswell, Jeffrey R.; Walensky, Loren D.; Hahn, William C.; Orkin, Stuart H.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1496</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity.  However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown.  Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence.  Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity.  These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymic inhibitors now in clin. development may not fully suppress the oncogenic activity of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjhQKP01U5bVg90H21EOLACvtfcHk0ljSwhpDr-T67Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK&md5=a30c11fe7ce3c20e982e824105b8d640</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnm.3968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3968%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHoward%26aufirst%3DT.%2BP.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHaswell%26aufirst%3DJ.%2BR.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26atitle%3DSWI%252FSNF-mutant%2520cancers%2520depend%2520on%2520catalytic%2520and%2520non-catalytic%2520activity%2520of%2520EZH2%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D1491%26epage%3D1496%26doi%3D10.1038%2Fnm.3968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weroha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnes, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e99599</span> <span class="refDoi"> DOI: 10.15252/embj.201899599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.15252%2Fembj.201899599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30723117" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&issue=5&author=Y.+Zhaoauthor=L.+Dingauthor=D.+Wangauthor=Z.+Yeauthor=Y.+Heauthor=L.+Maauthor=R.+Zhuauthor=Y.+Panauthor=Q.+Wuauthor=K.+Pangauthor=X.+Houauthor=S.+J.+Werohaauthor=C.+Hanauthor=R.+Colemanauthor=I.+Colemanauthor=R.+J.+Karnesauthor=J.+Zhangauthor=P.+S.+Nelsonauthor=L.+Wangauthor=H.+Huang&title=EZH2+cooperates+with+gain-of-function+p53+mutants+to+promote+cancer+growth+and+metastasis&doi=10.15252%2Fembj.201899599"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.15252%2Fembj.201899599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201899599%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DPang%26aufirst%3DK.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DWeroha%26aufirst%3DS.%2BJ.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DColeman%26aufirst%3DI.%26aulast%3DKarnes%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DP.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DEZH2%2520cooperates%2520with%2520gain-of-function%2520p53%2520mutants%2520to%2520promote%2520cancer%2520growth%2520and%2520metastasis%26jtitle%3DEMBO%2520J.%26date%3D2019%26volume%3D38%26issue%3D5%26doi%3D10.15252%2Fembj.201899599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garapaty-Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span> <span> </span><span class="NLM_article-title">EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1463</span>– <span class="NLM_lpage">1475</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2014.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25457180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1463-1475&issue=11&author=W.+D.+Bradleyauthor=S.+Aroraauthor=J.+Busbyauthor=S.+Balasubramanianauthor=V.+S.+Gehlingauthor=C.+G.+Nasveschukauthor=R.+G.+Vaswaniauthor=C.+C.+Yuanauthor=C.+Hattonauthor=F.+Zhaoauthor=K.+E.+Williamsonauthor=P.+Iyerauthor=J.+Mendezauthor=R.+Campbellauthor=N.+Cantoneauthor=S.+Garapaty-Raoauthor=J.+E.+Audiaauthor=A.+S.+Cookauthor=L.+A.+Dakinauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=D.+L.+Danielsauthor=R.+T.+Cummingsauthor=B.+M.+Bryantauthor=E.+Normantauthor=P.+Trojer&title=EZH2+inhibitor+efficacy+in+non-Hodgkin%E2%80%99s+lymphoma+does+not+require+suppression+of+H3K27+monomethylation&doi=10.1016%2Fj.chembiol.2014.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation</span></div><div class="casAuthors">Bradley, William D.; Arora, Shilpi; Busby, Jennifer; Balasubramanian, Srividya; Gehling, Victor S.; Nasveschuk, Christopher G.; Vaswani, Rishi G.; Yuan, Chih-Chi; Hatton, Charlie; Zhao, Feng; Williamson, Kaylyn E.; Iyer, Priyadarshini; Mendez, Jacqui; Campbell, Robert; Cantone, Nico; Garapaty-Rao, Shivani; Audia, James E.; Cook, Andrew S.; Dakin, Les A.; Albrecht, Brian K.; Harmange, Jean-Christophe; Daniels, Danette L.; Cummings, Richard T.; Bryant, Barbara M.; Normant, Emmanuel; Trojer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1463-1475</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an oncogenic driver in a subset of germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) and follicular lymphoma due to the presence of recurrent, monoallelic mutations in the EZH2 catalytic domain.  These genomic data suggest that targeting the EZH2 MT activity is a valid therapeutic strategy for the treatment of lymphoma patients with EZH2 mutations.  Here we report the identification of highly potent and selective EZH2 small mol. inhibitors, their validation by a cellular thermal shift assay, application across a large cell panel representing various non-Hodgkin's lymphoma (NHL) subtypes, and their efficacy in EZH2 mutant-contg. GCB-DLBCL xenograft models.  Surprisingly, our EZH2 inhibitors selectively affect the turnover of trimethylated, but not monomethylated histone H3 lysine 27 at pharmacol. relevant doses.  Importantly, we find that these inhibitors are broadly efficacious also in NHL models with wild-type EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxrMoLW0OWCbVg90H21EOLACvtfcHk0lgI2DPbE03NEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7rE&md5=40b8f604e762dda9420afedede75fd36</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DBusby%26aufirst%3DJ.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DWilliamson%26aufirst%3DK.%2BE.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DMendez%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DGarapaty-Rao%26aufirst%3DS.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DTrojer%26aufirst%3DP.%26atitle%3DEZH2%2520inhibitor%2520efficacy%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520does%2520not%2520require%2520suppression%2520of%2520H3K27%2520monomethylation%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D11%26spage%3D1463%26epage%3D1475%26doi%3D10.1016%2Fj.chembiol.2014.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span> <span> </span><span class="NLM_article-title">Discovery, design, and synthesis of indole-based EZH2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3644</span>– <span class="NLM_lpage">3649</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.06.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2015.06.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26189078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3644-3649&issue=17&author=V.+S.+Gehlingauthor=R.+G.+Vaswaniauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=A.+Gagnonauthor=J.+C.+Harmangeauthor=J.+E.+Audiaauthor=R.+T.+Cummingsauthor=E.+Normantauthor=P.+Trojerauthor=B.+K.+Albrecht&title=Discovery%2C+design%2C+and+synthesis+of+indole-based+EZH2+inhibitors&doi=10.1016%2Fj.bmcl.2015.06.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, design, and synthesis of indole-based EZH2 inhibitors</span></div><div class="casAuthors">Gehling, Victor S.; Vaswani, Rishi G.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Dakin, Les A.; Cook, Andrew S.; Gagnon, Alexandre; Harmange, Jean-Christophe; Audia, James E.; Cummings, Richard T.; Normant, Emmanuel; Trojer, Patrick; Albrecht, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3644-3649</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of small mol. EZH2 inhibitors is described.  Starting from dimethylpyridone HTS hit, a series of indole-based EZH2 inhibitors were identified.  Biochem. potency and microsomal stability were optimized during these studies and afforded compd. (I).  Compd. I demonstrates nanomolar levels of biochem. potency (IC50 = 0.002 μM), cellular potency (EC50 = 0.080 μM), and afforded tumor regression when dosed (200 mpk SC BID) in an EZH2 dependent tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3fNkOZEdBj7Vg90H21EOLACvtfcHk0lg8Fr2g-9DiHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhtrfF&md5=3c8dbee5ab370627568fd48082bf1719</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.056%26sid%3Dliteratum%253Aachs%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DDiscovery%252C%2520design%252C%2520and%2520synthesis%2520of%2520indole-based%2520EZH2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D17%26spage%3D3644%26epage%3D3649%26doi%3D10.1016%2Fj.bmcl.2015.06.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span> <span> </span><span class="NLM_article-title">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1 -(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-Cell lymphomas</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9928</span>– <span class="NLM_lpage">9941</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9928-9941&issue=21&author=R.+G.+Vaswaniauthor=V.+S.+Gehlingauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=N.+Cantoneauthor=R.+T.+Cummingsauthor=E.+Normantauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=P.+Trojerauthor=J.+E.+Audiaauthor=Y.+Zhangauthor=N.+Justinauthor=S.+Chenauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Identification+of+%28R%29-N-%28%284-Methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-2-methyl-1-%281-%281+-%282%2C2%2C2-trifluoroethyl%29piperidin-4-yl%29ethyl%29-1H-indole-3-carboxamide+%28CPI-1205%29%2C+a+potent+and+selective+inhibitor+of+histone+methyltransferase+EZH2%2C+suitable+for+phase+I+clinical+trials+for+B-Cell+lymphomas&doi=10.1021%2Facs.jmedchem.6b01315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span></div><div class="casAuthors">Vaswani, Rishi G.; Gehling, Victor S.; Dakin, Les A.; Cook, Andrew S.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Cantone, Nico; Cummings, Richard T.; Normant, Emmanuel; Bellon, Steven F.; Albrecht, Brian K.; Harmange, Jean-Christophe; Trojer, Patrick; Audia, James E.; Zhang, Ying; Justin, Neil; Chen, Shuyang; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9928-9941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3.  Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis.  EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncol. target for pharmacol. intervention.  Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochem. IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.  This compd. demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clin. trials.  Addnl., we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqnfg3FGdE7Vg90H21EOLACvtfcHk0lj7iaT4Lvjbeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I&md5=4096fa91399fef88a7ec8aabb5aaee13</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01315%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DIdentification%2520of%2520%2528R%2529-N-%2528%25284-Methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-2-methyl-1-%25281-%25281%2520-%25282%252C2%252C2-trifluoroethyl%2529piperidin-4-yl%2529ethyl%2529-1H-indole-3-carboxamide%2520%2528CPI-1205%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520histone%2520methyltransferase%2520EZH2%252C%2520suitable%2520for%2520phase%2520I%2520clinical%2520trials%2520for%2520B-Cell%2520lymphomas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9928%26epage%3D9941%26doi%3D10.1021%2Facs.jmedchem.6b01315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Roder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&issue=8&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-Roderauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Muller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lj7iaT4Lvjbeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-Roder%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D8%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taplin, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenfield, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartor, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordquist, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatta, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bupathi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedinsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span> <span> </span><span class="NLM_article-title">Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">CT094</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-CT094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F1538-7445.AM2019-CT094" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=CT094&issue=13%2C+Suppl.&author=M.-E.+Taplinauthor=A.+Hussainauthor=S.+Shahauthor=N.+D.+Shoreauthor=W.+J.+Edenfieldauthor=O.+A.+Sartorauthor=L.+T.+Nordquistauthor=M.+Agrawalauthor=W.+Clarkauthor=D.+R.+Wiseauthor=W.+K.+Ohauthor=M.+T.+Flemingauthor=J.+E.+Butrynskiauthor=G.+S.+Chattaauthor=M.+Bupathiauthor=C.+Lebedinskyauthor=A.+Senderowiczauthor=J.+Liauthor=G.+Colakauthor=D.+Nashauthor=P.+Trojerauthor=W.+D.+Bradleyauthor=J.+Pielauthor=E.+S.+Antonarakis&title=Abstract+CT094%3A+Phase+Ib+results+of+ProSTAR%3A+CPI-1205%2C+EZH2+inhibitor%2C+combined+with+enzalutamide+%28E%29+or+abiraterone%2Fprednisone+%28A%2FP%29+in+patients+with+metastatic+castration-resistant+prostate+cancer+%28mCRPC%29&doi=10.1158%2F1538-7445.AM2019-CT094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-CT094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-CT094%26sid%3Dliteratum%253Aachs%26aulast%3DTaplin%26aufirst%3DM.-E.%26aulast%3DHussain%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DShore%26aufirst%3DN.%2BD.%26aulast%3DEdenfield%26aufirst%3DW.%2BJ.%26aulast%3DSartor%26aufirst%3DO.%2BA.%26aulast%3DNordquist%26aufirst%3DL.%2BT.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DW.%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DOh%26aufirst%3DW.%2BK.%26aulast%3DFleming%26aufirst%3DM.%2BT.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DChatta%26aufirst%3DG.%2BS.%26aulast%3DBupathi%26aufirst%3DM.%26aulast%3DLebedinsky%26aufirst%3DC.%26aulast%3DSenderowicz%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DColak%26aufirst%3DG.%26aulast%3DNash%26aufirst%3DD.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DPiel%26aufirst%3DJ.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26atitle%3DAbstract%2520CT094%253A%2520Phase%2520Ib%2520results%2520of%2520ProSTAR%253A%2520CPI-1205%252C%2520EZH2%2520inhibitor%252C%2520combined%2520with%2520enzalutamide%2520%2528E%2529%2520or%2520abiraterone%252Fprednisone%2520%2528A%252FP%2529%2520in%2520patients%2520with%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520%2528mCRPC%2529%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%252C%2520Suppl%26spage%3DCT094%26doi%3D10.1158%2F1538-7445.AM2019-CT094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toulmonde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coindre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span> <span> </span><span class="NLM_article-title">Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30145-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS1470-2045%2818%2930145-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29650362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlCmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=649-659&issue=5&author=A.+Italianoauthor=J.+C.+Soriaauthor=M.+Toulmondeauthor=J.+M.+Michotauthor=C.+Lucchesiauthor=A.+Vargaauthor=J.+M.+Coindreauthor=S.+J.+Blakemoreauthor=A.+Clawsonauthor=B.+Suttleauthor=A.+A.+McDonaldauthor=M.+Woodruffauthor=S.+Ribichauthor=E.+Hedrickauthor=H.+Keilhackauthor=B.+Thomsonauthor=T.+Owaauthor=R.+A.+Copelandauthor=P.+T.+C.+Hoauthor=V.+Ribrag&title=Tazemetostat%2C+an+EZH2+inhibitor%2C+in+relapsed+or+refractory+B-cell+non-Hodgkin+lymphoma+and+advanced+solid+tumours%3A+a+first-in-human%2C+open-label%2C+phase+1+study&doi=10.1016%2FS1470-2045%2818%2930145-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study</span></div><div class="casAuthors">Italiano, Antoine; Soria, Jean-Charles; Toulmonde, Maud; Michot, Jean-Marie; Lucchesi, Carlo; Varga, Andrea; Coindre, Jean-Michel; Blakemore, Stephen J.; Clawson, Alicia; Suttle, Benjamin; McDonald, Alice A.; Woodruff, Mark; Ribich, Scott; Hedrick, Eric; Keilhack, Heike; Thomson, Blythe; Owa, Takashi; Copeland, Robert A.; Ho, Peter T. C.; Ribrag, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">649-659</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to aberrant histone methylation, oncogenic transformation, and a proliferative dependency on EZH2 activity.  In this first-in-human study, we aimed to investigate the safety, clin. activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of EZH2.  We did an open-label, multicentre, dose-escalation, phase 1 study using a 3 + 3 design with planned cohort expansion at the two highest doses below the maximally tolerated dose.  The study was done at two centers in France: Institut Gustave Roussy (Villejuif, Val de Marne) and Institut Bergonie´ (Bordeaux, Gironde).  Eligible patients had relapsed or refractory B-cell non-Hodgkin lymphoma or an advanced solid tumor and were older than 18 years, with Eastern Cooperative Oncol. Group performance status of 0 or 1, and adequate end-organ function.  Tazemetostat was administered orally from 100 mg twice daily to 1600 mg twice daily in 28-day cycles.  The primary endpoint was to establish the max. tolerated dose or recommended phase 2 dose of tazemetostat, as detd. by dose-limiting toxicities, lab. values, and other safety or pharmacokinetic measures in cycle one according to local investigator assessment.  Safety was assessed in patients who received at least one dose of tazemetostat; antitumor activity was assessed in the intention-to-treat population.  This study is registered with ClinicalTrials.gov, no. NCT01897571.  The phase 1 part of the study is complete, and phase 2 is ongoing.  Between June 13, 2013, and Sept 21, 2016, 64 patients (21 with B-cell non-Hodgkin lymphoma, and 43 with advanced solid tumors) received doses of tazemetostat.  The most common treatment-related adverse events, regardless of attribution, were asthenia (21 [33%] of 64 treatment-related events), anemia (nine [14%]), anorexia (four [6%]), muscle spasms (nine [14%]), nausea (13 [20%]), and vomiting (six [9%]), usually grade 1 or 2 in severity.  A single dose-limiting toxicity of grade 4 thrombocytopenia was identified at the highest dose of 1600 mg twice daily.  No treatment-related deaths occurred; seven (11%) patients had non-treatment-related deaths (one at 200 mg twice daily, four at 400 mg twice daily, and two at 1600 mg twice daily).  The recommended phase 2 dose was detd. to be 800 mg twice daily.  Durable objective responses, including complete responses, were obsd. in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumors.  Tazemetostat showed a favorable safety profile and antitumor activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumors, including epithelioid sarcoma.  Further clin. investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-neg. or SMARCA4-neg. tumors.Epizyme and Eisai.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_63Re30rP1LVg90H21EOLACvtfcHk0lhrAYrji-5Uxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlCmtLo%253D&md5=9c4d4c1d3241c1b5043547acd1ff078f</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930145-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930145-1%26sid%3Dliteratum%253Aachs%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DToulmonde%26aufirst%3DM.%26aulast%3DMichot%26aufirst%3DJ.%2BM.%26aulast%3DLucchesi%26aufirst%3DC.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DCoindre%26aufirst%3DJ.%2BM.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DClawson%26aufirst%3DA.%26aulast%3DSuttle%26aufirst%3DB.%26aulast%3DMcDonald%26aufirst%3DA.%2BA.%26aulast%3DWoodruff%26aufirst%3DM.%26aulast%3DRibich%26aufirst%3DS.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DThomson%26aufirst%3DB.%26aulast%3DOwa%26aufirst%3DT.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DHo%26aufirst%3DP.%2BT.%2BC.%26aulast%3DRibrag%26aufirst%3DV.%26atitle%3DTazemetostat%252C%2520an%2520EZH2%2520inhibitor%252C%2520in%2520relapsed%2520or%2520refractory%2520B-cell%2520non-Hodgkin%2520lymphoma%2520and%2520advanced%2520solid%2520tumours%253A%2520a%2520first-in-human%252C%2520open-label%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26issue%3D5%26spage%3D649%26epage%3D659%26doi%3D10.1016%2FS1470-2045%2818%2930145-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span>; <span class="NLM_string-name">Suttle, B.</span>; <span class="NLM_string-name">Waters, N. L.</span>; <span class="NLM_string-name">Ribrag, V.</span>; <span class="NLM_string-name">Italiano, A.</span>; <span class="NLM_string-name">Michot, J.-M.</span>; <span class="NLM_string-name">Postel-Vinay, S.</span>; <span class="NLM_string-name">Toulmonde, M.</span>; <span class="NLM_string-name">Cousin, S.</span>; <span class="NLM_string-name">Roche, M.</span>; <span class="NLM_string-name">Pimentel, P.</span>; <span class="NLM_string-name">Ho, P.</span></span> <span> </span><span class="NLM_article-title">The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors</span>. Presented at the AACR 107th Annual Meeting, <span class="NLM_year">2016</span>, New Orleans, LA; Abstract CT029.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Smith&author=B.+Suttle&author=N.+L.+Waters&author=V.+Ribrag&author=A.+Italiano&author=J.-M.+Michot&author=S.+Postel-Vinay&author=M.+Toulmonde&author=S.+Cousin&author=M.+Roche&author=P.+Pimentel&author=P.+Ho&title=The+effect+of+tazemetostat+on+CYP3A-mediated+metabolism+of+midazolam+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%26atitle%3DThe%2520effect%2520of%2520tazemetostat%2520on%2520CYP3A-mediated%2520metabolism%2520of%2520midazolam%2520in%2520patients%2520with%2520solid%2520tumors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruderek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levell, J. R.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacologicaleEvaluation of second generation EZH2 inhibitors with long residence time</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1205-1212&author=A.+Khannaauthor=A.+C%C3%B4t%C3%A9author=S.+Aroraauthor=L.+Moineauthor=V.+S.+Gehlingauthor=J.+Brennemanauthor=N.+Cantoneauthor=J.+I.+Stuckeyauthor=S.+Apteauthor=A.+Ramakrishnanauthor=K.+Bruderekauthor=W.+D.+Bradleyauthor=J.+E.+Audiaauthor=R.+T.+Cummingsauthor=R.+J.+Simsauthor=P.+Trojerauthor=J.+R.+Levell&title=Design%2C+synthesis%2C+and+pharmacologicaleEvaluation+of+second+generation+EZH2+inhibitors+with+long+residence+time&doi=10.1021%2Facsmedchemlett.0c00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time</span></div><div class="casAuthors">Khanna, Avinash; Cote, Alexandre; Arora, Shilpi; Moine, Ludivine; Gehling, Victor S.; Brenneman, Jehrod; Cantone, Nico; Stuckey, Jacob I.; Apte, Shruti; Ramakrishnan, Ashwin; Bruderek, Kamil; Bradley, William D.; Audia, James E.; Cummings, Richard T.; Sims, Robert J.; Trojer, Patrick; Levell, Julian R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1205-1212</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27-a transcriptionally repressive post-translational modification (PTM).  EZH2 is commonly mutated in hematol. malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis.  First generation EZH2 inhibitors are beginning to show clin. benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition.  During our medicinal chem. campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time.  Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochem. properties, which have the potential to expand the clin. use of EZH2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx-ixCY_R5KrVg90H21EOLACvtfcHk0lhrAYrji-5Uxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D&md5=e54bac34b75f41d6b82666016df08c1f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00045%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DMoine%26aufirst%3DL.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DBrenneman%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DStuckey%26aufirst%3DJ.%2BI.%26aulast%3DApte%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DA.%26aulast%3DBruderek%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DLevell%26aufirst%3DJ.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacologicaleEvaluation%2520of%2520second%2520generation%2520EZH2%2520inhibitors%2520with%2520long%2520residence%2520time%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1205%26epage%3D1212%26doi%3D10.1021%2Facsmedchemlett.0c00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardayfio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">21360</span>– <span class="NLM_lpage">21365</span>, <span class="refDoi"> DOI: 10.1073/pnas.1210371110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1210371110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23236167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21360-21365&issue=52&author=W.+Qiauthor=H.+Chanauthor=L.+Tengauthor=L.+Liauthor=S.+Chuaiauthor=R.+Zhangauthor=J.+Zengauthor=M.+Liauthor=H.+Fanauthor=Y.+Linauthor=J.+Guauthor=O.+Ardayfioauthor=J.+H.+Zhangauthor=X.+Yanauthor=J.+Fangauthor=Y.+Miauthor=M.+Zhangauthor=T.+Zhouauthor=G.+Fengauthor=Z.+Chenauthor=G.+Liauthor=T.+Yangauthor=K.+Zhaoauthor=X.+Liuauthor=Z.+Yuauthor=C.+X.+Luauthor=P.+Atadjaauthor=E.+Li&title=Selective+inhibition+of+EZH2+by+a+small+molecule+inhibitor+blocks+tumor+cells+proliferation&doi=10.1073%2Fpnas.1210371110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation</span></div><div class="casAuthors">Qi, Wei; Chan, Homan; Teng, Lin; Li, Ling; Chuai, Shannon; Zhang, Ruipeng; Zeng, Jue; Li, Min; Fan, Hong; Lin, Ying; Gu, Justin; Ardayfio, Ophelia; Zhang, Ji-Hu; Yan, Xiaoxia; Fang, Jialuo; Mi, Yuan; Zhang, Man; Zhou, Tao; Feng, Grace; Chen, Zijun; Li, Guobin; Yang, Teddy; Zhao, Kehao; Liu, Xianghui; Yu, Zhengtian; Lu, Chris X.; Atadja, Peter; Li, En</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21360-21365, S21360/1-S21360/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ezh2 (Enhancer of zeste homolog 2) protein is the enzymic component of the Polycomb repressive complex 2 (PRC2), which represses gene expression by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation and differentiation during embryonic development.  Recently, hot-spot mutations of Ezh2 were identified in diffused large B-cell lymphomas and follicular lymphomas.  To investigate if tumor growth is dependent on the enzymic activity of Ezh2, the authors developed a potent and selective small mol. inhibitor, EI1, which inhibits the enzymic activity of Ezh2 through direct binding to the enzyme and competing with the Me group donor S-Adenosyl methionine.  EI1-treated cells exhibit genome-wide loss of H3K27 methylation and activation of PRC2 target genes.  Furthermore, inhibition of Ezh2 by EI1 in diffused large B-cell lymphomas cells carrying the Y641 mutations results in decreased proliferation, cell cycle arrest, and apoptosis.  These results provide strong validation of Ezh2 as a potential therapeutic target for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR1oWnCAdMmrVg90H21EOLACvtfcHk0lh7QxwMLOG_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSnsA%253D%253D&md5=b85578201119e39887e323aad25d959b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1210371110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1210371110%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChuai%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DArdayfio%26aufirst%3DO.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DC.%2BX.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DE.%26atitle%3DSelective%2520inhibition%2520of%2520EZH2%2520by%2520a%2520small%2520molecule%2520inhibitor%2520blocks%2520tumor%2520cells%2520proliferation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D52%26spage%3D21360%26epage%3D21365%26doi%3D10.1073%2Fpnas.1210371110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satalkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shete, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severance, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span> <span> </span><span class="NLM_article-title">Novel 3-methylindoline inhibitors of EZH2: design, synthesis and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2016.11.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27923618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWmtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=217-222&issue=2&author=A.+Ansariauthor=S.+Satalkarauthor=V.+Patilauthor=A.+S.+Sheteauthor=S.+Kaurauthor=A.+Guptaauthor=S.+Singhauthor=M.+Rajaauthor=D.+L.+Severanceauthor=S.+Bernalesauthor=S.+Chakravartyauthor=D.+T.+Hungauthor=S.+M.+Phamauthor=F.+J.+Herreraauthor=R.+Rai&title=Novel+3-methylindoline+inhibitors+of+EZH2%3A+design%2C+synthesis+and+SAR&doi=10.1016%2Fj.bmcl.2016.11.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR</span></div><div class="casAuthors">Ansari, Amantullah; Satalkar, Sharad; Patil, Varshavekumar; Shete, Amit S.; Kaur, Simranjeet; Gupta, Ashu; Singh, Siddhartha; Raja, Mohd.; Severance, Daniel L.; Bernales, Sebastian; Chakravarty, Sarvajit; Hung, David T.; Pham, Son M.; Herrera, Francisco J.; Rai, Roopa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-222</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">EZH2 (enhancer of zeste homolog 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27).  Dysregulation of EZH2 activity is assocd. with several human cancers and therefore EZH2 inhibition has emerged as a promising therapeutic target.  Several small mol. EZH2 inhibitors with different chemotypes have been reported in the literature, many of which use a bicyclic heteroaryl core.  Herein, we report the design and synthesis of EZH2 inhibitors contg. an indoline core, such as I.  Partial satn. of an indole to an indoline provided lead compds. with nanomolar activity against EZH2, while also improving soly. and oxidative metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoExJWdsv7qhrVg90H21EOLACvtfcHk0lh7QxwMLOG_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWmtLvN&md5=7bfc9701f14188d45807afc0dcde1c50</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.080%26sid%3Dliteratum%253Aachs%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSatalkar%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DShete%26aufirst%3DA.%2BS.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DRaja%26aufirst%3DM.%26aulast%3DSeverance%26aufirst%3DD.%2BL.%26aulast%3DBernales%26aufirst%3DS.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DHung%26aufirst%3DD.%2BT.%26aulast%3DPham%26aufirst%3DS.%2BM.%26aulast%3DHerrera%26aufirst%3DF.%2BJ.%26aulast%3DRai%26aufirst%3DR.%26atitle%3DNovel%25203-methylindoline%2520inhibitors%2520of%2520EZH2%253A%2520design%252C%2520synthesis%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D2%26spage%3D217%26epage%3D222%26doi%3D10.1016%2Fj.bmcl.2016.11.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhzXRzuduDH4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneeringer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacks, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span> <span> </span><span class="NLM_article-title">A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.1084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23023262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVaqtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=890-896&issue=11&author=S.+K.+Knutsonauthor=T.+J.+Wigleauthor=N.+M.+Warholicauthor=C.+J.+Sneeringerauthor=C.+J.+Allainauthor=C.+R.+Klausauthor=J.+D.+Sacksauthor=A.+Raimondiauthor=C.+R.+Majerauthor=J.+Songauthor=M.+P.+Scottauthor=L.+Jinauthor=J.+J.+Smithauthor=E.+J.+Olhavaauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=V.+M.+Richonauthor=R.+A.+Copelandauthor=H.+Keilhackauthor=R.+M.+Pollockauthor=K.+W.+Kuntz&title=A+selective+inhibitor+of+EZH2+blocks+H3K27+methylation+and+kills+mutant+lymphoma+cells&doi=10.1038%2Fnchembio.1084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells</span></div><div class="casAuthors">Knutson, Sarah K.; Wigle, Tim J.; Warholic, Natalie M.; Sneeringer, Christopher J.; Allain, Christina J.; Klaus, Christine R.; Sacks, Joelle D.; Raimondi, Alejandra; Majer, Christina R.; Song, Jeffrey; Scott, Margaret Porter; Jin, Lei; Smith, Jesse J.; Olhava, Edward J.; Chesworth, Richard; Moyer, Mikel P.; Richon, Victoria M.; Copeland, Robert A.; Keilhack, Heike; Pollock, Roy M.; Kuntz, Kevin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">890-896</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27).  Point mutations of EZH2 at Tyr 641 and Ala 677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation.  Here the authors report the discovery of EPZ005687, a potent inhibitor of EZH2 (Ki of 24 nM).  EPZ005687 has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1.  The compd. reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr 641 or Ala 677 mutant cells, with minimal effects on the proliferation of wild-type cells.  These data suggest that genetic alteration of EZH2 (for example, mutations at Tyr 641 or Ala 677) results in a crit. dependency on enzymic activity for proliferation (i.e., the equiv. of oncogene addiction), thus portending the clin. use of EZH2 inhibitors for cancers in which EZH2 is genetically altered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohlduVbTgWJrVg90H21EOLACvtfcHk0lhzXRzuduDH4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVaqtrvP&md5=a9ad7a41505e3fd4aa087d9f5dae8825</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1084%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DSneeringer%26aufirst%3DC.%2BJ.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DSacks%26aufirst%3DJ.%2BD.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26atitle%3DA%2520selective%2520inhibitor%2520of%2520EZH2%2520blocks%2520H3K27%2520methylation%2520and%2520kills%2520mutant%2520lymphoma%2520cells%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D11%26spage%3D890%26epage%3D896%26doi%3D10.1038%2Fnchembio.1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federation, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Raedt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter-Sprie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainson, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cichowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F2159-8290.CD-16-0164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27312177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKrt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1006-1021&issue=9&author=H.+Zhangauthor=J.+Qiauthor=J.+M.+Reyesauthor=L.+Liauthor=P.+K.+Raoauthor=F.+Liauthor=C.+Y.+Linauthor=J.+A.+Perryauthor=M.+A.+Lawlorauthor=A.+Federationauthor=T.+De+Raedtauthor=Y.+Y.+Liauthor=Y.+Liuauthor=M.+A.+Duarteauthor=Y.+Zhangauthor=G.+S.+Herter-Sprieauthor=E.+Kikuchiauthor=J.+Carreteroauthor=C.+M.+Perouauthor=J.+B.+Reibelauthor=J.+Paulkauthor=R.+T.+Bronsonauthor=H.+Watanabeauthor=C.+F.+Brainsonauthor=C.+F.+Kimauthor=P.+S.+Hammermanauthor=M.+Brownauthor=K.+Cichowskiauthor=H.+Longauthor=J.+E.+Bradnerauthor=K.+K.+Wong&title=Oncogenic+deregulation+of+EZH2+as+an+opportunity+for+targeted+therapy+in+lung+cancer&doi=10.1158%2F2159-8290.CD-16-0164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer</span></div><div class="casAuthors">Zhang, Haikuo; Qi, Jun; Reyes, Jaime M.; Li, Lewyn; Rao, Prakash K.; Li, Fugen; Lin, Charles Y.; Perry, Jennifer A.; Lawlor, Matthew A.; Federation, Alexander; De Raedt, Thomas; Li, Yvonne Y.; Liu, Yan; Duarte, Melissa A.; Zhang, Yanxi; Herter-Sprie, Grit S.; Kikuchi, Eiki; Carretero, Julian; Perou, Charles M.; Reibel, Jacob B.; Paulk, Joshiawa; Bronson, Roderick T.; Watanabe, Hideo; Brainson, Christine Fillmore; Kim, Carla F.; Hammerman, Peter S.; Brown, Myles; Cichowski, Karen; Long, Henry; Bradner, James E.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1006-1021</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks.  Overexpression of EZH2 is commonly obsd. in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive.  Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma.  Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation.  As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression.  To target EZH2-dependent cancers, we developed a potent open-source EZH2 inhibitor, JQEZ5, that promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a subset of lung cancer.  Significance: EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity.  Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojSYdBWV-BlrVg90H21EOLACvtfcHk0lhzXRzuduDH4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKrt73K&md5=e67b20c867007aed77c08d858bd4d788</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0164%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DReyes%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DRao%26aufirst%3DP.%2BK.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26aulast%3DLawlor%26aufirst%3DM.%2BA.%26aulast%3DFederation%26aufirst%3DA.%26aulast%3DDe%2BRaedt%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDuarte%26aufirst%3DM.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DKikuchi%26aufirst%3DE.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DReibel%26aufirst%3DJ.%2BB.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DBrainson%26aufirst%3DC.%2BF.%26aulast%3DKim%26aufirst%3DC.%2BF.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCichowski%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DOncogenic%2520deregulation%2520of%2520EZH2%2520as%2520an%2520opportunity%2520for%2520targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D9%26spage%3D1006%26epage%3D1021%26doi%3D10.1158%2F2159-8290.CD-16-0164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konze, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macnevin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rougie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattenden, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1324</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1021/cb400133j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400133j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1324-1334&issue=6&author=K.+D.+Konzeauthor=A.+Maauthor=F.+Liauthor=D.+Barsyte-Lovejoyauthor=T.+Partonauthor=C.+J.+Macnevinauthor=F.+Liuauthor=C.+Gaoauthor=X.+P.+Huangauthor=E.+Kuznetsovaauthor=M.+Rougieauthor=A.+Jiangauthor=S.+G.+Pattendenauthor=J.+L.+Norrisauthor=L.+I.+Jamesauthor=B.+L.+Rothauthor=P.+J.+Brownauthor=S.+V.+Fryeauthor=C.+H.+Arrowsmithauthor=K.+M.+Hahnauthor=G.+G.+Wangauthor=M.+Vedadiauthor=J.+Jin&title=An+orally+bioavailable+chemical+probe+of+the+lysine+methyltransferases+EZH2+and+EZH1&doi=10.1021%2Fcb400133j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1</span></div><div class="casAuthors">Konze, Kyle D.; Ma, Anqi; Li, Fengling; Barsyte-Lovejoy, Dalia; Parton, Trevor; MacNevin, Christopher J.; Liu, Feng; Gao, Cen; Huang, Xi-Ping; Kuznetsova, Ekaterina; Rougie, Marie; Jiang, Alice; Pattenden, Samantha G.; Norris, Jacqueline L.; James, Lindsey I.; Roth, Bryan L.; Brown, Peter J.; Frye, Stephen V.; Arrowsmith, Cheryl H.; Hahn, Klaus M.; Wang, Gang Greg; Vedadi, Masoud; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1324-1334</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EZH2 or EZH1 is the catalytic subunit of the polycomb repressive complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27).  The trimethylation of H3K27 (H3K27me3) is a transcriptionally repressive post-translational modification.  Overexpression of EZH2 and hypertrimethylation of H3K27 have been implicated in a no. of cancers.  Several selective inhibitors of EZH2 have been reported recently.  Herein we disclose UNC1999, the first orally bioavailable inhibitor that has high in vitro potency for wild-type and mutant EZH2 as well as EZH1, a closely related H3K27 methyltransferase that shares 96% sequence identity with EZH2 in their resp. catalytic domains.  UNC1999 was highly selective for EZH2 and EZH1 over a broad range of epigenetic and non-epigenetic targets, competitive with the cofactor SAM and non-competitive with the peptide substrate.  This inhibitor potently reduced H3K27me3 levels in cells and selectively killed diffused large B cell lymphoma cell lines harboring the EZH2Y641N mutant.  Importantly, UNC1999 was orally bioavailable in mice, making this inhibitor a valuable tool for investigating the role of EZH2 and EZH1 in chronic animal studies.  We also designed and synthesized UNC2400, a close analog of UNC1999 with potency >1,000-fold lower than that of UNC1999 as a neg. control for cell-based studies.  Finally, we created a biotin-tagged UNC1999 (UNC2399), which enriched EZH2 in pull-down studies, and a UNC1999-dye conjugate (UNC2239) for co-localization studies with EZH2 in live cells.  Taken together, these compds. represent a set of useful tools for the biomedical community to investigate the role of EZH2 and EZH1 in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzhUO0iAe8BbVg90H21EOLACvtfcHk0lg9F58fHzt6fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsrk%253D&md5=311d77f5f0cc0b9e2610d8d002a6709c</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fcb400133j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400133j%26sid%3Dliteratum%253Aachs%26aulast%3DKonze%26aufirst%3DK.%2BD.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DParton%26aufirst%3DT.%26aulast%3DMacnevin%26aufirst%3DC.%2BJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DKuznetsova%26aufirst%3DE.%26aulast%3DRougie%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DPattenden%26aufirst%3DS.%2BG.%26aulast%3DNorris%26aufirst%3DJ.%2BL.%26aulast%3DJames%26aufirst%3DL.%2BI.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DHahn%26aufirst%3DK.%2BM.%26aulast%3DWang%26aufirst%3DG.%2BG.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DAn%2520orally%2520bioavailable%2520chemical%2520probe%2520of%2520the%2520lysine%2520methyltransferases%2520EZH2%2520and%2520EZH1%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26issue%3D6%26spage%3D1324%26epage%3D1334%26doi%3D10.1021%2Fcb400133j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uesugi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter-Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uenaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F1535-7163.MCT-13-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24563539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=842-854&issue=4&author=S.+K.+Knutsonauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=N.+M.+Warholicauthor=K.+C.+Huangauthor=Y.+Xiaoauthor=T.+Kadowakiauthor=M.+Uesugiauthor=G.+Kuznetsovauthor=N.+Kumarauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+Porter-Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=T.+Uenakaauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=A.+Yokoiauthor=H.+Keilhack&title=Selective+inhibition+of+EZH2+by+EPZ-6438+leads+to+potent+antitumor+activity+in+EZH2-mutant+non-Hodgkin+lymphoma&doi=10.1158%2F1535-7163.MCT-13-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span></div><div class="casAuthors">Knutson, Sarah K.; Kawano, Satoshi; Minoshima, Yukinori; Warholic, Natalie M.; Huang, Kuan-Chun; Xiao, Yonghong; Kadowaki, Tadashi; Uesugi, Mai; Kuznetsov, Galina; Kumar, Namita; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Waters, Nigel J.; Smith, Jesse J.; Porter-Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Uenaka, Toshimitsu; Pollock, Roy M.; Kuntz, Kevin W.; Yokoi, Akira; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-854</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL).  These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymic activity in these cancers.  We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small mol. inhibitors of EZH2.  Although both compds. are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals.  Here, we characterize the activity of EPZ-6438 in preclin. models of NHL.  EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concn.- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells.  Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations.  Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues.  Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compd. treatment in two EZH2-mutant xenograft models.  These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.  Mol Cancer Ther; 13(4); 842-54. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2o1v5F3GzLVg90H21EOLACvtfcHk0lg9F58fHzt6fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D&md5=89354e9453dcd7430978d1a6c5ee5846</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0773%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DHuang%26aufirst%3DK.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DUesugi%26aufirst%3DM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DSelective%2520inhibition%2520of%2520EZH2%2520by%2520EPZ-6438%2520leads%2520to%2520potent%2520antitumor%2520activity%2520in%2520EZH2-mutant%2520non-Hodgkin%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D842%26epage%3D854%26doi%3D10.1158%2F1535-7163.MCT-13-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pietra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquenne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span> <span> </span><span class="NLM_article-title">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span> (<span class="NLM_issue">7427</span>),  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/nature11606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnature11606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23051747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=108-112&issue=7427&author=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+Ganjiauthor=S.+Korenchukauthor=C.+Thompsonauthor=G.+S.+Van+Allerauthor=Y.+Liuauthor=A.+P.+Gravesauthor=A.+Della+Pietraauthor=E.+Diazauthor=L.+V.+LaFranceauthor=M.+Mellingerauthor=C.+Duquenneauthor=X.+R.+Tianauthor=R.+G.+Krugerauthor=C.+F.+McHughauthor=M.+Brandtauthor=W.+H.+Millerauthor=D.+Dhanakauthor=S.+K.+Vermaauthor=P.+J.+Tumminoauthor=C.+L.+Creasy&title=EZH2+inhibition+as+a+therapeutic+strategy+for+lymphoma+with+EZH2-activating+mutations&doi=10.1038%2Fnature11606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span></div><div class="casAuthors">McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; Della Pietra, Anthony , III; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7427</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In eukaryotes, post-translational modification of histones is crit. for regulation of chromatin structure and gene expression.  EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).  EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumor types.  Addnl., somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.  The Y641 residue is the most frequently mutated residue, with up to 22% of germinal center B-cell DLBCL and follicular lymphoma harbouring mutations at this site.  These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes.  However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.  Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-mol. inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.  GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.  Together, these data demonstrate that pharmacol. inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxw5cLmW3Lc7Vg90H21EOLACvtfcHk0lgGpefViLGyCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL&md5=a1dff99556de004c48aae88bc45dffab</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnature11606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11606%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DMellinger%26aufirst%3DM.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DX.%2BR.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DEZH2%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520lymphoma%2520with%2520EZH2-activating%2520mutations%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7427%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature11606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span> <span> </span><span class="NLM_article-title">Many paths to methyltransfer: a chronicle of convergence</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(03)00090-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2FS0968-0004%2803%2900090-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=12826405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=329-335&issue=6&author=H.+L.+Schubertauthor=R.+M.+Blumenthalauthor=X.+Cheng&title=Many+paths+to+methyltransfer%3A+a+chronicle+of+convergence&doi=10.1016%2FS0968-0004%2803%2900090-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Many paths to methyltransfer: a chronicle of convergence</span></div><div class="casAuthors">Schubert, Heidi L.; Blumenthal, Robert M.; Cheng, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">329-335</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  S-adenosyl-L-methionine (AdoMet) dependent methyltransferases (MTases) are involved in biosynthesis, signal transduction, protein repair, chromatin regulation and gene silencing.  Five different structural folds (I-V) have been described that bind AdoMet and catalyze Me transfer to diverse substrates, although the great majority of known MTases have the Class I fold.  Even within a particular MTase class the amino-acid sequence similarity can be as low as 10%.  Thus, the structural and catalytic requirements for Me transfer from AdoMet appear to be remarkably flexible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXf7A-x2vdrVg90H21EOLACvtfcHk0lgGpefViLGyCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCmsrw%253D&md5=7e6760df484f7d8d68dbd53533333620</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2803%2900090-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252803%252900090-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchubert%26aufirst%3DH.%2BL.%26aulast%3DBlumenthal%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DX.%26atitle%3DMany%2520paths%2520to%2520methyltransfer%253A%2520a%2520chronicle%2520of%2520convergence%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2003%26volume%3D28%26issue%3D6%26spage%3D329%26epage%3D335%26doi%3D10.1016%2FS0968-0004%2803%2900090-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquenne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newlander, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeril, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherzer, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machutta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span> <span> </span><span class="NLM_article-title">Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1096</span>, <span class="refDoi"> DOI: 10.1021/ml3003346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3003346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChs77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1091-1096&issue=12&author=S.+K.+Vermaauthor=X.+Tianauthor=L.+V.+LaFranceauthor=C.+Duquenneauthor=D.+P.+Suarezauthor=K.+A.+Newlanderauthor=S.+P.+Romerilauthor=J.+L.+Burgessauthor=S.+W.+Grantauthor=J.+A.+Brackleyauthor=A.+P.+Gravesauthor=D.+A.+Scherzerauthor=A.+Shuauthor=C.+Thompsonauthor=H.+M.+Ottauthor=G.+S.+Allerauthor=C.+A.+Machuttaauthor=E.+Diazauthor=Y.+Jiangauthor=N.+W.+Johnsonauthor=S.+D.+Knightauthor=R.+G.+Krugerauthor=M.+T.+McCabeauthor=D.+Dhanakauthor=P.+J.+Tumminoauthor=C.+L.+Creasyauthor=W.+H.+Miller&title=Identification+of+potent%2C+selective%2C+cell-active+inhibitors+of+the+histone+lysine+methyltransferase+EZH2&doi=10.1021%2Fml3003346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2</span></div><div class="casAuthors">Verma, Sharad K.; Tian, Xinrong; LaFrance, Louis V.; Duquenne, Celine; Suarez, Dominic P.; Newlander, Kenneth A.; Romeril, Stuart P.; Burgess, Joelle L.; Grant, Seth W.; Brackley, James A.; Graves, Alan P.; Scherzer, Daryl A.; Shu, Art; Thompson, Christine; Ott, Heidi M.; Van Aller, Glenn S.; Machutta, Carl A.; Diaz, Elsie; Jiang, Yong; Johnson, Neil W.; Knight, Steven D.; Kruger, Ryan G.; McCabe, Michael T.; Dhanak, Dashyant; Tummino, Peter J.; Creasy, Caretha L.; Miller, William H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1091-1096</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a crit. role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer.  As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, S-(S'-adenosyl)-L-methionine (SAM)-competitive, and cell-active EZH2 inhibitors, including GSK926 I (R1 = Me, R2 = Q) and GSK343 I (R1 = n-Pr, R2 = Q1).  These compds. are small mol. chem. tools that would be useful to further explore the biol. of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8NUzf0zjo0bVg90H21EOLACvtfcHk0lgLPXSQvTKLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChs77K&md5=a6540bb712ee52cba05bd0b074d8b26a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fml3003346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3003346%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DSuarez%26aufirst%3DD.%2BP.%26aulast%3DNewlander%26aufirst%3DK.%2BA.%26aulast%3DRomeril%26aufirst%3DS.%2BP.%26aulast%3DBurgess%26aufirst%3DJ.%2BL.%26aulast%3DGrant%26aufirst%3DS.%2BW.%26aulast%3DBrackley%26aufirst%3DJ.%2BA.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DScherzer%26aufirst%3DD.%2BA.%26aulast%3DShu%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DAller%26aufirst%3DG.%2BS.%26aulast%3DMachutta%26aufirst%3DC.%2BA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DN.%2BW.%26aulast%3DKnight%26aufirst%3DS.%2BD.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26atitle%3DIdentification%2520of%2520potent%252C%2520selective%252C%2520cell-active%2520inhibitors%2520of%2520the%2520histone%2520lysine%2520methyltransferase%2520EZH2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D1091%26epage%3D1096%26doi%3D10.1021%2Fml3003346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter-Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneeringer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">The importance of being Me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01501</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01501" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XotF2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1556-1564&issue=4&author=K.+W.+Kuntzauthor=J.+E.+Campbellauthor=H.+Keilhackauthor=R.+M.+Pollockauthor=S.+K.+Knutsonauthor=M.+Porter-Scottauthor=V.+M.+Richonauthor=C.+J.+Sneeringerauthor=T.+J.+Wigleauthor=C.+J.+Allainauthor=C.+R.+Majerauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=R.+Chesworth&title=The+importance+of+being+Me%3A+magic+methyls%2C+methyltransferase+inhibitors%2C+and+the+discovery+of+tazemetostat&doi=10.1021%2Facs.jmedchem.5b01501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat</span></div><div class="casAuthors">Kuntz, Kevin W.; Campbell, John E.; Keilhack, Heike; Pollock, Roy M.; Knutson, Sarah K.; Porter-Scott, Margaret; Richon, Victoria M.; Sneeringer, Chris J.; Wigle, Tim J.; Allain, Christina J.; Majer, Christina R.; Moyer, Mikel P.; Copeland, Robert A.; Chesworth, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1556-1564</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Posttranslational methylation of histones plays a crit. role in gene regulation.  Misregulation of histone methylation can lead to oncogenic transformation.  Enhancer of Zeste homolog 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers.  Tazemetostat, an EHZ2 inhibitor in clin. development, has shown activity in both preclin. models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors.  Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clin. development.  The importance of several Me groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryASbIgMDxAbVg90H21EOLACvtfcHk0lgLPXSQvTKLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotF2qsA%253D%253D&md5=a26ccc4a0109f57fbb64f7fded8965a1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01501%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DSneeringer%26aufirst%3DC.%2BJ.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26atitle%3DThe%2520importance%2520of%2520being%2520Me%253A%2520magic%2520methyls%252C%2520methyltransferase%2520inhibitors%252C%2520and%2520the%2520discovery%2520of%2520tazemetostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D4%26spage%3D1556%26epage%3D1564%26doi%3D10.1021%2Facs.jmedchem.5b01501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span> <span> </span><span class="NLM_article-title">Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7922</span>– <span class="NLM_lpage">7927</span>, <span class="refDoi"> DOI: 10.1073/pnas.1303800110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1303800110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=23620515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFGrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=7922-7927&issue=19&author=S.+K.+Knutsonauthor=N.+M.+Warholicauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=M.+Porter+Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=H.+Keilhack&title=Durable+tumor+regression+in+genetically+altered+malignant+rhabdoid+tumors+by+inhibition+of+methyltransferase+EZH2&doi=10.1073%2Fpnas.1303800110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2</span></div><div class="casAuthors">Knutson, Sarah K.; Warholic, Natalie M.; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Scott, Margaret Porter; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Pollock, Roy M.; Kuntz, Kevin W.; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7922-7927, S7922/1-S7922/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Inactivation of the switch/sucrose nonfermentable complex component SMARCB1 is extremely prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tumors.  This alteration is hypothesized to confer oncogenic dependency on EZH2 in these cancers.  The authors report the discovery of a potent, selective, and orally bioavailable small-mol. inhibitor of EZH2 enzymic activity, (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide).  The compd. induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.  Treatment of xenograft-bearing mice with (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide) leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation.  These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymic activity and portend the utility of EZH2-targeted drugs for the treatment of these genetically defined cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWRIJfPhwLA7Vg90H21EOLACvtfcHk0lgLPXSQvTKLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFGrurw%253D&md5=c2c6470d48a13ab8343db0a09465ba42</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1303800110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1303800110%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DPorter%2BScott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DDurable%2520tumor%2520regression%2520in%2520genetically%2520altered%2520malignant%2520rhabdoid%2520tumors%2520by%2520inhibition%2520of%2520methyltransferase%2520EZH2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D19%26spage%3D7922%26epage%3D7927%26doi%3D10.1073%2Fpnas.1303800110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span>; <span class="NLM_string-name">Sammons, M.</span>; <span class="NLM_string-name">Favours, E.</span>; <span class="NLM_string-name">Wu, J.</span>; <span class="NLM_string-name">Kurmashev, D.</span>; <span class="NLM_string-name">Cosmopoulos, K.</span>; <span class="NLM_string-name">Keilhack, H.</span>; <span class="NLM_string-name">Klaus, C. R.</span>; <span class="NLM_string-name">Houghton, P. J.</span>; <span class="NLM_string-name">Smith, M. A.</span></span>, <span> </span><span class="NLM_article-title">Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program</span>.  <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">64</span> (<span class="NLM_issue">3</span>), <span class="refDoi"> DOI: 10.1002/pbc.26218</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1002%2Fpbc.26218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&issue=3&author=R.+T.+Kurmasheva&author=M.+Sammons&author=E.+Favours&author=J.+Wu&author=D.+Kurmashev&author=K.+Cosmopoulos&author=H.+Keilhack&author=C.+R.+Klaus&author=P.+J.+Houghton&author=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+tazemetostat+%28EPZ-6438%29%2C+a+novel+EZH2+inhibitor%2C+by+the+Pediatric+Preclinical+Testing+Program&doi=10.1002%2Fpbc.26218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fpbc.26218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.26218%26sid%3Dliteratum%253Aachs%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520tazemetostat%2520%2528EPZ-6438%2529%252C%2520a%2520novel%2520EZH2%2520inhibitor%252C%2520by%2520the%2520Pediatric%2520Preclinical%2520Testing%2520Program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2017%26volume%3D64%26issue%3D3%26doi%3D10.1002%2Fpbc.26218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">EPZ011989, a potent, orally-available EZH2 inhibitor with robust in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslelsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=491-495&issue=5&author=J.+E.+Campbellauthor=K.+W.+Kuntzauthor=S.+K.+Knutsonauthor=N.+M.+Warholicauthor=H.+Keilhackauthor=T.+J.+Wigleauthor=A.+Raimondiauthor=C.+R.+Klausauthor=N.+Riouxauthor=A.+Yokoiauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=H.+W.+Choiauthor=M.+Porter+Scottauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copeland&title=EPZ011989%2C+a+potent%2C+orally-available+EZH2+inhibitor+with+robust+in+vivo+activity&doi=10.1021%2Facsmedchemlett.5b00037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity</span></div><div class="casAuthors">Campbell, John E.; Kuntz, Kevin W.; Knutson, Sarah K.; Warholic, Natalie M.; Keilhack, Heike; Wigle, Tim J.; Raimondi, Alejandra; Klaus, Christine R.; Rioux, Nathalie; Yokoi, Akira; Kawano, Satoshi; Minoshima, Yukinori; Choi, Hyeong-Wook; Porter Scott, Margaret; Waters, Nigel J.; Smith, Jesse J.; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">491-495</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications.  The ability of the scientific community to explore fully the spectrum of EZH2-assocd. pathobiol. has been hampered by the lack of in vivo-active tool compds. for this enzyme.  Here the authors report the discovery and characterization of EPZ011989, a potent, selective, orally bioavailable inhibitor of EZH2 with useful pharmacokinetic properties.  EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenograft model of human B cell lymphoma.  Hence, this compd. represents a powerful tool for the expanded exploration of EZH2 activity in biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqfVfbr3kS67Vg90H21EOLACvtfcHk0lhXsE2QY_5dWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslelsL8%253D&md5=21fa182b2474678f663459a9dc2878e6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00037%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DRioux%26aufirst%3DN.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DH.%2BW.%26aulast%3DPorter%2BScott%26aufirst%3DM.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DEPZ011989%252C%2520a%2520potent%252C%2520orally-available%2520EZH2%2520inhibitor%2520with%2520robust%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D491%26epage%3D495%26doi%3D10.1021%2Facsmedchemlett.5b00037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of EBI-2511: a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslyqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=98-102&issue=2&author=B.+Luauthor=X.+D.+Shenauthor=L.+Zhangauthor=D.+Liuauthor=C.+H.+Zhangauthor=J.+S.+Caoauthor=R.+Shenauthor=J.+Y.+Zhangauthor=D.+Wangauthor=H.+Wanauthor=Z.+B.+Xuauthor=M.+H.+Hoauthor=M.+S.+Zhangauthor=L.+S.+Zhangauthor=F.+Heauthor=W.+K.+Tao&title=Discovery+of+EBI-2511%3A+a+highly+potent+and+orally+active+EZH2+inhibitor+for+the+treatment+of+Non-Hodgkin%E2%80%99s+Lymphoma&doi=10.1021%2Facsmedchemlett.7b00437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma</span></div><div class="casAuthors">Lu, Biao; Shen, Xiaodong; Zhang, Lei; Liu, Dong; Zhang, Caihua; Cao, Jingsong; Shen, Ru; Zhang, Jiayin; Wang, Dan; Wan, Hong; Xu, Zhibin; Ho, Ming-Hsun; Zhang, Minsheng; Zhang, Lianshan; He, Feng; Tao, Weikang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of benzofuran derived EZH2 inhibitors were discovered through a scaffold hopping approach based on the clin. compd. of EPZ-6438.  Further rational structure-activity relationship exploration and optimization led to the discovery of more potent EZH2 inhibitors with oral bioavailability in mice and rats.  A lead compd. EBI-2511 (compd. 34) demonstrated excellent in vivo efficacy in Pfeiffer tumor Xenograft models in mouse and is under preclin. development for the treatment of cancers assocd. with EZH2 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAjNckZVf2n7Vg90H21EOLACvtfcHk0lhXsE2QY_5dWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslyqsbc%253D&md5=ce0c8e7f336ddb14b15b82c80c23f02e</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00437%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DX.%2BD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DCao%26aufirst%3DJ.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%2BB.%26aulast%3DHo%26aufirst%3DM.%2BH.%26aulast%3DZhang%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DL.%2BS.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DW.%2BK.%26atitle%3DDiscovery%2520of%2520EBI-2511%253A%2520a%2520highly%2520potent%2520and%2520orally%2520active%2520EZH2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D98%26epage%3D102%26doi%3D10.1021%2Facsmedchemlett.7b00437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryskin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of Enhancer of Zeste Homolog 2 (EZH2) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8306</span>– <span class="NLM_lpage">8325</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8306-8325&issue=18&author=P.+P.+Kungauthor=E.+Ruiauthor=S.+Bergqvistauthor=P.+Binghamauthor=J.+Braganzaauthor=M.+Collinsauthor=M.+Cuiauthor=W.+Diehlauthor=D.+Dinhauthor=C.+Fanauthor=V.+R.+Fantinauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=S.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=G.+Liauthor=K.+A.+Maegleyauthor=I.+McAlpineauthor=L.+Nguyenauthor=S.+Ninkovicauthor=M.+Ornelasauthor=M.+Ryskinauthor=S.+Scalesauthor=S.+Suttonauthor=J.+Tatlockauthor=D.+Verhelleauthor=F.+Wangauthor=P.+Wellsauthor=M.+Wythesauthor=S.+Yamazakiauthor=B.+Yipauthor=X.+Yuauthor=L.+Zehnderauthor=W.+G.+Zhangauthor=R.+A.+Rollinsauthor=M.+Edwards&title=Design+and+synthesis+of+pyridone-containing+3%2C4-dihydroisoquinoline-1%282H%29-ones+as+a+novel+class+of+Enhancer+of+Zeste+Homolog+2+%28EZH2%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors</span></div><div class="casAuthors">Kung, Pei-Pei; Rui, Eugene; Bergqvist, Simon; Bingham, Patrick; Braganza, John; Collins, Michael; Cui, Mei; Diehl, Wade; Dinh, Dac; Fan, Connie; Fantin, Valeria R.; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kephart, Susan; Krivacic, Cody; Kumpf, Robert A.; Li, Gary; Maegley, Karen A.; McAlpine, Indrawan; Nguyen, Lisa; Ninkovic, Sacha; Ornelas, Martha; Ryskin, Michael; Scales, Stephanie; Sutton, Scott; Tatlock, John; Verhelle, Dominique; Wang, Fen; Wells, Peter; Wythes, Martin; Yamazaki, Shinji; Yip, Brian; Yu, Xiu; Zehnder, Luke; Zhang, Wei-Guo; Rollins, Robert A.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8306-8325</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted Ph ring joined to a dimethylpyridone moiety via an amide linkage has been designed.  A preferential amide torsion that improved the binding properties of the compds. was identified for this series via computational anal.  Cyclization of the amide linker resulted in a six-membered lactam analog, compd. I.  This transformation significantly improved the ligand efficiency/potency of the cyclized compd. relative to its acyclic analog.  Addnl. optimization of the lactam-contg. EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compd. II.  Compd. II displayed improved LipE and on-target potency in both biochem. and cellular readouts relative to compd. I.  Inhibitor II also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50CIrIhlikrVg90H21EOLACvtfcHk0ljBtKewaD9mMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM&md5=eb6f2b053e5ba2c2d214d847ad8d9f1f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00515%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DRui%26aufirst%3DE.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBraganza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%26aulast%3DRyskin%26aufirst%3DM.%26aulast%3DScales%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520pyridone-containing%25203%252C4-dihydroisoquinoline-1%25282H%2529-ones%2520as%2520a%2520novel%2520class%2520of%2520Enhancer%2520of%2520Zeste%2520Homolog%25202%2520%2528EZH2%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D18%26spage%3D8306%26epage%3D8325%26doi%3D10.1021%2Facs.jmedchem.6b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grantner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamphavong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of orally bioavailable Enhancer of Zeste Homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01375</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01375" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=650-665&issue=3&author=P.+P.+Kungauthor=P.+Binghamauthor=A.+Broounauthor=M.+Collinsauthor=Y.+L.+Dengauthor=D.+Dinhauthor=C.+Fanauthor=K.+S.+Gajiwalaauthor=R.+Grantnerauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=R.+Kaniaauthor=S.+E.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=P.+Khamphavongauthor=M.+Krausauthor=W.+Liuauthor=K.+A.+Maegleyauthor=L.+Nguyenauthor=S.+Renauthor=D.+Richterauthor=R.+A.+Rollinsauthor=N.+Sachauthor=S.+Sharmaauthor=J.+Sherrillauthor=J.+Spanglerauthor=A.+E.+Stewartauthor=S.+Suttonauthor=S.+Uryuauthor=D.+Verhelleauthor=H.+Wangauthor=S.+Wangauthor=M.+Wythesauthor=S.+Xinauthor=S.+Yamazakiauthor=H.+Zhuauthor=J.+Zhuauthor=L.+Zehnderauthor=M.+Edwards&title=Optimization+of+orally+bioavailable+Enhancer+of+Zeste+Homolog+2+%28EZH2%29+inhibitors+using+ligand+and+property-based+design+strategies%3A+identification+of+development+candidate+%28R%29-5%2C8-Dichloro-7-%28methoxy%28oxetan-3-yl%29methyl%29-2-%28%284-methoxy-6-methyl-2-oxo-1%2C2-+dihydropyridin-3-yl%29methyl%29-3%2C4-dihydroisoquinolin-1%282H%29-one+%28PF-06821497%29&doi=10.1021%2Facs.jmedchem.7b01375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)</span></div><div class="casAuthors">Kung, Pei-Pei; Bingham, Patrick; Brooun, Alexei; Collins, Michael; Deng, Ya-Li; Dinh, Dac; Fan, Connie; Gajiwala, Ketan S.; Grantner, Rita; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kania, Robert; Kephart, Susan E.; Krivacic, Cody; Kumpf, Robert A.; Khamphavong, Penney; Kraus, Manfred; Liu, Wei; Maegley, Karen A.; Nguyen, Lisa; Ren, Shijian; Richter, Dan; Rollins, Robert A.; Sach, Neal; Sharma, Shikhar; Sherrill, John; Spangler, Jillian; Stewart, Albert E.; Sutton, Scott; Uryu, Sean; Verhelle, Dominique; Wang, Hui; Wang, Shuiwang; Wythes, Martin; Xin, Shuibo; Yamazaki, Shinji; Zhu, Huichun; Zhu, JinJiang; Zehnder, Luke; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochem.-property-based strategies to address metabolic stability and thermodn. soly. issues assocd. with previous lead compd. (I).  The new inhibitors incorporated an Sp3 hybridized carbon atom at the 7-position of the lactam moiety present in lead compd. (I) as a replacement for a dimethylisoxazole group.  This transformation enabled optimization of the physicochem. properties and potency compared to compd. (I).  Anal. of relationships between calcd. log D (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single mol.  Compd. 23a (5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one) exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497).  A crystal structure of 23a in complex with the three-protein PRC2 complex enabled understanding of the key structural features required for optimal binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro0-Aa0AZgXLVg90H21EOLACvtfcHk0ljBtKewaD9mMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF&md5=96ff75b96f5eea2dc82013a6bad8096b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01375%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DGrantner%26aufirst%3DR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DKhamphavong%26aufirst%3DP.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSherrill%26aufirst%3DJ.%26aulast%3DSpangler%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520orally%2520bioavailable%2520Enhancer%2520of%2520Zeste%2520Homolog%25202%2520%2528EZH2%2529%2520inhibitors%2520using%2520ligand%2520and%2520property-based%2520design%2520strategies%253A%2520identification%2520of%2520development%2520candidate%2520%2528R%2529-5%252C8-Dichloro-7-%2528methoxy%2528oxetan-3-yl%2529methyl%2529-2-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-%2520dihydropyridin-3-yl%2529methyl%2529-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2520%2528PF-06821497%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1021%2Facs.jmedchem.7b01375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garapaty-Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1021/ml400494b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400494b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=378-383&issue=4&author=C.+G.+Nasveschukauthor=A.+Gagnonauthor=S.+Garapaty-Raoauthor=S.+Balasubramanianauthor=R.+Campbellauthor=C.+Leeauthor=F.+Zhaoauthor=L.+Bergeronauthor=R.+Cummingsauthor=P.+Trojerauthor=J.+E.+Audiaauthor=B.+K.+Albrechtauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+tetramethylpiperidinyl+benzamides+as+inhibitors+of+EZH2&doi=10.1021%2Fml400494b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2</span></div><div class="casAuthors">Nasveschuk, Christopher G.; Gagnon, Alexandre; Garapaty-Rao, Shivani; Balasubramanian, Srividya; Campbell, Robert; Lee, Christina; Zhao, Feng; Bergeron, Louise; Cummings, Richard; Trojer, Patrick; Audia, James E.; Albrecht, Brian K.; Harmange, Jean-Christophe P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">378-383</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification and development of a novel series of small mol. Enhancer of Zeste Homolog 2 (EZH2) inhibitors is described.  A concise and modular synthesis enabled the rapid development of structure-activity relationships, which led to the identification of I as a potent, SAM-competitive inhibitor of EZH2 that dose-dependently decreased global H3K27me3 in KARPAS-422 lymphoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-T4S47cYnxrVg90H21EOLACvtfcHk0ljU7IaETZ1rTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjtw%253D%253D&md5=059381c9e416ee50fb37a8cf3ccef239</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fml400494b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400494b%26sid%3Dliteratum%253Aachs%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DGarapaty-Rao%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520tetramethylpiperidinyl%2520benzamides%2520as%2520inhibitors%2520of%2520EZH2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D4%26spage%3D378%26epage%3D383%26doi%3D10.1021%2Fml400494b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garapaty-Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span> <span> </span><span class="NLM_article-title">Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=24183969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1329-1339&issue=11&author=S.+Garapaty-Raoauthor=C.+Nasveschukauthor=A.+Gagnonauthor=E.+Y.+Chanauthor=P.+Sandyauthor=J.+Busbyauthor=S.+Balasubramanianauthor=R.+Campbellauthor=F.+Zhaoauthor=L.+Bergeronauthor=J.+E.+Audiaauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=R.+Cummingsauthor=P.+Trojer&title=Identification+of+EZH2+and+EZH1+small+molecule+inhibitors+with+selective+impact+on+diffuse+large+B+cell+lymphoma+cell+growth&doi=10.1016%2Fj.chembiol.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth</span></div><div class="casAuthors">Garapaty-Rao, Shivani; Nasveschuk, Christopher; Gagnon, Alexandre; Chan, Eric Y.; Sandy, Peter; Busby, Jennifer; Balasubramanian, Srividya; Campbell, Robert; Zhao, Feng; Bergeron, Louise; Audia, James E.; Albrecht, Brian K.; Harmange, Jean-Christophe; Cummings, Richard; Trojer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1329-1339</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due to its prevalent overexpression in malignant diseases, including late stage prostate and breast cancers.  The dependency of cancer cells on EZH2 activity is also predicated by recurrent missense mutations residing in the catalytic domain of EZH2 that have been identified in subtypes of diffuse large B cell lymphoma, follicular lymphoma and melanoma.  Herein, we report the identification of a highly selective small mol. inhibitor series of EZH2 and EZH1.  These compds. inhibit wild-type and mutant versions of EZH2 with nanomolar potency, suppress global histone H3-lysine 27 methylation, affect gene expression, and cause selective proliferation defects.  These compds. represent a structurally distinct EZH2 inhibitor chemotype for the exploration of the role of Polycomb Repressive Complex 2-mediated H3K27 methylation in various biol. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNGhFRO6LRbVg90H21EOLACvtfcHk0ljU7IaETZ1rTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmtrrP&md5=6079ba01ae1f1964ac1d8108aa5e1227</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DGarapaty-Rao%26aufirst%3DS.%26aulast%3DNasveschuk%26aufirst%3DC.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DE.%2BY.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBusby%26aufirst%3DJ.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DTrojer%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520EZH2%2520and%2520EZH1%2520small%2520molecule%2520inhibitors%2520with%2520selective%2520impact%2520on%2520diffuse%2520large%2520B%2520cell%2520lymphoma%2520cell%2520growth%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26issue%3D11%26spage%3D1329%26epage%3D1339%26doi%3D10.1016%2Fj.chembiol.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span> <span> </span><span class="NLM_article-title">SAH derived potent and selective EZH2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2015.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25746813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVWjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1532-1537&issue=7&author=P.+P.+Kungauthor=B.+Huangauthor=L.+Zehnderauthor=J.+Tatlockauthor=P.+Binghamauthor=C.+Krivacicauthor=K.+Gajiwalaauthor=W.+Diehlauthor=X.+Yuauthor=K.+A.+Maegley&title=SAH+derived+potent+and+selective+EZH2+inhibitors&doi=10.1016%2Fj.bmcl.2015.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">SAH derived potent and selective EZH2 inhibitors</span></div><div class="casAuthors">Kung, Pei-Pei; Huang, Buwen; Zehnder, Luke; Tatlock, John; Bingham, Patrick; Krivacic, Cody; Gajiwala, Ketan; Diehl, Wade; Yu, Xiu; Maegley, Karen A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1532-1537</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel enhancer of zeste homolog 2 (EZH2) inhibitors was designed based on the chem. structure of the histone methyltransferase (HMT) inhibitor SAH (S-adenosyl-L-homocysteine).  These nucleoside-based EZH2 inhibitors blocked the methylation of nucleosomes at H3K27 in biochem. assays employing both WT PRC2 complex as well as a Y641N mutant PRC2 complex.  The most potent compd., 27, displayed IC50's against both complexes of 270 nM and 70 nM, resp.  To our knowledge, compd. 27 is the most potent SAH-derived inhibitor of the EZH2 PRC2 complex yet identified.  This compd. also displayed improved potency, lipophilic efficiency (LipE), and selectivity profile against other lysine methyltransferases compared with SAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD6-bRuJKI9LVg90H21EOLACvtfcHk0ligMnQSkoFEeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVWjsrk%253D&md5=c223e65ceadad748c164b6bbcb38b3df</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26atitle%3DSAH%2520derived%2520potent%2520and%2520selective%2520EZH2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D7%26spage%3D1532%26epage%3D1537%26doi%3D10.1016%2Fj.bmcl.2015.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvaraju, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comess, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">The, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima-Fernandes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinge, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliushchev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petros, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweis, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigelow, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senisterra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindley, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasinski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappano, W. N.</span></span> <span> </span><span class="NLM_article-title">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.2306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28135237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=389-395&issue=4&author=Y.+Heauthor=S.+Selvarajuauthor=M.+L.+Curtinauthor=C.+G.+Jakobauthor=H.+Zhuauthor=K.+M.+Comessauthor=B.+Shawauthor=J.+Theauthor=E.+Lima-Fernandesauthor=M.+M.+Szewczykauthor=D.+Chengauthor=K.+L.+Klingeauthor=H.+Q.+Liauthor=M.+Pliushchevauthor=M.+A.+Algireauthor=D.+Maagauthor=J.+Guoauthor=J.+Dietrichauthor=S.+C.+Panchalauthor=A.+M.+Petrosauthor=R.+F.+Sweisauthor=M.+Torrentauthor=L.+J.+Bigelowauthor=G.+Senisterraauthor=F.+Liauthor=S.+Kennedyauthor=Q.+Wuauthor=D.+J.+Osterlingauthor=D.+J.+Lindleyauthor=W.+Gaoauthor=S.+Galasinskiauthor=D.+Barsyte-Lovejoyauthor=M.+Vedadiauthor=F.+G.+Buchananauthor=C.+H.+Arrowsmithauthor=G.+G.+Chiangauthor=C.+Sunauthor=W.+N.+Pappano&title=The+EED+protein-protein+interaction+inhibitor+A-395+inactivates+the+PRC2+complex&doi=10.1038%2Fnchembio.2306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span></div><div class="casAuthors">He, Yupeng; Selvaraju, Sujatha; Curtin, Michael L.; Jakob, Clarissa G.; Zhu, Haizhong; Comess, Kenneth M.; Shaw, Bailin; The, Juliana; Lima-Fernandes, Evelyne; Szewczyk, Magdalena M.; Cheng, Dong; Klinge, Kelly L.; Li, Huan-Qiu; Pliushchev, Marina; Algire, Mikkel A.; Maag, David; Guo, Jun; Dietrich, Justin; Panchal, Sanjay C.; Petros, Andrew M.; Sweis, Ramzi F.; Torrent, Maricel; Bigelow, Lance J.; Senisterra, Guillermo; Li, Fengling; Kennedy, Steven; Wu, Qin; Osterling, Donald J.; Lindley, David J.; Gao, Wenqing; Galasinski, Scott; Barsyte-Lovejoy, Dalia; Vedadi, Masoud; Buchanan, Fritz G.; Arrowsmith, Cheryl H.; Chiang, Gary G.; Sun, Chaohong; Pappano, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is a regulator of epigenetic states required for development and homeostasis.  PRC2 trimethylates histone H3 at lysine 27 (H3K27me3), which leads to gene silencing, and is dysregulated in many cancers.  The embryonic ectoderm development (EED) protein is an essential subunit of PRC2 that has both a scaffolding function and an H3K27me3-binding function.  Here we report the identification of A-395, a potent antagonist of the H3K27me3 binding functions of EED.  Structural studies demonstrate that A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2.  Phenotypic effects obsd. in vitro and in vivo are similar to those of known PRC2 enzymic inhibitors; however, A-395 retains potent activity against cell lines resistant to the catalytic inhibitors.  A-395 represents a first-in-class antagonist of PRC2 protein-protein interactions (PPI) for use as a chem. probe to investigate the roles of EED-contg. protein complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5rHeR_Z5mLVg90H21EOLACvtfcHk0ligMnQSkoFEeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D&md5=d41eee098ed123f8c7f50babe93d7692</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2306%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DSelvaraju%26aufirst%3DS.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DJakob%26aufirst%3DC.%2BG.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DComess%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DB.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DLima-Fernandes%26aufirst%3DE.%26aulast%3DSzewczyk%26aufirst%3DM.%2BM.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DKlinge%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DPliushchev%26aufirst%3DM.%26aulast%3DAlgire%26aufirst%3DM.%2BA.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DSweis%26aufirst%3DR.%2BF.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DBigelow%26aufirst%3DL.%2BJ.%26aulast%3DSenisterra%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DLindley%26aufirst%3DD.%2BJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DGalasinski%26aufirst%3DS.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBuchanan%26aufirst%3DF.%2BG.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPappano%26aufirst%3DW.%2BN.%26atitle%3DThe%2520EED%2520protein-protein%2520interaction%2520inhibitor%2520A-395%2520inactivates%2520the%2520PRC2%2520complex%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D389%26epage%3D395%26doi%3D10.1038%2Fnchembio.2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanacci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cambillau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5108</span>– <span class="NLM_lpage">5113</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508200103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.0508200103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=16549795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsVGltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5108-5113&issue=13&author=E.+Minskaiaauthor=T.+Hertzigauthor=A.+E.+Gorbalenyaauthor=V.+Campanacciauthor=C.+Cambillauauthor=B.+Canardauthor=J.+Ziebuhr&title=Discovery+of+an+RNA+virus+3%27-%3E5%27+exoribonuclease+that+is+critically+involved+in+coronavirus+RNA+synthesis&doi=10.1073%2Fpnas.0508200103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an RNA virus 3'→5' exoribonuclease that is critically involved in coronavirus RNA synthesis</span></div><div class="casAuthors">Minskaia, Ekaterina; Hertzig, Tobias; Gorbalenya, Alexander E.; Campanacci, Valerie; Cambillau, Christian; Canard, Bruno; Ziebuhr, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5108-5113</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Replication of the giant RNA genome of severe acute respiratory syndrome (SARS) coronavirus (CoV) and synthesis of as many as eight subgenomic (sg) mRNAs are mediated by a viral replicase-transcriptase of outstanding complexity that includes an essential endoribonuclease activity.  Here, we show that the CoV replicative machinery, unlike that of other RNA viruses, also uses an exoribonuclease (ExoN) activity, which is assocd. with nonstructural protein (nsp) 14.  Bacterially expressed forms of SARS-CoV nsp14 were shown to act on both ssRNAs and dsRNAs in a 3'→5' direction.  The activity depended on residues that are conserved in the DEDD exonuclease superfamily.  The protein did not hydrolyze DNA or ribose-2'-O-methylated RNA substrates and required divalent metal ions for activity.  A range of 5'-labeled ssRNA substrates were processed to final products of ≈8-12 nucleotides.  When part of dsRNA or in the presence of nonlabeled dsRNA, the 5'-labeled RNA substrates were processed to significantly smaller products, indicating that binding to dsRNA in cis or trans modulates the exonucleolytic activity of nsp14.  Characterization of human CoV 229E ExoN active-site mutants revealed severe defects in viral RNA synthesis, and no viable virus could be recovered.  Besides strongly reduced genome replication, specific defects in sg RNA synthesis, such as aberrant sizes of specific sg RNAs and changes in the molar ratios between individual sg RNA species, were obsd.  Taken together, the study identifies an RNA virus ExoN activity that is involved in the synthesis of multiple RNAs from the exceptionally large genomic RNA templates of CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6SF6y0gH--rVg90H21EOLACvtfcHk0lg0K_-uQasN2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsVGltr0%253D&md5=bdf193d90a45d6b9433dbdd4d74d4a4f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508200103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508200103%26sid%3Dliteratum%253Aachs%26aulast%3DMinskaia%26aufirst%3DE.%26aulast%3DHertzig%26aufirst%3DT.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DCampanacci%26aufirst%3DV.%26aulast%3DCambillau%26aufirst%3DC.%26aulast%3DCanard%26aufirst%3DB.%26aulast%3DZiebuhr%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520an%2520RNA%2520virus%25203%2527-%253E5%2527%2520exoribonuclease%2520that%2520is%2520critically%2520involved%2520in%2520coronavirus%2520RNA%2520synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D13%26spage%3D5108%26epage%3D5113%26doi%3D10.1073%2Fpnas.0508200103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibaja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Vash, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejtar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span> <span> </span><span class="NLM_article-title">Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/onc.2015.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fonc.2015.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25893294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=558-566&issue=5&author=V.+Gibajaauthor=F.+Shenauthor=J.+Harariauthor=J.+Kornauthor=D.+Ruddyauthor=V.+Saenz-Vashauthor=H.+Zhaiauthor=T.+Rejtarauthor=C.+G.+Parisauthor=Z.+Yuauthor=M.+Liraauthor=D.+Kingauthor=W.+Qiauthor=N.+Keenauthor=A.+Q.+Hassanauthor=H.+M.+Chan&title=Development+of+secondary+mutations+in+wild-type+and+mutant+EZH2+alleles+cooperates+to+confer+resistance+to+EZH2+inhibitors&doi=10.1038%2Fonc.2015.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors</span></div><div class="casAuthors">Gibaja, V.; Shen, F.; Harari, J.; Korn, J.; Ruddy, D.; Saenz-Vash, V.; Zhai, H.; Rejtar, T.; Paris, C. G.; Yu, Z.; Lira, M.; King, D.; Qi, W.; Keen, N.; Hassan, A. Q.; Chan, H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">558-566</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) is frequently dysregulated in cancers, and gain-of-function (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas.  Small-mol. inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entered clin. trials.  Here, we developed models of acquired resistance to EZH2 inhibitor EI1 with EZH2-mutated lymphoma cells.  Resistance was generated by secondary mutations in both wild-type (WT) and GOF Y641N EZH2 alleles.  These EZH2 mutants retained the substrate specificity of their predecessor complexes but became refractory to biochem. inhibition by EZH2 inhibitors.  Resistant cells were able to maintain a high level of H3K27Me3 in the presence of inhibitors.  Interestingly, mutation of EZH2 WT alone generated an intermediate resistance phenotype, which is consistent with a previously proposed model of cooperation between EZH2 WT and Y641N mutants to promote tumorigenesis.  In addn., the findings presented here have implications for the clin. translation of EZH2 inhibitors and underscore the need to develop novel EZH2 inhibitors to target potential resistance emerging in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUaTpSYCtEf7Vg90H21EOLACvtfcHk0lg0K_-uQasN2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt74%253D&md5=fcfebb482305effcb67f258ce8c589e8</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.114%26sid%3Dliteratum%253Aachs%26aulast%3DGibaja%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DHarari%26aufirst%3DJ.%26aulast%3DKorn%26aufirst%3DJ.%26aulast%3DRuddy%26aufirst%3DD.%26aulast%3DSaenz-Vash%26aufirst%3DV.%26aulast%3DZhai%26aufirst%3DH.%26aulast%3DRejtar%26aufirst%3DT.%26aulast%3DParis%26aufirst%3DC.%2BG.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLira%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DD.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26atitle%3DDevelopment%2520of%2520secondary%2520mutations%2520in%2520wild-type%2520and%2520mutant%2520EZH2%2520alleles%2520cooperates%2520to%2520confer%2520resistance%2520to%2520EZH2%2520inhibitors%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D5%26spage%3D558%26epage%3D566%26doi%3D10.1038%2Fonc.2015.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalvez, F.</span></span> <span> </span><span class="NLM_article-title">Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">32646</span>– <span class="NLM_lpage">32655</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.18632%2Foncotarget.5066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=26360609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC283htF2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=32646-32655&issue=32&author=T.+Bakerauthor=S.+Nerleauthor=J.+Pritchardauthor=B.+Zhaoauthor=V.+M.+Riveraauthor=A.+Garnerauthor=F.+Gonzalvez&title=Acquisition+of+a+single+EZH2+D1+domain+mutation+confers+acquired+resistance+to+EZH2-targeted+inhibitors&doi=10.18632%2Foncotarget.5066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors</span></div><div class="casAuthors">Baker Theresa; Nerle Sujata; Pritchard Justin; Zhao Boyang; Rivera Victor M; Garner Andrew; Gonzalvez Francois</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">32646-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although targeted therapies have revolutionized cancer treatment, overcoming acquired resistance remains a major clinical challenge.  EZH2 inhibitors (EZH2i), EPZ-6438 and GSK126, are currently in the early stages of clinical evaluation and the first encouraging signs of efficacy have recently emerged in the clinic.  To anticipate mechanisms of resistance to EZH2i, we used a forward genetic platform combining a mutagenesis screen with next generation sequencing technology and identified a hotspot of secondary mutations in the EZH2 D1 domain (Y111 and I109).  Y111D mutation within the WT or A677G EZH2 allele conferred robust resistance to both EPZ-6438 and GSK126, but it only drove a partial resistance within the Y641F allele.  EZH2 mutants required histone methyltransferase (HMT) catalytic activity and the polycomb repressive complex 2 (PRC2) components, SUZ12 and EED, to drive drug resistance.  Furthermore, D1 domain mutations not only blocked the ability of EZH2i to bind to WT and A677G mutant, but also abrogated drug binding to the Y641F mutant.  These data provide the first cellular validation of the mechanistic model underpinning the oncogenic function of WT and mutant EZH2.  Importantly, our findings suggest that acquired-resistance to EZH2i may arise in WT and mutant EZH2 patients through a single mutation that remains targetable by second generation EZH2i.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrjQ7fThFnJ75XHngOXiV_fW6udTcc2eZvVQpqlt7gubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htF2msw%253D%253D&md5=c1af5705275e07526267d5d322cf3fac</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5066%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DT.%26aulast%3DNerle%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DGarner%26aufirst%3DA.%26aulast%3DGonzalvez%26aufirst%3DF.%26atitle%3DAcquisition%2520of%2520a%2520single%2520EZH2%2520D1%2520domain%2520mutation%2520confers%2520acquired%2520resistance%2520to%2520EZH2-targeted%2520inhibitors%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D32%26spage%3D32646%26epage%3D32655%26doi%3D10.18632%2Foncotarget.5066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span> <span> </span><span class="NLM_article-title">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fnchembio.2304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28135235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=381-388&issue=4&author=W.+Qiauthor=K.+Zhaoauthor=J.+Guauthor=Y.+Huangauthor=Y.+Wangauthor=H.+Zhangauthor=M.+Zhangauthor=J.+Zhangauthor=Z.+Yuauthor=L.+Liauthor=L.+Tengauthor=S.+Chuaiauthor=C.+Zhangauthor=M.+Zhaoauthor=H.+Chanauthor=Z.+Chenauthor=D.+Fangauthor=Q.+Feiauthor=L.+Fengauthor=L.+Fengauthor=Y.+Gaoauthor=H.+Geauthor=X.+Geauthor=G.+Liauthor=A.+Lingelauthor=Y.+Linauthor=Y.+Liuauthor=F.+Luoauthor=M.+Shiauthor=L.+Wangauthor=Z.+Wangauthor=Y.+Yuauthor=J.+Zengauthor=C.+Zengauthor=L.+Zhangauthor=Q.+Zhangauthor=S.+Zhouauthor=C.+Oyangauthor=P.+Atadjaauthor=E.+Li&title=An+allosteric+PRC2+inhibitor+targeting+the+H3K27me3+binding+pocket+of+EED&doi=10.1038%2Fnchembio.2304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span></div><div class="casAuthors">Qi, Wei; Zhao, Kehao; Gu, Justin; Huang, Ying; Wang, Youzhen; Zhang, Hailong; Zhang, Man; Zhang, Jeff; Yu, Zhengtian; Li, Ling; Teng, Lin; Chuai, Shannon; Zhang, Chao; Zhao, Mengxi; Chan, Ho Man; Chen, Zijun; Fang, Douglas; Fei, Qi; Feng, Leying; Feng, Lijian; Gao, Yuan; Ge, Hui; Ge, Xinjian; Li, Guobin; Lingel, Andreas; Lin, Ying; Liu, Yueqin; Luo, Fangjun; Shi, Minlong; Wang, Long; Wang, Zhaofu; Yu, Yanyan; Zeng, Jue; Zeng, Chenhui; Zhang, Lijun; Zhang, Qiong; Zhou, Shaolian; Oyang, Counde; Atadja, Peter; Li, En</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) consists of three core subunits, EZH2, EED and SUZ12, and plays pivotal roles in transcriptional regulation.  The catalytic subunit EZH2 methylates histone H3 lysine 27 (H3K27), and its activity is further enhanced by the binding of EED to trimethylated H3K27 (H3K27me3).  Small-mol. inhibitors that compete with the cofactor S-adenosylmethionine (SAM) have been reported.  Here we report the discovery of EED226, a potent and selective PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED.  EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity.  EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors.  Interestingly, EED226 also effectively inhibits PRC2 contg. a mutant EZH2 protein resistant to SAM-competitive inhibitors.  Together, we show that EED226 inhibits PRC2 activity via an allosteric mechanism and offers an opportunity for treatment of PRC2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjpXExCMohI7Vg90H21EOLACvtfcHk0ljDBG0OouUBFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D&md5=62d10723685450ca7ffd599a61134d42</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2304%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DChuai%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DFei%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DOyang%26aufirst%3DC.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DE.%26atitle%3DAn%2520allosteric%2520PRC2%2520inhibitor%2520targeting%2520the%2520H3K27me3%2520binding%2520pocket%2520of%2520EED%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D381%26epage%3D388%26doi%3D10.1038%2Fnchembio.2304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliushchev, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarris, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvaraju, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweis, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span> <span> </span><span class="NLM_article-title">SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1583</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.bmcl.2017.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28254486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Oju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1576-1583&issue=7&author=M.+L.+Curtinauthor=M.+A.+Pliushchevauthor=H.-Q.+Liauthor=M.+Torrentauthor=J.+D.+Dietrichauthor=C.+G.+Jakobauthor=H.+Zhuauthor=H.+Zhaoauthor=Y.+Wangauthor=Z.+Jiauthor=R.+F.+Clarkauthor=K.+A.+Sarrisauthor=S.+Selvarajuauthor=B.+Shawauthor=M.+A.+Algireauthor=Y.+Heauthor=P.+L.+Richardsonauthor=R.+F.+Sweisauthor=C.+Sunauthor=G.+G.+Chiangauthor=M.+R.+Michaelides&title=SAR+of+amino+pyrrolidines+as+potent+and+novel+protein-protein+interaction+inhibitors+of+the+PRC2+complex+through+EED+binding&doi=10.1016%2Fj.bmcl.2017.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding</span></div><div class="casAuthors">Curtin, Michael L.; Pliushchev, Marina A.; Li, Huan-Qiu; Torrent, Maricel; Dietrich, Justin D.; Jakob, Clarissa G.; Zhu, Haizhong; Zhao, Hongyu; Wang, Ying; Ji, Zhiqin; Clark, Richard F.; Sarris, Kathy A.; Selvaraju, Sujatha; Shaw, Bailin; Algire, Mikkel A.; He, Yupeng; Richardson, Paul L.; Sweis, Ramzi F.; Sun, Chaohong; Chiang, Gary G.; Michaelides, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1576-1583</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we disclose SAR studies of a series of dimethylamino pyrrolidines which we recently reported as novel inhibitors of the PRC2 complex through disruption of EED/H3K27me3 binding.  Modification of the indole and benzyl moieties of screening hit 1 provided analogs with substantially improved binding and cellular activities.  This work culminated in the identification of compd. 2, our nanomolar proof-of-concept (PoC) inhibitor which provided on-target tumor growth inhibition in a mouse xenograft model.  X-ray crystal structures of several inhibitors bound in the EED active-site are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkdonJy6cBnbVg90H21EOLACvtfcHk0ljDBG0OouUBFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Oju7s%253D&md5=3396f3f4c2d3944237cfde004ac4204b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DPliushchev%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DH.-Q.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DJ.%2BD.%26aulast%3DJakob%26aufirst%3DC.%2BG.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DClark%26aufirst%3DR.%2BF.%26aulast%3DSarris%26aufirst%3DK.%2BA.%26aulast%3DSelvaraju%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DB.%26aulast%3DAlgire%26aufirst%3DM.%2BA.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DRichardson%26aufirst%3DP.%2BL.%26aulast%3DSweis%26aufirst%3DR.%2BF.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DSAR%2520of%2520amino%2520pyrrolidines%2520as%2520potent%2520and%2520novel%2520protein-protein%2520interaction%2520inhibitors%2520of%2520the%2520PRC2%2520complex%2520through%2520EED%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D7%26spage%3D1576%26epage%3D1583%26doi%3D10.1016%2Fj.bmcl.2017.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of first-in-class, potent, and orally bioavailable embryonic ectoderm development (EED) inhibitor with robust anticancer efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2215</span>– <span class="NLM_lpage">2226</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2215-2226&issue=6&author=Y.+Huangauthor=J.+Zhangauthor=Z.+Yuauthor=H.+Zhangauthor=Y.+Wangauthor=A.+Lingelauthor=W.+Qiauthor=J.+Guauthor=K.+Zhaoauthor=M.+D.+Shultzauthor=L.+Wangauthor=X.+Fuauthor=Y.+Sunauthor=Q.+Zhangauthor=X.+Jiangauthor=J.+Zhangauthor=C.+Zhangauthor=L.+Liauthor=J.+Zengauthor=L.+Fengauthor=C.+Zhangauthor=Y.+Liuauthor=M.+Zhangauthor=L.+Zhangauthor=M.+Zhaoauthor=Z.+Gaoauthor=X.+Liuauthor=D.+Fangauthor=H.+Guoauthor=Y.+Miauthor=T.+Gabrielauthor=M.+P.+Dillonauthor=P.+Atadjaauthor=C.+Oyang&title=Discovery+of+first-in-class%2C+potent%2C+and+orally+bioavailable+embryonic+ectoderm+development+%28EED%29+inhibitor+with+robust+anticancer+efficacy&doi=10.1021%2Facs.jmedchem.6b01576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy</span></div><div class="casAuthors">Huang, Ying; Zhang, Jeff; Yu, Zhengtian; Zhang, Hailong; Wang, Youzhen; Lingel, Andreas; Qi, Wei; Gu, Justin; Zhao, Kehao; Shultz, Michael D.; Wang, Long; Fu, Xingnian; Sun, Yongfeng; Zhang, Qiong; Jiang, Xiangqing; Zhang, Jiangwei; Zhang, Chunye; Li, Ling; Zeng, Jue; Feng, Lijian; Zhang, Chao; Liu, Yueqin; Zhang, Man; Zhang, Lijun; Zhao, Mengxi; Gao, Zhenting; Liu, Xianghui; Fang, Douglas; Guo, Haibing; Mi, Yuan; Gabriel, Tobias; Dillon, Michael P.; Atadja, Peter; Oyang, Counde</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2215-2226</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression and somatic heterozygous mutations of EZH2, the catalytic subunit Polycomb repressive complex 2 (PRC2), are assocd. with several tumor types.  EZH2 inhibitor, EPZ-6438 (Tazemetostat), demonstrated clin. efficacy in patients with acceptable safety profile as monotherapy.  EED, another subunit of PRC2 complex, is essential for its histone methyltransferase activity through direct binding to trimethylated lysine 27 on histone 3 (H3K27Me3).  Herein the authors disclose the discovery of a first-in-class potent, selective and orally bioavailable EED inhibitor EED226 (compd. 43).  Guided by x-ray crystallog., compd. 43 discovered by fragmentation and regrowth of Compd. (I), a PRC2 HTS hit that directly binds EED.  Scaffold hopping followed by ensuing multi-parameter optimization led to the discovery compd. 43.  Compd. 43 induces robust and sustained tumor regression in EZH2MUT pre-clin. DLBCL model.  For the first time specific and direct inhibition of EED can be effective as an anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRnKW75ksfdbVg90H21EOLACvtfcHk0lhF4VIrnK-EMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKisLo%253D&md5=c53a43e71d22a315b99f39929f666744</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01576%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DOyang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520first-in-class%252C%2520potent%252C%2520and%2520orally%2520bioavailable%2520embryonic%2520ectoderm%2520development%2520%2528EED%2529%2520inhibitor%2520with%2520robust%2520anticancer%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D6%26spage%3D2215%26epage%3D2226%26doi%3D10.1021%2Facs.jmedchem.6b01576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span> <span> </span><span class="NLM_article-title">An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5587</span>– <span class="NLM_lpage">5596</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-0428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F0008-5472.CAN-19-0428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31395608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1KitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=5587-5596&issue=21&author=H.+Dongauthor=S.+Liuauthor=X.+Zhangauthor=S.+Chenauthor=L.+Kangauthor=Y.+Chenauthor=S.+Maauthor=X.+Fuauthor=Y.+Liuauthor=H.+Zhangauthor=B.+Zou&title=An+allosteric+PRC2+inhibitor+targeting+EED+suppresses+tumor+progression+by+modulating+the+immune+response&doi=10.1158%2F0008-5472.CAN-19-0428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response</span></div><div class="casAuthors">Dong, Hongping; Liu, Shaojun; Zhang, Xuejie; Chen, Sheng; Kang, Lijing; Chen, Yanni; Ma, Shichao; Fu, Xianlei; Liu, Yanchao; Zhang, Hailong; Zou, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5587-5596</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant activity of polycomb repressive complex 2 (PRC2) is involved in a wide range of human cancer progression.  The WD40 repeat-contg. protein EED is a core component of PRC2 and enhances PRC2 activity through interaction with H3K27me3.  In this study, we report the discovery of a class of pyrimidone compds., represented by BR-001 as potent allosteric inhibitors of PRC2.  X-ray co-crystallog. showed that BR-001 directly binds EED in the H3K27me3-binding pocket.  BR-001 displayed antitumor potency in vitro and in vivo.  In Karpas422 and Pfeiffer xenograft mouse models, twice daily oral dosing with BR-001 resulted in robust anti-tumor activity.  BR-001 was also efficacious in syngeneic CT26 colon tumor-bearing mice; oral dosing of 30 mg/kg of BR-001 led to 59.3% tumor growth suppression and increased frequency of effector CD8+ T-cell infiltrates in tumors.  Pharmacodynamic anal. revealed that CXCL10 was highly upregulated, suggesting that CXCL10 triggers the trafficking of CD8+ T cells toward tumor sites.  Our results demonstrate for the first time that inhibition of EED modulates the tumor immune microenvironment to induce regression of colon tumors and therefore has the potential to be used in combination with immune-oncol. therapy.  Significance: BR-001, a potent inhibitor of the EED subunit of the PRC2 complex, suppresses tumor progression by modulating the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriYcNHbku1ZbVg90H21EOLACvtfcHk0lhF4VIrnK-EMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1KitL8%253D&md5=51331eac62193271e40ea4b9246a348c</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-0428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-0428%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DB.%26atitle%3DAn%2520allosteric%2520PRC2%2520inhibitor%2520targeting%2520EED%2520suppresses%2520tumor%2520progression%2520by%2520modulating%2520the%2520immune%2520response%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D21%26spage%3D5587%26epage%3D5596%26doi%3D10.1158%2F0008-5472.CAN-19-0428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.08.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.cell.2018.08.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=30220457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslahs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=186-199&issue=1&author=X.+Huangauthor=J.+Yanauthor=M.+Zhangauthor=Y.+Wangauthor=Y.+Chenauthor=X.+Fuauthor=R.+Weiauthor=X.+L.+Zhengauthor=Z.+Liuauthor=X.+Zhangauthor=H.+Yangauthor=B.+Haoauthor=Y.+Y.+Shenauthor=Y.+Suauthor=X.+Congauthor=M.+Huangauthor=M.+Tanauthor=J.+Dingauthor=M.+Geng&title=Targeting+epigenetic+crosstalk+as+a+therapeutic+strategy+for+EZH2-aberrant+solid+tumors&doi=10.1016%2Fj.cell.2018.08.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors</span></div><div class="casAuthors">Huang, Xun; Yan, Juan; Zhang, Min; Wang, Yafang; Chen, Yi; Fu, Xuhong; Wei, Rongrui; Zheng, Xing-ling; Liu, Zhiwei; Zhang, Xiong; Yang, Hong; Hao, Bingbing; Shen, Yan-yan; Su, Yi; Cong, Xiaoji; Huang, Min; Tan, Minjia; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-199.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clin. benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematol. malignancies.  We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i.  We report here oncogenic transcriptional reprogramming mediated by MLL1's interaction with the p300/CBP complex, which directs H3K27me loss to reciprocal H3K27ac gain and restricts EZH2i response.  Concurrent inhibition of H3K27me and H3K27ac results in transcriptional repression and MAPK pathway dependency in cancer subsets.  In preclin. models encompassing a broad spectrum of EZH2-aberrant solid tumors, a combination of EZH2 and BRD4 inhibitors, or a triple-combination including MAPK inhibition display robust efficacy with very tolerable toxicity.  Our results suggest an attractive precision treatment strategy for EZH2-aberrant tumors on the basis of tumor-intrinsic MLL1 expression and concurrent inhibition of epigenetic crosstalk and feedback MAPK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgroiKQYI5RLVg90H21EOLACvtfcHk0lhF4VIrnK-EMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslahs7%252FM&md5=1879411de33f088e3c197d6175e02e18</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.08.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.08.058%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DX.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHao%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%2BY.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DCong%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DTargeting%2520epigenetic%2520crosstalk%2520as%2520a%2520therapeutic%2520strategy%2520for%2520EZH2-aberrant%2520solid%2520tumors%26jtitle%3DCell%26date%3D2018%26volume%3D175%26issue%3D1%26spage%3D186%26epage%3D199%26doi%3D10.1016%2Fj.cell.2018.08.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rej, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrunak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawacki, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">EEDi-5285: an exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic ectoderm development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">7252</span>– <span class="NLM_lpage">7267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1arsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=7252-7267&issue=13&author=R.+K.+Rejauthor=C.+Wangauthor=J.+Luauthor=M.+Wangauthor=E.+Petrunakauthor=K.+P.+Zawackiauthor=D.+McEachernauthor=E.+Fernandez-Salasauthor=C.+Y.+Yangauthor=L.+Wangauthor=R.+Liauthor=K.+Chinnaswamyauthor=B.+Wenauthor=D.+Sunauthor=J.+Stuckeyauthor=Y.+Zhouauthor=J.+Chenauthor=G.+Tangauthor=S.+Wang&title=EEDi-5285%3A+an+exceptionally+potent%2C+efficacious%2C+and+orally+active+small-molecule+inhibitor+of+embryonic+ectoderm+development&doi=10.1021%2Facs.jmedchem.0c00479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development</span></div><div class="casAuthors">Rej, Rohan Kalyan; Wang, Changwei; Lu, Jianfeng; Wang, Mi; Petrunak, Elyse; Zawacki, Kaitlin P.; McEachern, Donna; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Lu; Li, Ruiting; Chinnaswamy, Krishnapriya; Wen, Bo; Sun, Duxin; Stuckey, Jeanne; Zhou, Yunlong; Chen, Jianyong; Tang, Guozhi; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7252-7267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of embryonic ectoderm development (EED) is a new cancer therapeutic strategy.  Herein, we report our discovery of EEDi-5285 as an exceptionally potent, efficacious, and orally active EED inhibitor.  EEDi-5285 binds to the EED protein with an IC50 value of 0.2 nM and inhibits cell growth with IC50 values of 20 pM and 0.5 nM in the Pfeiffer and KARPAS422 lymphoma cell lines, resp., carrying an EZH2 mutation.  EEDi-5285 is approx. 100 times more potent than EED226 in binding to EED and >300 times more potent than EED226 in inhibition of cell growth in the KARPAS422 cell line.  EEDi-5285 has excellent pharmacokinetics and achieves complete and durable tumor regression in the KARPAS422 xenograft model in mice with oral administration.  The cocrystal structure of EEDi-5285 in a complex with EED defines the precise structural basis for their high binding affinity.  EEDi-5285 is the most potent and efficacious EED inhibitor reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiIQoP1xeDu7Vg90H21EOLACvtfcHk0liDjn4Cfb08iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1arsL7J&md5=8438554230a2258e3d4d7748a090bc7f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00479%26sid%3Dliteratum%253Aachs%26aulast%3DRej%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DPetrunak%26aufirst%3DE.%26aulast%3DZawacki%26aufirst%3DK.%2BP.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DEEDi-5285%253A%2520an%2520exceptionally%2520potent%252C%2520efficacious%252C%2520and%2520orally%2520active%2520small-molecule%2520inhibitor%2520of%2520embryonic%2520ectoderm%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D13%26spage%3D7252%26epage%3D7267%26doi%3D10.1021%2Facs.jmedchem.0c00479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisserier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajapeyee, N.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">2125</span>– <span class="NLM_lpage">2137</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-08-804344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1182%2Fblood-2017-08-804344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=29572378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFenurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2125-2137&issue=19&author=M.+Bisserierauthor=N.+Wajapeyee&title=Mechanisms+of+resistance+to+EZH2+inhibitors+in+diffuse+large+B-cell+lymphomas&doi=10.1182%2Fblood-2017-08-804344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas</span></div><div class="casAuthors">Bisserier, Malik; Wajapeyee, Narendra</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2125-2137</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Resistance to targeted therapies has become increasingly prevalent.  We noted that resistance to different targeted therapies occurs by largely common mechanisms.  In this study, we used this information for identifying the mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphoma (DLBCL) harboring EZH2 mutations.  We discovered that EZH2 inhibitor-resistant DLBCL cells showed activation of the insulin-like growth factor 1 receptor (IGF-1R), MEK, and PI3K pathways.  Constitutive activation of IGF-1R, MEK, or PI3K pathways was sufficient to confer resistance to EZH2 inhibitors in DLBCL.  The activation of the PI3K/AKT andMAPK pathways decreased TNFSF10 and BAD expression through a FOXO3-dependent mechanism, which was required for the antitumor effects of EZH2i GSK126.  We also identified multiple acquired mutations in EZH2 inhibitor-resistant DLBCL cell lines.  Acquired EZH2 mutations that confer resistance to EZH2 inhibitors prevent EZH2 inhibitor binding to the EZH2 mutants.  Notably, EZH2 inhibitor GSK126- and EPZ-6438-resistant DLBCL cells remained sensitive to the EZH2 inhibitor UNC1999 and embryonic ectoderm development protein inhibitor EED226, which provides an opportunity to treat DLBCLs that are resistant to these drugs.  Collectively, our results underpin the importance for developing a unified approach for forestalling drug resistance by prospectively considering lessons learned from the use of different targeted therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8bPfbf3K8qrVg90H21EOLACvtfcHk0liDjn4Cfb08iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFenurrO&md5=e1e626bc16271b40be809c7587279cff</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-08-804344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-08-804344%26sid%3Dliteratum%253Aachs%26aulast%3DBisserier%26aufirst%3DM.%26aulast%3DWajapeyee%26aufirst%3DN.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EZH2%2520inhibitors%2520in%2520diffuse%2520large%2520B-cell%2520lymphomas%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26issue%3D19%26spage%3D2125%26epage%3D2137%26doi%3D10.1182%2Fblood-2017-08-804344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D. E.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of EED binders allosterically inhibiting the epigenetic Polycomb Repressive Complex 2 (PRC2) methyltransferase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaiurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=415-427&issue=1&author=A.+Lingelauthor=M.+Sendzikauthor=Y.+Huangauthor=M.+D.+Shultzauthor=J.+Cantwellauthor=M.+P.+Dillonauthor=X.+Fuauthor=J.+Fullerauthor=T.+Gabrielauthor=J.+Guauthor=X.+Jiangauthor=L.+Liauthor=F.+Liangauthor=M.+McKennaauthor=W.+Qiauthor=W.+Raoauthor=X.+Shengauthor=W.+Shuauthor=J.+Suttonauthor=B.+Taftauthor=L.+Wangauthor=J.+Zengauthor=H.+Zhangauthor=M.+Zhangauthor=K.+Zhaoauthor=M.+Lindvallauthor=D.+E.+Bussiere&title=Structure-guided+design+of+EED+binders+allosterically+inhibiting+the+epigenetic+Polycomb+Repressive+Complex+2+%28PRC2%29+methyltransferase&doi=10.1021%2Facs.jmedchem.6b01473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase</span></div><div class="casAuthors">Lingel, Andreas; Sendzik, Martin; Huang, Ying; Shultz, Michael D.; Cantwell, John; Dillon, Michael P.; Fu, Xingnian; Fuller, John; Gabriel, Tobias; Gu, Justin; Jiang, Xiangqing; Li, Ling; Liang, Fang; McKenna, Maureen; Qi, Wei; Rao, Weijun; Sheng, Xijun; Shu, Wei; Sutton, James; Taft, Benjamin; Wang, Long; Zeng, Jue; Zhang, Hailong; Zhang, Maya; Zhao, Kehao; Lindvall, Mika; Bussiere, Dirksen E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">415-427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PRC2 is a multisubunit methyltransferase involved in epigenetic regulation of early embryonic development and cell growth.  The catalytic subunit EZH2 methylates primarily lysine 27 of histone H3, leading to chromatin compaction and repression of tumor suppressor genes.  Inhibiting this activity by small mols. targeting EZH2 was shown to result in antitumor efficacy.  Here, the authors describe for the first time the optimization of a chem. series representing a new class of PRC2 inhibitors which acts allosterically via the trimethyllysine pocket of the noncatalytic EED subunit.  Deconstruction of a larger and complex screening hit to a simple fragment-sized mol. followed by structure-guided regrowth and careful property modulation were employed to yield compds. which achieve sub-micromolar inhibition in functional assays and cellular activity.  The resulting mols. can serve as a simplified entry point for lead optimization and can be utilized to study this new mechanism of PRC2 inhibition and the assocd. biol. in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRo2rkeTDLibVg90H21EOLACvtfcHk0lgRDTGnHpTMpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaiurrF&md5=3aec108471439f4ac99728a57b4eaf8e</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01473%26sid%3Dliteratum%253Aachs%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DFuller%26aufirst%3DJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DMcKenna%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DX.%26aulast%3DShu%26aufirst%3DW.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DTaft%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%2BE.%26atitle%3DStructure-guided%2520design%2520of%2520EED%2520binders%2520allosterically%2520inhibiting%2520the%2520epigenetic%2520Polycomb%2520Repressive%2520Complex%25202%2520%2528PRC2%2529%2520methyltransferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D1%26spage%3D415%26epage%3D427%26doi%3D10.1021%2Facs.jmedchem.6b01473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardayfio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and molecular basis of a diverse set of Polycomb repressive complex 2 inhibitors recognition by EED</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e0169855</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0169855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1371%2Fjournal.pone.0169855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28072869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFyjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&issue=1&author=L.+Liauthor=H.+Zhangauthor=M.+Zhangauthor=M.+Zhaoauthor=L.+Fengauthor=X.+Luoauthor=Z.+Gaoauthor=Y.+Huangauthor=O.+Ardayfioauthor=J.-H.+Zhangauthor=Y.+Linauthor=H.+Fanauthor=Y.+Miauthor=G.+Liauthor=L.+Liuauthor=L.+Fengauthor=F.+Luoauthor=L.+Tengauthor=W.+Qiauthor=J.+Ottlauthor=A.+Lingelauthor=D.+E.+Bussiereauthor=Z.+Yuauthor=P.+Atadjaauthor=C.+Luauthor=E.+Liauthor=J.+Guauthor=K.+Zhao&title=Discovery+and+molecular+basis+of+a+diverse+set+of+Polycomb+repressive+complex+2+inhibitors+recognition+by+EED&doi=10.1371%2Fjournal.pone.0169855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and molecular basis of a diverse set of polycomb repressive complex 2 inhibitors recognition by EED</span></div><div class="casAuthors">Li, Ling; Zhang, Hailong; Zhang, Man; Zhao, Mengxi; Feng, Lijian; Luo, Xiao; Gao, Zhenting; Huang, Ying; Ardayfio, Ophelia; Zhang, Ji-Hu; Lin, Ying; Fan, Hong; Mi, Yuan; Li, Guobin; Liu, Lei; Feng, Leying; Luo, Fangjun; Teng, Lin; Qi, Wei; Ottl, Johannes; Lingel, Andreas; Bussiere, Dirksen E.; Yu, Zhengtian; Atadja, Peter; Lu, Chris; Li, En; Gu, Justin; Zhao, Kehao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0169855/1-e0169855/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2), a histone H3 lysine 27 methyltransferase, plays a key role in gene regulation and is a known epigenetics drug target for cancer therapy.  The WD40 domain-contg. protein EED is the regulatory subunit of PRC2.  It binds to the tri-methylated lysine 27 of the histone H3 (H3K27me3), and through which stimulates the activity of PRC2 allosterically.  Recently, we disclosed a novel PRC2 inhibitor EED226 which binds to the K27me3-pocket on EED and showed strong antitumor activity in xenograft mice model.  Here, we further report the identification and validation of four other EED binders along with EED162, the parental compd. of EED226.  The crystal structures for all these five compds. in complex with EED revealed a common deep pocket induced by the binding of this diverse set of compds.  This pocket was created after significant conformational rearrangement of the arom. cage residues (Y365, Y148 and F97) in the H3K27me3 binding pocket of EED, the width of which was delineated by the side chains of these rearranged residues.  In addn., all five compds. interact with the Arg367 at the bottom of the pocket.  Each compd. also displays unique features in its interaction with EED, suggesting the dynamics of the H3K27me3 pocket in accommodating the binding of different compds.  Our results provide structural insights for rational design of novel EED binder for the inhibition of PRC2 complex activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBpGXyLD21irVg90H21EOLACvtfcHk0lgRDTGnHpTMpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFyjsb8%253D&md5=69c8c6b0f83866296d21f5fd23927c3e</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0169855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0169855%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DArdayfio%26aufirst%3DO.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DOttl%26aufirst%3DJ.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%2BE.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520molecular%2520basis%2520of%2520a%2520diverse%2520set%2520of%2520Polycomb%2520repressive%2520complex%25202%2520inhibitors%2520recognition%2520by%2520EED%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D1%26doi%3D10.1371%2Fjournal.pone.0169855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnash, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">The, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholensky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worley, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptidomimetic ligands of EED as allosteric inhibitors of PRC2</span>. <i>ACS Comb. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1021/acscombsci.6b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscombsci.6b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=161-172&issue=3&author=K.+D.+Barnashauthor=J.+Theauthor=J.+L.+Norris-Drouinauthor=S.+H.+Cholenskyauthor=B.+M.+Worleyauthor=F.+Liauthor=J.+I.+Stuckeyauthor=P.+J.+Brownauthor=M.+Vedadiauthor=C.+H.+Arrowsmithauthor=S.+V.+Fryeauthor=L.+I.+James&title=Discovery+of+peptidomimetic+ligands+of+EED+as+allosteric+inhibitors+of+PRC2&doi=10.1021%2Facscombsci.6b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2</span></div><div class="casAuthors">Barnash, Kimberly D.; The, Juliana; Norris-Drouin, Jacqueline L.; Cholensky, Stephanie H.; Worley, Beau M.; Li, Fengling; Stuckey, Jacob I.; Brown, Peter J.; Vedadi, Masoud; Arrowsmith, Cheryl H.; Frye, Stephen V.; James, Lindsey I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Combinatorial Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-172</span>CODEN:
                <span class="NLM_cas:coden">ACSCCC</span>;
        ISSN:<span class="NLM_cas:issn">2156-8944</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The function of EED within Polycomb repressive complex 2 (PRC2) is mediated by a complex network of protein-protein interactions.  Allosteric activation of PRC2 by binding of methylated proteins to EED's arom. cage is essential for full catalytic activity, but details of this regulation are not fully understood.  EED's recognition of the product of PRC2 activity, histone H3 lysine 27 trimethylation (H3K27me3), stimulates PRC2 methyltransferase activity at adjacent nucleosomes leading to H3K27me3 propagation and, ultimately, gene repression.  By coupling combinatorial chem. and structure-based design, we optimized a low affinity methylated Jarid2 peptide to a smaller, more potent peptidomimetic ligand (Kd = 1.14 ± 0.14 μM) of the arom. cage of EED.  Our strategy illustrates the effectiveness of applying combinatorial chem. to achieve both ligand potency and property optimization.  Furthermore, the resulting ligands, UNC5114 and UNC5115, demonstrate that targeted disruption of EED's reader function can lead to allosteric inhibition of PRC2 catalytic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwOqOVJ8hSD7Vg90H21EOLACvtfcHk0lgRDTGnHpTMpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWgsrw%253D&md5=0e7da46fc40d89f4095ac979374338fc</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facscombsci.6b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscombsci.6b00174%26sid%3Dliteratum%253Aachs%26aulast%3DBarnash%26aufirst%3DK.%2BD.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%2BL.%26aulast%3DCholensky%26aufirst%3DS.%2BH.%26aulast%3DWorley%26aufirst%3DB.%2BM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DStuckey%26aufirst%3DJ.%2BI.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DJames%26aufirst%3DL.%2BI.%26atitle%3DDiscovery%2520of%2520peptidomimetic%2520ligands%2520of%2520EED%2520as%2520allosteric%2520inhibitors%2520of%2520PRC2%26jtitle%3DACS%2520Comb.%2520Sci.%26date%3D2017%26volume%3D19%26issue%3D3%26spage%3D161%26epage%3D172%26doi%3D10.1021%2Facscombsci.6b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnash, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">The, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelberg, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective activators of PRC2 mutant EED-I363M</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">6524</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-43005-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41598-019-43005-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31024026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fptlajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=6524&issue=1&author=J.+L.+Suhauthor=K.+D.+Barnashauthor=T.+M.+Abramyanauthor=F.+Liauthor=J.+Theauthor=I.+A.+Engelbergauthor=M.+Vedadiauthor=P.+J.+Brownauthor=D.+B.+Kireevauthor=C.+H.+Arrowsmithauthor=L.+I.+Jamesauthor=S.+V.+Frye&title=Discovery+of+selective+activators+of+PRC2+mutant+EED-I363M&doi=10.1038%2Fs41598-019-43005-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective activators of PRC2 mutant EED-I363M</span></div><div class="casAuthors">Suh Junghyun L; Barnash Kimberly D; Abramyan Tigran M; Engelberg Isabelle A; Kireev Dmitri B; James Lindsey I; Frye Stephen V; Barnash Kimberly D; Li Fengling; The Juliana; Vedadi Masoud; Brown Peter J; Arrowsmith Cheryl H; Arrowsmith Cheryl H</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6524</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many common disease-causing mutations result in loss-of-function (LOF) of the proteins in which they occur.  LOF mutations have proven recalcitrant to pharmacologic intervention, presenting a challenge for the development of targeted therapeutics.  Polycomb repressive complex 2 (PRC2), which contains core subunits (EZH2, EED, and SUZ12), regulates gene activity by trimethylation of histone 3 lysine 27.  The dysregulation of PRC2 catalytic activity by mutations has been implicated in cancer and other diseases.  Among the mutations that cause PRC2 malfunction, an I363M LOF mutation of EED has been identified in myeloid disorders, where it prevents allosteric activation of EZH2 catalysis.  We describe structure-based design and computational simulations of ligands created to ameliorate this LOF.  Notably, these compounds selectively stimulate the catalytic activity of PRC2-EED-I363M over wildtype-PRC2.  Overall, this work demonstrates the feasibility of developing targeted therapeutics for PRC2-EED-I363M that act as allosteric agonists, potentially correcting this LOF mutant phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy_y3UKz_BfTQLBVDQn4bCfW6udTcc2eYRM0tXvJRu4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fptlajtg%253D%253D&md5=92fb9e3260bdc49440a1b803c833ed9e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-43005-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-43005-z%26sid%3Dliteratum%253Aachs%26aulast%3DSuh%26aufirst%3DJ.%2BL.%26aulast%3DBarnash%26aufirst%3DK.%2BD.%26aulast%3DAbramyan%26aufirst%3DT.%2BM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DEngelberg%26aufirst%3DI.%2BA.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DKireev%26aufirst%3DD.%2BB.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DJames%26aufirst%3DL.%2BI.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26atitle%3DDiscovery%2520of%2520selective%2520activators%2520of%2520PRC2%2520mutant%2520EED-I363M%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D6524%26doi%3D10.1038%2Fs41598-019-43005-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Z.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span> <span> </span><span class="NLM_article-title">Propagation of trimethylated H3K27 regulated by Polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">10370</span>– <span class="NLM_lpage">10375</span>, <span class="refDoi"> DOI: 10.1073/pnas.1600070113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1073%2Fpnas.1600070113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=27578866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVegs7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=10370-10375&issue=37&author=T.+Uedaauthor=Y.+Nakataauthor=A.+Nagamachiauthor=N.+Yamasakiauthor=A.+Kanaiauthor=Y.+Seraauthor=M.+Sasakiauthor=H.+Matsuiauthor=Z.-i.+Hondaauthor=H.+Odaauthor=L.+Wolffauthor=T.+Inabaauthor=H.+Honda&title=Propagation+of+trimethylated+H3K27+regulated+by+Polycomb+protein+EED+is+required+for+embryogenesis%2C+hematopoietic+maintenance%2C+and+tumor+suppression&doi=10.1073%2Fpnas.1600070113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Propagation of trimethylated H3K27 regulated by polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression</span></div><div class="casAuthors">Ueda, Takeshi; Nakata, Yuichiro; Nagamachi, Akiko; Yamasaki, Norimasa; Kanai, Akinori; Sera, Yasuyuki; Sasaki, Masato; Matsui, Hirotaka; Honda, Zen-ichiro; Oda, Hideaki; Wolff, Linda; Inaba, Toshiya; Honda, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">10370-10375</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) catalyzes the monomethylation, dimethylation, and trimethylation of histone H3 Lys27 (H3K27) and acts as a central epigenetic regulator that marks the repressive chromatin domain.  Embryonic ectoderm development (EED), an essential component of PRC2, interacts with trimethylated H3K27 (H3K27me3) through the arom. cage structure composed of its three arom. amino acids, Phe97, Trp364, and Tyr365.  This interaction allosterically activates the histone methyltransferase activity of PRC2 and thereby propagates repressive histone marks.  In this study, we report the anal. of knock-in mice harboring the myeloid disorder-assocd. EED Ile363Met (I363M) mutation, analogous to the EED arom. cage mutants.  The I363M homozygotes displayed a remarkable and preferential redn. of H3K27me3 and died at mid-gestation.  The heterozygotes increased the clonogenic capacity and bone marrow repopulating activity of hematopoietic stem/progenitor cells (HSPCs) and were susceptible to leukemia.  Lgals3, a PRC2 target gene encoding a multifunctional galactose-binding lectin, was derepressed in I363M heterozygotes, which enhanced the stemness of HSPCs.  Thus, our work provides in vivo evidence that the structural integrity of EED to H3K27me3 propagation is crit., esp. for embryonic development and hematopoietic homeostasis, and that its perturbation increases the predisposition to hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLX-SDuRygrVg90H21EOLACvtfcHk0li9noiNWu4Kdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVegs7rN&md5=3770f9cd696a1a69424f38326d25007f</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1600070113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1600070113%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DNakata%26aufirst%3DY.%26aulast%3DNagamachi%26aufirst%3DA.%26aulast%3DYamasaki%26aufirst%3DN.%26aulast%3DKanai%26aufirst%3DA.%26aulast%3DSera%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DHonda%26aufirst%3DZ.-i.%26aulast%3DOda%26aufirst%3DH.%26aulast%3DWolff%26aufirst%3DL.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DH.%26atitle%3DPropagation%2520of%2520trimethylated%2520H3K27%2520regulated%2520by%2520Polycomb%2520protein%2520EED%2520is%2520required%2520for%2520embryogenesis%252C%2520hematopoietic%2520maintenance%252C%2520and%2520tumor%2520suppression%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D37%26spage%3D10370%26epage%3D10375%26doi%3D10.1073%2Fpnas.1600070113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Z. i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span> <span> </span><span class="NLM_article-title">EED mutants impair Polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2557</span>– <span class="NLM_lpage">2560</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fleu.2012.146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=22733077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVChs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2557-2560&issue=12&author=T.+Uedaauthor=M.+Sanadaauthor=H.+Matsuiauthor=N.+Yamasakiauthor=Z.+i.+Hondaauthor=L.+Y.+Shihauthor=H.+Moriauthor=T.+Inabaauthor=S.+Ogawaauthor=H.+Honda&title=EED+mutants+impair+Polycomb+repressive+complex+2+in+myelodysplastic+syndrome+and+related+neoplasms.&doi=10.1038%2Fleu.2012.146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms</span></div><div class="casAuthors">Ueda, T.; Sanada, M.; Matsui, H.; Yamasaki, N.; Honda, Z.-I.; Shih, L.-Y.; Mori, H.; Inaba, T.; Ogawa, S.; Honda, H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2557-2560</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This paper describes EED mutants impair Polycomb recessive complex 2 (PRC2) in myelodysplastic syndrome and related neoplasms.  The six mutated forms of EED displayed functional defects involving changes: (i) protein stability, (ii) interaction with EZH2 and/or (iii) binding to H3K27me3, thereby impairing PRC2 function.  Recurrent mutations in PRC2 may constitute a new mol.-based disease category of myeloid malignancies are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN5kgOaBYnbbVg90H21EOLACvtfcHk0liZ6NbGGSYyvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVChs73I&md5=a830e98f1f7e09c77be26e653442d198</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.146%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DYamasaki%26aufirst%3DN.%26aulast%3DHonda%26aufirst%3DZ.%2Bi.%26aulast%3DShih%26aufirst%3DL.%2BY.%26aulast%3DMori%26aufirst%3DH.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DHonda%26aufirst%3DH.%26atitle%3DEED%2520mutants%2520impair%2520Polycomb%2520repressive%2520complex%25202%2520in%2520myelodysplastic%2520syndrome%2520and%2520related%2520neoplasms.%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D12%26spage%3D2557%26epage%3D2560%26doi%3D10.1038%2Fleu.2012.146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of Polycomb repressive complex 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9512</span>– <span class="NLM_lpage">9521</span>, <span class="refDoi"> DOI: 10.1021/jm501230c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501230c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9512-9521&issue=22&author=X.+Kongauthor=L.+Chenauthor=L.+Jiaoauthor=X.+Jiangauthor=F.+Lianauthor=J.+Luauthor=K.+Zhuauthor=D.+Duauthor=J.+Liuauthor=H.+Dingauthor=N.+Zhangauthor=J.+Shenauthor=M.+Zhengauthor=K.+Chenauthor=X.+Liuauthor=H.+Jiangauthor=C.+Luo&title=Astemizole+arrests+the+proliferation+of+cancer+cells+by+disrupting+the+EZH2-EED+interaction+of+Polycomb+repressive+complex+2&doi=10.1021%2Fjm501230c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2</span></div><div class="casAuthors">Kong, Xiangqian; Chen, Limin; Jiao, Lianying; Jiang, Xiangrui; Lian, Fulin; Lu, Junyan; Zhu, Kongkai; Du, Daohai; Liu, Jingqiu; Ding, Hong; Zhang, Naixia; Shen, Jingshan; Zheng, Mingyue; Chen, Kaixian; Liu, Xin; Jiang, Hualiang; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9512-9521</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb Repressive Complex 2 (PRC2) modulates the chromatin structure and transcriptional repression by trimethylation lysine 27 of histone H3 (H3K27me3), a process that necessitates the protein-protein interaction (PPI) between the catalytic subunit EZH2 and EED.  Deregulated PRC2 is intimately involved in tumorigenesis and progression, making it an invaluable target for epigenetic cancer therapy.  However, until now, there have been no reported small mol. compds. targeting the EZH2-EED interactions.  In the present study, we identified astemizole, an FDA-approved drug, as a small mol. inhibitor of the EZH2-EED interaction of PRC2.  The disruption of the EZH2-EED interaction by astemizole destabilizes the PRC2 complex and inhibits its methyltransferase activity in cancer cells.  Multiple lines of evidence have demonstrated that astemizole arrests the proliferation of PRC2-driven lymphomas primarily by disabling the PRC2 complex.  Our findings demonstrate the chem. tractability of the difficult PPI target by a small mol. compd., highlighting the therapeutic promise for PRC2-driven human cancers via targeted destruction of the EZH2-EED complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUoHR0GppdWLVg90H21EOLACvtfcHk0liZ6NbGGSYyvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nO&md5=9aa407fe354ba7e272bdfb6c6445f7f3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm501230c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501230c%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLian%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DAstemizole%2520arrests%2520the%2520proliferation%2520of%2520cancer%2520cells%2520by%2520disrupting%2520the%2520EZH2-EED%2520interaction%2520of%2520Polycomb%2520repressive%2520complex%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D22%26spage%3D9512%26epage%3D9521%26doi%3D10.1021%2Fjm501230c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">13049</span>– <span class="NLM_lpage">13059</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.18632%2Foncotarget.3790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=25944687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A280%3ADC%252BC2MfgvFGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=13049-13059&issue=15&author=H.+Chenauthor=S.+Gaoauthor=J.+Liauthor=D.+Liuauthor=C.+Shengauthor=C.+Yaoauthor=W.+Jiangauthor=J.+Wuauthor=S.+Chenauthor=W.+Huang&title=Wedelolactone+disrupts+the+interaction+of+EZH2-EED+complex+and+inhibits+PRC2-dependent+cancer&doi=10.18632%2Foncotarget.3790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer</span></div><div class="casAuthors">Chen Huiming; Gao Shijuan; Li Jiandong; Liu Dong; Sheng Chunjie; Yao Chen; Jiang Wei; Wu Jiaoxiang; Chen Shuai; Huang Wenlin; Chen Huiming; Yao Chen; Wu Jiaoxiang; Chen Shuai; Huang Wenlin; Huang Wenlin</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">13049-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2), which is responsible for the trimethylation of H3K27 (H3K27me3), plays a part in tumorigenesis, development and/or maintenance of adult tissue specificity.  The pivotal role of PRC2 in cancer makes it a therapeutic target for epigenetic cancer therapy.  However, natural compounds targeting the enhancer of zeste homolog 2 (EZH2) - embryonic ectoderm development (EED) interaction to disable PRC2 complex are scarcely reported.  Here, we reported the screening and identification of natural compounds which could disrupt the EZH2-EED interaction.  One of these compounds, wedelolactone, binds to EED with a high affinity (KD = 2.82 μM), blocks the EZH2-EED interaction in vitro, induces the degradation of PRC2 core components and modulates the expression of detected PRC2 downstream targets and cancer-related genes.  Furthermore, some PRC2-dependent cancer cells undergone growth arrest upon treatment with wedelolactone.  Thus, wedelolactone and its derivatives which target the EZH2-EED interaction could be candidates for the treatment of PRC2-dependent cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVWfUI8TyID75XHngOXiV_fW6udTcc2eZSe6NFal64Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfgvFGiuw%253D%253D&md5=409700e2287c7af5ed9ea2a504b5675f</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3790%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DWedelolactone%2520disrupts%2520the%2520interaction%2520of%2520EZH2-EED%2520complex%2520and%2520inhibits%2520PRC2-dependent%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D15%26spage%3D13049%26epage%3D13059%26doi%3D10.18632%2Foncotarget.3790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostic, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in selective and irreversible covalent ligand development and validation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1486</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2019.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31631011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1486-1500&issue=11&author=T.+Zhangauthor=J.+M.+Hatcherauthor=M.+Tengauthor=N.+S.+Grayauthor=M.+Kostic&title=Recent+advances+in+selective+and+irreversible+covalent+ligand+development+and+validation&doi=10.1016%2Fj.chembiol.2019.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation</span></div><div class="casAuthors">Zhang, Tinghu; Hatcher, John M.; Teng, Mingxing; Gray, Nathanael S.; Kostic, Milka</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1486-1500</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Some of the most widely used drugs, such as aspirin and penicillin, are covalent drugs.  Covalent binding can improve potency, selectivity, and duration of the effects, but the intrinsic reactivity represents a potential liability and may result in idiosyncratic toxicity.  For decades, the cons were believed to outweigh the pros, and covalent targeting was deprioritized in drug discovery.  Recently, several covalent inhibitors have been approved for cancer treatment, thus rebooting the field.  In this review, we briefly reflect on the history of selective covalent targeting, and provide a comprehensive overview of emerging developments from a chem. biol. stand-point.  Our discussion will reflect on efforts to validate irreversible covalent ligands, expand the scope of targets, and discover new ligands and warheads.  We conclude with a brief commentary of remaining limitations and emerging opportunities in selective covalent targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc9UIuWjfX97Vg90H21EOLACvtfcHk0li09_txevyaIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO&md5=ce957a868ca27f545243d28e60dc5868</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKostic%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520selective%2520and%2520irreversible%2520covalent%2520ligand%2520development%2520and%2520validation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D11%26spage%3D1486%26epage%3D1500%26doi%3D10.1016%2Fj.chembiol.2019.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span> <span> </span><span class="NLM_article-title">A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.15252/embj.201694058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.15252%2Fembj.201694058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=28320739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=1243-1260&issue=9&author=X.+Wangauthor=W.+Caoauthor=J.+Zhangauthor=M.+Yanauthor=Q.+Xuauthor=X.+Wuauthor=L.+Wanauthor=Z.+Zhangauthor=C.+Zhangauthor=X.+Qinauthor=M.+Xiaoauthor=D.+Yeauthor=Y.+Liuauthor=Z.+Hanauthor=S.+Wangauthor=L.+Maoauthor=W.+Weiauthor=W.+Chen&title=A+covalently+bound+inhibitor+triggers+EZH2+degradation+through+CHIP-mediated+ubiquitination&doi=10.15252%2Fembj.201694058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination</span></div><div class="casAuthors">Wang, Xu; Cao, Wei; Zhang, Jianjun; Yan, Ming; Xu, Qin; Wu, Xiangbing; Wan, Lixin; Zhang, Zhiyuan; Zhang, Chenping; Qin, Xing; Xiao, Meng; Ye, Dongxia; Liu, Yuyang; Han, Zeguang; Wang, Shaomeng; Mao, Li; Wei, Wenyi; Chen, Wantao</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1243-1260</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2) has been characterized as a crit. oncogene and a promising drug target in human malignant tumors.  The current EZH2 inhibitors strongly suppress the enhanced enzymic function of mutant EZH2 in some lymphomas.  However, the recent identification of a PRC2- and methyltransferase-independent role of EZH2 indicates that a complete suppression of all oncogenic functions of EZH2 is needed.  Here, we report a unique EZH2-targeting strategy by identifying a gambogenic acid (GNA) deriv. as a novel agent that specifically and covalently bound to Cys668 within the EZH2-SET domain, triggering EZH2 degrdn. through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.  This class of inhibitors significantly suppressed H3K27Me3 and effectively reactivated polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes.  Moreover, the novel inhibitors significantly suppressed tumor growth in an EZH2-dependent manner, and tumors bearing a non-GNA-interacting C668S-EZH2 mutation exhibited resistance to the inhibitors.  Together, our results identify the inhibition of the signaling pathway that governs GNA-mediated destruction of EZH2 as a promising anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRQknSdWy5T7Vg90H21EOLACvtfcHk0li09_txevyaIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D&md5=b9b8a266537e2922648784d9cd4edf02</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.15252%2Fembj.201694058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201694058%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26atitle%3DA%2520covalently%2520bound%2520inhibitor%2520triggers%2520EZH2%2520degradation%2520through%2520CHIP-mediated%2520ubiquitination%26jtitle%3DEMBO%2520J.%26date%3D2017%26volume%3D36%26issue%3D9%26spage%3D1243%26epage%3D1260%26doi%3D10.15252%2Fembj.201694058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratikopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rialdi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class EZH2 selective degrader</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0421-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1038%2Fs41589-019-0421-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31819273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCht7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=214-222&issue=2&author=A.+Maauthor=E.+Stratikopoulosauthor=K.+S.+Parkauthor=J.+Weiauthor=T.+C.+Martinauthor=X.+Yangauthor=M.+Schwarzauthor=V.+Leshchenkoauthor=A.+Rialdiauthor=B.+Daleauthor=A.+Laganaauthor=E.+Guccioneauthor=S.+Parekhauthor=R.+Parsonsauthor=J.+Jin&title=Discovery+of+a+first-in-class+EZH2+selective+degrader&doi=10.1038%2Fs41589-019-0421-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a first-in-class EZH2 selective degrader</span></div><div class="casAuthors">Ma, Anqi; Stratikopoulos, Elias; Park, Kwang-Su; Wei, Jieli; Martin, Tiphaine C.; Yang, Xiaobao; Schwarz, Megan; Leshchenko, Violetta; Rialdi, Alexander; Dale, Brandon; Lagana, Alessandro; Guccione, Ernesto; Parekh, Samir; Parsons, Ramon; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-222</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The enhancer of zeste homolog 2 (EZH2) is the main enzymic subunit of the PRC2 complex, which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3) to promote transcriptional silencing.  EZH2 is overexpressed in multiple types of cancer including triple-neg. breast cancer (TNBC), and high expression levels correlate with poor prognosis.  Several EZH2 inhibitors, which inhibit the methyltransferase activity of EZH2, have shown promise in treating sarcoma and follicular lymphoma in clinics.  However, EZH2 inhibitors are ineffective at blocking proliferation of TNBC cells, even though they effectively reduce the H3K27me3 mark.  Using a hydrophobic tagging approach, we generated MS1943, a first-in-class EZH2 selective degrader that effectively reduces EZH2 levels in cells.  Importantly, MS1943 has a profound cytotoxic effect in multiple TNBC cells, while sparing normal cells, and is efficacious in vivo, suggesting that pharmacol. degrdn. of EZH2 can be advantageous for treating the cancers that are dependent on EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPb6bK3v_gQrVg90H21EOLACvtfcHk0li09_txevyaIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCht7zJ&md5=e1ccae457eba9b298f8b0e583bbaa833</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0421-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0421-4%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DA.%26aulast%3DStratikopoulos%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DK.%2BS.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DT.%2BC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DLeshchenko%26aufirst%3DV.%26aulast%3DRialdi%26aufirst%3DA.%26aulast%3DDale%26aufirst%3DB.%26aulast%3DLagana%26aufirst%3DA.%26aulast%3DGuccione%26aufirst%3DE.%26aulast%3DParekh%26aufirst%3DS.%26aulast%3DParsons%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520EZH2%2520selective%2520degrader%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26issue%3D2%26spage%3D214%26epage%3D222%26doi%3D10.1038%2Fs41589-019-0421-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konze, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meslamani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaniskan, H. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7617</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00855</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00855" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmtr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7617-7633&issue=16&author=X.+Yangauthor=F.+Liauthor=K.+D.+Konzeauthor=J.+Meslamaniauthor=A.+Maauthor=P.+J.+Brownauthor=M.+M.+Zhouauthor=C.+H.+Arrowsmithauthor=H.+U.+Kaniskanauthor=M.+Vedadiauthor=J.+Jin&title=Structure-activity+relationship+studies+for+Enhancer+of+Zeste+Homologue+2+%28EZH2%29+and+Enhancer+of+Zeste+Homologue+1+%28EZH1%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors</span></div><div class="casAuthors">Yang, Xiaobao; Li, Fengling; Konze, Kyle D.; Meslamani, Jamel; Ma, Anqi; Brown, Peter J.; Zhou, Ming-Ming; Arrowsmith, Cheryl H.; Kaniskan, H. Umit; Vedadi, Masoud; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7617-7633</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EZH2 or EZH1 (enhancer of zeste homolog 2 or 1) is the catalytic subunit of polycomb repressive complex 2 (PRC2) that catalyzes methylation of histone H3 lysine 27 (H3K27).  PRC2 hyperactivity and/or hypertrimethylation of H3K27 are assocd. with numerous human cancers, therefore inhibition of PRC2 complex has emerged as a promising therapeutic approach.  Recent studies have shown that EZH2 and EZH1 are not functionally redundant and inhibition of both EZH2 and EZH1 is necessary to block the progression of certain cancers such as MLL (mixed-lineage leukemia)-rearranged leukemias.  Despite the significant advances in discovery of EZH2 inhibitors, there has not been a systematic structure-activity relation (SAR) study to investigate the selectivity between EZH2 and EZH1 inhibition.  Here, the authors report the authors SAR studies that focus on modifications to various regions of the EZH2/1 inhibitor UNC1999 (5) to investigate the impact of the structural changes on EZH2 and EZH1 inhibition and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7AOr5A2kOH7Vg90H21EOLACvtfcHk0ljWwdGXNsNjOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmtr3P&md5=14d5dba978adc28baaf2b781ae9a1541</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00855%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKonze%26aufirst%3DK.%2BD.%26aulast%3DMeslamani%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DZhou%26aufirst%3DM.%2BM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DKaniskan%26aufirst%3DH.%2BU.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%2520studies%2520for%2520Enhancer%2520of%2520Zeste%2520Homologue%25202%2520%2528EZH2%2529%2520and%2520Enhancer%2520of%2520Zeste%2520Homologue%25201%2520%2528EZH1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D16%26spage%3D7617%26epage%3D7633%26doi%3D10.1021%2Facs.jmedchem.6b00855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmusson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Donovan, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloecher, A.</span></span> <span> </span><span class="NLM_article-title">EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2019.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31786184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1KqsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=41-46&issue=1&author=J.+H.+Hsuauthor=T.+Rasmussonauthor=J.+Robinsonauthor=F.+Pachlauthor=J.+Readauthor=S.+Kawatkarauthor=D.+H.+O%27Donovanauthor=S.+Bagalauthor=E.+Codeauthor=P.+Rawlinsauthor=A.+Argyrouauthor=R.+Tomlinsonauthor=N.+Gaoauthor=X.+Zhuauthor=E.+Chiarparinauthor=K.+Jacquesauthor=M.+Shenauthor=H.+Woodsauthor=E.+Bednarskiauthor=D.+M.+Wilsonauthor=L.+Drewauthor=M.+P.+Castaldiauthor=S.+Fawellauthor=A.+Bloecher&title=EED-targeted+PROTACs+degrade+EED%2C+EZH2%2C+and+SUZ12+in+the+PRC2+complex&doi=10.1016%2Fj.chembiol.2019.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex</span></div><div class="casAuthors">Hsu, Jessie Hao-Ru; Rasmusson, Timothy; Robinson, James; Pachl, Fiona; Read, Jon; Kawatkar, Sameer; O' Donovan, Daniel H.; Bagal, Sharan; Code, Erin; Rawlins, Philip; Argyrou, Argyrides; Tomlinson, Ronald; Gao, Ning; Zhu, Xiahui; Chiarparin, Elisabetta; Jacques, Kelly; Shen, Minhui; Woods, Haley; Bednarski, Emma; Wilson, David M.; Drew, Lisa; Castaldi, M. Paola; Fawell, Stephen; Bloecher, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-46.e17</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Deregulation of the PRC2 complex, comprised of the core subunits EZH2, SUZ12, and EED, drives aberrant hypermethylation of H3K27 and tumorigenicity of many cancers.  Although inhibitors of EZH2 have shown promising clin. activity, preclin. data suggest that resistance can be acquired through secondary mutations in EZH2 that abrogate drug target engagement.  To address these limitations, we have designed several hetero-bifunctional PROTACs (proteolysis-targeting chimera) to efficiently target EED for elimination.  Our PROTACs bind to EED (pKD ~ 9.0) and promote ternary complex formation with the E3 ubiquitin ligase.  The PROTACs potently inhibit PRC2 enzyme activity (pIC50 ~ 8.1) and induce rapid degrdn. of not only EED but also EZH2 and SUZ12 within the PRC2 complex.  Furthermore, the PROTACs selectively inhibit proliferation of PRC2-dependent cancer cells (half maximal growth inhibition [GI50] = 49-58 nM).  In summary, our data demonstrate a therapeutic modality to target PRC2-dependent cancer through a PROTAC-mediated degrdn. mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WGn283nfDLVg90H21EOLACvtfcHk0ljWwdGXNsNjOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1KqsrnO&md5=791238d7d1423f4a715529cfa14bfb65</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DJ.%2BH.%26aulast%3DRasmusson%26aufirst%3DT.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DO%2527Donovan%26aufirst%3DD.%2BH.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DCode%26aufirst%3DE.%26aulast%3DRawlins%26aufirst%3DP.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DTomlinson%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DJacques%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DH.%26aulast%3DBednarski%26aufirst%3DE.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DCastaldi%26aufirst%3DM.%2BP.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DBloecher%26aufirst%3DA.%26atitle%3DEED-targeted%2520PROTACs%2520degrade%2520EED%252C%2520EZH2%252C%2520and%2520SUZ12%2520in%2520the%2520PRC2%2520complex%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D41%26epage%3D46%26doi%3D10.1016%2Fj.chembiol.2019.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potjewyd, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rectenwald, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholensky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. I.</span></span> <span> </span><span class="NLM_article-title">Degradation of Polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1016%2Fj.chembiol.2019.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=31831267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlOmt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=47-56&issue=1&author=F.+Potjewydauthor=A.+W.+Turnerauthor=J.+Beriauthor=J.+M.+Rectenwaldauthor=J.+L.+Norris-Drouinauthor=S.+H.+Cholenskyauthor=D.+M.+Margolisauthor=K.+H.+Pearceauthor=L.+E.+Herringauthor=L.+I.+James&title=Degradation+of+Polycomb+repressive+complex+2+with+an+EED-targeted+bivalent+chemical+degrader&doi=10.1016%2Fj.chembiol.2019.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader</span></div><div class="casAuthors">Potjewyd, Frances; Turner, Anne-Marie W.; Beri, Joshua; Rectenwald, Justin M.; Norris-Drouin, Jacqueline L.; Cholensky, Stephanie H.; Margolis, David M.; Pearce, Kenneth H.; Herring, Laura E.; James, Lindsey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-56.e15</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein degrdn. via the use of bivalent chem. degraders provides an alternative strategy to block protein function and assess the biol. roles of putative drug targets.  This approach capitalizes on the advantages of small-mol. inhibitors while moving beyond the restrictions of traditional pharmacol.  Here, we report a chem. degrader (UNC6852) that targets polycomb repressive complex 2 (PRC2).  UNC6852 contains an EED226-derived ligand and a ligand for VHL which bind to the WD40 arom. cage of EED and CRL2VHL, resp., to induce proteasomal degrdn. of PRC2 components, EED, EZH2, and SUZ12.  Degrdn. of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B cell lymphoma (DLBCL) cells contg. EZH2 gain-of-function mutations.  UNC6852 degrades both wild-type and mutant EZH2, and addnl. displays anti-proliferative effects in this cancer model system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF3p-HFdD9KLVg90H21EOLACvtfcHk0ljWwdGXNsNjOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlOmt7bM&md5=7d9ca2726bad4e40003310951edc09d4</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DPotjewyd%26aufirst%3DF.%26aulast%3DTurner%26aufirst%3DA.%2BW.%26aulast%3DBeri%26aufirst%3DJ.%26aulast%3DRectenwald%26aufirst%3DJ.%2BM.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%2BL.%26aulast%3DCholensky%26aufirst%3DS.%2BH.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26aulast%3DPearce%26aufirst%3DK.%2BH.%26aulast%3DHerring%26aufirst%3DL.%2BE.%26aulast%3DJames%26aufirst%3DL.%2BI.%26atitle%3DDegradation%2520of%2520Polycomb%2520repressive%2520complex%25202%2520with%2520an%2520EED-targeted%2520bivalent%2520chemical%2520degrader%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.chembiol.2019.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">A Polycomb repression signature in metastatic prostate cancer predicts cancer outcome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10657</span>– <span class="NLM_lpage">10663</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=10.1158%2F0008-5472.CAN-07-2498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=18006806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=10657-10663&issue=22&author=J.+Yuauthor=J.+Yuauthor=D.+R.+Rhodesauthor=S.+A.+Tomlinsauthor=X.+Caoauthor=G.+Chenauthor=R.+Mehraauthor=X.+Wangauthor=D.+Ghoshauthor=R.+B.+Shahauthor=S.+Varamballyauthor=K.+J.+Pientaauthor=A.+M.+Chinnaiyan&title=A+Polycomb+repression+signature+in+metastatic+prostate+cancer+predicts+cancer+outcome&doi=10.1158%2F0008-5472.CAN-07-2498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome</span></div><div class="casAuthors">Yu, Jindan; Yu, Jianjun; Rhodes, Daniel R.; Tomlins, Scott A.; Cao, Xuhong; Chen, Guoan; Mehra, Rohit; Wang, Xiaoju; Ghosh, Debashis; Shah, Rajal B.; Varambally, Sooryanarayana; Pienta, Kenneth J.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10657-10663</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Polycomb Group (PcG) protein EZH2 is a crit. component of a multiprotein complex that methylates Lys27 of histone 3 (H3K27), which consequently leads to the repression of target gene expression.  We have previously reported that EZH2 is overexpressed in metastatic prostate cancer and is a marker of aggressive diseases in clin. localized solid tumors.  However, the global set of genes directly regulated by PcG in tumors is largely unknown, and thus how PcG mediates tumor progression remains unclear.  Herein we mapped genome-wide H3K27 methylation in aggressive, disseminated human prostate cancer tissues.  Integrative anal. revealed that a significant subset of these genes are also targets of PcG in embryonic stem cells, and their repression in tumors is assocd. with poor prognosis.  By stepwise cross-validation, we developed a "Polycomb repression signature" composed of 14 direct targets of PcG in metastatic tumors.  Notably, solid tumor subtypes in which this gene signature is repressed show poor clin. outcome in multiple microarray data sets of tumors including breast and prostate cancer.  Taken together, our results show a fingerprint of PcG-mediated transcriptional repression in metastatic prostate cancer that is reminiscent of stem cells and assocd. with cancer progression.  Therefore, PcG proteins play a central role in the epigenetic silencing of target genes and functionally link stem cells, metastasis, and cancer survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVnXl_rXgadbVg90H21EOLACvtfcHk0lglbXur_Q7pIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7rO&md5=27bcf577683e5be369d74bfd380b267d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2498%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DRhodes%26aufirst%3DD.%2BR.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DShah%26aufirst%3DR.%2BB.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DA%2520Polycomb%2520repression%2520signature%2520in%2520metastatic%2520prostate%2520cancer%2520predicts%2520cancer%2520outcome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D22%26spage%3D10657%26epage%3D10663%26doi%3D10.1158%2F0008-5472.CAN-07-2498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maneiro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shchepinova, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kounde, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span> <span> </span><span class="NLM_article-title">Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1021/acschembio.0c00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.0c00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1306-1312&issue=6&author=M.+A.+Maneiroauthor=N.+Forteauthor=M.+M.+Shchepinovaauthor=C.+S.+Koundeauthor=V.+Chudasamaauthor=J.+R.+Bakerauthor=E.+W.+Tate&title=Antibody-PROTAC+conjugates+enable+HER2-dependent+targeted+protein+degradation+of+BRD4&doi=10.1021%2Facschembio.0c00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4</span></div><div class="casAuthors">Maneiro, Maria; Forte, Nafsika; Shchepinova, Maria M.; Kounde, Cyrille S.; Chudasama, Vijay; Baker, James Richard; Tate, Edward W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-1312</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting protein degrdn. with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery.  Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity and do not discriminate between cells of different types.  Here, we describe a strategy for selective protein degrdn. in a specific cell type.  We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internalization, releasing the active PROTAC and inducing catalytic protein degrdn.  We show that 3 selectively targets bromodomain-contg. protein 4 (BRD4) for degrdn. only in HER2 pos. breast cancer cell lines, while sparing HER2 neg. cells.  Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 pos. cells, leading to the release of active PROTAC in quantities sufficient to induce potent BRD4 degrdn.  These studies demonstrate proof-of-concept for tissue-specific BRD4 degrdn., overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPwGNLaGmRbbVg90H21EOLACvtfcHk0lglbXur_Q7pIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D&md5=544b53e54d3f0696f0b425c3f6e48e46</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facschembio.0c00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.0c00285%26sid%3Dliteratum%253Aachs%26aulast%3DManeiro%26aufirst%3DM.%2BA.%26aulast%3DForte%26aufirst%3DN.%26aulast%3DShchepinova%26aufirst%3DM.%2BM.%26aulast%3DKounde%26aufirst%3DC.%2BS.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DTate%26aufirst%3DE.%2BW.%26atitle%3DAntibody-PROTAC%2520conjugates%2520enable%2520HER2-dependent%2520targeted%2520protein%2520degradation%2520of%2520BRD4%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D1306%26epage%3D1312%26doi%3D10.1021%2Facschembio.0c00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LS6','PDB','5LS6'); return false;">PDB: 5LS6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HYN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HYN','PDB','5HYN'); return false;">PDB: 5HYN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R','PDB','4W2R'); return false;">PDB: 4W2R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JZG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JZG','PDB','3JZG'); return false;">PDB: 3JZG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GSA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GSA','PDB','5GSA'); return false;">PDB: 5GSA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U5H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U5H','PDB','5U5H'); return false;">PDB: 5U5H</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01344&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01344%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01344" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a75b2dc0c3de3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
